### 27th ECVIM-CA Congress, 2017

#### Thursday, September 14, 2017

<table>
<thead>
<tr>
<th>Time/Society</th>
<th>CDCI</th>
<th>CDCII</th>
<th>CDCIII</th>
<th>NEPTUNE</th>
<th>PALM SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.40</td>
<td>ESVNU</td>
<td>ESVC</td>
<td>ESC/SCH</td>
<td>ESVIM/ISCAID</td>
<td>EDUCATION STREAM</td>
</tr>
<tr>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
<td>The metabolic signature(s) of ageing organs using the kidney as a paradigm</td>
</tr>
<tr>
<td>of ageing organs using the kidney as a paradigm</td>
<td>of ageing organs using the kidney as a paradigm</td>
<td>of ageing organs using the kidney as a paradigm</td>
<td>of ageing organs using the kidney as a paradigm</td>
<td>of ageing organs using the kidney as a paradigm</td>
<td>of ageing organs using the kidney as a paradigm</td>
</tr>
<tr>
<td>Michelangelo Campanella (GB)</td>
<td>Michelangelo Campanella (GB)</td>
<td>Michelangelo Campanella (GB)</td>
<td>Michelangelo Campanella (GB)</td>
<td>Michelangelo Campanella (GB)</td>
<td>Michelangelo Campanella (GB)</td>
</tr>
<tr>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
</tr>
<tr>
<td>Hepatic and intestinal organoids</td>
<td>Hepatic and intestinal organoids</td>
<td>Hepatic and intestinal organoids</td>
<td>Hepatic and intestinal organoids</td>
<td>Hepatic and intestinal organoids</td>
<td>Hepatic and intestinal organoids</td>
</tr>
<tr>
<td>Hedwig Kruijswagen (NL)</td>
<td>Hedwig Kruijswagen (NL)</td>
<td>Hedwig Kruijswagen (NL)</td>
<td>Hedwig Kruijswagen (NL)</td>
<td>Hedwig Kruijswagen (NL)</td>
<td>Hedwig Kruijswagen (NL)</td>
</tr>
<tr>
<td>09.45-10.25</td>
<td>ESVIM abstracts</td>
<td>ESVIM abstracts</td>
<td>ESVIM abstracts</td>
<td>ESVIM abstracts</td>
<td>ESVIM abstracts</td>
</tr>
<tr>
<td>Living and working mindfully: more than just an antidote to stress?</td>
<td>Living and working mindfully: more than just an antidote to stress?</td>
<td>Living and working mindfully: more than just an antidote to stress?</td>
<td>Living and working mindfully: more than just an antidote to stress?</td>
<td>Living and working mindfully: more than just an antidote to stress?</td>
<td>Living and working mindfully: more than just an antidote to stress?</td>
</tr>
<tr>
<td>Mike Scanlan (GB)</td>
<td>Mike Scanlan (GB)</td>
<td>Mike Scanlan (GB)</td>
<td>Mike Scanlan (GB)</td>
<td>Mike Scanlan (GB)</td>
<td>Mike Scanlan (GB)</td>
</tr>
<tr>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
</tr>
<tr>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
<td>Faiez Zannad (FR)</td>
</tr>
<tr>
<td>Gallbladder mucoceles</td>
<td>Gallbladder mucoceles</td>
<td>Gallbladder mucoceles</td>
<td>Gallbladder mucoceles</td>
<td>Gallbladder mucoceles</td>
<td>Gallbladder mucoceles</td>
</tr>
<tr>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
<td>Use of meteriologic data to predict parasite spread: should we expect more in the future?</td>
</tr>
<tr>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
</tr>
<tr>
<td>10.30-11.15</td>
<td>COFFEE BREAK – EXHIBITION</td>
<td>COFFEE BREAK – EXHIBITION</td>
<td>COFFEE BREAK – EXHIBITION</td>
<td>COFFEE BREAK – EXHIBITION</td>
<td>COFFEE BREAK – EXHIBITION</td>
</tr>
<tr>
<td>11.20-12.00</td>
<td>The pathology of renal ageing</td>
<td>The pathology of renal ageing</td>
<td>The pathology of renal ageing</td>
<td>The pathology of renal ageing</td>
<td>The pathology of renal ageing</td>
</tr>
<tr>
<td>Luca Aresu (IT)</td>
<td>Luca Aresu (IT)</td>
<td>Luca Aresu (IT)</td>
<td>Luca Aresu (IT)</td>
<td>Luca Aresu (IT)</td>
<td>Luca Aresu (IT)</td>
</tr>
<tr>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
</tr>
<tr>
<td>Feline Triaditis</td>
<td>Feline Triaditis</td>
<td>Feline Triaditis</td>
<td>Feline Triaditis</td>
<td>Feline Triaditis</td>
<td>Feline Triaditis</td>
</tr>
<tr>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
<td>Factors influencing geographical spread of Angiostrongylus vasorum through Europe</td>
</tr>
<tr>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
<td>Eric Morgan (GB)</td>
</tr>
<tr>
<td>12.05-12.45</td>
<td>Sarcopenia and cachexia in chronic kidney disease</td>
<td>Sarcopenia and cachexia in chronic kidney disease</td>
<td>Sarcopenia and cachexia in chronic kidney disease</td>
<td>Sarcopenia and cachexia in chronic kidney disease</td>
<td>Sarcopenia and cachexia in chronic kidney disease</td>
</tr>
<tr>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
<td>Jessica Quimby (US)</td>
</tr>
<tr>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
<td>The LOOK mitral study: is there any standard treatment for dogs with mitral valve disease?</td>
</tr>
<tr>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
<td>Michele Borgarelli (US)</td>
</tr>
<tr>
<td>Canine cholangitis and cholecystitis</td>
<td>Canine cholangitis and cholecystitis</td>
<td>Canine cholangitis and cholecystitis</td>
<td>Canine cholangitis and cholecystitis</td>
<td>Canine cholangitis and cholecystitis</td>
<td>Canine cholangitis and cholecystitis</td>
</tr>
<tr>
<td>Feline lungworms, what are we missing?</td>
<td>Feline lungworms, what are we missing?</td>
<td>Feline lungworms, what are we missing?</td>
<td>Feline lungworms, what are we missing?</td>
<td>Feline lungworms, what are we missing?</td>
<td>Feline lungworms, what are we missing?</td>
</tr>
<tr>
<td>Donato Traversa (IT)</td>
<td>Donato Traversa (IT)</td>
<td>Donato Traversa (IT)</td>
<td>Donato Traversa (IT)</td>
<td>Donato Traversa (IT)</td>
<td>Donato Traversa (IT)</td>
</tr>
<tr>
<td>Time/Society</td>
<td>ESVNU abstracts</td>
<td>ESVC abstracts</td>
<td>ESCG/SCH</td>
<td>ESVMISCAID</td>
<td>EDUCATION STREAM</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------</td>
<td>---------------</td>
<td>---------</td>
<td>------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>13.20-14.15</td>
<td>ESVNU AGM</td>
<td>Cardiology Diplomate Meeting</td>
<td>SCH AGM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.25-15.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Are Dirofilaria infections really spreading throughout Europe? Epidemiology, clinical concerns and prevention Claudio Genchi (IT)</td>
</tr>
<tr>
<td>14.25-15.05</td>
<td>Sargent ESVNU-O-1</td>
<td>Vitt ESVC-O-1</td>
<td></td>
<td>Host-defence strategies for minimally-invasive epithelial pathogens Jody Gookin (US)</td>
<td></td>
</tr>
<tr>
<td>14.40-15.10</td>
<td>van den Broek ESVNU-2</td>
<td>Rocchi ESVC-O-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.10-15.50</td>
<td>Buresova ESVNU-O-4</td>
<td>Lee ESVC-O-4</td>
<td></td>
<td>The emergence of macrocyclic lactone resistance in microfilariae; identification and risk assessment Roger Prichard (CA)</td>
<td></td>
</tr>
<tr>
<td>15.10-15.50</td>
<td>Chen ESVNU-O-5</td>
<td>Vezzosi ESVC-O-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.40-15.55</td>
<td>Segev ESVNU-O-6</td>
<td>Mervaille ESVC-O-6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.55-16.35</td>
<td>Lamoureux ESVNU-O-7</td>
<td>Blake ESVC-O-7</td>
<td></td>
<td>What have Dirofilaria and Wolbachia taught us about endosymbiotic relationships? Claudio Genchi (IT)</td>
<td></td>
</tr>
<tr>
<td>15.55-16.10</td>
<td>Johnstone ESVNU-O-8</td>
<td>Kies ESVC-O-8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ECVM-CA AGM</td>
</tr>
</tbody>
</table>

16.40-17.40 POSTER RECEPTION

17.45
# Friday, September 15, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>CDCI</th>
<th>CDCII</th>
<th>CDCIII</th>
<th>NEPTUNE</th>
<th>PALM SUITE</th>
<th>Scientific Committee Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00</td>
<td>07.00-08.00</td>
<td>ESVONC abstracts</td>
<td>ESVC</td>
<td>ESVC</td>
<td>SCH</td>
<td>ESVM/ISCAID</td>
<td>EDUCATION STREAM</td>
</tr>
<tr>
<td>08.00</td>
<td>08.00-08.15</td>
<td>LeBlanc</td>
<td>ESVC-O-10</td>
<td>08.00-08.15</td>
<td>Bayton</td>
<td>SCH-O-1</td>
<td></td>
</tr>
<tr>
<td>08.00</td>
<td>08.15-08.30</td>
<td>Damoiseaux</td>
<td>ESVC-O-11</td>
<td>08.15-08.30</td>
<td>Ullal</td>
<td>SCH-O-2</td>
<td></td>
</tr>
<tr>
<td>08.00</td>
<td>08.30-08.45</td>
<td>Corda</td>
<td>ESVC-O-12</td>
<td>08.30-08.45</td>
<td>Kortum</td>
<td>SCH-O-3</td>
<td></td>
</tr>
<tr>
<td>08.00</td>
<td>08.45-09.00</td>
<td>Bree</td>
<td>ESVC-O-13</td>
<td>08.45-09.00</td>
<td>Sato</td>
<td>SCH-O-4</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>09.00-09.15</td>
<td>Allerton</td>
<td>SCH-O-5</td>
<td>09.00-09.15</td>
<td>Valiente</td>
<td>SCH-O-6</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>09.15-09.30</td>
<td>Kortum</td>
<td>SCH-O-7</td>
<td>09.15-09.30</td>
<td>Neiger</td>
<td>SCH-O-8</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>09.30-09.45</td>
<td>Zandvliet</td>
<td>SCH-O-1</td>
<td>09.30-09.45</td>
<td>Sato</td>
<td>SCH-O-9</td>
<td></td>
</tr>
<tr>
<td>09.45</td>
<td>09.45-10.00</td>
<td>Guiliano</td>
<td>SCH-O-10</td>
<td>09.45-10.00</td>
<td>Jepsen</td>
<td>SCH-O-11</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>10.00-10.15</td>
<td>Elliott</td>
<td>SCH-O-12</td>
<td>10.00-10.15</td>
<td>Williams</td>
<td>SCH-O-13</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>10.15-10.30</td>
<td>Lyons</td>
<td>SCH-O-14</td>
<td>10.15-10.30</td>
<td>Schiele</td>
<td>SCH-O-15</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>10.30-10.45</td>
<td>Zandvliet</td>
<td>SCH-O-16</td>
<td>10.30-10.45</td>
<td>Schiele</td>
<td>SCH-O-17</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>11.00-11.15</td>
<td>Berresen</td>
<td>SCH-O-18</td>
<td>11.00-11.15</td>
<td>Neiger</td>
<td>SCH-O-19</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>11.20-11.35</td>
<td>Aghazadeh</td>
<td>SCH-O-20</td>
<td>11.20-11.35</td>
<td>Botha</td>
<td>SCH-O-21</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>11.50-12.05</td>
<td>Boye</td>
<td>SCH-O-22</td>
<td>11.50-12.05</td>
<td>Cartwright</td>
<td>SCH-O-23</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>12.00-12.15</td>
<td>Treggiari</td>
<td>SCH-O-24</td>
<td>12.00-12.15</td>
<td>Cartwright</td>
<td>SCH-O-25</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>12.20-12.35</td>
<td>Aupperle-Lellbach</td>
<td>SCH-O-26</td>
<td>12.20-12.35</td>
<td>Konstantinidis</td>
<td>SCH-O-27</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>12.35-12.50</td>
<td>Bechtel</td>
<td>SCH-O-28</td>
<td>12.35-12.50</td>
<td>Allen</td>
<td>SCH-O-29</td>
<td></td>
</tr>
<tr>
<td>12.45</td>
<td>12.45-13.00</td>
<td>Aupperle-Lellbach</td>
<td>SCH-O-30</td>
<td>12.45-13.00</td>
<td>Allen</td>
<td>SCH-O-31</td>
<td></td>
</tr>
</tbody>
</table>

**ESVONC abstracts**
- **08.00-08.15**: LeBlanc (ESVC-O-10)
- **08.15-08.30**: Damoiseaux (ESVC-O-11)
- **08.30-08.45**: Corda (ESVC-O-12)
- **08.45-09.00**: Bree (ESVC-O-13)

**ESVC abstracts**
- **08.00-08.15**: LeBlanc (ESVC-O-10)
- **08.15-08.30**: Damoiseaux (ESVC-O-11)
- **08.30-08.45**: Corda (ESVC-O-12)
- **08.45-09.00**: Bree (ESVC-O-13)

**SCH abstracts**
- **08.00-08.15**: Bayton (SCH-O-1)
- **08.15-08.30**: Ullal (SCH-O-2)
- **08.30-08.45**: Kortum (SCH-O-3)
- **08.45-09.00**: Sato (SCH-O-4)

**ESVC oral Exam demonstration for internal medicine residents**
- **Mike Scanlan (GB)**

**ECVM-CA oral Exam demonstration for internal medicine residents**
- **Mike Scanlan (GB)**

**SCH abstracts**
- **09.00-09.15**: Allerton (SCH-O-5)
- **09.15-09.30**: Valiente (SCH-O-6)
- **09.30-09.45**: Neiger (SCH-O-7)

**ESVC abstracts**
- **09.00-09.15**: LeBlanc (ESVC-O-10)
- **09.15-09.30**: Damoiseaux (ESVC-O-11)
- **09.30-09.45**: Corda (ESVC-O-12)
- **09.45-10.00**: Bree (ESVC-O-13)

**ESCVG abstracts**
- **09.45-10.00**: Guiliano (ESVC-O-2)
- **10.00-10.15**: Elliott (ESVC-O-3)
- **10.15-10.30**: Lyons (ESVC-O-4)

**ESVC abstracts**
- **10.00-10.15**: Elliott (ESVC-O-3)
- **10.15-10.30**: Lyons (ESVC-O-4)

**ESCVG abstracts**
- **10.00-10.15**: Elliott (ESVC-O-3)
- **10.15-10.30**: Lyons (ESVC-O-4)

**ESVC abstracts**
- **10.15-10.30**: Lyons (ESVC-O-4)
- **10.30-10.45**: Zandvliet (ESVC-O-1)

**ESVC abstracts**
- **10.45-10.50**: Treggiari (ESVC-O-1)
- **10.50-12.00**: Treggiari (ESVC-O-1)

**ESVC abstracts**
- **12.00-12.15**: Treggiari (ESVC-O-1)
- **12.15-12.30**: Treggiari (ESVC-O-1)

**ESVC abstracts**
- **12.20-12.35**: Aupperle-Lellbach (ESVC-O-9)
- **12.35-12.50**: Aupperle-Lellbach (ESVC-O-10)

**ESVC abstracts**
- **12.45-12.50**: Aupperle-Lellbach (ESVC-O-10)

**RESIDENT MASTERCLASS: Cytology**
- Martina Piviani (GB)

**RESIDENT MASTERCLASS: Cytology (continued)**
- Martina Piviani (GB)

**Microcirculation and the glycocalyx: does it matter?**
- Claire Sharp (AU)

**Colloids in small animals: what's the evidence?**
- Katja Adamik (CH)

**Initial stabilisation via early goal-directed fluid therapy**
- Claire Sharp (AU)

**Fluid status and responsiveness: what's new?**
- Kris Gommeren (BE)

**RESIDENT MASTERCLASS: Cytology**
- Martina Piviani (GB)

**RESIDENT MASTERCLASS: Cytology (continued)**
- Martina Piviani (GB)
Friday, September 15, 2017 - continued

<table>
<thead>
<tr>
<th>Room</th>
<th>CDCI</th>
<th>CDCII</th>
<th>CDCIII</th>
<th>NEPTUNE</th>
<th>PALM SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.20-14.15</td>
<td>ESVAGM</td>
<td>ESCAGM</td>
<td>ESVAGM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Time/Society**

<table>
<thead>
<tr>
<th>Time/Society</th>
<th>ESVONC</th>
<th>VBPS</th>
<th>ESCG/SCH</th>
<th>ESVIM abstracts</th>
</tr>
</thead>
</table>

**15.55-16.25**

**COFFEE BREAK - EXHIBITION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30-17.10</td>
<td>Immunohistochemistry for neoplastic disease: reaching a final diagnosis and more</td>
<td>Debra Kamstock (US)</td>
</tr>
<tr>
<td>17.15-17.55</td>
<td>Prognostic biomarkers in veterinary oncology: are we there yet?</td>
<td>Laura Garrett (US)</td>
</tr>
</tbody>
</table>

18.00-18.30  | Meet the Executive ECVIM-CA  |

19.45 - 01.30 | CONGRESS EVENING AND DANCE PARTY |
<table>
<thead>
<tr>
<th>Time/Society</th>
<th>Room</th>
<th>ESVCN abstracts</th>
<th>ESVE abstracts</th>
<th>ESVEC abstracts</th>
<th>ESVIM/ISCAID</th>
<th>EDUCATION STREAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td>CDCI</td>
<td>ESVCN-O-1</td>
<td>ESVE-O-1</td>
<td>ESVECP-O-3</td>
<td>ESVIM/ISCAID</td>
<td>Blending acceptance into mindfulness practice Mike Scanlan (GB)</td>
</tr>
<tr>
<td>08.15-08.30</td>
<td>CDCII</td>
<td>Söder</td>
<td>Eig</td>
<td>ESVECP-O-2</td>
<td>ESVIM/ISCAID</td>
<td>Evidence-based medical assessment Julian Archer (GB)</td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>CDCIII</td>
<td>Kiefer-Hecker</td>
<td>van Staalduinen</td>
<td>ESVECP-O-3</td>
<td>ESVIM/ISCAID</td>
<td></td>
</tr>
<tr>
<td>09.00-09.40</td>
<td>NEPTUNE</td>
<td>Dobenecker</td>
<td>de Wit</td>
<td>ESVECP-O-3</td>
<td>ESVIM/ISCAID</td>
<td></td>
</tr>
<tr>
<td>09.45-10.25</td>
<td>PALM SUITE</td>
<td></td>
<td></td>
<td></td>
<td>ESVIM/ISCAID</td>
<td></td>
</tr>
<tr>
<td>10.30-11.15</td>
<td>COFFEE BREAK – EXHIBITION</td>
<td></td>
<td></td>
<td></td>
<td>ESVIM/ISCAID</td>
<td></td>
</tr>
<tr>
<td>11.20-12.00</td>
<td>ISCAID abstracts</td>
<td>Leynaud</td>
<td>Bremer</td>
<td>Aroch</td>
<td>ESVCP-O-6</td>
<td>Postgraduate assessment/how do you judge competence? Mariam Naveed (US)</td>
</tr>
<tr>
<td>12.05-12.45</td>
<td>Nutritional management of dermatological diseases in dogs and cats: the latest research insights</td>
<td>Zoes</td>
<td>Burchell</td>
<td>de Luca</td>
<td>ESVCP-O-09</td>
<td>How should we train residents? Adrian Boswood (GB)</td>
</tr>
<tr>
<td>12.50-14.20</td>
<td>LUNCH BREAK – EXHIBITION</td>
<td></td>
<td></td>
<td></td>
<td>ESVIM/ISCAID</td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, September 16, 2017 - continued

<table>
<thead>
<tr>
<th>Time/Society</th>
<th>ESVNU abstracts</th>
<th>ESVE abstracts</th>
<th>ESVCP</th>
<th>ISCAID abstracts</th>
<th>EVIDENCE-BASED EDUCATION STREAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.20-14.15</td>
<td>ESVE AGM</td>
<td>Internal Medicine Diplomate Meeting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.25-15.05</td>
<td>Crisi (ESVNU-O-12)</td>
<td>Scudder (ESVE-O-6)</td>
<td></td>
<td>14.55-15.10</td>
<td>Barash (ISCAID-O-9)</td>
</tr>
<tr>
<td>15.10-15.50</td>
<td>Reynolds (ESVNU-O-13)</td>
<td>Woolhead (ESVE-O-7)</td>
<td>Infectious diseases affecting the bone marrow in dogs and cats: Mathios Mylonakis (GR)</td>
<td>15.10-15.25</td>
<td>Pomba (ISCAID-O-10)</td>
</tr>
<tr>
<td>15.10-15.50</td>
<td>Garcia (ESVNU-O-14)</td>
<td>Zeit (ESVE-O-8)</td>
<td></td>
<td>15.25-15.40</td>
<td>Leutenegger (ISCAID-O-11)</td>
</tr>
<tr>
<td>15.55-16.25</td>
<td>ESCG abstracts</td>
<td>ESVC abstracts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.10</td>
<td>Coddou (ESCG-O-10)</td>
<td>Finch (ESVE-O-10)</td>
<td>A case-based approach to BM Cytology: Elizabeth Villiers (GB) Mathios Mylonakis (GR)</td>
<td>16.30-16.45</td>
<td>Gomart (ESVC-O-26)</td>
</tr>
<tr>
<td>16.30-17.10</td>
<td>Allenspach (ESCG-O-11)</td>
<td>Casado Diaz (ESVE-O-11)</td>
<td></td>
<td>16.45-17.00</td>
<td>Glen (ESVC-O-26)</td>
</tr>
<tr>
<td>16.30-17.10</td>
<td>Freische (ESCG-O-12)</td>
<td>Spence (ESVE-O-12)</td>
<td></td>
<td>17.00-17.15</td>
<td>Romito (ESVC-O-27)</td>
</tr>
<tr>
<td>17.15-17.55</td>
<td>Dominguez Ruiz (ESGC-O-13)</td>
<td>Hagberg (ESVE-O-13)</td>
<td></td>
<td>17.15-17.30</td>
<td></td>
</tr>
<tr>
<td>17.15-17.55</td>
<td>Woolhead (ESGC-O-14)</td>
<td>Pijlacker (ESVE-O-14)</td>
<td></td>
<td>17.30-17.45</td>
<td></td>
</tr>
<tr>
<td>17.15-17.55</td>
<td>De Rij (ESGC-O-15)</td>
<td>Scarpa (ESVE-O-15)</td>
<td></td>
<td>17.45-18.00</td>
<td></td>
</tr>
<tr>
<td>18.00-19.00</td>
<td>FAREWELL DRINK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents

Education Stream  
Scientific Programme  

ESCG - European Society of Comparative Gastroenterology  
Oral Presentations  
Poster Presentations  

ESCG/SCH - European Society of Comparative Gastroenterology / Society of Comparative Hepatology  
Scientific Programme  

ESVC - European Society of Veterinary Cardiology  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVCN - European Society of Veterinary Comparative Nutrition  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVCP - European Society of Veterinary Clinical Pathology  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVE - European Society of Veterinary Endocrinology  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVIM - European Society of Veterinary Internal Medicine  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVIM/ISCAID - European Society of Veterinary Internal Medicine / International Society for Companion Animal Infectious Diseases  
Scientific Programme  

ESVNU - European Society of Veterinary Nephrology and Urology  
Oral Presentations  
Poster Presentations  
Scientific Programme  

ESVONC - European Society of Veterinary Oncology  
Oral Presentations  
Poster Presentations  
Scientific Programme  

Evidence-Based Veterinary Medicine  
Scientific Programme  

ISCAID - International Society for Companion Animal Infectious Diseases  
Oral Presentations  
Poster Presentations  

SCH - Society of Comparative Hepatology  
Oral Presentations  
Poster Presentations  

VBPS - Veterinary Blood Pressure Society  
Oral Presentations  
Scientific Programme
Education Stream

Scientific Programme
Scientific Programme

**Living and Working Mindfully - More Than Just an Antidote to Stress**  Mike Scanlan, BA Hons, Doctorate

**Advanced ECG Interpretation**  N. Sydney Moise, DVM, MS, DACVIM

**Resident Masterclass: Cytology**  Martina Piviani, DVM, MSc, DACVP (Clinical Pathology), MRCVS

**Evidence Based Medical Assessment**  Julian Archer, MRCPCH, MEd, PhD, FAcadMed

**Multisource Feedback**  Julian Archer, MRCPCH, MEd, PhD, FAcadMed

**Post-Graduate Assessment: How Do You Judge Competence?**  Mariam Naveed, MD

**How Should We Train Residents?**  Adrian Boswood, DVC, MA, MRCVS, VetMB
KEYNOTE MESSAGE

In the last decade interest in researching mindfulness-based stress reduction (MBSR) interventions has increased. Interventions that utilize MBSR have shown to be effective in reducing symptoms of depression & anxiety. MBSR has also been shown to be effective in treating physical conditions such as chronic pain and heart disease. Sources of stress that impact negatively on veterinarians include giving bad news, managing adverse events, interacting with difficult clients, working in teams, and balancing work and home life. But it is thought that handling ethical dilemmas is the worst stressor, and research indicates that veterinarians face ethical dilemmas three to five times per week (Bartram & Baldwin 2010).

This session explores how over 1000 participants from the veterinarian industry engaged on a mindful journey towards becoming more psychologically adept at managing the stress associated with working within the veterinarian industry. The session describes how Mike Scanlan, a pioneer in delivering high volume, low intensity MBSR courses collaborated with Anthony Chadwick, the founder of ‘The Webinar Vet’ and Lizzie Locket from Mind Matters to develop and deliver the 8-week MBSR course. The session explores the findings of the research carried out over the 8 weeks and highlights that the benefits are wider than mere stress reduction.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Mike Scanlan, BA Hons, Doctorate
Mental Health Consultant
University of Northampton, UK

URL: http://www.vin.com/doc/?id=8172758
Advanced ECG Interpretation

N. Sydney Moise, DVM, MS, DACVIM
College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

KEYNOTE MESSAGE

To obtain a high level of interpretive skills in the diagnostic approach to difficult electrocardiograms requires the use of a systematic approach, deductive reasoning, information assimilation, and mechanistic hypotheses. Consequently, to master these processes necessitates careful examination of many electrocardiograms, reading not only about electrocardiography but electrophysiology (including cellular electrophysiology), and discussions with others who are practiced in ECG analysis. One of the most important learning tools to master difficult electrocardiograms is to take the time necessary to carefully examine the individual beats as well as the patterns of the heart beating. It is not possible to become skilled in this field by rapid scanning of the recording during a busy clinic day. Careful and methodical examination with investigation cannot be replaced. Learning the language of advanced electrocardiography/electrophysiology would include becoming familiar with terms that reflect mechanism (e.g., gap phenomenon, AV dissociation, concealed conduction, decremental conduction, electrotonic potentials, supernormal conduction, QT:TQ restitution, exit block). Additionally, one of the most important factors to understand during the interpretation of electrocardiograms is the influence of the sympathetic and parasympathetic system, not only on arrhythmias, but also on the patterns of sinus node function. During this session, example electrocardiograms and Holter recordings will be used to illustrate these and other points in the interpretation of difficult electrocardiograms. Focused learning for each tracing will be emphasized.

Key References


SPEAKER INFORMATION

N. Sydney Moise, DVM, MS, DACVIM
College of Veterinary Medicine
Cornell University
Ithaca, NY, USA

URL: http://www.vin.com/doc/?id=8172775
CYTOMETRY MESSAGE

Cytology can be employed by clinicians in the diagnostic workup of a wide variety of disease processes. Applications are endless and the diagnostic value of this tool can be further maximised by combining it with appropriate complementary diagnostic investigations such as imaging, cytochemistry, immunocytochemistry, flow cytometry, PCR, culture, and serology. In the introduction of this masterclass, indications, expectations and limitations of cytology, and the general principles of sample acquisition, slide examination, and cytology reporting will be briefly discussed. Cytology of skin masses, lymph nodes and internal organs will then be illustrated by critically appraising value and limitations in the diagnosis of different conditions, using also case examples.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Martina Piviani, DVM, MSc, DACVP (Clinical Pathology), MRCVS
Institute of Veterinary Science, University of Liverpool
Liverpool, UK

URL: http://www.vin.com/doc/?id=8172776
Evidence Based Medical Assessment

Julian Archer, MRCPCH, MEd, PhD, FAcadMEd
Collaboration for the Advancement of Medical Education Research & Assessment (CAMERA), Plymouth University Peninsula Schools of Medicine & Dentistry, Plymouth University, UK

KEYNOTE MESSAGE

Medicine, like all vocational degrees and career paths, has an important additional outcome when one considers the selection of the 'best' candidates, their training and continuing professional development; and that is the need to assure patient safety and quality of care. This additional onus, alongside an increasingly neoliberal political landscape, is driving a proliferation in the development and implementation of assessment methods. But what is the evidence base for what works and what helps to keep the recipients of their care safer? This talk will introduce concepts around validity, including the ‘APA’ validity framework, and how one might then critically appraise assessment instruments and methods. The framework can also be used when thinking about developing or modifying assessment methods for specific aims. This framework will then be used to explore the evidence and best practice from the continuum of medical assessment and how these principles might be useful in developing and quality assuring assessment practices in veterinary medicine.

Key References


SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Julian Archer, MRCPCH, MEd, PhD, FAcadMEd
Collaboration for the Advancement of Medical Education Research & Assessment (CAMERA)
Plymouth University Peninsula Schools of Medicine & Dentistry
Plymouth University, UK

URL: http://www.vin.com/doc/?id=8172777
Multisource Feedback
Julian Archer, MRCPCH, MEd, PhD, FAcadMed
Collaboration for the Advancement of Medical Education Research & Assessment (CAMERA), Plymouth University Peninsula Schools of Medicine & Dentistry, Plymouth University, UK

Keynote Message

Multisource Feedback (MSF) or 360-degree feedback has become endemic across the continuum of medical education. Collecting feedback using a standardised questionnaire from colleagues, and in medicine sometimes from patients, is often advocated as a valid way to assess skills such as communication and professionalism. This talk will discuss in some detail what MSF is, where it has come from, what evidence there is (mapped to a newly introduced validity framework) for its use and what the limitations might be. Lastly, there will be an opportunity to discuss how this instrument might be useful in veterinary medicine and, if so, what might be the opportunities and barriers.

Key References

Speaker Information

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Julian Archer, MRCPCH, MEd, PhD, FAcadMed
Collaboration for the Advancement of Medical Education Research & Assessment (CAMERA)
Plymouth University Peninsula Schools of Medicine & Dentistry
Plymouth University, UK

URL: http://www.vin.com/doc/?id=8172778
Post-Graduate Assessment: How Do You Judge Competence?
Mariam Naveed, MD
Digestive & Liver Disease, University of Iowa Hospital & Clinics, Iowa City, IA, USA

KEYNOTE MESSAGE
Increasing complexity within the healthcare system has led to a need for change within the current medical education training model. There has been a gradual shift from the traditional time and process-based format to a competency-based model that emphasizes clinical outcomes and patient-centered quality. Additionally, there has been an increased focus on assessing trainee ability with promotion of learner-centeredness.

In the field of Gastroenterology, the shift to a competency-based approach has led to changes in the educational approach to teaching endoscopy. Traditionally, programs relied on case number thresholds to ensure trainees achieved procedural competency. However, with the heightened emphasis on quality, the use of threshold numbers is now considered a poor surrogate marker for competence. Trainees are now increasingly expected to achieve certain quality metrics when performing endoscopic procedures before they are deemed competent. As the competency-based model emphasizes outcomes rather than the process, appropriate assessment is a critical component of training. Several tools/processes are available to ensure trainees in both procedural and non-procedural oriented programs are meeting developmental milestones.

In this session, the competency-based medical education paradigm will be further explored. We will also focus on the ACGME core competencies and the Next Accreditation System (NAS) assessment model as a framework for developing competency-based curricula. Strategies for evaluating trainees and specifically assessing the technical and non-technical components of endoscopic competence will also be discussed.

Key References
How Should We Train Residents?
Adrian Boswood, MA, VetMB, DVC, DECVIM-CA (Cardiology), FHEA, MRCVS
Department of Clinical Science and Services, The Royal Veterinary College, North Mymms, Hatfield, Herts, UK

KEYNOTE MESSAGE

In designing and assuring the quality of resident training, European Speciality colleges, including ECVIM, have a responsibility to numerous different stakeholders; these include the general public, national and international professional, statutory and regulatory bodies (PSRBs), existing college members and residents in training. The European Board of Veterinary Specialisation (EBVS) is applying under the Common Training Framework for recognition of European College Diplomas as being equivalent to level 8 higher education qualifications (Doctoral level). These levels give clear guidance regarding the generic characteristics of holders of this type of qualification. It is therefore timely to reflect on how we currently train residents to achieve these standards and how this training might evolve in future.

In order to be adequately prepared for their future careers as independently practising specialists, residents need to reach or exceed the level of a minimally qualified specialist. It is currently the responsibility of ECVIM to define, in each of its three specialties, what constitutes a minimally qualified specialist. ECVIM also defines and quality assures ideal training programs that enable trainees to achieve the appropriate standard in a reasonable timeframe. Additionally, ECVIM administers the assessment which determines whether or not trainees have reached the defined standard.

Medical and veterinary medical training involves the development of appropriate knowledge, skills, and professional attitudes in trainees. It is inevitable that the knowledge skills and attitudes required of minimally qualified specialists will change with time and therefore there is an obligation for ECVIM to consider whether current methods of training and assessment remain fit for purpose.

There are several key questions which the college should address:

- Do the knowledge, skills, and professional attitudes the college expects of its minimally qualified specialists match what is expected of those specialists by the public they serve, and how would we know if they did not?
- Are current training programs sufficiently similar to ensure that all ECVIM residents have equal opportunities to develop the requisite knowledge, skills and professional attitudes?
- Should the college better quality assure approved residencies and if so how?
- Is the current emphasis of the assessment appropriate? We employ little continuous assessment and have high-stakes terminal examinations that focus on knowledge, understanding, and application of knowledge with proportionately less testing of skills and professional attitudes.

Key References
1. Descriptors defining levels in the European Qualifications Framework (EQF)

**SPEAKER INFORMATION**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Adrian Boswood, DVC, MA, MRCVS, VetMB
Royal Veterinary College
Hertfordshire, UK

URL: http://www.vin.com/doc/?id=8172780
ESCG - European Society of Comparative Gastroenterology

Oral Presentations
Poster Presentations
Oral Presentations

**Serum S100/Calgranulin Concentrations in Miniature Schnauzers with Idiopathic Hyperlipidemia**  
R.M. Heilmann

**Serum Tocopherol and Retinol Concentrations in Dogs with Exocrine Pancreatic Insufficiency**  
D.A. Williams

**Effect of Mirtazapine on Canine Gastric Emptying Assessed by 13C-Sodium Acetate Breath Test (13C-SABT)**  
N. Schleifenbaum

**Prevalence of Clostridium difficile and Salmonella spp. in Juvenile Dogs Affected with Parvoviral Enteritis**  
W.J. Botha

**Risk Factors for C. difficile Carriage in Dogs and Associations with Clinical Disease**  
C. Albuquerque

**Long-Term Impact of Tylosin on the Faecal Microbiota of Healthy Dogs**  
A.C. Manchester

**Vitamin D Receptor Expression in the Dog and the Effect of Intestinal Inflammation**  
J.A. Cartwright

**Serum Circulating MicroRNAs as a Marker for Canine Lymphocytic-Plasmacytic Inflammatory Bowel Disease**  
F. Vessieres

**Specific Virulence Factors in Mucosa-Associated E. coli of Dogs with Inflammatory Bowel Disease (IBD) are Associated with Survival**  
A.O. Konstantinidis

**Identification of IgG4-Related Disease in the English Cocker Spaniel and Dogs of Other Breeds**  
F. Vessieres

**Correlating Gastrointestinal Histopathologic Findings to Clinical Disease Activity in Dogs with Inflammatory Bowel Disease**  
M. Dominguez Ruiz

**Prevalence of Gastric Lymphoid Follicular Hyperplasia in French Bulldogs**  
F. Da Riz

**A Retrospective Evaluation of Ileocecal Perforations Associated with Routine Diagnostic Lower Gastrointestinal Endoscopy in Dogs and Cats**  
V.L. Woolhead

V.L. Woolhead
Serum S100/Calgranulin Concentrations in Miniature Schnauzers with Idiopathic Hyperlipidemia

R.M. Heilmann1; P.G. Xenoulis2; K. Müller1; E. Stavroulaki2; J. Suchodolski3; J. Steiner3
1College of Veterinary Medicine, University of Leipzig, Leipzig, Germany; 2Small Animal Clinic, University of Thessaly, Karditsa, Greece; 3Gastrointestinal Laboratory, Texas A&M University, College Station, TX, USA

Idiopathic hyperlipidemia (IH) is a common condition in Miniature Schnauzers (MS), with more than 75% of dogs ≥9 years old being affected and >45% of these dogs having moderate to severe fasting hypertriglyceridemia (HTG) with or without combined hypercholesterolemia (HCHOL). Severe HTG poses an increased risk for the development of several conditions (e.g., pancreatitis, insulin resistance). Recent studies in humans suggest IH to be associated with low-grade inflammation involved in the pathogenesis of diseases associated with IH. The risk of such complications decreases with medical control of IH. Given that biomarkers of inflammation have not been investigated in MS with IH, the aims of the study were to evaluate serum calprotectin and S100A12 concentrations (1) in healthy MS and in MS with IH, and (2) in MS with IH in response to dietary intervention for the management of IH.

Serum samples were collected from 152 clinically healthy MS, and a study questionnaire was completed for each dog to confirm the health status and medication history. Serum triglyceride, cholesterol, calprotectin, and S100A12 concentrations were measured in all samples. Paired serum samples were obtained from 17 of the IH dogs after being placed on a commercial ultra-low fat diet without any additional lipid-lowering medications. Statistical analyses were performed using non-parametric (paired or unpaired) group comparisons and Fisher's exact or likelihood ratio tests, with statistical significance set at p<0.05.

A total of 34%, 5%, and 11% of dogs had isolated HTG, hypercholesterolemia (HCHOL), and combined hyperlipidemia, respectively. Compared to MS without IH, both HTG and HCHOL were associated with increased serum calprotectin (p=0.0007, odds ratio [OR]=4.2 and p=0.0051, OR=4.1, respectively) but not S100A12 concentrations (both p>0.05). There was no significant difference in serum calprotectin or S100A12 concentrations among MS with isolated HTG, HCHOL, or combined hyperlipidemia. Presence and severity of HTG decreased in MS with IH within 14–26 weeks after being placed on an ultra-low fat diet (p=0.0052 and p=0.0032). Dietary intervention also yielded a significant decrease in serum cholesterol (p=0.0356) but neither serum calprotectin nor S100A12 concentrations changed significantly during that time (both p>0.05).

These results suggest that subclinical inflammation is present in MS with HTG due to IH and that an ultra-low fat diet does not reduce the concentrations of the inflammatory S100 proteins in MS with HTG. Whether this presumable inflammatory phenotype in MS with IH contributes to the development of pancreatitis, insulin resistance, or other conditions warrants further research.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.M. Heilmann
University of Leipzig
College of Veterinary Medicine
Leipzig, Germany

URL:  http://www.vin.com/doc/?id=8172897
Serum Tocopherol and Retinol Concentrations in Dogs with Exocrine Pancreatic Insufficiency

P.C. Barko; D.A. Williams
University of Illinois, Urbana, IL, USA

Exocrine pancreatic insufficiency (EPI) in dogs is diagnosed by observing serum canine trypsin-like immunoreactivity (cTLI) to be less than 2.5 µg/L; affected dogs have severe fat malabsorption. Some dogs with signs of EPI have marginally subnormal serum cTLI (3–6 µg/L) and do not respond to enzyme replacement therapy (subclinical EPI, SEPI), but given their clinical signs, abnormal serum cobalamin or folate, and absence of other detectable non-enteric disease presumably have an idiopathic chronic enteropathy (ICE). Unpublished preliminary data indicate decreased serum tocopherol concentrations in dogs with EPI that do not resolve after pancreatic enzyme supplementation. The objectives of this study were to measure serum tocopherol and retinol in dogs with EPI and those with subclinical EPI and ICE (SEPI/ICE).

Inclusion criteria for the EPI group (n=8) were clinical signs of EPI and serum cTLI concentrations <2.5 µg/L. Dogs in the SEPI/ICE group (n=9) had clinical signs of ICE and serum cTLI concentrations in the 3.0–6.0 µg/L range. Diets of dogs in both groups were supplemented with oral pancreatic enzyme extract. Control samples were collected from 10 healthy dogs before and after 10 days of pancreatic enzyme supplementation. All samples were surplus from another study approved by our institutional ethics committee, and stored at -80 C prior to assay of tocopherol and retinol by high-performance liquid chromatography.

Dogs with EPI and SEPI/ICE had significantly lower serum concentrations of tocopherol (means 14.02 and 16.66 µg/mL; p=0.015 and p=0.0002 respectively) and retinol (means 509 and 673.78 ng/mL; p=0.0003 and 0.004, respectively) than enzyme-supplemented control dogs (means 41.6 µg/mL and 1124.86 ng/mL, respectively). Neither tocopherol nor retinol concentrations were significantly different between the EPI and SEPI/ICE groups, nor were there differences between the control dogs before and after enzyme supplementation.

These findings indicate that dogs with EPI and SEPI/ICE have relative deficiencies in tocopherol and retinol, likely reflecting fat malabsorption, and may share a similar enteropathy that may precede the onset of EPI. The clinical significance of these decreased fat soluble vitamin concentrations is unknown though retinol has been shown to influence enteric mucosal immune responses though its effects on T-cell differentiation, IgA secretion in GALT, and homing of innate lymphoid cells to the gut. Tocopherol is an important antioxidant and studies have revealed increased reactive oxygen species in intestinal biopsies from humans with IBD.

Clinical trials to assess the value of tocopherol and retinol supplementation in dogs with EPI and ICE are warranted.

DISCLOSURES

Disclosures to report.
David Williams is a consultant with IDEXX Laboratories and the GI Laboratory at Texas A&M University, and is involved in a collaborative research study with Nestle-Purina. He is a member of the Nestle-Purina Advisory Board.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

D.A. Williams
University of Illinois
Urbana, IL, USA

URL: http://www.vin.com/doc/?id=8172904
Effect of Mirtazapine on Canine Gastric Emptying Assessed by 13C-Sodium Acetate Breath Test (13C-SABT)

N. Schleifenbaum\textsuperscript{1}; S. Salavati\textsuperscript{2}; R. Neiger\textsuperscript{1}

\textsuperscript{1}Small Animal Clinic, Justus-Liebig-University Giessen, Giessen, Germany; \textsuperscript{2}University of Edinburgh, The Royal (Dick) School of Veterinary Studies, Edinburgh, UK

Delayed gastric emptying is suspected to occur in several common conditions in dogs, for example metabolic/endocrine disorders or inflammatory bowel disease. It can also be a sequela in critical care patients suffering from sepsis, peritonitis or pancreatitis. Treating the underlying cause is indicated, but additional supportive treatment in the form of prokinetic drugs is scarce, especially as 5-HT4 receptor agonists are not widely available. The antidepressant mirtazapine, routinely used at low dosages for its appetite stimulating properties in small animals, has been reported to accelerate gastric emptying both in people and (at high dosages) in experimental healthy dogs. The effects of mirtazapine on gastric emptying times using a non-invasive test have not been assessed. Hence, assessing the effect of different dosages of this drug on gastric half emptying times (G50\%) in healthy dogs using the 13C-SABT was sought.

Six healthy Beagle dogs (3–5 years, 9.7–11.6 kg body weight) were included. Mirtazapine was used at increasing dosages (0.6 mg/kg=MLo, 2 mg/kg=MMMe, 20 mg/kg=MHi). Initially, MLo, placebo and prucalopride (1 mg/kg as a positive control) were administered orally in a cross-over design. Subsequently, MMMe and MHi were administered and compared to a second and third placebo treatment. This approach was chosen to enable interim analysis of data, as ethical approval only allowed to progress to a higher mirtazapine dose if no effect was seen with the lower one. On day 4 of each treatment, a test meal consisting of each dog's half daily calorie requirement and 150 mg 13C-sodium acetate was fed after an overnight fast and a 13C-SABT was performed. Breath samples were obtained with a facial mask before (0 minutes) and 30, 60, 120, 180, 240, 300, and 360 minutes after test meal ingestion. \(^{12}\text{CO}_2/^{13}\text{CO}_2\) ratio in the breath was measured by non-dispersive infrared spectroscopy and delta-over baseline (DOB) values plotted against time. G50\% was calculated for each treatment based on cumulative non-linear curve fitting of the DOB values. Median G50\% was 78.3 minutes (range 48.4–93.3) with MLo, 84.4 minutes (69.2–109.6) with MMMe and 106.4 minutes (range 83.1–144.2) with MHi. Median G50\% for prucalopride and for placebo was 61.9 minutes (43.1–159.0) and 67.1 minutes (38.1–146.1), respectively.

MLo (p=0.75) and MMMe (p=0.12) had no effect on G50\% compared to placebo. Unexpectedly, MHi prolonged gastric emptying (p=0.046). G50\% was not significantly different between prucalopride and placebo (p=0.75). In conclusion, mirtazapine does not accelerate G50\% in healthy dogs. In high dosages, it might prolong gastric emptying, even though with borderline significance.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

N. Schleifenbaum
Small Animal Clinic
Justus-Liebig-University Giessen
Giessen, Germany

URL: http://www.vin.com/doc/?id=8172905
Prevalence of *Clostridium difficile* and *Salmonella* spp. in Juvenile Dogs Affected with Parvoviral Enteritis

W.J. Botha¹; J.P. Schoeman¹; S.L. Marks²; P.S. Morley³; Z. Whitehead¹; C.H. Annandale¹

¹University of Pretoria, Onderstepoort, South Africa; ²University of California, Davis, Davis, CA, USA; ³Colorado State University, Fort Collins, CO, USA

*Clostridium difficile* (CD) is a common cause of hospital-acquired diarrhoea in humans and has been associated with diarrhoea in dogs. Salmonellosis is a major zoonotic disease but the transmission pathway is unclear. It is thus important to evaluate the risk factors that increase the likelihood of infection. Canine parvovirus (CPV) is a prevalent and fatal cause of canine enteritis often exacerbated by concurrent infection with other enteropathogens. Persistent isolation of *Salmonella* spp. during hospital environmental surveys of the isolation ward prompted further investigation. This study was designed to determine the comparative prevalence of CD and *Salmonella* spp. in dogs with CPV and healthy dogs.

The study was approved by the ethics committee of the University of Pretoria and conducted from October 2015 to March 2017. Fresh faecal samples were collected from dogs aged 6 weeks to 9 months diagnosed and admitted with CPV infection, and healthy dogs presented for vaccination or routine hospital procedures. CPV shedding was confirmed using negative staining electron microscopy. CD was detected via commercial faecal antigen enzyme immunoassay for glutamate dehydrogenase (GDH), TcdA and TcdB. In addition, faeces was submitted for the isolation, antimicrobial susceptibility and serotyping of *Salmonella* spp.

Seventy-five dogs with CPV and 41 healthy dogs comprised the study. The prevalence of CD was 2.7% and 5% in CPV and healthy dogs, respectively, whereas the prevalence of *Salmonella* spp. was 21.3% and 32.5% in CPV and healthy dogs, respectively. No statistically significant associations between *Salmonella* infection status and possible risk factors or continuous variables such as age, weight and length of hospitalisation were identified. Statistical analysis was not performed on CD positive animals, because only two animals in either groups tested positive. Moreover, all the *Salmonella* spp. isolates (n = 32) were resistant to penicillin G, lincomycin and tylosin. Nine of the isolates were resistant to Linco-Spectin and 21 showed intermediate (n=20) or complete resistance (n=1) to doxycycline/oxytetracycline. Nine different serotypes of *Salmonella* spp. were identified.

In conclusion, the prevalence of *Salmonella* spp. in dogs with CPV infection was not statistically different from that in a healthy cohort. However, the prevalence in both groups was considerably higher than those previously reported (0–3.6%), yet similar to that reported for shelter dogs or dogs fed a raw diet (30–69%). This is the first report of the prevalence of CD and *Salmonella* spp. in dogs in South Africa.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

W.J. Botha
University of Pretoria
Onderstepoort, South Africa

URL: [http://www.vin.com/doc/?id=8172906](http://www.vin.com/doc/?id=8172906)
**Risk Factors for *C. difficile* Carriage in Dogs and Associations with Clinical Disease**

C. Albuquerque; C. Millins; G. Douce; A. Ridyard; G. Mclaughlan
SAH, University of Glasgow, Glasgow, UK

*Clostridium difficile* is the most common cause of antimicrobial and hospital-associated diarrhoea in humans. Several risk factors have been identified for development of community-associated *C. difficile* infection in humans. Information about prevalence, strain types and risk factors for *C. difficile* carriage in dogs is scarce.

This prospective study aimed at quantifying the prevalence and strain types of *C. difficile* in dogs with and without diarrhoea presented to a small animal teaching hospital; and identifying risk factors for *C. difficile* carriage through retrospective analysis of the clinical histories.

Stool samples were collected from 199 dogs within 48 h of admission to the hospital. These included 52 dogs presented for investigation of diarrhoea and 147 dogs presented for reasons other than diarrhoea. At the time of sampling 24 of the dogs presenting for reasons unrelated to diarrhoea were found to have acute diarrhoea and were moved to the diarrhoeal cohort. The prevalence of *C. difficile* carriage in dogs in the diarrhoeal cohort was 25% (95% C.I. 16.6–35.8%, 19/76 samples culture positive) and in the non-diarrhoeal cohort was 13.8% (95% C.I. 8.8–21%; 17/123 samples culture positive). Dogs presented with chronic diarrhoea had a prevalence of *C. difficile* carriage of 34.8% (95% C.I. 18.8–55.3%, 8/23 samples culture positive) while dogs with acute diarrhoea had a prevalence of 17.2% (95% C.I. 7.7–34.7%, 5/29 samples culture positive). A number of ribotypes were detected and the predominate types identified. PCR testing of all ribotypes was carried out to detect alpha and beta toxins which are associated with clinical disease.

Epidemiological risk factors which were assessed included those associated with the dog's household environment including the number of pets and presence of elderly people or infants, individual animal information including age, gender, neutering status and clinical information on medical treatment including antibiotic administration and visits to a veterinary practice in the previous three months. This type of study has the power to provide evidence-based data to support clinical decision making in evaluating the significance of detecting *C. difficile* in a faecal sample in dogs with acute and chronic diarrhoea. It can also inform whether dogs carry similar or different ribotypes of *C. difficile* to humans, and their potential significance as a reservoir for human infection.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Albuquerque
SAH
University of Glasgow
Glasgow, UK

URL: [http://www.vin.com/doc/?id=8172907](http://www.vin.com/doc/?id=8172907)
The intestinal microbiota is thought to play a major role in the pathogenesis of intestinal disease. Antibiotics are commonly employed in the treatment of acute and chronic enteropathy, in some cases with the goal of eradicating specific pathogens. The aim of this study was to prospectively evaluate the impact of tylosin administration on specific bacterial components of the fecal microbiota.

Sixteen healthy pet dogs were randomly assigned to one of two groups in a double-blinded fashion: Eight dogs were given oral tylosin at 20 mg/kg while the other 8 dogs were administered a placebo capsule, each given q 12 h for 7 days. All dogs were maintained on their usual diet and a standardized fecal score (range: 1 to 7) was noted daily during drug administration. Fecal samples were collected on day 0 prior to drug administration as well as on days 7, 10, 21, and 63. Fecal samples were assessed using quantitative PCR for 7 bacterial taxa, belonging to the Firmicutes, Proteobacteria and Fusobacteria phyla. Relative abundance of *Clostridium perfringens* was also assessed pre- and post-treatment via qPCR. Parameters were compared using a Friedman's test, followed by Dunn's post-test. A p-value <0.05 was considered statistically significant.

None of the dogs in either group developed diarrhea, though significant changes were seen in the abundance of various bacterial taxa. Significantly decreased *Faecalibacterium*, *Clostridium hiranonis*, *Turicibacter* and *Fusobacterium* were observed in the fecal microbiota of dogs treated with tylosin at day 7. At 2 months post-tylosin cessation, 5 and 4 of 6 dogs failed to have regained their pre-treatment *Faecalibacterium* and *C. hiranonis* levels, respectively. Tylosin administration was not associated with a significant decrease of *C. perfringens* (p=0.38), but dogs in the placebo group had a significant decrease in *C. perfringens* (p=0.02). There was no significant change in relative abundance of *E. coli* in dogs treated with tylosin (p=0.64) or placebo (p=0.38).

Tylosin leads to alterations in the fecal microbiota without predictable effects of potential enteric pathobionts. Further studies are warranted to determine the long-term effects of antimicrobial-induced changes as well as the efficacy of recommended therapies for bacterial enteritis.

**DISCLOSURES**

Disclosures to report.

Some authors are employed by the Texas A&M GI lab which offers tests on a fee basis. The study was funded by grants from the Comparative Gastroenterology Society and Naniboujou Research Legacy.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**A.C. Manchester**
Colorado State University  
Fort Collins, CO, USA

URL: [http://www.vin.com/doc/?id=8172908](http://www.vin.com/doc/?id=8172908)
Vitamin D plays an important role in skeletal health in dogs. Due to the inability to cutaneously produce vitamin D, dogs are heavily reliant on dietary sources of vitamin D. We have previously shown that dogs with a protein losing enteropathy have significantly lower concentrations of the major vitamin D metabolite, 25 hydroxyvitamin D (25(OH)D). Furthermore, we have shown that serum 25(OH)D concentrations negatively correlate with extent of inflammation in dogs with a chronic enteropathy (CE). In addition, low vitamin D status has been found to be a negative prognostic marker in dogs with a CE.

Vitamin D influences cellular function by signalling through the vitamin D receptor (VDR). Despite the growing awareness of the potential impact gastrointestinal diseases have on vitamin D metabolism in dogs, little is known about the sites of VDR expression and whether intestinal inflammation influences VDR expression. The aim of this study was to define the non-skeletal tissues which express VDR in the dog and to investigate how extent of inflammation correlated with VDR expression in the small intestine.

Twelve non-skeletal tissues were collected prospectively from 6 dogs, euthanised for non-health related problems. These included stomach, duodenum, ileum, colon, skin, kidney, spleen, liver, mesenteric lymph node, heart and lung. VDR expression was assessed with immunohistochemistry using a Rat IgG VDR monoclonal antibody.

Thirty-five dogs diagnosed with a chronic enteropathy were prospectively enrolled and biopsies taken at endoscopy from the duodenum were evaluated for VDR expression with both immunohistochemistry and quantitative polymerase chain reaction (qPCR). Twenty-three control dogs were also prospectively enrolled without clinical signs of gastrointestinal disease.

The VDR was found to be highly expressed in the duodenum of all 6 control dogs. It was also found in the skin of these 6 dogs and in the majority of the kidney samples, and occasionally in spleen and ileum.

There was no statistical difference in the relative expression, by qPCR, of the VDR between dogs with chronic enteropathy and dogs not clinically affected. VDR expression was also not different between healthy and CE dogs when assessed by protein expression via immunohistochemistry scoring.

Our study has defined the tissues which express VDR in healthy dogs. The lack of down regulation of VDR expression in intestinal inflammation contrasts with humans and provides support for future studies which aim to investigate whether vitamin D and its analogues can be used to modulate intestinal inflammation in the dog.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.A. Cartwright
University of Edinburgh
Edinburgh, UK

URL: [http://www.vin.com/doc/?id=8172909](http://www.vin.com/doc/?id=8172909)
Serum Circulating MicroRNAs as a Marker for Canine Lymphocytic-Plasmacytic Inflammatory Bowel Disease

A.O. Konstantinidis1; T.S. Rallis1; M. Gazouli2; E. Legaki2; G.D. Brellou1; I. Savvas1; K.K. Adamama-Moraitou1; D. Pardali1; A.E. Jergens3; K. Allenspach3

1 Aristotle University of Thessaloniki, Thessaloniki, Greece; 2 School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 3 College of Veterinary Medicine, Iowa State University, Ames, IA, USA

MicroRNAs (miRs) are small, non-coding RNA molecules with gene regulatory function. MiRs appear to play a critical role in the pathogenesis of a variety of diseases in humans, including inflammatory bowel disease (IBD). Furthermore, recent studies suggest that miRs have altered expression profiles in the serum of humans with IBD, suggesting they could be promising non-invasive serum biomarkers.

The aim of the current study was to evaluate the expression of a selection of serum circulating miR-16, miR-21, miR-122, miR-146a, miR-147, miR-185, miR-192 and miR-223 in canine lymphocytic-plasmacytic (LP) IBD based on published data on human IBD.

Serum samples were collected from 21 dogs diagnosed with active LP IBD. All dogs had undergone upper and/or lower GI endoscopy according to clinical signs, were diagnosed histopathologically according to the guidelines of the WSAVA International Gastrointestinal Standardization Group (Washabau et al. 2010) and by clinical exclusion diagnosis. In addition, serum samples were available from 14 clinically healthy control dogs for comparison. Total RNA from serum was isolated using Trizol, and reverse transcribed into cDNA. The expression of serum miRs genes was measured using real-time quantitative reverse transcriptase polymerase chain reaction (real-time qRT-PCR). Clinical disease activity was recorded for all dogs using the Canine Chronic Enteropathy Clinical Activity Index (CCECAI; Allenspach et al. 2008). Endoscopies were performed and graded according to the canine IBD endoscopic index (Slovak et al. 2014).

Compared to healthy controls, there was a significantly increased expression of the following miR in the serum of dogs: miR-16 (IBD: median 1.56, range 1.24–1.89, p<0.0005; controls: median 1.4, range 0.89–1.64), miR-21 (IBD: median 1.85, range 0.87–6.89; controls: median 1.54, range 0.37–2.18; p= 0.009), miR-122 (IBD: median 1.85, range 1.08–6.28; controls: median 1.49, range 1.02–2.21; p=0.012), miR146a (IBD: median 1.86, range 0.93–5.92; controls: median 1.575, range 1.33–2.33; p=0.016) and miR-147 (IBD: median 3.63, range 2.73–5.46, p<0.0005; controls: median 1.85, range 1.27–2.53, p<0.0005), as well as a significantly decreased expression of miR-185 (IBD: median 0.86, range 0.44–1.53, p<0.0005; controls: median 1.68, range 0.89–1.64, p<0.0005), miR-192 (IBD: median 1.56, range 1.24–1.89, p<0.0005; controls: median 1.4, range 1.19–2.3, p<0.0005) and miR-223 (IBD: median 0.54, range 0.32–0.96, p<0.0005; controls: median 0.9, range 0.62–1.68, p<0.0005).

This study shows that some circulating miRs are differentially expressed in the serum of dogs with LP IBD versus healthy dogs. Further studies are needed to evaluate the usefulness of these markers in the diagnosis and treatment of canine IBD.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.O. Konstantinidis
Aristotle University of Thessaloniki
Thessaloniki, Greece

URL: http://www.vin.com/doc/?id=8172910
Specific Virulence Factors in Mucosa-Associated *E. coli* of Dogs with Inflammatory Bowel Disease (IBD) are Associated with Survival

K. Allenspach1; F. Vessieres2; Y. Du1; D.D. Kingsbury1; F. Procoli2; C.M. Logue1; L.K. Nolan1; G. L1; K.W. Simpson3; J.P. Mochel1; A.E. Jergens1

1Iowa State University, Ames, IA, USA; 2Anderson Moores Specialty Practice, Winchester, UK; 3Department of Veterinary Clinical Sciences, Cornell University, Ithaca, NY, USA

Growing evidence suggests that resident *E. coli* play an important role in the pathogenesis of inflammatory bowel disease (IBD) across species. Among the genes that may contribute to *E. coli*'s role in the development of IBD are those typical of extraintestinal pathogenic *E. coli* (ExPEC). Here, we tested the hypothesis that mucosal *E. coli* harboring ExPEC virulence genes may drive inflammation in the small intestine of dogs with lymphoplasmacytic IBD and contribute to a more severe clinical presentation.

A comprehensive investigation of virulence genes in *E. coli* strains from dogs diagnosed with IBD was performed using a 17-panel multiplex PCR, targeting for 8 genes typical for human IBD-associated adherent and invasive *E. coli* [Group 1 genes: eaeH, irp2, fimH, ratA, fepC, colV, dsbA] and 9 genes more typically associated with ExPEC [Group 2 genes: cvaC, ompTp, hlyF, elaB, iss, aerJ, ereA, papC] (Johnson TJ J Microbiol. 2008). A cohort of 12 German Shepherd Dogs (GSDs) and 20 non-GSDs diagnosed with lympho-plasmacytic IBD on the basis of clinical signs, intestinal histopathology, and exclusion of other known causes of chronic gastro-intestinal signs was enrolled. *E. coli* was cultured from endoscopically collected biopsies using MacConkey and sheep blood agar, and identified using API20E (BioMérieux). Statistical analysis was performed using univariate linear mixed effect models and Fisher's exact tests for continuous and categorical variables, respectively. The following dependent variables were considered: i) clinical activity of disease (CCECAI; Allenspach K 2007), ii) histological severity score (WSAVA index; Day M 2008), iii) use of immunosuppressive agents, and iv) euthanasia due to intractable IBD or survival within 1 year after diagnosis. Results revealed that none of the tested virulence factors were significantly associated with the CCECAI index. However, one virulence factor from group 1 [colV: colicin V, antimicrobial peptide; p=0.03] had a significant effect on the WSAVA index. Two of the virulence genes typically associated with ExPEC (Group 2: ompTP: inactivates antimicrobials, and cvaC: secreted toxin resulting in cytolyis) were significantly associated with euthanasia due to intractable IBD (ompTP: OR: 19, cvaC: OR: 30, p=0.05), as well as an increased likelihood of having been treated with immunosuppressives (p=0.03). These data are reminiscent of reports on human ulcerative colitis cases harboring mucosal *E. coli* with multiple ExPEC virulence factors that were associated with clinical severity. Similarly, our data indicate that specific microbial factors may be important determinants and predictors of disease progression and survival in a sub-group of dogs with IBD.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

F. Vessieres

Anderson Moores Specialty Practice

Winchester, UK

URL: [http://www.vin.com/doc/?id=8172911](http://www.vin.com/doc/?id=8172911)
Identification of IgG4-Related Disease in the English Cocker Spaniel and Dogs of Other Breeds

M.F. Coddou1; F. Constantino-Casas1; B. Blacklaws1; T. Scase2; M.J. Day3; P.J. Watson1

1University of Cambridge, Cambridge, UK; 2Bridge Pathology Ltd., Bristol, UK; 3School of Veterinary Sciences, University of Bristol, Bristol, UK

Chronic pancreatitis (CP) is common in the English Cocker Spaniel (ECS), and is characterised histologically by duct destruction, interlobular fibrosis and dense periductular and perivenous lymphocytic aggregates. These changes are characteristic of human autoimmune pancreatitis type 1, part of a steroid-responsive, multi-organ syndrome, newly recognised as IgG4-Related Disease (IgG4-RD). Human IgG4-RD affects one or several organs, often showing a predominance of IgG4+ plasma cells histologically, with an IgG4+/total IgG+ plasma cell ratio >40%.

This study investigated whether ECSs with CP and inflammatory disease in several organs show an increase in IgG4+ plasma cells within affected tissues. Histological sections of pancreas (n=12), liver (n=10), kidney (n=12), salivary gland (n=4), anal sacs (n=9), and conjunctiva (n=2) were obtained from 37 ECSs with idiopathic chronic inflammatory disease affecting those tissues. Control samples were identified from 18 age-matched dogs of other breeds with chronic pancreatitis (n=6), chronic idiopathic hepatitis (n=2), chronic nephritis (n=6), anal sacculitis (n=5), chronic sialadenitis (n=2) or chronic conjunctivitis (n=1). Eleven ECSs and 6 control dogs presented with disease in more than one organ. Immunohistochemistry was performed for canine total IgG and IgG subclasses (IgG2, IgG3, and IgG4). Normal tissue sections were labelled as controls. The number of plasma cells was counted in three high power fields (400x). The number of IgG4+ cells and the percentage of total IgG+ plasma cells were compared between groups using Mann-Whitney U tests.

Nineteen sections from 17 ECSs and 11 sections from 10 controls showed elevated numbers of IgG4+ plasma cells and IgG4+/IgG+ ratios >40%. Individual dogs (ECSs and other breeds) showed marked increases in IgG4+ cells. There were no significant differences in numbers of IgG4+ plasma cells between ECSs and controls for affected pancreas, liver, anal sacs, salivary glands and conjunctiva. Anal sacs showed high numbers of total IgG and IgG4+ plasma cells. Kidney sections had more IgG4+ cells in both cases and controls than other organs. Dogs of other breeds had significantly more IgG4+ plasma cells in affected kidneys.

In conclusion, several ECSs and dogs of other breeds fulfilled the histological criteria for diagnosis of IgG4-RD, supporting the existence of a multi-organ immune-mediated disease in ECS and some other dogs. Strict inclusion criteria for controls with multi-organ inflammatory disease likely selected for dogs of other breeds with IgG4-RD. Anal sacculitis showed histological changes suggesting an immune-mediated aetiology. Future studies will focus on the immunology and treatment of the disease.

DISCLOSURES

Disclosures to report.

This study was financially supported by the Kennel Club Charitable Trust and the Cocker Spaniel Club.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.F. Coddou

University of Cambridge

Cambridge, UK

URL: http://www.vin.com/doc/?id=8172898
Correlating Gastrointestinal Histopathologic Findings to Clinical Disease Activity in Dogs with Inflammatory Bowel Disease

K. Allenspach¹; J. Mochel¹; D. Yingzhou¹; S. Priestnall²; F. Moore³; M. Slaytor³; A. Rodrigues⁴; M. Day⁵; M. Ackermann¹; M. Krockenberger⁷; J. Mansell⁵; W. Gi Standardization Group¹, J. Suchodolski⁵; N. Berghoff⁸; N. Luckschander⁹; A. Jergens¹

¹Iowa State University, Ames, IA, USA; ²Royal Veterinary College, London, UK; ³Marshfield Clinic, Marshfield, WI, USA; ⁴IDEXX, San Diego, CA, USA; ⁵Texas A&M University, College Station, TX, USA; ⁶University of Bristol, Bristol, UK; ⁷University of Sydney, Sydney, Australia; ⁸Michigan State University, Lansing, MI, USA; ⁹University of Vienna, Vienna, Austria

Diagnosis of canine inflammatory bowel disease (IBD) requires confirmation of histopathologic inflammation in intestinal biopsies. Different studies have found it difficult to correlate histopathologic findings with clinical disease severity due to a lack of consistency between pathologists when describing histopathologic changes and the questionable quality of specimens submitted for diagnostic evaluation. The WSAVA* GI standardization grading scheme (Day 2008) was an attempt to rectify some of these problems but even it is associated with poor agreement among pathologists. The aim of the present study was to utilize a new grading scheme for improved consistency of evaluation of GI histopathologic findings and to correlate these features to clinical disease activity in dogs with IBD.

Paraffin-embedded tissues from the stomach, duodenum, ileum, and colon of 70 healthy dogs and 163 IBD dogs were evaluated for histopathologic lesions using a simplified model for defining GI inflammation (Jergens 2013). Morphologic/inflammatory features were independently scored by 8 pathologists for total lesion scores for each GI organ and sub-scores within each organ. Clinical disease activity was calculated using CCECAI/CIBDAI scores. Pearson’s correlation coefficients were used to evaluate the association between clinical and histopathologic scores.

The estimated correlation between CCECAI/CIBDAI and total histology score was found to be significant (p<0.05) for duodenum (r=0.42, 95% CI=[0.08–0.65]) and colon (r=0.33, 95% CI=[0.04–0.57]). The correlation was borderline significant for ileum (p: 0.06, r=0.29, 95% CI=[-0.02–0.55]) but non-significant for stomach (p: 0.7, r=0.05, 95% CI=[-0.24–0.34]). In evaluating the relationship between histopathologic sub-scores and disease activity, the correlation was significant for: i) crypt dilation (p<0.001, r=0.52), ii) LP macrophages (p<0.01, r=0.34), iii) LP neutrophils (p: 0.03, r=0.28), iv) mucosal fibrosis (p<0.001, r=0.53), v) surface epithelium (p: 0.01, r=0.34), and vi) villus stunting (p: 0.002, r=0.43). The correlation to CCECAI/CIBDAI for colonic goblet cells, intraepithelial lymphocytes, LP eosinophils, LP lymphocytes, and lactic acid dilatation was non-significant. There was agreement between pathologists for total histology scores, while sub-scores for mucosal fibrosis and villus stunting differed significantly (p<0.05).

In conclusion, a simplified model for GI inflammation shows utility in correlating histologic features to clinical disease activity. Gastric biopsies would appear to be less clinically useful versus duodenal and colonic biopsies for defining intestinal inflammation in canine IBD.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

K. Allenspach
Iowa State University
Ames, IA, USA

URL: http://www.vin.com/doc/?id=8172899

J.S. Béguin¹; M. Manassero¹; M. Faucher²; V. Freiche¹

¹Université Paris Est, École Nationale Vétérinaire d’Alfort, Maisons-Alfort, France; ²Clinique Vétérinaire Alliance, Bordeaux, France

Balloon dilatation is the most commonly used therapy for esophageal strictures. The objective of this study was to assess outcome and complications of balloon dilatation and/or stenting for treatment of acquired esophageal strictures in dogs and cats.

Medical records were reviewed from animals presented with esophageal strictures that underwent endoscopic balloon dilatation or stenting. All cases were managed by the same clinician (VF). Values are expressed as percentage and median [interquartile range].

Twenty-four cases (19 dogs and 5 cats) were included. The median age was 6 years [2.7; 10.7] for dogs and 1 year [0.4; 4] for cats. Strictures resulted from recent anesthesia in 11 cases (45.8%). Other causes included foreign body (29%), toxic ingestion (10.4%), acute vomiting (6.2%) and one benign neoplasia (4.2%). Clinical signs reported by owners were regurgitation (24/24), vomiting (11/24), dysphagia (13/23), dysorexia or anorexia (10/22), ptyalism (6/23) and cough (6/24). Median duration of clinical signs prior to endoscopy was 15 days [10; 26]. Thirty-two strictures were identified at initial esophagoscopy. Seventeen animals had one stricture, six had two strictures and one had three strictures. Seven strictures (29.2%) were located within the cervical esophagus, 10 of 32 (41.6%) were in the mid-esophagus, and 15 of 32 (62.5%) were in the distal esophagus. The median stricture diameter was 4 mm [3; 8]. Annular strictures were observed in 21 of 32 stenosis (65.6%).

Balloon dilatation procedures were performed for 19/24 animals using a dilatator (Olympus®) with an inflated diameter of 10 to 12 mm. Median numbers of dilatation were 2 [1; 3]. Clinical improvement was noted for 15 cases. Perforation of the esophagus was the only complication (1/19). Stenting was considered for 6 animals (Boston Scientific® "Ultraflex" half covered stent in 2 cases and "Symphony" nitinol uncovered stent in 4 cases). Stent placement was considered for the last 4 refractory cases and as first-line treatment for 2 cases. Clinical improvement was observed in 5 of 6 cases. Complications included discomfort (1/6) and stent migration (1/6). Long-term follow up was available for 17 animals, median survival time was 730 days [100.7; 1368.7].

The limited number of cases precluded statistical analysis to determine the best treatment option. To the author's opinion, balloon dilatation remains a good first-line therapeutic modality. Esophageal stenting appears safe and effective for refractory cases or ductal strictures but needs to be compared to balloon dilatation in a prospective study on a more substantial number of cases.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Freiche
Université Paris Est
Ecole Nationale Vétérinaire d'Alfort
Maisons-Alfort, France

URL: http://www.vin.com/doc/?id=8172900
Gastric lymphoid follicular hyperplasia (GLFH) has been reported as highly prevalent in French Bulldogs (FB). However, screening for confounders was never performed. In humans and cats, an association between Helicobacter/ Helicobacter-like organism (HLO) infection and GLFH is recognized.

This study aimed to 1) confirm the association between GLFH and FB and 2) screen for confounders, especially regarding HLO presence.

A total of 288 client-owned dogs were included. Medical records of dogs that underwent gastroscopy between January 2013 and December 2015 were retrospectively reviewed. Two univariate analyses were performed in order to identify the association between signalment, clinical signs, endoscopic and histopathologic variables with GLFH and FB, respectively. Significant variables of both analyses were included in a multivariate analysis. Backward elimination was used to select the final model.

Variables associated with GLFH on univariate analysis included: FB (p=0.04), intact male (p=0.03), age (p<0.001), vomiting (p=0.03), discoloration (p=0.02), hemorrhage (p<0.001), ulcerations (p=0.004) on gastric endoscopy, and epithelial and lamina propria lymphocyte invasion (p<0.001) and HLO presence (p<0.001) on histopathology. Variables associated with FB on univariate analysis included intact male (p=0.005), age (p<0.001), vomiting (p<0.001), discoloration (p=0.001) and hemorrhage (p=0.01) on gastric endoscopy, and HLO presence (p=0.001) on histopathology. Final model included FB, age, vomiting, gastric hemorrhage and HLO presence. FB (p=0.87) and age (p=0.18) were no longer associated with GLFH on multivariate analysis. HLO colonization was associated with young age (p<0.001) but not with FB (p=0.1).

Although an association between HLO colonization and young age was identified, this study shows that GLFH is not more frequent in FB as it would be expected.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

M. Dominguez Ruiz
CHV Frégis
Arcueil, France

URL:  http://www.vin.com/doc/?id=8172901
A Retrospective Evaluation of Ileocecocolic Perforations Associated with Routine Diagnostic Lower Gastrointestinal Endoscopy in Dogs and Cats

V.L. Woolhead¹, J.C. Whittemore², R. Geddes¹, S.A. Stewart¹

¹Royal Veterinary College, North Mymms, UK; ²University of Tennessee, Knoxville, TN, USA

Colonic perforation is a known complication of ileocolonoscopy in human medicine. Most perforations are immediately detected during endoscopy; however, up to 40% are diagnosed 24 hours post-procedure. Recent veterinary studies documented that obtaining ileal biopsies can increase the diagnostic yield of gastrointestinal [GI] endoscopy for workup of diffuse intestinal diseases; therefore, this procedure is being conducted more frequently. Currently, there are no published cases in the veterinary literature documenting iatrogenic ileocecal [ICC] perforations or delayed diagnosis of endoscopic perforations. The purpose of the study was to identify iatrogenic ICC perforations in dogs and cats associated with lower gastrointestinal [LGI] endoscopy, including anatomical location of perforation, timing of diagnosis, risk factors and outcome. Canine and feline medical records from two university veterinary hospitals between 2012 and 2017 were retrospectively evaluated for cases with iatrogenic ICC perforation associated with diagnostic LGI endoscopy. Cases were included if full medical records, including histopathological reports, were available. Five ICC perforations associated with canine LGI endoscopy were identified; no feline endoscopic perforations were documented. All perforations occurred adjacent to the ICC valve; two were ileal and three colonic. Three perforations were immediately identified by visualisation of abdominal contents during endoscopy, and one perforation was suspected intra-procedure due to excessive abdominal distension and confirmed with demonstration of pneumoperitoneum on plain radiographs. Pneumoperitoneum was detected on abdominal ultrasound and radiographs in one dog 5 days post-endoscopy, following evaluation for lethargy and anorexia post procedure. All dogs underwent immediate surgical correction following diagnosis of perforation, with four patients surviving beyond discharge. Histopathology from the area of perforation revealed no significant underlying pathology. The patient with delayed diagnosis of perforation died as a consequence of complications from septic peritonitis following two surgical procedures. Patient signalment, adequacy of colonic preparation and visualization, method of ileal intubation (direct intubation versus scope advancement over biopsy forceps) and underlying GI pathology did not appear to contribute to risk of iatrogenic perforation. Recent publications suggest that ileal biopsies should be obtained in all patients undergoing diagnostic LGI endoscopy; however, clinicians should be aware that iatrogenic ICC perforation can occur in canine patients with minimal underlying GI pathology. Delayed diagnosis of ICC perforation was associated with a negative outcome; if patients become unwell within the days immediately following endoscopy, perforation should be rapidly excluded with abdominal radiography to screen for pneumoperitoneum.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V.L. Woolhead
Royal Veterinary College
North Mymms, UK

URL: http://www.vin.com/doc/?id=8172902
F. Da Riz; E. Laloy; G. Bencheckroun; V. Freiche
Université Paris Est, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, France

Pyloric stenosis (PSt) is a rare condition in cats and can be a diagnostic challenge as ultrasonography lacks specificity in this context. Few reports describe congenital PSt in young cats presented for chronic alimentary vomiting. A retrospective study conducted on 34 cases (ECVIM 2016) suggested that acquired PSt in cats, associated with inflammatory bowel disease (IBD) is probably an underdiagnosed feature. For the first time, a prospective study conducted on 22 cats (ECVIM 2016) measured the pyloric diameter (PD) by per-endoscopic assessment, using biocompatible graduated olives: PD was reported to be between 9 to 10 mm in 22 healthy cats.

The aim of this prospective study was to describe a cohort of cats with acquired PSt confirmed by per-endoscopic measurement. All procedures were performed by the same operator (VF), using a GIF, Olympus 180 8,8 mm diameter video-gastroscope. Group A included 15 cats with acquired PSt. Cats were included in group A if PD was less than 9 mm. The control group (group B) included 12 cats presented during the same period with a normal PD. Gastrointestinal biopsies were submitted for histologic analysis in all cats (including stomach, pylorus and duodenum, n=14). Signalment, clinical signs, endoscopic and histopathological findings were compared between both groups.

Age, sex and weight were similar between groups. Chronic vomiting was the most frequent clinical complaint in both groups (100% in group A, 67% in group B). Food vomiting occurred more frequently in group A (12/15) than in group B (6/12) but this was not statistically different. Endoscopic findings were consistent with mild gastritis in both groups. Oedema and hyperaemia were frequently noted around the pylorus in group A (8/15), less in group B (2/12). Median value of the PD in group A was 7 mm, which was statistically different from group B (9 mm; p <0,05; Wilcoxon/Mann-Whitney test). Histologic changes were non-specific (lymphocytic-plasmacytic infiltration of the gastric mucosa in 6 cats in group A, in 3 cats in group B). Pyloric fibrosis was found in 11/15 cats from group A and in 4/9 cats from group B.

Our results confirm that acquired pyloric stenosis can occur in cats suffering from IBD. Pathogenic mechanisms are not clearly understood but could imply mucosal scar pyloric fibrosis. This study should be pursued with inclusion of additional cases in each group in order to increase statistical power.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
F. Da Riz
Université Paris Est
École Nationale Vétérinaire d'Alfort
Maisons-Alfort, France

URL: http://www.vin.com/doc/?id=8172903
Poster Presentations

Factors Affecting Gastric Mucosal Barrier Function in Dogs  T.L. Hill
Evaluation of the Hemoccult® Faecal Occult Blood Test Kit in Cats  J.E. Slovak
Fecal Occult Blood Testing in a Presumed Healthy Population of Cats  J.E. Slovak
Specificity of SNAP fPLTM for the Diagnosis of Pancreatitis in Healthy Cats and Sick Cats Without Clinical Suspicion of Pancreatitis  P.G. Xenoulis
Metabolic and Clinical Follow-Up of Seven Inappetent Cats During Enteral Refeeding  M. Hugonnard
S100A12 and Myeloperoxidase as Possible Biomarkers for Intestinal Inflammation in Dogs  M. Hanifeh
Fasting and Postprandial Variations of Plasma TLI, Cobalamin and Folate Concentration in Healthy Beagle Dogs  F. Jolivet
Total Serum Magnesium and Cobalamin Concentration in 20 Cats with Inflammatory Small Bowel Disease or Small Intestinal Neoplasia  O.M. Ioannidi
Feasibility of Measuring Fecal Calprotectin Concentrations in Dogs and Cats by the fCAL® Turbo Immunoassay  R.M. Heilmann
Clinical Features of English Cocker Spaniels with Chronic Pancreatitis Mimic Human IgG4RD  P.J. Watson
Contrast-Enhanced Ultrasonography of the Duodenum in Dogs with Inflammatory Bowel Disease: Preliminary Findings  D. Caivano
Utility of Capsule Endoscopy as a Complement to Traditional Endoscopy  T.L. Hill
Serum Protein Profiling of 100 cats with Inflammatory Bowel Disease and Lymphoma  E. Benvenuti
Factors Affecting Gastric Mucosal Barrier Function in Dogs

T.L. Hill1; D. Lascelles2; M. Law2; I. Handel3; A.T. Blikslager2

1University of Georgia, Athens, GA, USA; 2North Carolina State University, Raleigh, SC, USA; 3University of Edinburgh, Edinburgh, UK

Gastroduodenal ulceration is a recognized complication of NSAID or corticosteroid therapy, liver disease, sepsis, and neoplasia. Retrospective studies indicate that male, middle-aged and large breed dogs are most commonly affected. Rottweilers were affected at younger ages. Helicobacter has been associated with chronic gastritis; its effect on gastric mucosal barrier function (GMBF) is unknown. Previous Ussing chamber ex vivo injury models have examined changes in GMBF that relate to ulcer injury in vivo. Identification of factors associated with GMBF, as measured by transepithelial electrical resistance (TER), could identify risk factors for gastroduodenal ulceration in vivo. In this prospective study, TER was measured in control and acid-injured canine tissue to determine factors associated with changes in GMBF. These included: age, sex, neuter status, breed (large/small), and presence/degree of Helicobacter infection.

Canine gastric mucosa was collected immediately post-mortem from random-source dogs scheduled for euthanasia by an animal control facility. Acidic Ringer's solution (pH 1.2) was applied to the mucosa for 45-minutes. Tissue from each dog was also maintained at neutral pH Ringer's solution as control. GMBF was assessed using TER. Age, gender, neuter status, breed (large versus small breed) and presence/degree of Helicobacter infection were correlated with baseline TER, change in control TER over time, change in TER with acid injury, and recovery of TER after acid injury. T-tests or Mann-Whitney Rank Sum tests were used to compare gender, neuter status, breed (large versus small) and presence of Helicobacter with TER based on normality. Helicobacter infection was correlated with TER using Spearman rank correlation. Age was compared to TER using linear regression. Multiple linear regression identified predictive factors. Significance was set at p<0.05.

Female dogs and neutered dogs had a higher baseline TER (p=0.025, 0.028). Higher age was associated with decreased recovery from acid injury (p=0.011). Helicobacter and breed size were not associated with changes in TER. Sex and neuter status were predictive of baseline TER; age was predictive of recovery from acid injury.

This study demonstrated factors associated with decreased GMBF either at baseline or with injury. Elevated baseline TER in female dogs may support previously reported male sex predilection. Because most of the dogs in the current study were young to middle-aged, decreased recovery of injured mucosa may support previous findings of predilection for middle-aged dogs to develop ulcers. Further work is needed to determine if these factors are relevant in vivo and to determine overall prevalence of disease.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T.L. Hill
University of Georgia
Athens, GA, USA

URL: http://www.vin.com/doc/?id=8172913
Evaluation of the Hemoccult® Faecal Occult Blood Test Kit in Cats
J.E. Slovak; K. Spies; N. Villarino
College of Veterinary Medicine, Washington State University, Pullman, WA, USA

Fecal occult blood (FOB) testing provides a quick and easy way to screen patients for gastrointestinal bleeding. The sensitivity of the Hemoccult® FOB test kit has been recently evaluated for use in cats fed canine packed red blood cells. However, the development time for test interpretation and the limit of detection of fresh whole blood in a given stool sample has not yet been reported. Our goal was to determine the limit of detection of whole blood in a feline stool sample, as well as determine the most accurate time to assess the FOB sample utilizing the Hemoccult® testing kit in a population of cats.

Stool from recently dewormed, healthy, indoor cats were enrolled in the study. Two grams of stool from 3 separate cats that tested negative on the Hemoccult® FOB test were utilized as sample controls. Incremental quantities of EDTA whole blood (1–200 µl) were added to the 6 gram pooled stool controls. The stool samples were set up in triplicate and interpreted for each of the following time points; fresh, 24, 48, and 72 hours. The lowest repeatable and reliable quantity of blood detected in the stool at all time points was 50 µl of blood. However, as little as 2 µl of blood was detected in all control samples at fresh, and 24 hours. A minimum of 6 grams or 0.2 ounces of stool should be collected to detect 50 µl of blood in a stool sample. Additionally, results are repeatable when FOB tests are interpreted as fresh, 24, 48, and 72 hours post set-up. FOB testing is a fast non-invasive diagnostic tool to screen for low levels of blood in the stool of cats.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.E. Slovak
College of Veterinary Medicine
Washington State University
Pullman, WA, USA

URL: http://www.vin.com/doc/?id=8172920
Fecal occult blood (FOB) testing, can be a useful screening test for cats. Unfortunately, there is limited information on using human point-of-care tests in our feline patients. There are no recent published reports of clinical FOB tests used as surveillance for disease in a population of cats.

Our goal was to perform FOB testing using the human point-of-care test Hemoccult®, on healthy cats to screen for potential subclinical disease. Fresh stool samples were collected from the litterbox within 12 hours of defecation for sample testing at three separate time points. All cats were presumably healthy, recently dewormed, and individually housed, ranging in age from 6 weeks to 5 years. A total of 30 stool samples from 18 cats were analyzed.

The stool from each cat at each time point was tested in triplicate using the Hemoccult® FOB test kit. Test interpretation was performed as fresh, 24, 48, and 72 hours after the FOB test was set-up. Nine stool samples were positive (30%) when tests were interpreted as fresh. Only 4 or (13%) of samples remained positive at subsequent test interpretation at 24, 48, and 72 hours. The fresh positive stools were from 6 different cats. The subsequent positive stools were from 2 different cats, one of which was later diagnosed with ulcerative stomatitis and the other, a kitten, with significant parasitism.

When used as a screening test, the Hemoccult® FOB test detected a positive result in 30% of the studied patient population when interpreted as a fresh sample. However, when the test was interpreted at 24, 48, and 72 hours post set up, the positive results were only 13% of the patient population. The FOB test is a useful screening test in cats. Repeated testing is recommended to differentiate transient from active bleeding.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.E. Slovak
College of Veterinary Medicine
Washington State University
Pullman, WA, USA

URL: http://www.vin.com/doc/?id=8172921
Specificity of SNAP fPLTM for the Diagnosis of Pancreatitis in Healthy Cats and Sick Cats Without Clinical Suspicion of Pancreatitis

P.G. Xenoulis; M.K. Chatzis; K. Kokkinaki; E.M. Stavroulaki; M.N. Saridomichelakis
University of Thessaly, Karditsa, Greece

Clinical diagnosis of pancreatitis in cats is challenging. Clinical signs are non-specific, and most available serum tests, including serum amylase and lipase activities and feline trypsin-like immunoreactivity (fTLI) lack specificity and/or sensitivity in this species. Serum specific feline pancreatic lipase (Spec fPL) is currently the most useful serum test for pancreatitis in cats. Based on this test, a rapid, in-clinic, semi-quantitative test for the estimation of fPL (SNAP fPLTM) in serum has been developed. Currently, no studies have evaluated the sensitivity and specificity of this tool for pancreatitis in cats. The aim of this study was to evaluate the specificity of SNAP fPL in two groups of cats: a) healthy cats and b) sick cats without clinical suspicion of pancreatitis.

A total of 196 cats were included in the study. Of them, 105 were clinically healthy (based on history and physical examination) and 91 cats were sick. The group of sick cats consisted of cats with a wide variety of diseases, for which pancreatitis was not considered a major differential or for which a final diagnosis other than pancreatitis that would explain the clinical signs was available. Whole blood was collected from all cats, and serum was separated and stored until analysis. The SNAP fPL test was performed and interpreted according to the manufacturer's instructions. Specificity was calculated for each group of cats separately and for both groups combined.

A total of 8 of the 196 cats (4.1%) were found to have an abnormal SNAP fPL result. All 8 cats belonged to the group of sick cats. The specificity of SNAP fPL was 100% and 91.2% among healthy and sick cats, respectively, with an overall specificity of 95.9%.

The SNAP fPL test has a high specificity for pancreatitis in both healthy cats and sick cats without clinical suspicion of pancreatitis. An abnormal SNAP fPL result is not always indicative of pancreatitis and should be followed by quantitative analysis. In addition, due to the lack of histopathologic examination of the pancreas, subclinical pancreatic inflammation cannot be excluded in any of the 8 cats with abnormal SNAP fPL results. Further studies are needed to evaluate the specificity of this diagnostic tool in cats with clinical signs compatible with pancreatitis but no histopathologic evidence of pancreatitis.

DISCLOSURES

Disclosures to report.
1) Dr. Xenoulis has presented lectures sponsored by IDEXX Laboratories in the past. 2) The SNAP fPL tests were provided by IDEXX but had no involvement in the design of the study or the interpretation of the results.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P.G. Xenoulis
University of Thessaly
Karditsa, Greece

URL: http://www.vin.com/doc/?id=8172922
Refeeding after starvation can lead to a range of fluid, electrolyte and hematologic shifts associated with metabolic abnormalities that is called "refeeding syndrome" in humans. Refeeding syndrome is not well documented in cats.

A prospective study was conducted on ill cats hospitalized in an internal medicine service who had inadequate food intake for more than three days and were refeed with enteral feeding. The objective was to follow clinical and biological parameters known to be modified in refeeding syndrome during the first five days of enteral refeeding. An initial nutritional assessment was done for each cat. Sodium, phosphorus, potassium, ionized calcium, magnesium, glucose, insulin, albumin, haematocrit, creatine kinase, cardiac troponin I and serum amyloid A were evaluated at the time of feeding tube placement, and then after three and five days of refeeding. Physiological parameters were recorded twice a day. A daily weight was done. A nutritional plan based on the nutritional assessment was implemented for each cat.

From February 2015 to December 2015, 16 cats were recruited. Seven cats completed the study (stress precluded adequate blood sampling in six cats, one cat removed the feeding tube before day 5, two cats died). The seven cats were 9.3±3.8 years old. Six cats were anorectic from three to seven days, one cat was dysorexic for three months. Two cats with a hepatic lipidosis were considered at risk to develop a refeeding syndrome. One of them with a three-month history of dysorexia, icterus and marked emaciation at admission developed at day 3 of refeeding severe electrolyte shifts (marked hypokalaemia and hypomagnesaemia, moderate hypophosphatemia), aggravation of anaemia, acute elevation of creatine kinase activity and bilirubinemia concomitantly with respiratory distress, vomiting, muscle weakness and hypotension. He was strongly suspected of refeeding syndrome. None of the six other cats developed clinical signs or remarkable biological abnormalities potentially linked with refeeding. Glycaemia and insulinaemia were consistently higher on day 3 and 5 than on day 0 on all cats. Mild to moderate hypophosphatemia was documented in 4/6 cats, mild hypokalaemia in 2/6 cats and mild hypomagnesaemia in 1/6 cats.

In this pilot study, significant combined biological abnormalities suspected to be linked with refeeding were observed in 1/7 cats. A careful nutritional plan and an adequate electrolyte supplementation are critical to avoid refeeding complications. Strongly debilitated cats could be at risk to develop complications despite adequate precautions.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Hugonnard
VetAgro Sup
Campus Vétérinaire de Lyon
Marcy l'Etoile, France

URL: http://www.vin.com/doc/?id=8172923
S100A12 and myeloperoxidase (MPO) are considered inflammatory markers of chronic enteropathy (CE) and mainly originate from granulocytes. Increased concentrations of canine S100A12 (cA12) in feces and serum were found in dogs with CE. Intestinal mucosal MPO activities have been reported to be increased in humans with inflammatory bowel disease (IBD) and also in animal models of human IBD. However, intestinal mucosal cA12 and MPO have not been investigated in dogs with CE.

We evaluated the levels of mucosal cA12 and MPO in dogs with CE in comparison with healthy dogs using an enzyme-linked immunoassay and a spectrophotometric method, respectively. Additionally, we assessed the association of mucosal cA12 and MPO levels with the canine clinical IBD activity index (CIBDAI), histopathologic findings, clinical outcome, and serum albumin concentration. Intestinal mucosal biopsies were collected from 40 dogs with CE (duodenum \( n=35 \), ileum \( n=12 \), colon \( n=15 \), and caecum \( n=6 \)). Historical intestinal tissue samples from 18 healthy beagle dogs served as controls (duodenum, ileum, and colon \( n=18 \), each and caecum \( n=6 \)). Data are presented as medians (interquartile range).

In comparison to healthy controls, mucosal cA12 concentrations in CE-dogs were higher in duodenum \( (43.93 \ [23.62–78.03] \ vs. \ 11.86 \ [7.66–29.1] \ \mu g/L; \ p<0.0001) \) and colon \( (63.04 \ [33.53–211.53] \ vs. \ 15.94 \ [6.95–59.3] \ \mu g/L; \ p<0.001) \). Mucosal MPO activities of CE-dogs were higher than in control dogs in duodenum \( (1.3 \ [0.77–2.16] \ vs. \ 0.41 \ [0.11–0.64] \ \Delta A/min; \ p<0.0001) \), ileum \( (1.91 \ [0.72–2.83] \ vs. \ 0.75 \ [0.21–1.27] \ \Delta A/min; \ p<0.01) \), colon \( (1.46 \ [0.57–3.01] \ vs. \ 0.09 \ [0.03–0.17] \ \Delta A/min; \ p<0.0001) \), and caecum \( (0.68 \ [0.3–1.55] \ vs. \ 0.19 \ [0.08–0.4] \ \Delta A/min; \ p<0.05) \).

Mucosal cA12 concentrations showed a significant association \( (p<0.05) \) with severity of macrophage infiltration in the duodenum and total histopathologic injury and epithelial injury in the colon. Mucosal MPO activities showed a significant association \( (p<0.05) \) with severity of total histopathologic injury, epithelial injury, and eosinophil infiltration in the duodenum. Duodenal cA12 concentrations showed a strong negative correlation with serum albumin concentration \( (r=-0.449; \ p=0.007) \). There was no significant association between mucosal cA12 and MPO levels with CIBDAI or clinical outcome.

This study showed that both mucosal cA12 concentrations and MPO activities are increased in the duodenum and colon of dogs with CE, with mucosal MPO being also increased in the ileum and caecum. The results provide supporting evidence for the possible diagnostic value of cA12 and MPO for dogs with CE.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

M. Hanifeh
University of Helsinki
Helsinki, Finland

URL: http://www.vin.com/doc/?id=8172924
Fasting and Postprandial Variations of Plasma TLI, Cobalamin and Folate Concentration in Healthy Beagle Dogs

F. Jolivet1; B. Rannou2; J. Dahan1; D. Concordet3; O. Dossin1
1Ecole Vétérinaire, Toulouse, France; 2Laboratoire de Biologie Médicale, VetAgro Sup, University of Lyon, Lyon, France; 3TOXALIM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France

Trypsin-like immunoreactivity (TLI), cobalamin and folate are frequently measured in canine gastrointestinal disorders. However, the effects of preanalytical conditions on canine TLI, cobalamin and folate have not been clearly documented. This study evaluated the circadian variations of canine TLI, cobalamin, and folate concentrations in fasted and postprandial conditions.

Plasma TLI, cobalamin, and folate concentrations were measured after 12 hours of fast (Time 0), every 2 hours for 12 hours and at 24 hours in 8 healthy dogs. The same protocol was repeated after feeding after T0 samples. TLI, cobalamin and folate were measured by immunoassays validated in dogs (Siemens). Changes of TLI, cobalamin and folate were evaluated with a generalized linear model and Dunnett post hoc test.

Mean±SD circadian TLI concentrations in fasted dogs varied between 13.8±4.3 and 21.3±7.7 ng/mL and were significantly lower than T0 (p<0.01) at 2, 4, 6, 10, and 12 hours. In contrast TLI concentrations were not affected by feeding. Folate concentrations had no circadian variation in fasted dogs but were above the upper limit of quantification (24 ng/mL) in most time points after feeding. Mean fasted circadian cobalamin concentrations varied between 466±134 and 559±170 pmol/mL and were significantly different from T0 at 6, 8, 10, 12, and 24 hours (p<0.01). At 4, 6, 8, 10, and 12 hours post-feeding, cobalamin concentrations were significantly lower than at T0 (p<0.01).

Plasma TLI and cobalamin concentrations have significant circadian variations in fasted dogs. Plasma cobalamin is significantly decreased for 12 hours after feeding but plasma TLI remains unchanged.

DISCLOSURES

Disclosures to report.
Benoit Rannou is an employee of the Laboratoire de Biologie Médicale, VetAgro Sup, University of Lyon, France where the sample TLI, cobalamin and folates measurements were performed.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
F. Jolivet
Ecole Vétérinaire
Toulouse, France

URL: http://www.vin.com/doc/?id=8172925
Total Serum Magnesium and Cobalamin Concentration in 20 Cats with Inflammatory Small Bowel Disease or Small Intestinal Neoplasia

O.M. Ioannidi; F.C. Fragkou; A.O. Konstantinidis; D. Pardali; T.S. Rallis
Aristotle University of Thessaloniki, Thessaloniki, Greece

Magnesium is the second most abundant intracellular cation. Magnesium concentration is predominantly regulated by ileum absorption and renal excretion. In human medicine hypomagnesaemia may accompany inflammatory small bowel disease (IBD), affecting treatment and prognosis. The aim of this study was to evaluate total serum magnesium (tMg) and cobalamin (CBL) concentrations in cats with IBD and small intestinal neoplasia (IN) and to reveal possible correlations.

Thirty-two client owned cats were included in this study. Twelve clinically healthy cats had comprised the control group, 13 cats histopathologically diagnosed with lymphocytic-plasmacytic IBD and 7 cats with IN (5 small intestinal lymphoma, 2 small intestinal adenocarcinoma). Blood serum tMg concentration was measured by atomic absorption using the Perkin-Elmer, A Analyst 100, while serum CBL was measured by direct chemiluminescence technology using the ADVIA Centaur, Siemens.

Mean (SD) tMg serum concentration was 2.2 (0.3) mg/dL (median: 2.2 mg/dL, range: 2–3.1 mg/dL) in the control group, 2.34 (0.33) mg/dL (median: 2.3 mg/dL, range: 2.1–3 mg/dL) in the IN group and 2.05 (0.35) mg/dL (median: 2 mg/dL, range: 1.3–2.9 mg/dL) in the IBD group. Mean (SD) CBL serum concentration was 838 (306) pg/ml (median: 795 pg/ml, range: 494–1429 pg/ml) in the control group, 358 (204) pg/ml (median: 402 pg/ml, range: 130–572 pg/ml) in the IN group and 445 (314) pg/ml (median: 420 pg/ml, range: 114–1176 pg/ml) in the IBD group.

Kruskal-Wallis test indicated that there was a statistically significant effect of group on the median tMg values, $\chi^2(2)= 7.089$, $p=0.029$, but the Mann-Whitney test after conducted the Bonferroni-Dunn correction did not find significant differences among the three groups. Also, correlation between tMg and CBL groups was non-significant, $r(24)=0.3$, $p=0.155$.

Although there was a significant difference in the concentration of serum tMg among the three groups, statistical analysis failed to verify a correlation between tMg and CBL concentrations. This could be attributed to the limited number of animals.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

O.M. Ioannidi
Aristotle University of Thessaloniki
Thessaloniki, Greece

URL: http://www.vin.com/doc/?id=8172926
Oesophageal neoplasia has been reported in dogs with regurgitations but only anecdotal case-reports describe megaesophagus associated with gastroesophageal junction (GEJ) neoplasia. This retrospective case series reports 7 cases of megaesophagus associated with GEJ neoplasia in dogs. Median (range) age and weight at presentation were 12 (10–14) years and 26 (19–29.3) kg, respectively. All cases were medium to large breed dogs. Duration of clinical signs ranged from 3 days to 3 months with clinical signs including regurgitations (7), weight loss (6), cough (4), polydipsia (3), ptyalism (2), lethargy (2), cachexia (2), and increased lung sounds (2). Plain thoracic radiographs showed a megaesophagus (7), a soft-tissue opacity within the caudal oesophagus (3), and signs of aspiration pneumonia (2). GEJ mass was confirmed by contrast oesophagogram in two dogs. Transabdominal ultrasonography of the GEJ was performed in 6 dogs and was abnormal in 5 dogs. Endoscopy performed in 4 cases revealed a protruding mass in all cases. CT imaging performed in 3 cases showed a mass at the GEJ. One dog was treated by GEJ stenting, resulting in resolution of clinical signs; this dog is still alive. Six dogs were euthanized before diagnosis or lost to follow-up. Biopsies of the oesophageal masses were obtained endoscopically (2), surgically (1) or after necropsy (3) and revealed oesophageal leiomyoma (3) and leiomyosarcoma (1) but the endoscopic samples were non-diagnostic. Considering that long term survival is possible, this case series emphasizes the importance of using additional imaging diagnostic procedures before diagnosing idiopathic megaesophagus.

DISCLOSURES

Disclosures to report.
The residency program of Dr V. Fabres is partly financed by Royal Canin. Unrelated to the subject matter of the abstract.

SPAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Fabres
National School of Alfort
Maisons-Alfort, France

URL: http://www.vin.com/doc/?id=8172914
Calprotectin, also referred to as the S100A8/A9 protein complex, is involved in acute and chronic inflammatory responses. Fecal calprotectin concentrations have been demonstrated to be increased in dogs diagnosed with inflammatory bowel disease (IBD) and to decrease with successful treatment. Fecal calprotectin concentrations in dogs with IBD were also correlated with the severity of clinical signs, microscopic inflammatory lesions in the small intestine, and the need for more aggressive (i.e., anti-inflammatory/immunosuppressive) treatment (cut-off concentration: 15 μg/g). In-house canine calprotectin assays were found to also reliably measure calprotectin in feline samples. Given the lack of wide availability of the in-house canine calprotectin assay, the aim of the study was to assess the feasibility of measuring fecal calprotectin concentrations in dogs and cats by the commercial fCAL® turbo immunoassay used routinely for the diagnosis and monitoring of IBD in human medicine.

Fecal samples were obtained from 58 animals (45 dogs and 13 cats) with acute or chronic gastrointestinal disease (n=29), other diseases (n=11), and clinically healthy individuals (n=18). Fecal samples were collected into the CALEX® Cap stool extraction device, extracted at a 1:500 dilution, and stored frozen until analysis using the commercial fCAL® turbo particle-enhanced turbidimetric immunoassay. Statistical analysis was performed by a non-parametric (unpaired) group comparison, with statistical significance set at p<0.05.

Fecal calprotectin concentrations ranged from 0–3,468.5 μg/g (median: 18.9 μg/g) in this study, with a fecal calprotectin concentration of <10 μg/g in 28 (48.3%) animals, 10–50 μg/g in 8 (13.8%), 50–200 μg/g in 13 (22.4%), and >200 μg/g in 9 (15.5%). Significantly higher concentrations of fecal calprotectin were detected in dogs with acute or chronic gastrointestinal diseases (median: 89.7 μg/g; n=21) compared to healthy controls and patients with diseases not localized to the gastrointestinal tract (median: 0 μg/g; n=24; p=0.0017). Fecal calprotectin levels were also higher in cats with acute or chronic gastrointestinal diseases (median: 49.7 μg/g; n=8) compared to healthy controls and cats with conditions not localized to the gastrointestinal tract (median: 2.9 μg/g; n=5), but the difference did not reach significance (p>0.05).

These results suggest that the fCAL® turbo immunoassay can detect fecal calprotectin in dogs and cats and can separate those animals with gastrointestinal diseases from healthy controls. An assay validation is currently underway and will allow further studies on the clinical utility of the assay for fecal calprotectin in dogs and cats with gastrointestinal diseases.

DISCLOSURES

Disclosures to report.

Drs. Gabris, Kock, and Niederberger are employed by Bühmann Laboratories AG where the fCAL® turbo immunoassay is offered on a fee-for-service basis.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.M. Heilmann
University of Leipzig
College of Veterinary Medicine
Leipzig, Germany

URL: http://www.vin.com/doc/?id=8172915
Clinical Features of English Cocker Spaniels with Chronic Pancreatitis Mimic Human IgG4RD

P.J. Watson¹; M.F. Coddou¹; F. Capaldo¹; J. Bazelle²; F. Constantino-Casas¹; B. Blacklaws¹; J. Archer¹

¹University of Cambridge, Cambridge, UK; ²Davies Veterinary Specialists, Higham Gobion, UK

English Cocker Spaniels (ECS) suffer from a distinctive form of chronic pancreatitis (CP) associated with large numbers of duct and vein-centred T-lymphocytes on histology. Recent studies show a predominance of IgG4 positive plasma cells on immunohistochemistry in affected dogs, suggesting a disease similar to human IgG4-related disease (IgG4-RD). IgG4-RD typically affects older men and multiple organs, particularly causing inflammatory mass lesions in the pancreas and dry eye, dry mouth and glomerulonephritis. We recognized a similar spectrum of diseases in ECSs presenting to our centre with CP and observed an over-representation of roan dogs. The aim of this study was to describe the clinical features of these ECS.

ECSs with CP presenting to the QVSH between December 2011 and March 2017 were recruited. CP was diagnosed either with pancreatic histology (n=2) or with both elevated cPLI and abnormal pancreatic ultrasound (n= 9, of which one had positive fine needle aspirate cytology). Case records were searched for details of signalment, clinical and clinicopathological findings, particularly evidence of keratoconjunctivitis sicca (KCS); xerostomia; proteinuria or other immune-mediated diseases.

Twenty ECS presented with suspected CP but only 12 dogs fulfilled the strict inclusion criteria. There were 8 females and 4 males. Median age was 9 years (range 4.3 years–14 years). Six out of 10 dogs were blue roan and 1/10 was orange roan. All dogs had gastrointestinal signs and pain. Seven out of 10 dogs where tears were checked had KCS. Six out of 7 cases had dry oral mucous membranes suggesting xerostomia; 8/11 dogs had proteinuria (urine protein:creatinine ratio range 0.7–8.3). Four cases had UPC <2 but in 2/4 cases it increased >2 on subsequent visits. Glomerulonephritis was confirmed post mortem in one dog. Two dogs had atopy; one had inflammatory bowel disease and one had pemphigus foliaceus. Three dogs had biliary tract disease. One dog had epilepsy and two dogs developed intervertebral disc disease. Three dogs had large mass lesions in the pancreas which resolved on symptomatic treatment.

CP in ECSs shows remarkable clinical similarities to human IgG4-RD with a high prevalence of KCS, xerostomia, proteinuria and other immune-mediated diseases. Affected dogs can present with benign mass-like pancreatic lesions. The disease appears to be more common in blue roan dogs.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P J Watson
University of Cambridge
Cambridge, UK

URL: http://www.vin.com/doc/?id=8172916
Inflammatory bowel disease (IBD) commonly causes chronic diarrhea in dogs. Diagnosis is often challenging and relies on results of subjective clinical indices, gastrointestinal endoscopy and histopathological assessment of intestinal mucosal biopsies. In humans, contrast-enhanced ultrasonography (CEUS) can quantify intramural intestinal perfusion and correlates with disease severity in Crohn’s disease.

We sought to evaluate the feasibility of, and describe perfusion patterns of CEUS in the duodenum of dogs affected by IBD. We hypothesized that CEUS would demonstrate changes in the perfusion of inflamed duodenum and provide additional information in the diagnosis of canine IBD.

We prospectively enrolled seventeen dogs with IBD (based on Canine Inflammatory Bowel Disease Activity Index-CIBDAI, endoscopic evaluation and histopathological assessment of duodenal mucosa samples). Each dog was placed in left lateral recumbency and the cranial portion of the duodenum was imaged in a transversal plane. Before the endoscopy, each dog received two boluses (0.03–0.06 ml/kg IV) of contrast agent (SonoVue®, Bracco, Italy): first, while conscious and then after being anesthetized (using the same anesthetic protocol). Duodenal enhancement patterns were first evaluated qualitatively, then quantified using dedicated software (Qontrast®, Bracco, Italy).

In all dogs, the duodenal vascularization pattern was characterized by an initial rapid enhancement of the submucosal layer, followed by a gradual enhancement of the mucosa. Serosa and muscularis propria showed poor enhancement. We identified 2 patterns at peak enhancement: (A) complete enhancement of the submucosal and mucosal layers without subjective demarcation between the wall layers; (B) incomplete enhancement of the mucosal layer that had a non-homogeneous, pointed, or streaked appearance. Dogs had similar perfusion patterns whether conscious or anesthetized. We quantitatively analyzed enhancement only in anesthetized dogs because of improved image quality. Analysis revealed a 50% reduced peak enhancement intensity, reduced regional blood flow and reduced regional blood volume in dogs with CIBDAI scores >6 (n=4). These dogs all showed the non-homogeneous, pointed or streaked pattern. However, we found no relationship between perfusion patterns/parameters and endoscopic or histopathological findings.

Our study demonstrates that CEUS of the duodenum in dogs is feasible, and highlights the presence of different vascular patterns and contrast-enhancement features in dogs with IBD. Our findings showed some association with dogs that had higher clinical grades of IBD, but did not correlate with histopathological findings. Our study offers a novel, non-invasive imaging modality for the diagnosis and monitoring of canine IBD.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

D. Caivano
University of Perugia
Perugia, Italy

URL: http://www.vin.com/doc/?id=8172917
Utility of Capsule Endoscopy as a Complement to Traditional Endoscopy

T.L. Hill\textsuperscript{1}; J. Pomrantz\textsuperscript{2}; J. Solomon\textsuperscript{2}

\textsuperscript{1}University of Georgia, Athens, GA, USA; \textsuperscript{2}Infiniti Medical LLC, Menlo Park, CA, USA

Capsule endoscopy (CE) has a number of advantages over traditional endoscopy (TE): it allows for assessment of mucosal abnormalities of the entire gastrointestinal tract and can be performed in conscious dogs. CE has been described in dogs as a method to evaluate for gastrointestinal mucosal lesions. CE may be a valuable tool in reassessment of dogs that previously were evaluated by TE. This study describes the use of capsule endoscopy (CE) in dogs following traditional endoscopy (TE). Ten dogs were retrospectively identified that received CE within 6 months of TE (range 0–151 days). Seven dogs received CE for assessment of suspected gastrointestinal hemorrhage; CE detected gastrointestinal mucosal lesions in the stomach and jejunum (n=2), diffusely throughout SI and colon (n=2), jejunum (n=1), ileum (n=1), and colon (n=1) that were not detected with TE. Three dogs received CE to assess lack of response to therapy in dogs with chronic enteropathy. In these dogs, CE detected persistent gastric erosions and duodenal mucosal changes seen previously with TE; in 2/3 dogs, CE also identified lesions in additional locations not seen with TE. CE detected gastrointestinal mucosal lesions not detected by TE in 9/10 dogs. Though further investigation is needed, CE appears to be a complementary and informative technique in the management of dogs with chronic GI signs that have undergone TE.

DISCLOSURES
Disclosures to report.
Jill Pomrantz is an employee of Infiniti Medical LLC. Jeff Solomon is an equity holder of Infiniti Medical LLC.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T.L. Hill
University of Georgia
Athens, GA, USA

URL: http://www.vin.com/doc/?id=8172918
Serum Protein Profiling of 100 cats with Inflammatory Bowel Disease and Lymphoma

E. Benvenuti; E. Bottero; P. Ruggiero; A. Pierini; E. Magnanini; G. Lubas; V. Marchetti

1University of Pisa, San Piero a Grado (Pisa), Italy; 2Associazione Professionale Endovet, Rome, Italy

Inflammatory bowel disease (IBD) and lymphoma are common in middle-aged to older cats, associated with chronic vomiting, weight loss, and diarrhea, included in the chronic enteropathy (CE) disorder. In cats, hypoalbuminemia in CE is considered infrequent, but specific investigations about protein profile in these patients have been not published. The aim of this study was to evaluate serum protein profiling in cats with IBD and lymphoma, and to compare it with clinical symptoms, endoscopic assessments and histopathological diagnoses. FCEAI clinical index score, CBC, serum biochemical profile and urinalysis were evaluated in 100 cats affected by IBD and lymphoma. Endoscopy of upper and lower gastrointestinal tract was performed and a severity score from 0 to 3 was assigned based on WSAVA guidelines. Histopathological diagnosis was based on WSAVA guidelines. Total serum protein, serum protein agarose gel electrophoresis, and albumin-globulin ratio (A/G) were evaluated at time of diagnosis. Cats ranged from 1 to 17 years old (10 median), 46% were females and 93% were European shorthair. The histologic diagnosis was IBD (66%) and lymphoma (34%). The most common symptoms were vomiting (70%), weight loss (67%) and diarrhea (37%). Mean FCEAI score was 9.4±2.59. Mean serum total protein was 6.01±0.99 g/dL. Low total protein (5.04±0.63 g/dL) occurred in 41% of cats and only 10% had hypoalbuminemia. Beta globulins were decreased in 70% of cats, and gamma globulins were increased in 75% of cats. A/G ratio was significantly higher in cats with hypoproteinemia (1.1±0.3) compared to non-hypoproteinemic cats (0.9±0.1). No statistical differences between protein profile and symptoms, FCEAI, gastrointestinal tract concerned, endoscopic score, type and severity of histologic pattern were found. Despite the hypoproteinemia was a relatively frequent finding in this work, a correlation with the clinical variables was not established. In addition, the clinical severity, the endoscopic and histological grading was not related to protein profile. Dysproteinemia with low beta globulin and high gamma globulin were the most common alterations. In hypoproteinemic cats A/G was higher than in non-hypoproteinemic cats. The decrease of beta globulin could be due to malnutrition but also to iron metabolism modifications occurring in chronic inflammatory disease, with reduction of transferrin and ferritin. Hypergammaglobulinemia is reported in human medicine as a common feature of IBD associated to extraintestinal manifestation. No data so far are available for the prevalence and clinical significance in cats.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Benvenuti
University of Pisa
San Piero a Grado, Pisa, Italy

URL: http://www.vin.com/doc/?id=8172919
ESCG/SCH - European Society of Comparative Gastroenterology / Society of Comparative Hepatology

Scientific Programme
Scientific Programme

Hepatic and Intestinal Organoids  Hedwig S. Kruitwagen, DVM, PhD candidate
Gallbladder Mucoceles  Jody L. Gookin, DVM, PhD, DACVIM-SAIM
Feline Triaditis  Kenneth W. Simpson
Canine Cholangitis and Cholecystitis  Emma J. O'Neill, BSc, BVSc, PhD, DSAM, DECVIM-CA, PGDipUTL, MRCVS
Host Defense Strategies for Minimally Invasive Epithelial Pathogens  Jody L. Gookin, DVM, PhD, DACVIM-SAIM
Host Genetics in Granulomatous Colitis  Kenneth W. Simpson
The Role of the Intestinal Luminal Environment in Colitis  Kenneth W. Simpson
Intestinal Microbiome and Metabolome Profiles Across Various Gastrointestinal Diseases  Jan S. Suchodolski, DrMedVet, PhD, DACVM, AGAF
Intestinal Microbiota and Bile Acid Metabolism  Blake C. Guard, MS, PhD
How to Alter the Gut Microbiota - Effects of Antibiotics and Fecal Microbiota Transplantation  Jan S. Suchodolski, DrMedVet, PhD, DACVM, AGAF
The development of organoid cultures by the lab of Hans Clevers (Hubrecht Institute) is considered a major scientific breakthrough. Since their first publication in 2009 on mouse ‘mini-guts,’ organoids have gained a massive amount of attention from both academia and clinic, but also from the media. Organoids are defined as ‘structures resembling an organ’ and have already been created from for example intestine, liver, pancreas, and stomach tissue. The 3D culture is based on specific medium components that drive proliferation of adult tissue-specific stem cells and as a result allow for a culture of primary cells with impressive expansion capacity. Organoids were first derived from mouse and then from human (patient-) samples. In collaboration with the Hubrecht Institute our lab has established organoid cultures from dog and cat liver (Nantasanti et al. 2015; Kruitwagen et al. 2017) and dog intestine (Conceicao Meneses et al. manuscript in preparation). Organoids have already proved to be a valuable tool for disease modeling research (e.g., in human cystic fibrosis) and are also considered for transplantation purposes. But the question arises how far we are from actual clinical application and how also veterinary medicine can benefit from organoid development. Currently, our lab is performing a transplantation study of autologous canine liver organoids in dogs with genetic copper storage disease. A second project is the culture of feline liver organoids and their application as preclinical disease model for hepatic lipidosis. A third study focuses on canine intestinal organoids to model viral enteritis. In this session, the potential and limitations of organoids will be discussed using examples from previous publications and examples from own experience.

Key References
Gallbladder mucocele formation in dogs is characterized by an unrelenting accumulation of thick, immobile, and rubbery mucus within the gallbladder until the contents eventually obstruct bile flow or rupture into the abdomen. The syndrome was rarely reported prior to 15 years ago and has emerged as one of the most common, deadliest and poorly understood causes of gallbladder disease in the dog. Mucocele formation afflicts older dogs and has a strong breed predisposition. Cholecystectomy is currently considered the treatment of choice for dogs with symptomatic gallbladder mucocele formation. However, after surgery a median of 27% of dogs (range 7–45%) don't survive long enough to be discharged from the hospital. There is no cost-effective way to screen dogs for mucocele formation. There are no clear strategies for medical management of the disorder. The cause of gallbladder mucocele formation in dogs is entirely unknown. In this session, we will discuss what we do know about this unusual disease of dogs and look at the evidence in support of existing theories of why mucoceles form. Finally, we will talk about the latest research findings and how they are shedding light on the probable pathogenesis of mucocele formation.

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Jody L. Gookin, DVM, PhD, DACVIM-SAIM
College of Veterinary Medicine
North Carolina State University
Raleigh, NC, USA

URL: http://www.vin.com/doc/?id=8172747
"Triaditis" is the term used to describe concurrent inflammation of the pancreas, liver, and small intestines. Triaditis has been reported in 50–56% of cats diagnosed with pancreatitis and 32–50% of those with cholangitis/inflammatory liver disease. A definitive diagnosis of triaditis is based on the histopathological evaluation of each organ. However, the specific conditions of each organ that constitute a diagnosis triaditis remains to be defined. While the etiopathogenesis of pancreatitis and its relationship to inflammation in other organ systems is unclear, preliminary studies point to a heterogeneous group of conditions with differential involvement of host inflammatory and immune responses and enteric bacteria. Comprehensive, prospective studies that simultaneously evaluate the presence of pre-defined clinical, clinicopathological, and histopathological abnormalities, coupled with high-resolution evaluation of pancreaticobiliary morphology, immunological profiling, and screening for bacterial colonization are required to advance diagnosis and therapy.

Key References

Speaker Information
Kenneth W. Simpson
College of Veterinary Medicine
Cornell University
Ithaca, NY, USA

URL: http://www.vin.com/doc/?id=8172748
Canine Cholangitis and Cholecystitis
Emma J. O’Neill, BSc, BVSc, PhD, DSAM, DECVM-CA, PGDipUTL, MRCVS
Veterinary Clinical Studies, University College Dublin, Dublin, Ireland

KEYNOTE MESSAGE

Historically, both bacterial cholangitis and cholecystitis have been reported infrequently in the dog; however, our recent work suggests that these conditions occur more frequently than has been previously recognised, having significant implications for patient management. In a multi-centre, retrospective study, we identified twenty-seven confirmed cases of bacterial cholangitis or cholecystitis against a background of approximately 460 cases of hepatitis diagnosed in the same institutions over the equivalent time period, far in excess of what would have generally been suggested by the paucity of publications.

Evaluation of the clinical characteristics of bacterial cholangitis and cholecystitis in this large case series identified important information about the presentation of the condition in this species. It highlighted that both bacterial cholangitis and cholecystitis should be considered as differential diagnoses in dogs presenting with jaundice and fever, abdominal pain or an inflammatory leucogram or with ultrasonographic evidence of gallbladder abnormalities. In addition, as bacteriological culture results documented both aerobic and anaerobic isolates, frequent antimicrobial resistance in aerobic isolates (approaching two thirds of E. coli isolates resistant to three or more antimicrobial classes) along with changes in resistance patterns and persistence of positive cultures in some patients despite antimicrobial therapy, the bacteriological culture of bile with sensitivity testing is recommended over empirical treatment.

In this session, the important features of bacterial cholangitis and cholecystitis in the dog will be reviewed along with more recent work, using fluorescence in situ hybridization (FISH) with oligonucleotide probes directed against bacterial ribosomal RNA, aimed at further investigating the aetiopathogenesis of these conditions and their potential inter-relationship.

Key References

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)
Emma J. O’Neill, BSc, BVSc, PhD, DSAM, DECVM-CA, PGDipUTL, MRCVS
Veterinary Clinical Studies, University College Dublin
Dublin, Ireland
URL: http://www.vin.com/doc/?id=8172749
Host Defense Strategies for Minimally Invasive Epithelial Pathogens
Jody L. Gookin, DVM, PhD, DACVIM (SAIM)
College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA

Key Note Message
The intestinal tract is lined by a single layer of epithelial cells that is responsible for digestion and absorption of all of the nutrients and water that sustain life, while at the same time preventing the translocation of bacteria, antigens, and ingested toxins into the body. The last several years have seen great advances in our understanding of the intestinal microbiome and particularly the role of the mucosa-associated bacteria in host defense. With the advent of fluorescence in situ hybridization, individual bacteria can now be visually localized and identified to the genus, and sometimes species level. Increasing use of molecular diagnostics has made detection of diarrheal pathogens much easier but has also revealed that many of these infectious agents can also be observed in animals and people without clinical signs of disease. Host- and pathogen-specific factors that are responsible for why some patients are susceptible to disease while others remain asymptomatic has become an important focus toward a better understanding of the nuances of disease pathogenesis. In this session, we will discuss several minimally invasive diarrheal pathogens of dogs and cats and what is currently understood about their pathogenic effects and host strategies to combat them. A particular emphasis will be given to recent research findings identifying an association between enteropathogenic E. coli infection and diarrhea-related mortality in kittens and the impact of commensal bacteria in mediating colonization resistance.

Key References

Speaker Information
(click the speaker’s name to view other papers and abstracts submitted by this speaker)
Jody L. Gookin, DVM, PhD, DACVIM-SAIM
College of Veterinary Medicine
North Carolina State University
Raleigh, NC, USA

URL: http://www.vin.com/doc/?id=8172750
Host Genetics in Granulomatous Colitis
Kenneth W. Simpson
College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

KEYNOTE MESSAGE

Granulomatous colitis (GC) is a severe inflammatory bowel disease (IBD), typically diagnosed in boxer dogs and French bulldogs, but also other mastiff breeds, younger than four years of age. Affected dogs have diarrhea that leads to chronic weight loss, anemia, and debilitation. Previous studies have identified invasive bacteria within immune system cells, macrophages, in the colons of diseased dogs. Antibiotic treatments usually yield clinical improvement; however, antibiotic-resistant bacteria are present in some cases and persistently affected dogs suffer greatly. Elimination of this disease would be greatly facilitated by a genetic screening test to identify carriers. Identifying the genetic basis of GC could also provide comparative insights to inform the diagnosis and treatment of people with CD/IBD. Using a GWAS approach we have identified a region of DNA on chromosome 38 that is strongly associated with GC. It contains multiple genes that are known to impact the killing of E.coli bacteria and inflammatory responses. To identify the specific gene or genes that are affected, we are analyzing DNA sequences and expression patterns of these genes in dogs with GC and controls.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Kenneth W. Simpson
College of Veterinary Medicine
Cornell University
Ithaca, NY, USA

URL: [http://www.vin.com/doc/?id=8172751](http://www.vin.com/doc/?id=8172751)
The Role of the Intestinal Luminal Environment in Colitis
Kenneth W. Simpson
College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

KEYNOTE MESSAGE

Inflammatory bowel disease (IBD) reflects a spectrum of intestinal disorders, across species that are characterized by a dysregulated immune response to environmental and microbial antigens in genetically susceptible individuals. The interplay between the intestinal environment (chemical and microbial) and the host that leads to chronic inflammation is only beginning to be unraveled. It is emerging that inflammation in the absence of genetic susceptibility to IBD can trigger alterations in the enteric microbiote that can promote and perpetuate chronic inflammation and immune dysregulation in a susceptible individual. Genetic susceptibility impacts the threshold and magnitude of dysbiosis and inflammation, and mucosal healing. Concordant analysis of the microbiome and the metabolome has helped to identify bacteria and metabolic pathways that are adapted to utilize inflammation-associated substrates and promote inflammation. These discoveries provide unique opportunities for therapeutic intervention in the dysbiotic, inflamed gut.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Kenneth W. Simpson
College of Veterinary Medicine
Cornell University
Ithaca, NY, USA

URL: http://www.vin.com/doc/?id=8172752
Intestinal microbiota (bacteria, fungi, archaea, protozoa, and viruses) are of fundamental importance in maintaining gut homeostasis. Various studies have reported changes in microbial communities in acute and chronic gastrointestinal diseases, which result in functional and immunological consequences for the host. The depletion of commensal groups and their respective immunoregulatory metabolites (e.g., indoles, and secondary bile acids) may impair the ability of the host to downregulate the aberrant intestinal immune response, making dysbiosis an integral part of the pathogenesis of GI disease. Better characterization of dysbiosis and functional consequences may guide treatment decisions (e.g., antimicrobials vs. dietary modulation, use of probiotics, and/or immunosuppression). This talk will summarize recent work using wide screen microbiome and metabolome analysis to better define the differences in the pathophysiology of various acute and chronic GI disorders.

Key References
The intestinal microbiota affect host health through stimulation of the immune system, development of gut structure, and aiding in the defence against invading pathogens. Microbial metabolism helps to promote host health through the production of metabolic end products (e.g., short-chain fatty acids, secondary bile acids, vitamins). Inflammatory bowel disease (IBD), metabolic syndrome, cancer, asthma, diabetes, obesity, and stress-related disorders are examples of human diseases where the microbiota have been implicated. Chronic diarrhoea in dogs is thought to be a multifactorial disease which can involve genetic predisposition, improper activation of the immune system, dietary sensitivities, and microbial dysbiosis. Recently, alterations in faecal bile acids have been noted in human patients with IBD. Preliminary studies in dogs with chronic diarrhoea suggest that faecal bile acids in dogs are altered. During this session, microbial dysbiosis, metabolomics, and faecal bile acid dysmetabolism in healthy dogs and dogs with chronic diarrhoea will be described. Furthermore, methods for altering bile acid dysmetabolism in dogs will be discussed.

Key References


How to Alter the Gut Microbiota - Effects of Antibiotics and Fecal Microbiota Transplantation
Jan S. Suchodolski, DrMedVet, PhD, DACVM, AGAF
Gastrointestinal Laboratory, Texas A&M University, College Station, TX, USA

Keynote Message

Various studies have shown that the intestinal microbiota is altered in dogs and cats with intestinal disease. This highlights the need for modulating the microbiota as part of therapy of intestinal diseases. New genomic and metabolomic approaches have characterized the functional changes that occur in gut dysbiosis and may allow a more defined approach to therapy. Recent studies have shown that indiscriminate antibiotic administration may amplify dysbiosis, even in dogs that undergo clinical remission. While probiotics have shown clinical benefits in a subset of patients, they typically do not improve dysbiosis. Fecal microbiota transplantation may lead to normalization of gut dysbiosis, the duration of this effect depends on the underlying disease process. Larger studies are needed to elucidate which patients may benefit most from this therapeutic strategy. This talk will summarize the current knowledge and challenges associated with the approaches to modulate the intestinal microbiota.

Key References

ESVC - European Society of Veterinary Cardiology

Oral Presentations
Poster Presentations
Scientific Programme
<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utility of VHS to Predict Echocardiographic EPIC Trial Inclusion Criteria in Dogs with Myxomatous Mitral Valve Disease: A Retrospective Multicentre Study</td>
<td>J.P. Vitt</td>
</tr>
<tr>
<td>Evaluation of Continuous Positive Airway Pressure in Dogs with Cardiogenic Pulmonary Oedema Secondary to Severe Mitral Valve Disease</td>
<td>P.M. Rocchi</td>
</tr>
<tr>
<td>Development of a Simple Algorithm for Diagnosis of Left-Sided Congestive Heart Failure in Dogs with Mitral Valve Disease</td>
<td>M. Rishniw</td>
</tr>
<tr>
<td>Effects of Treatment with Thromboxane A2 Synthase Inhibitor on Pulmonary Hypertension: A Pilot Study</td>
<td>J. Lee</td>
</tr>
<tr>
<td>Echocardiographic Evaluation of Right Ventricular Dimension and Systolic Function in Dogs with Pulmonary Hypertension</td>
<td>T. Vezzosi</td>
</tr>
<tr>
<td>Caudal Vena Cava Assessment in Dogs with Right-Sided Congestive Heart Failure: A Pilot Study</td>
<td>A.C. Merelle</td>
</tr>
<tr>
<td>Heart Rate Variability in Dogs with Intracranial Disease</td>
<td>R.R. Blake</td>
</tr>
<tr>
<td>Genetic Background of Focal Junctional Tachycardia with Isorhythmic Atrioventricular Dissociation in Labrador Retrievers</td>
<td>G. Kiss</td>
</tr>
<tr>
<td>Immunofluorescent Localization of Plakoglobin in Endomyocardial Biopsy Samples to Diagnose Arrhythogenic Right Ventricular Cardiomyopathy (ARVC) in the Dog</td>
<td>E.M. Oxford</td>
</tr>
<tr>
<td>Right Ventricular Volume Quantification Measured by Real-Time 3D Echocardiography and ECG-Gated 64 Slice MDCT in Healthy Dogs</td>
<td>N.L. Leblanc</td>
</tr>
<tr>
<td>Feasibility of Intracardiac Echocardiography in Dogs: A Pilot Study</td>
<td>C. Damoiseaux</td>
</tr>
<tr>
<td>Use of Two-Dimensional Speckle Tracking Echocardiography to Assess Left Ventricular Systolic Function in Dogs with Systemic Inflammatory Response Syndrome</td>
<td>A. Corda</td>
</tr>
<tr>
<td>Major Histocompatibility Complex Class II Haplotypes Associated with Remodelling in Cavalier King Charles Spaniels with Chronic Valvular Heart Disease</td>
<td>L. Bree</td>
</tr>
<tr>
<td>MiRNAS in Progressing Canine Myxomatous Mitral Valve Disease</td>
<td>F. Traub</td>
</tr>
<tr>
<td>White Coat Effect in Client-Owned Dogs, as Assessed by High Definition Oscillometry (HDO)</td>
<td>R.S. Tims</td>
</tr>
<tr>
<td>Prevalence and Murmur Characteristics of Incidentally Detected Heart Murmurs and Heart Disease in 12,958 Young Healthy Shelter Cats</td>
<td>B.A.M. Mckeever</td>
</tr>
<tr>
<td>When Should We Talk about Tachypnoea in Cats at the Veterinarian's Consultation Room?</td>
<td>V. Szatmari</td>
</tr>
<tr>
<td>How Often Do Primary Care Practitioners Recognise Innocent Cardiac Murmurs in Puppies during the First Veterinary Health Check?</td>
<td>V. Szatmari</td>
</tr>
<tr>
<td>Towards Cardiac Stem Cell Therapy: Characterisation and Cryopreservation of Canine Cardiosphere-Derived Cells</td>
<td>D.J. Connolly</td>
</tr>
<tr>
<td>Assessing the Feasibility of Allogeneic Stem Cell Therapy for Canine Dilated Cardiomyopathy</td>
<td>L.C. Dutton</td>
</tr>
<tr>
<td>The Association of Clinical, Laboratory, and Echocardiographic Findings with Survival in 108 Dogs Undergoing Pericardiocentesis: A Retrospective Study</td>
<td>D.G. Ohad</td>
</tr>
<tr>
<td>Usefulness of Colour TDI at the Level of Lateral Atrial Tissue as a Predictor of Future Development of Atrial Fibrillation in Dogs</td>
<td>J. Neves</td>
</tr>
<tr>
<td>Is Prophylactic Antibiotic Therapy Necessary to Prevent Infectious Endocarditis in Dogs That Undergo Transecatheter Embolisation of a Patent Ductus Arteriosus?</td>
<td>V. Szatmari</td>
</tr>
<tr>
<td>Biological Variability of N-Terminal Pro-B-Type Natriuretic Peptide in Fifty-Three Healthy Labrador Retrievers Over an 8 Month Period</td>
<td>S. Gomart</td>
</tr>
<tr>
<td>Clinical Use of a Patient-Side Feline NT-ProBNP ELISA Test in 281 Cats in General Practice</td>
<td>F. Glen</td>
</tr>
<tr>
<td>Diagnostic and Prognostic Utility of Surface ECG in Cats with Left Ventricular Hypertrophy</td>
<td>G. Romito</td>
</tr>
<tr>
<td>Notched QRS Complexes in Dogs With and Without Structural Cardiac Disease: 85 Cases</td>
<td>R.L. Winter</td>
</tr>
</tbody>
</table>
Utility of VHS to Predict Echocardiographic EPIC Trial Inclusion Criteria in Dogs with Myxomatous Mitral Valve Disease: A Retrospective Multicentre Study

J.P. Vitt1; S. Gordon2; R.C. Fries1; J.D. Rhinehart3; S.E. Achen4; I. Sosa5; A.H. Estrada6; J.A. Carlson7; R.L. Winter8; S. Kadotani1; K.E. Lamb9

1University of Illinois, Urbana, IL, USA; 2Texas A&M University, College Station, TX, USA; 3The Ohio State University, Columbus, OH, USA; 4Blue Pearl Specialty and Emergency Pet Hospital, Southfield, MI, USA; 5Massachusetts Veterinary Referral Hospital, Boston, MA, USA; 6University of Florida, Gainesville, FL, USA; 7Veterinary Emergency and Referral Group, Brooklyn, NY, USA; 8Auburn University, Auburn, AL, USA; 9Lamb Consulting LLC, West Saint Paul, MN, USA

The EPIC Trial reported three cardiac size inclusion criteria including radiographic vertebral heart size (VHS) >10.5, and echocardiographically derived normalized left ventricular internal dimension in diastole (LVIDDN) >1.7 and left atrial to aortic ratio (LA:Ao) >1.6 as measured by the Swedish method. However, echocardiography may not always be available and, therefore, there is interest in identification of a VHS cutoff that predicts EPIC echocardiography inclusion criteria (EPIC-ECHO+) in dogs with preclinical myxomatous mitral valve disease (MMVD). Medical records from 8 sites were searched for MMVD cases that had contemporaneous thoracic radiographic and echocardiographic studies. A total of 247 cases were identified and descriptive statistics are reported as mean, median, and interquartile range for VHS (11.4, 11.2, 10.8–11.9), LVIDDN (1.80, 1.79, 1.58–2.05), and LA:Ao (1.78, 1.69, 1.42–2.06). Dogs that were EPIC-ECHO+ (N=126) were identified and compared to the remaining population (N=121). Receiver operator curves were constructed for VHS and performance was explored for optimal cutoffs. The percent correct, sensitivity, specificity, false positive and negative rates for a VHS of 11.1 (72%, 0.730, 0.707, 12%, 16%), 11.7 (60%, 0.439, 0.85, 6%, 34%) and 11.9 (58%, 0.365, 0.90, 4%, 38%) were determined. Based on these data, dogs with MMVD and a VHS >11.7 have a high likelihood of meeting EPIC-ECHO+ (85% specificity) and an acceptable false positive rate (6%), however, approximately 34% dogs with a VHS between 10.6–11.7 may meet EPIC-ECHO+ and warrant further echocardiographic evaluation. These results may help veterinarians apply the results of the EPIC Trial to dogs with preclinical MMVD when an echocardiogram is not readily available.

DISCLOSURES
Disclosures to report.
Drs. Vitt, Gordon, Estrada, and Achen have received funding from Boehringer Ingelheim Animal Health GmbH and IDEXX Laboratories within the last 5 years for some or all of the following activities: research, travel, speaking fees, consultancy fees, and preparation of educational materials. No funding was provided by Boehringer Ingelheim for this study and is a retrospective evaluation, so no funding was used. The statistical analysis was also performed by an independent party.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.P. Vitt
University of Illinois
Urbana, IL, USA

URL: http://www.vin.com/doc/?id=8172666
Evaluation of Continuous Positive Airway Pressure in Dogs with Cardiogenic Pulmonary Oedema Secondary to Severe Mitral Valve Disease

P.M. Rocchi; E. Cardone; L. Cagnazzo; S. Lugetti; A. Ruggeri; F.S. Greco; P.M. Knafelz
Gegorio VII Veterinary Hospital, Rome, Italy

The aim of this study was to evaluate the application, tolerability and outcome of continuous positive airway pressure (CPAP) compared to another non-invasive oxygen therapy (flow-by), in dogs diagnosed with cardiogenic pulmonary oedema secondary to severe mitral valve disease (MVD).

Records of dogs diagnosed with cardiogenic pulmonary oedema based on clinical findings, thoracic radiographs and echocardiography were retrospectively evaluated. Newly diagnosed dogs with MVD and dogs already in treatment for MVD were included in the study.

Thirty dogs were included in the study between February 2016 and 2017. All dogs received medical treatment based on clinical status and echocardiography results and were divided into 2 groups: group 1 (14 dogs) received oxygen administration by CPAP-helmet at a positive expiratory pressure (PEP) of 5 cm H₂O and group 2 (16 dogs) received oxygen flow-by (2–15 L/min).

Oxygen administration was discontinued based on clinical improvement, decreased respiratory labour and RR (respiratory rate), emogas-analysis parameters (PaCO₂, or PaO₂and PaO₂/FiO₂) and improvement of radiographic signs of pulmonary oedema.

In group 1 the mean age was 12.5 years (2–16) and mean body weight was 6 kg (3–39). Eleven dogs (78%, 11/14) showed improvement of RR, respiratory labour, blood gas parameters within 30 minutes after CPAP treatment initiation; radiographic signs of pulmonary oedema improved within 8 hours. Treatment with CPAP was intermittent, mean wearing time of the CPAP-helmet was 13.4 h/day (3–12) for 50 hours (3–23 h). Butorphanol was administered only at the time of application of the CPAP-helmet. The mortality rate was 35% (5/14).

In group 2, the mean age was 11.3 years (8–15) and mean body weight 8 kg (2–22). In seven dogs (43%, 7/16), RR, respiratory labour and blood gas parameters improved within 30 minutes after oxygen flow-by administration. Radiographic signs of pulmonary oedema improved after a median of 19 h (12–26 h). Oxygen delivery was continuous. Butorphanol administration was necessary more than three times per day. The mortality rate was 62% (10/16).

Respiratory failure due to cardiogenic pulmonary oedema secondary to MVD is a very common disease in dogs; in this study, CPAP-helmet interface was a valid alternative to oxygen flow-by therapy. Though clinical improvement was similar in the first 30 minutes, CPAP-helmet reduced the need for butorphanol administration, quickened both clinical and radiographic signs of pulmonary oedema improvement and showed a decrease of the mortality rate compared to oxygen flow-by. CPAP-helmet was well tolerated by all dogs.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P.M. Rocchi
Gegorio VII Veterinary Hospital
Rome, Italy

URL: http://www.vin.com/doc/?id=8172677
Development of a Simple Algorithm for Diagnosis of Left-Sided Congestive Heart Failure in Dogs with Mitral Valve Disease

M. Rishniw 1; D. Dickson 2; D. Caivano 3; L.I. Vatne 4; J. Harris 5; E. Pavelkova 6

1 Cornell University, Ithaca, NY, USA; 2 HeartVets UK, Portcawl, UK; 3 University of Perugia, Perugia, Italy; 4 AniCura Oslo, Oslo, Norway; 5 The Animal Hospital, Dursley, UK; 6 Wright and Morten Vets, Macclesfield, UK

Clinicians in first-opinion practice commonly diagnose congestive heart failure (CHF) in small breed dogs with myxomatous mitral valve disease (MMVD) that do not have CHF. To improve the accuracy of CHF diagnosis, we developed an initial algorithm based on historical, physical and radiographic findings that might help a clinician in first opinion practice to more accurately diagnose CHF in these dogs. We then sought to refine and validate the algorithm by determining which of these historical, physical and radiographic findings help discriminate dogs with MMVD into CHF and "not CHF" groups.

We collected the following historical and physical examination information on 52 small-breed dogs presenting for evaluation of a cough, murmur, or suspicion of CHF to the referral clinician: presence or absence of coughing, duration of coughing, recent worsening of cough, presence of loud crackles, murmur intensity, presence of sinus arrhythmia, heart rate, in-clinic respiratory rate, presence or absence of dyspnea, sleeping respiratory rate, response to a diuretic trial (if considered necessary by the referral clinician) and radiographic evaluation of left atrial size. Additionally, all dogs underwent echocardiographic evaluation. The diagnosis of "CHF" or "not CHF" was made by each investigator on their own cases, using all required diagnostic tests and treatment, and not validated by other investigators.

Historical and physical variables that excluded a diagnosis of CHF included presence of a sinus arrhythmia (never identified in CHF dogs), a murmur that was "less than loud", a heart rate <120 bpm, an in-clinic RR <35 breaths/min, less-than-moderate left atrial enlargement on radiographs. A positive diuretic trial which alleviated dyspnea confirmed a diagnosis of CHF. Twenty out of 21 coughing dogs with CHF showed a recently worsening cough.

Based on these findings, we refined our algorithm so that detection of either a sinus arrhythmia, a soft murmur, a sinus rate <100 bpm, or an in-clinic RR<30 breaths per minute excludes a diagnosis of CHF. Presence of a cough or crackles does not help, but a recently worsening cough warrants increases the suspicion of CHF. In cases where CHF is suspected, a resolution of dyspnea with appropriate diuresis strongly supports the diagnosis of CHF. How well the refined algorithm performs with first opinion clinicians remains to be determined.

DISCLOSURES

Disclosures to report.

Dr. Rishniw is currently funded for a study evaluating laryngeal paralysis (ACVIM Foundation Grant) and has provided continuing education talks for general practitioners over the last 4 years, for which he has received honoraria. Dr. Rishniw is a paid employee of Veterinary Information Network.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Rishniw
Cornell University
Ithaca, NY, USA

URL: http://www.vin.com/doc/?id=8172687
Effects of Treatment with Thromboxane A$_2$ Synthase Inhibitor on Pulmonary Hypertension: A Pilot Study

J. Lee$^1$; W. Kim$^2$; W. Yoon$^3$; H. Kim$^1$

$^1$VIP Animal Medical Center, Seoul, South-Korea; $^2$Columbia University, New York, NY, USA; $^3$Guardian Angel Veterinary Hospital, Anyang, South-Korea

Thromboxane A$_2$ (TXA$_2$) is an important multifactorial mediator in the pathogenesis of pulmonary hypertension. Although endothelium-derived TXA$_2$ causes excessive pulmonary vascular resistance by acting as a potent vasoconstrictor, mitogen of vascular smooth muscle cells and promoter of platelet aggregation, there is no current therapeutic strategy for pulmonary hypertension, targeting TXA$_2$ formation. The aim of this study is to assess possible beneficial effects of inhibiting TXA$_2$ synthesis in patients with pulmonary hypertension.

Sixteen client-owned dogs with proven moderate-to-severe pulmonary hypertension were randomly assigned to the treatment (n=8; ozagrel hydrochloride, 5 mg/kg bid PO) or control group (n=8; sildenafil citrate, 1 mg/kg BID PO). All patients have already been treated with standard protocol including sildenafil (1.8±0.6 mg/kg, BID). Pulmonary hypertension associated with left-side heart failure (LA/Ao >1.6 and LVIDDn >1.7) was excluded in the population. Several clinical indices, which relate to hypoxia (lactate, SpO$_2$, base excess), thrombosis (d-dimer), azotemia (BUN, creatinine), congestion (NT-proBNP) and echocardiographic indices (peak velocity of tricuspid regurgitation, Ao/MPA), were tracked down for four weeks.

The treatment led to significant and gradual decreases in lactate and d-dimer (p<0.01; from 5.6±1.9 mmol/L to 1.8±1.0 and from 7.4±6.8 to 1.2±1.1 μg/ml, respectively) but significantly increased SpO$_2$ and base excess (p<0.01; from 87±5.3 to 95±1.8% and from -8.4±3.2 to -3.1±1.9 mmol/L, respectively) in the patients. Compared to controls, the treatment group exhibited statistically significant changes in only lactate level (p=0.02) and SpO$_2$ (p=0.016). However, treatment of TXA$_2$ synthase inhibitor showed the tendency to improve the other variables, such as NT-proBNP and tricuspid regurgitant flow, implicating the potential role of TXA$_2$ synthase inhibitor in pulmonary vascular impedance. Abnormal behavior such as licking footpads and joints has been reported to be a putative side effect of the treatment in one case.

These results suggest that TXA$_2$ synthase inhibitor may contribute to the improvement of pulmonary hemodynamics in pulmonary hypertension by alleviating pulmonary vasoconstriction and preventing thrombosis.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Lee
VIP Animal Medical Center
Seoul, South Korea

URL: http://www.vin.com/doc/?id=8172688
Echocardiographic Evaluation of Right Ventricular Dimension and Systolic Function in Dogs with Pulmonary Hypertension

T. Vezzosi1; R. Tognetti2; G. Costa2; F. Marchesotti3; L. Venco4; E. Zini5; O. Domenech3

1University of Pisa, San Piero a Grado (PI), Italy; 2Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Pisa, Italy; 3Department of Cardiology, Istituto Veterinario di Novara, Granazzo con Monticello, Novara, Italy; 4Clinica Veterinaria Lago Maggiore, Dormelletto, Novara, Italy; 5Department of Internal Medicine, Istituto Veterinario di Novara, Granazzo con Monticello, Novara, Italy

Pulmonary hypertension (PH) may lead to right ventricular (RV) remodeling, dysfunction and right-sided congestive heart failure (R-CHF). RV enlargement and dysfunction are strongly associated with prognosis in humans with PH. Reference intervals for RV size and systolic function have been described in healthy dogs. The aims of this study were to assess RV size and systolic function in dogs with PH and to verify if they are associated with severity of PH.

This was a prospective, multicenter, observational study. We included 138 client-owned dogs: 64 with PH and 74 healthy. PH was classified according to tricuspid regurgitation pressure gradient (TRPG) in mild (TRPG: 36–50 mm Hg; n=18 dogs), moderate (TRPG: 51–75 mm Hg; n=14 dogs) and severe (TRPG>75 mm Hg; n=32 dogs). Fourteen dogs with PH had R-CHF. Echocardiographic evaluation of the RV was obtained from the left apical 4-chamber view optimized for the right heart. RV dimension was evaluated through the RV end-diastolic area (RVEDA) index, calculated as RVEDA divided by body surface area. Echocardiographic indices of RV systolic function were tricuspid annular plane systolic excursion (TAPSE) and RV fractional area change (FAC) normalized for body weight (TAPSEn and FACn, respectively).

RVEDA index was significantly higher in dogs with mild, moderate and severe PH than in healthy dogs (p<0.05 for each contrast). No differences in RVEDA index were found between dogs with moderate and severe PH. RVEDA index was significantly higher in dogs with R-CHF in comparison to dogs without R-CHF (p<0.0001). TAPSEn below the reference interval was found in 1/14 dogs with moderate PH and in 4/32 with severe PH, but did not significantly differ among dogs with mild, moderate and severe PH in comparison to healthy. FACn below the reference interval was found in 4/14 dogs with moderate PH and 6/32 with severe PH, and did not significantly differ between dogs with and without PH, irrespective of the severity. No differences in TAPSEn and FACn were found between dogs with and without R-CHF.

In conclusion, the RVEDA index was increased in dogs with PH and in those with R-CHF, suggesting that it may represent a useful parameter to assess PH severity. Because TAPSEn and FACn were abnormal in only a few dogs with moderate-to-severe PH, these parameters of RV dysfunction do not seem to be linked to R-CHF in this species. Further studies are therefore needed to identify additional factors associated with R-CHF in dogs with PH.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Vezzosi
University of Pisa
San Piero a Grado, PI, Italy

URL: http://www.vin.com/doc/?id=8172689
Caudal Vena Cava Assessment in Dogs with Right-Sided Congestive Heart Failure: A Pilot Study

A.C. Merveille¹; E. Darnis¹; S. Boysen²; K. Gommeren¹

¹University of Liège, Liège, Belgium; ²University of Calgary, Calgary, AB, Canada

Right-sided congestive heart failure (R-CHF) secondary to right-sided heart or pericardial diseases is characterized by increased right atrial, systemic venous and capillary pressures. Direct right atrial pressure measurements are considered the gold standard for identifying R-CHF, but are invasive. In human medicine, sonographically identifying a distended, non-compliant caudal vena cava (CVC) is a non-invasive means of detecting R-CHF and/or estimating intravascular volume. Sonographic CVC dimensions in healthy dogs have been reported. However, the effect of R-CHF on CVC dimensions is not well described. The objective of this study was to determine if CVC measurements, obtained via three different sonographic views, from dogs with R-CHF are outside reference intervals (RI).

Dogs presenting with right-sided heart disease and ascites were prospectively evaluated. Via longitudinal subxiphoid views (SV), maximal and minimal CVC diameter (SV-CVCMax, expiration, SV-CVCMin, inspiration) and collapsibility index (CI) were measured. Transverse 11–13th right hepatic intercostal views (HV) were used to measure maximal and minimal CVC (HV-CVCMax, HV-CVCMin) and aortic diameter. A single CVC and aortic diameter (PV-CVC, PV-Ao) were measured via longitudinal right paralumbar views (PV). CVC dimensions were adjusted for the three views using allometric scaling as well as indexed to aortic diameter for HV and PV. Data were compared to a RI previously established by the authors using 126 healthy dogs of various breeds. Data were expressed as median and range.

Six dogs weighing 19.2 kg (7.2 – 33.9), were included. Diagnosis included pulmonary hypertension (n=3), congenital heart disease (n=2) and pericardial effusion (n=1). Six out of 6 and 5/6 dogs had SV-CVCMax and SV-CVCMin above RI, respectively. All dogs had CI (19% (7–24) within RI. HV-CVCMax and HV-CVCMin were above RI in 5/6 and 4/6 dogs, respectively. Two out of 6 HV-CVCMax/Ao and HV-CVCMin/Ao ratios were above RI. The PV-CVC/Ao ratio was 1.28 (1.13–1.47), and above RI in 4 dogs. The PV-CVC diameter, using allometric scaling, was above RI in one dog.

This pilot study suggests that an enlarged CVC is observed in dogs with evidence of R-CHF. CVC distension may be easiest to identify at the SV. This could be due to the proximity CVC in relation to the right atrium and/or the influence of the respiratory cycle on the CVC diameter between healthy dogs and dogs with R-CHF when measured at the SV. In contrast to human medicine, there was no difference in CI between dogs with R-CHF and healthy dogs. A larger study is needed to confirm these findings.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.C. Merveille
University of Liège
Liège, Belgium

URL: http://www.vin.com/doc/?id=8172690
In humans, alterations in heart rate variability (HRV) have been associated with various forms of intracranial disease due to disturbances in the autonomic nervous system. HRV has been shown to hold prognostic value in these patients.

The aims of this study were to evaluate alterations in HRV in dogs with clinical signs of intracranial disease and the relationship of HRV with the results of brain imaging and outcome.

Ambulatory electrocardiographic recordings were prospectively obtained from 12 client-owned dogs with a history and/or neurological examination consistent with intracranial disease. Data was collected for a minimum of 12 hours the night before brain imaging (MRI or CT), while the dogs were hospitalized. Control data was gathered from 25 healthy dogs used in a parallel study on HRV. The data was analysed using Novacor Holtersoft Ultima Version 2.5.5. Time and frequency-domain measurements of HRV, Poincaré plots and their descriptors were generated from the data.

Two dogs from the diseased group were excluded, one due to the presence of persistent arrhythmia and another due to a recording time of less than 12 hours. The mean heart rate of the diseased group was higher than that of the control group when HRV parameters were calculated from 6 hours of resting data for each group. All of the measured parameters of HRV (SDNN, SDNNIDX, PNN50%, RMSSD, SD1, SD2, SD1/SD2, HF msec², LF msec²), apart from SDANN, were lower in the diseased group than the control group (p<0.03). There was no distinct Poincaré plot pattern evident for the diseased group when compared to the healthy controls. There was no significant difference in any of the HRV measurements over 12 hours of recording between dogs with intracranial lesions present on imaging (n=7) and those with no imaging abnormalities (n=3). Neither was there a significant difference between those who were alive 3 months following data collection (n=5) and those who were not (n=5).

This pilot study suggests that the presence of intracranial disease may be associated with a reduction in HRV in dogs, regardless of the underlying aetiology. HRV does not appear to be predictive of brain imaging findings in a small cohort of dogs with clinical signs of intracranial disease, and there does not appear to be a relationship between HRV and survival.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.R. Blake
University of Edinburgh
Roslin, UK

URL: http://www.vin.com/doc/?id=8172691
Genetic Background of Focal Junctional Tachycardia with Isorhythmic Atrioventricular Dissociation in Labrador Retrievers

G. Kiss¹; G. Nyírõ²; A. Patócs²; E. Jávorszky³; B. Bálint¹; I. Nagy⁴,⁵; F. Manczur¹

¹Department and Clinic of Internal Medicine, University of Veterinary Medicine, Budapest, Hungary; ²Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary; ³Department of Pediatrics, Semmelweis University, Budapest, Hungary; ⁴Seqomics Biotechnology Ltd, Mórahalom, Hungary; ⁵Institute of Biochemistry, Biological Research Centre of the Academy of Sciences, Szeged, Hungary

Focal junctional tachycardia with isorhythmic atrioventricular dissociation is a known arrhythmia in Labrador Retrievers. Because of breed predisposition of this type of arrhythmia, genetic background is strongly suspected in the dog. Recently, we diagnosed the disease in several Labradors including a family with three consecutive generations. The aim of our study was to describe the inheritance pattern and to identify potentially causative gene mutations in our population.

Study population consisted of 12 Labradors. Eight dogs were diagnosed with different severity of the disease, one was a 13-year-old healthy littermate in an affected family, three dogs (>10 years old) from different breed lines served as controls. Clinical diagnosis was made by electrocardiography and echocardiography. Inheritance pattern was studied by pedigree analysis. Genomic DNA was isolated from EDTA-anticoagulated blood samples using a commercial kit. Whole exome sequencing (WES) of healthy and diseased littermates was used to identify candidate mutations (Illumina HiSeq2500 next generation sequencing system, Agilent SureSelect Canine All Exon 54Mb library-kit, 50x-coverage, CanFam3.1 annotation). Selection of target mutations in genes related to calcium transport was based on clinical experience with calcium channel blocker diltiazem that could effectively control the disease. Sanger-sequencing was used to validate WES results in the study population and in controls (ABI3500 capillary-sequencing system, BigDye3.1 chemistry). The disease was present in all generations (affecting both genders) of the affected Labrador family, although the symptoms varied among the individuals. Sudden death at young age occurred in the offspring of parents that were both clinically affected. Development of congestive heart failure between 5 and 8 years of age due to tachycardiomyopathy was another observed phenotype, while there were also some clinically asymptomatic dogs with or without the arrhythmia. Comparison of the WES data of the healthy and diseased littermates resulted in 1629 differences in coding regions. After filtering for calcium turnover-related targets a homozygous single nucleotide variant (c.[3019C>A]; [Gln1007Lys]) in Ryanodine receptor-2 (RyR2) gene and a heterozygous insertion (c.246_247insCAG; p.Gln92_Ser93insGln) in the calcium activated potassium channel gene (KCNN2) were identified. Both were confirmed to be present in all of the clinically affected (related and unrelated) dogs and absent in healthy controls by Sanger-sequencing. Pedigree analysis suggests an autosomal dominant inheritance pattern with strong but incomplete penetrance and variable expression in the affected Labrador family. The identified RyR2 and KCNN2 mutations may have a causative role in the disease development in Labrador retrievers.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

G. Kiss
Department and Clinic of Internal Medicine
University of Veterinary Medicine
Budapest, Hungary

URL: http://www.vin.com/doc/?id=8172692
Immunofluorescent Localization of Plakoglobin in Endomyocardial Biopsy Samples to Diagnose Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in the Dog

E.M. Oxford1; R. Pariaut1; M. Tursi2; P.R. Fox3; R.A. Santilli1

1Cornell University Hospital for Animals, Ithaca, NY, USA; 2Department of Veterinary Sciences, University of Turin, Turin, Italy; 3Caspary Institute, The Animal Medical Center, New York, NY, USA

In early stages of ARVC, diagnosis is difficult due to the absence of echocardiographic changes and day-to-day arrhythmia variability. A definitive diagnosis requires histopathologic identification of transmural fibrofatty replacement of the right ventricle. Reduction of immunofluorescent signal for the desmosomal protein plakoglobin has been reported in ARVC-affected humans and boxers. Reduction in plakoglobin signal within endomyocardial biopsy samples (EMBs) may help diagnose ARVC.

EMBs were obtained with owner consent from 48 dogs: 42 with advanced cardiac disease and six asymptomatic boxers (>5 years) with mild to moderate ventricular arrhythmia (VA) burden. Investigators were blinded to breed and clinical signs of the dogs. ARVC was diagnosed from EMBs by histopathology (MT) in 5 dogs. Of these, 3 had clinical signs consistent with ARVC (2 Boxers, 1 English Bulldog). Two were asymptomatic boxers with a moderate VA burden. Confocal microscopy was performed (EMO) to detect immunoreactive signal for plakoglobin in EMBs. Samples were prepared with antibodies recognizing cadherin (intercalated disc marker) and plakoglobin.

Forty-two samples were positive for cadherin signal and 6 were non-diagnostic. Plakoglobin signal was reduced in 4 samples: 2 Boxers and 1 English Bulldog with clinical signs and histopathologic diagnoses of ARVC. The fourth sample was from a mongrel diagnosed with myocarditis. Plakoglobin signal was present in all 6 asymptomatic Boxers, including those with a histopathologic diagnosis of ARVC.

These results suggest that reduced plakoglobin signal in EMBs may help to differentiate ARVC from other myocardial diseases in dogs, specifically when clinical signs of disease are present.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E.M. Oxford
Cornell University Hospital for Animals
Ithaca, NY, USA

URL: http://www.vin.com/doc/?id=8172693
Right Ventricular Volume Quantification Measured by Real-Time 3D Echocardiography and ECG-Gated 64 Slice MDCT in Healthy Dogs

N.L. Leblanc; K.F. Scollan
Oregon State University, Corvallis, OR, USA

Accurate assessment of right ventricular (RV) structure and function is an integral component of a complete cardiology evaluation in veterinary patients. Assessment of RV performance is particularly important in patients with pulmonary hypertension, congenital heart disease, and acquired myocardial disease affecting the RV. There is evidence in human medicine suggesting RV function is strongly associated with outcomes in many conditions. The aim of this study was to evaluate the accuracy of right ventricular volume (RVV) and function quantification using three-dimensional echocardiography (3DE) compared to electrocardiogram-gated multidetector computed tomography (ECG-gated MDCT).

Six intact hound cross dogs weighing between 19.5–23.8 kg were anesthetized using a standardized protocol and spontaneous ventilation. Each dog underwent an ECG-gated MDCT and complete 3DE examination. Right ventricular end-diastolic volumes (EDV), end-systolic volumes (ESV), stroke volume (SV), and ejection fraction (EF) were measured using software specific for RVV quantification from 3DE and MDCT data sets. Correlation and levels of agreement between methods were determined, and intra- and interobserver variability was assessed for 3DE.

There were no statistically significant differences between SV (p=0.16) and EF (p=0.31) obtained by MDCT and 3DE. There were significant differences between EDV (p=0.03) and ESV (p=0.01) RVV obtained by MDCT and 3DE. No statistically significant difference in HR was noted between methods (p=0.84).

The correlation between MDCT and 3DE was very good for EDV and ESV (R=0.87), moderate for EF (R=0.60) and poor for SV (R=0.31). Bland-Altman analysis showed a systematic underestimation of RVV derived from 3DE compared to MDCT, with an average bias of 15 and 10.3 mL for EDV and ESV, respectively. The intra- (EDV 12%, ESV 18%) and interobserver (EDV 14%, ESV 11%) variability was acceptable for 3DE.

The results of this study suggested use of 3DE to measure RVV in healthy dogs was feasible with acceptable reproducibility. Measures of RVV by 3DE underestimate those made by MDCT, therefore absolute volumes of these imaging techniques are not interchangeable. However, there were no significant differences for EF between methods, which suggests that 3DE may be used to evaluate global RV function and monitor trends with disease states. A larger prospective study in dogs with and without cardiac disease is needed to delineate the benefits and constraints of these methods.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

N.L. Leblanc
Oregon State University
Corvallis, OR, USA

URL: http://www.vin.com/doc/?id=8172967
Feasibility of Intracardiac Echocardiography in Dogs: A Pilot Study

C. Damoiseaux1; V. Chetboul1; V. Gours1; M. Lavennes1; C. Poissonnier1; L.E. Carazo Arias1; M.P. Alvarado1; L. Behr2; A. Morlet2; F. Laborde2; N. Borenstein2

1Unité de Cardiologie d’Alfort, École Nationale Vétérinaire d’Alfort, Maisons-Alfort, France; 2IMMR, Paris, France

The intracardiac echocardiography (ICE) technology uses a catheter-based steerable ultrasound probe passed into the vessels to image intracardiac structures and blood flow from inside the cardiovascular system, with a similar to superior image resolution as compared to transesophageal echocardiography (TEE). Its clinical applications in human cardiology are growing, particularly for interventional procedures. The aim of this pilot study was thus to assess the feasibility of ICE in the dog during interventional procedures, i.e., transcatheter PDA closures using Amplatz© Canine Ductal Occluder (ACDO).

MATERIAL AND METHODS

The study population consisted of 4 dogs (median age: 0.75 year [0.3–2.1]; body weight: 15.1 kg [9.2–20.8]). A type II morphology PDA with left-to-right shunting was visualized in all cases based on transthoracic echocardiography (TTE) using two-dimensional (2D) and three-dimensional modes, as well as color-flow Doppler recordings. In 2 dogs, previous unsuccessful surgical closure of a PDA by thoracotomy was reported by the referent veterinarians, with placement of several hemostatic clips (Case #1) and mild hemorrhage of the PDA corrected with resorbable hemostatic compresses (Case #2). The ICE ultrasound system ViewMate Z© and the ViewFlex Plus catheter© (St Jude Medical, 4.5–8.5 MHz) were manipulated in all cases by a trained highly experienced observer in ICE imaging modality and a second observer for imaging settings if needed.

RESULTS

The ViewFlex Plus catheter was introduced by the left or the right femoral artery using a 9 to 10 French introducer (depending on dog’s size) in all cases except for the smallest dog (9.2 kg), and was placed in the descending aorta dorsally to the ductus. In the two dogs that underwent a previous unsuccessful surgical closure of a PDA by thoracotomy, ICE provided a better evaluation of the PDA morphology (Case #1) and associated lesions (Case #2) than TEE. For Case #1, unlike ICE, TEE did not allow an optimal acoustic window to accurately visualize the PDA area because of the hemostatic clips. In all cases, ICE allowed confirmation of complete PDA occlusion using combined 2D and color-flow Doppler modes. Furthermore, in two dogs, ICE was used as the sole guidance for deployment of the ACDO device.

In conclusion, this report illustrates the safe and effective use of ICE in dogs during transcatheter procedures.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Damoiseaux
Unité de Cardiologie d’Alfort
École Nationale Vétérinaire d’Alfort
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8172668
Use of Two-Dimensional Speckle Tracking Echocardiography to Assess Left Ventricular Systolic Function in Dogs with Systemic Inflammatory Response Syndrome

A. Corda 1; P. Gomez-Ochoa 2; G. Sotgiu 3; R. Zobba 1; M.L. Pinna Parpaglia 1; J. Prieto Ramos 4; A. French 4

1 Department of Veterinary Medicine, University of Sassari, Sassari, Italy; 2 Faculty of Veterinary Medicine, University of Zaragoza, Zaragoza, Spain; 3 Department of Biomedical Sciences, University of Sassari, Sassari, Italy; 4 School of Veterinary Medicine, University of Glasgow, Glasgow, UK

Systemic inflammatory response syndrome (SIRS) is a clinical syndrome caused by systemic inflammation of infectious or non-infectious origin. SIRS is characterized by an endogenous cascade of interleukins and other inflammatory mediators such as TNF-α, IL-6 and IL-1 which are responsible for myocardial depression during systemic inflammation. Conventional echocardiographic indices of left ventricular systolic function such as fractional shortening (FS) and ejection fraction (EF) are not sensitive enough to detect mild or early systolic dysfunction in dogs suffering from SIRS. Two-dimensional speckle-tracking echocardiography (2D-STE) is a new echocardiographic technique that allows an objective and quantitative evaluation of global and regional myocardial function through the analysis of the motion of speckles that are created by the interaction of ultrasonic beams and the myocardium during the 2-dimensional examination. We tested the hypothesis that 2D-STE may detect left ventricular systolic dysfunction, not diagnosed by conventional echocardiography, in dogs with SIRS. Seventeen dogs with evidence of SIRS and 17 healthy dogs as a control group were included in this prospective study. All the procedures were performed for diagnostic purpose; the control group was composed of healthy dogs undergoing surgical castration or ovariohysterectomy. We excluded from the study breeds predisposed to dilated cardiomyopathy, pregnant females, dogs treated with opioids, sedatives, or anaesthetic drugs during the 12 hours before echocardiography. We also excluded dogs with previous diagnosis of, or echocardiographic evidence of congenital or acquired cardiac disease and dogs with an arrhythmia. At the time of hospital admission each dog was submitted to standard 2D, M-mode, Doppler, and 2D-STE with simultaneous ECG and blood pressure measurement. Furthermore, blood samples were obtained for CBC, biochemical profile, and the measurements of cTnI and CRP serum levels. The results showed that the standard echocardiographic indices of systolic function such as EF, FS were not significantly different between the two groups. On the contrary, the left ventricular global longitudinal peak strain of endomyocardial layer and the STE-derived ejection fraction (STE-EF) were significantly lower in the SIRS group than in the control group. We did not find significant correlation between CRP serum levels and 2D-STE variables and between cTnI and STE variables. Furthermore, we did not find a significant difference in cTnI serum levels between the two groups. Our study demonstrated that 2D-STE was more sensitive than standard echocardiography in detecting early or mild to moderate myocardial dysfunction, not detected by conventional echocardiography, in a population of dogs with SIRS.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Corda
Department of Veterinary Medicine
University of Sassari
Sassari, Italy

URL: http://www.vin.com/doc/?id=8172669
Major Histocompatibility Complex Class II Haplotypes Associated with Remodelling in Cavalier King Charles Spaniels with Chronic Valvular Heart Disease

L. Bree¹; R.E. Shiel¹; A.T. French²; L.J. Tong³; J. Prieto-Ramos²; L.J. Kennedy⁴

¹University Veterinary Hospital, University College Dublin, Dublin, Ireland; ²Small Animal Hospital, University of Glasgow, Glasgow, Scotland; ³Murdoch University, Melville, Australia; ⁴Glasgow University, Glasgow, Scotland

Chronic valvular heart disease is common in the Cavalier King Charles Spaniel (CKCS). However, genetic factors contributing to development or progression of the disease are unknown. Although classically considered a non-inflammatory disease, upregulated expression of genes involved in inflammation and immune function has been identified in affected valvular tissue. Therefore, genetic determinants of the immune response could influence disease progression in individual dogs.

The aims of this study were to document major histocompatibility haplotype (MHC) dog leukocyte antigen (DLA) class II haplotypes in the CKCS, and to examine potential associations between individual haplotypes and progression of disease.

DLA three-locus haplotypes were determined in 190 CKCS from the UK (n=95) and Australia (n=95) using sequence-based typing methods. Six haplotypes were identified.

Echocardiography was performed in 187 dogs; 72 had evidence of remodelling and 115 did not. Three dogs were not tested. Remodelling was defined as increased left-atrial-to-aortic ratio (>1.5) or increased left ventricular internal diameter during diastole or systole (normalised to bodyweight) (LVIDD>1.85 or LVIDS>1.26). Associations between individual haplotypes and the presence of remodelling were investigated using the Fisher’s exact test. Odds ratios (OR) and 95% confidence intervals (CI) were also calculated. The age of the dogs ranged from 0.6–16.3 years.

When data from all 187 dogs were considered, two haplotypes (DRB1*01101/DQA1*00201/DQB1*01303 and DRB1*02001/DQA1*00401/DQB1*01303) were significantly associated with the presence of remodelling (p=0.0239 and p=0.0357; OR 3.562 [95% CI 1.188–10.68] and 0.5181 [0.2831–0.9482], respectively).

Echocardiographic evidence of remodelling was present in 24 dogs <9 years old and absent in 37 dogs >/=9 years old. DRB1*01101/DQA1*00201/DQB1*01303 was significantly (p=0.035) associated with the presence of remodelling at a younger age (odds ratio 3.562, [1.188–10.68]).

These results suggest an association between MHC DLA haplotype and the progression of chronic valvular heart disease in the CKCS. Further studies are recommended to explore the potential role of the immune system in the pathogenesis of this disease.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

L. Bree
University Veterinary Hospital
University College Dublin
Dublin, Ireland

URL: http://www.vin.com/doc/?id=8172670
MiRNAs in Progressing Canine Myxomatous Mitral Valve Disease

F. Traub; K. Weber; G. Wess
Clinic of Small Animal Medicine, Veterinary Faculty, LMU Munich, München, Germany

Microribonucleic acids (miRNAs) are short RNA molecules which regulate gene expression. They show a varying expression in many diseases, including heart disease. miRNAs are stable and detectable from blood. Therefore, they are potential biomarkers. Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs. In the long preclinical phase, progressive degeneration of the mitral valve leads to eccentric left-ventricular and -atrial hypertrophy, eventually succeeded by congestive heart failure and death. We aimed to investigate the expression of miRNAs in blood plasma of dogs in consecutive stages of MMVD.

One hundred-eighty-three miRNAs were quantified from blood plasma using RT-qPCR in 10 dogs passing 3 stages of MMVD (modified CHIEF stage B1, B2, and C2/C3). One-way repeated measures ANOVA and pairwise comparisons using Benjamini-Hochberg-correction showed significant differences (p<0.05) in expression within 3 miRNAs: cfa-miR-92b was downregulated in MMVD stage C2 compared to stage B1 and B2 by the factor of 0.52 and 0.61, respectively. cfa-miR-92a and cfa-miR-1306 were downregulated in MMVD stage C2 compared to stage B1 by the factor of 0.60 and 0.53, respectively. There was no significant difference between any other stages.

The results show that there were miRNAs in canine blood plasma that differed in expression with progressing MMVD. However, the total number of miRNAs varying and the difference between stages were small. To evaluate the role of miRNAs as potential biomarkers, further studies are needed - with a bigger population eventually including more stages of disease and healthy control subjects.

DISCLOSURES

The authors have the following disclosures related to the study described in their abstract: The American Kennel Club, Canine Health Foundation, Inc. (Raleigh, NC, USA) provided a research grant ($24,850) that covered the laboratory consumables used in this study. There was no further financial or other form of support. The authors do not have commercial interests and have not made investments related to the study. The authors’ institution does not benefit from the results of the study. There were no gifts, hospitality, or travel support.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

F. Traub
Clinic of Small Animal Medicine
Veterinary Faculty, LMU Munich
München, Germany

URL: http://www.vin.com/doc/?id=8172671
White coat effect is an elevation in blood pressure due to stress or anxiety in a clinical setting. Differentiating white coat effect from true systemic hypertension can be challenging. The objective of this study was to further characterize white coat effect in client-owned dogs and to determine if pharmacologic manipulation (butorphanol) decreases this effect.

Thirty client-owned dogs were enrolled. Clients were trained to collect high definition oscillometric (HDO) blood pressure measurements at home, and then HDO measurements were obtained in the hospital before and after the administration of butorphanol. A client questionnaire was completed to assess level of anxiety with measurements at home and in hospital.

Diastolic blood pressure (DYS), mean arterial pressure (MAP), and arterial pulse rate (HR) were significantly higher in the hospital before butorphanol as compared with at home. The administration of butorphanol abrogated these differences. The HR was significantly lower after sedation as compared with before sedation in the hospital, but it remained significantly higher as compared with that obtained at home.

The subjective anxiety scores at home and in the hospital were significantly positively correlated with the systolic (SYS), DYS, and MAP. Anxiety scores at home and in hospital were significantly positively correlated.

In conclusion, higher DYS, MAP, and HR seen in the hospital is likely related to a white-coat effect. The administration of butorphanol decreased this effect.

**DISCLOSURES**

No disclosures to report.

---

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**R.S. Tims**  
Oklahoma State University  
Stillwater, OK, USA

URL: [http://www.vin.com/doc/?id=8172672](http://www.vin.com/doc/?id=8172672)
Prevalence and Murmur Characteristics of Incidentally Detected Heart Murmurs and Heart Disease in 12,958 Young Healthy Shelter Cats

B.A.M. Mckeever¹; G.P. Nicolson¹; M. Awad²; M. Lawler²; B. Sette¹; N.J. Beijerink¹

¹Faculty of Science, Sydney School of Veterinary Science, The University of Sydney, Camperdown, NWS, Australia; ²RSPCA NSW, Yagoona, NWS, Australia

Information on the prevalence and cause of heart murmurs in young cats is scarce. This prospective study was performed to investigate prevalence of heart murmurs, and heart disease, and to explore the association between auscultatory and echocardiographic findings in clinically healthy young cats.

Between May 2012 and March 2017, 12,958 healthy cats aged ≤12 months were screened by auscultation by shelter veterinarians in a single animal shelter (RSPCA Yagoona, NSW, Australia). Heart murmurs were detected in 221 (1.7%) cats, which were subsequently within 1 month investigated by a veterinary cardiologist (NB) or cardiology resident (GN). Murmurs were confirmed in 163 cats. Murmur characteristics (timing, grade, point of maximal intensity) were recorded. All but one murmur were systolic. The point of maximum intensity of murmurs was often difficult to localise.

Subsequently transthoracic echocardiography was performed in all 221 cats, after which the murmur was assessed to be pathological or non-pathological. Cats with multiple congenital heart anomalies were classified according to the most severe condition. No efforts were made to differentiate between physiological and innocent murmurs, both were considered non-pathological.

Heart disease was detected in 51 cats (prevalence 0.4% total population). Diagnoses included obstructive (n=19) and non-obstructive (n=6) mitral valve dysplasia, ventricular septal defect (n=15), tricuspid valve dysplasia (n=7), pulmonic stenosis (n=1), double chamber right ventricle (n=1), subvalvular aortic stenosis (n=1), and hypertrophic cardiomyopathy (n=1). The murmur was non-pathological in 170 cats (of which 3 cats had dynamic right ventricular outflow tract obstruction).

Grade 5–6 murmurs (n=5) were all pathological. A positive predictive value of a grade 3–4 murmur being associated with pathological heart disease was 58.9% (CI 48.5% to 68.7%), whilst negative predictive values of grade 0 and grade 1–2 murmurs being associated with non-pathological heart disease were 96.6% (CI 87.0% to 99.1%) and 88.4% (CI 82.1% to 92.6%), respectively.

In conclusion, in this study the prevalence of heart murmurs and heart disease were 1.7% and 0.4%, respectively, with mitral valve dysplasia and ventricular septal defects most commonly diagnosed. Murmur grading was helpful in differentiating non-pathological from pathological heart murmurs.

DISCLOSURES
Disclosures to report.

This study received funding from Australian Pet Welfare Foundation (APWF) Authors: Niek Beijerink Speaking & Consultancies: Boehringer Ingelheim, Elanco Animal Health, Bova Compounding, CEVA Animal Health, Blackmores, Grants/Research: Luoda Pharma.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B.A.M. Mckeever
Faculty of Science
Sydney School of Veterinary Science
The University of Sydney
Camperdown, NSW, Australia

URL: http://www.vin.com/doc/?id=8172673
When Should We Talk about Tachypnoea in Cats at the Veterinarian's Consultation Room?

V. Szatmári; E. Dijkstra
Utrecht University, Utrecht, Netherlands

Tachypnea is an important clinical finding in dogs with cardiac and respiratory disorders. Many healthy cats, however, have a high respiratory rate at the veterinarian's consultation room, making the interpretation of this finding difficult. The purpose of the present study was to establish a reference range of the respiratory rate in clinically healthy cats at the veterinarian's consultation room.

Clinically healthy, client-owned cats in 6 private veterinary practices were observed by a single investigator between May and August 2016. The cats were brought for consultations for various reasons. Medical history and clinical examination revealed no abnormalities. The respiratory rates were recorded under 4 circumstances: by the investigator at the veterinarian's consultation room prior to and after manipulation, by the owner at home when the cat was resting or sleeping, and by the investigator by watching a video that was recorded by the owner at home when the cat was resting or sleeping. The owners were asked to perform the video-recording immediately after that they counted the respiratory rate.

A total of 95 adult cats with a median age of 4.7 years (range 8 months–17.1 years) fulfilled the inclusion criteria. Calculated reference interval for the respiratory rate at the veterinarian's consultation room was 33–133 breaths/minute.

Physical examination by a veterinarian led to either increased (n=13), decreased (n=10), or unchanged (n=3) respiratory rates in the 26 cats, on which this second measurement could be performed.

Video-recordings were provided by 77 owners. The resting and sleeping respiratory rates were 14–48 breaths/min (n=36) and 13–31 breaths/min (n=41), respectively, both counted by a single investigator on the video-recordings. A significant decline in sleeping respiratory rate with older age was noted: -0.4 breaths/minute/year. Only 32 owners were able to count the respiratory rate of her/his cat. In 17 out of these 32 cases the reported value differed from the respiratory rate that was observed from the video-recordings. The owners’ results were either higher or lower than the respiratory rates counted by the investigator on the videos.

We conclude that the reference intervals that veterinary textbooks usually report for healthy cats is the resting respiratory rate. These values are not applicable at the veterinarian's consultation room because many cats would erroneously be categorized to have tachypnea. Since the resting and sleeping respiratory rates show less variations, owners should be educated and encouraged to count or record their pets respiratory rate before they visit their veterinarian.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Szatmári
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172674
Innocent cardiac murmurs are often found in asymptomatic puppies at the age of 7–10 weeks. To what extent these soft murmurs are recognized by first opinion veterinary practitioners is unknown.

Between October 2015 and June 2016, 354 client-owned clinically healthy puppies of 11 different breeds with an age of 45–76 days were auscultated by a veterinary cardiology specialist and a final year veterinary student. The same dogs had been auscultated by various veterinary practitioners too, when they were 34–69 days old. Several practitioners of 43 different practices performed the auscultation, in average 9 days earlier than the cardiologist and the student. The student had undergone a 3-hour practical training in cardiac auscultation before starting the study.

The findings of the cardiologist, student, and practitioners were compared for agreement. The practitioners' judgements about the presence or absence of a murmur were looked up in the puppies' passport.

Of the 330 puppies that were auscultated by both the cardiologist and a practitioner, the cardiologist detected a murmur in 97 puppies. All murmurs were systolic and had a maximal intensity of 1 or 2 out of 6. The agreement between the findings of the cardiologist and the veterinary practitioners was poor (κ=0.008) and significantly different (p<0.001). Cardiac murmur was heard by the practitioners in only 1 of the 97 puppies with a murmur. A total of 255 puppies were auscultated by both the cardiologist and the student. A fair agreement (κ=0.401) and a significant difference (p=0.046) was found.

A weakness of the study is that the practitioners performed the auscultation on a different day and under various circumstances. However, because physiologic anemia is known to contribute to the genesis of innocent murmurs, the prevalence of innocent murmurs at the first veterinary health check should have been the same or higher than at the second time point.

We conclude that soft (innocent) cardiac murmurs in puppies at the age of 6–10 weeks are seldom recognized by first opinion veterinarians. Soft murmurs that are detected by practitioners are probably louder and therefore they are possibly not innocent, but are caused by congenital cardiac anomalies. Based on the better agreement between the findings of the cardiologist and the student, compared to the findings of the cardiologist and the practitioners we conclude that training has much higher effect on the recognition of soft cardiac murmurs than experience, even if the training is short.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Szatmári
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172675
Towards Cardiac Stem Cell Therapy: Characterisation and Cryopreservation of Canine Cardiosphere-Derived Cells

L.C. Dutton¹; S.A.V. Church¹; H. Hodgkiss-Geere²; B. Catchpole¹; A. Huggins¹; J. Dudhia¹; D.J. Connolly¹

¹Royal Veterinary College, Potters Bar, UK; ²University of Liverpool, Liverpool, UK

The use of stem cells to treat cardiac disease has gained increasing interest in recent years. Cardiosphere-derived cells (CDCs), an adult cardiac progenitor cell population, are the most promising candidates for cellular therapy. Their application in rodent models and phase 1 human trials of ischaemic myocardial disease showed promise measured by increased left ventricular function. However, much remains unknown about their basic biology, especially in dogs. To expand this treatment to treat canine dilated cardiomyopathy requires the creation of cryopreserved allogeneic cell banks since this allows timely access to large cell numbers and avoids obtaining diseased autologous myocardial tissue from potentially unstable dogs. However, CDCs in culture conditions are subject to plasticity similar to other adult stem cell populations. We therefore investigated how passage number or cryopreservation may affect cellular potency of CDCs obtained from canine atrial explants.

CDCs were isolated and characterised from five cadavers with consent. Mesenchymal stem cells (MSCs) were isolated for comparison. CDCs demonstrated a population doubling time that was slower than MSCs (p<0.05) but importantly was unchanged by cryopreservation (p=0.71). Cryopreserved CDCs also demonstrated the same multi-lineage potential as fresh cells by showing commitment to myocardial, endothelial and smooth muscle lineages and maintained the ability to form clonal colonies. Flow cytometry analysis revealed fresh CDCs had a high proportion of cells expressing CD105 (89.0±4.98) and CD44 (99.68±0.13) with varying proportions of CD90⁺ (23.36±9.78), CD34⁺ (7.18±4.03) and c-Kit⁺ (13.17±8.67) cells. CD45⁺ (0.015±0.005) and CD29⁺ (2.92±2.46) populations were negligible. Increasing passage number correlated with an increase in the proportion of CD34⁺ cells and a decrease in CD90⁺ cells (p=0.003 and 0.03 respectively). Cryopreserved populations displayed increased positive populations for CD34⁺ (p<0.001) and fewer CD90⁺ cells (p=0.042).

Our data revealed the impact of different canine donors on cell phenotype, as there was significant inter-donor variability on cellular morphology and marker expression. Overall, this study shows that despite these differences in the CD marker population, cryopreservation of canine CDCs is feasible without altering their differentiation potential. Importantly the CDCs we obtained from atrial tissue conformed to the generally accepted profile of CDCs obtained from other species and canine ventricular tissue. Further studies are required to investigate the fundamental biology and further characterise the phenotype of this heterogeneous stem cell population prior to clinical application.

Disclosures

Disclosures to report.

PetPlan Charitable Trust funded the research.

Speaker Information

click the speaker's name to view other papers and abstracts submitted by this speaker

D.J. Connolly
Royal Veterinary College
Potters Bar, UK

URL: http://www.vin.com/doc/?id=8172676
Assessing the Feasibility of Allogeneic Stem Cell Therapy for Canine Dilated Cardiomyopathy

L.C. Dutton1; H. Hodgkiss-Geere2; B. Catchpole1; D. Werling1; J. Dudhia1; D.J. Connolly1

1Royal Veterinary College, Potters Bar, UK; 2University of Liverpool, Liverpool, UK

Dilated cardiomyopathy (DCM) causes significant morbidity and mortality with the prevalence in European Dobermans >8 years at 44%. Clinical manifestations include a dilated phenotype with congestive heart failure or malignant arrhythmia causing sudden cardiac death. As treatment options are limited, there is interest in using cardiac stem cells. Cardiosphere-derived cells (CDCs) are an adult cardiac progenitor cell population that can be derived in large numbers from myocardial biopsies. Administration of CDCs to murine models of DCM showed improved survival and to Dobermans marginally increased systolic function. Allogeneic CDC therapy avoids obtaining cells from unhealthy donors and allows access to large cell numbers. Mesenchymal stem cells (MSCs) have been shown to induce an immune-tolerant phenotype in recipients from unrelated donors. However, MSCs are inferior to CDCs in their cardiac regenerative capability and it is currently unknown if canine CDCs possess a similar immune-privileged status.

Our aim was to characterise the immune-regulatory status of canine CDCs. Cardiosphere-derived cells (CDCs), MSCs and lymph node cells (LNCs) were obtained from five dogs immediately post-mortem with owners’ consent and university ethical approval. These cells were isolated as previously published. The ability of CDCs to form clones, self-renew, and commit to multiple lineages was assessed. Dogs were genotyped for DLA-88 and DRB-1 and cells assessed for MHC antigens by flow cytometry. Mixed lymphocyte reactions (MLR) incorporating responder LNCs and allogeneic stimulator CDCs or MSCs were performed. LNCs were also cultured alone or in combination with concanavalin A. Proliferation was assessed by 3H-thymidine uptake.

Canine CDCs demonstrated the ability to self-renew, form clonal colonies and commit to multiple lineages (myocardial, endothelial, and smooth muscle). All dogs in the study were heterozygous for both DLA-88 and DRB-1 and varied in haplotype. In MLR assays, lymphocyte proliferation ability was confirmed by response to concanavalin A stimulation. CDCs did not produce a significant proliferation in responder LNCs when compared to non-stimulated LNCs (p=0.36). This lack of response was confirmed across multiple donor and responder cells with mismatched MHC I and II haplotypes. Interestingly, allogeneic MSCs stimulated a response in LNCs when compared to non-stimulated cell LNCs (p=0.011).

These results show that CDCs do not produce an immunological response in an in vitro model of transplant immune-reactivity. This demonstrates that CDCs possess immune-privileged status. Our study provides evidence for the safe use of allogeneic CDCs to treat canine DCM.

DISCLOSURES
Disclosures to report.

PetPlan Charitable Trust funded this research.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

L.C. Dutton
Royal Veterinary College
Potters Bar, UK

URL: http://www.vin.com/doc/?id=8172678
The Association of Clinical, Laboratory, and Echocardiographic Findings with Survival in 108 Dogs Undergoing Pericardiocentesis: A Retrospective Study

D.G. Ohad1; G. Segev1; Y. Hazul1; Y. Bruchim1; S. Klainbart1; J. Milgram1; I. Aroch1; E. Kelmer1

1Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel; 2Givatayim Vet Clinic, Givatayim, Israel

The median survival time (MST) for dogs with cardiac tamponade (CT) varies from 1–3 months with hemangiosarcoma, to 5.2–24.8 months in heart-base-tumor related or non-neoplastic effusions. We evaluated the prognostic usefulness of clinical, laboratory and echocardiographic findings in dogs with CT. Data were collected retrospectively from 108 dogs with CT undergoing pericardiocentesis (PC) from 2006 to 2011. Dogs alive at 30 days following the first PC were defined as short-term survivors. Longer-term MST was determined from the medical records, and from follow-up telephone interviews. The prevalence of CT was one of 265 presented dogs (0.004%). The overall long-term MST was 44 days (range 0.5–1455). Dogs with a sonographically demonstrated cardiac mass had a shorter MST compared to others (19 vs. 90 days, p=0.005). Males were significantly over-represented. Golden Retriever dogs were over-represented and had a higher occurrence of idiopathic CT. Mixed breed dogs were under-represented. PC at the cardiology service, ascites upon presentation, an idiopathic CT, and pericardiectomy, were associated with a higher, while pallor and an inability to ambulate upon presentation were associated with a lower 30-day survival rate. Survival rates did not differ between dogs undergoing PC from the right or the left hemithorax. Survival rates did not differ between dogs undergoing a single and those undergoing several PCs. However, median time-intervals from the first-to-second and from the second-to-third PCs were significantly longer in survivors compared to non-survivors (35 vs. 9, p=0.001, and 21 vs. 5 days, p=0.04, respectively). Two dogs died prior to PC completion. Seven dogs had an underlying myxomatous mitral valve disease. Four of these were Dachshunds, of which three had a left atrial-wall rupture leading to an acute, hemorrhagic CT. In the remaining three, the pericardial effusate was a modified transudate. In 31 dogs, the drained effusate volume in the first PC significantly and positively correlated (r=0.77, p<0.0001) with the pre-PC sonographic apex-to-pericardial distance. There was no association between apex-to-pericardial distance (p=0.086) or volume of fluid drained during PC (p=0.5) with the 30-day survival. Generally, dogs presenting with CT have a poor long-term prognosis. However, Golden Retrievers, dogs selected for surgical pericardiectomy, those that present with ascites, without pallor, and are ambulatory and those with longer inter-pericardiocentesis intervals have higher survival rates. Survival rate is not affected by the side of hemithorax from which pericardiocentesis is performed.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

D.G. Ohad
Koret School of Veterinary Medicine
Hebrew University of Jerusalem
Rehovot, Israel

URL: http://www.vin.com/doc/?id=8172679
Usefulness of Colour TDI at the Level of Lateral Atrial Tissue as a Predictor of Future Development of Atrial Fibrillation in Dogs

J. Neves¹; P. Pedro²; X. Navarro-Cubas¹; E. Bode¹; J. Dukes-Mcewan¹

¹University of Liverpool, Neston, UK; ²Willows Vets, Solihull, UK

The total atrial conduction time is an independent predictor of atrial fibrillation (AF) in humans. It can be estimated by pulsed-wave tissue Doppler imaging (TDI) by measuring the time from onset of the P wave until the peak of A’ velocity of the lateral left atrial wall (P-PA’). A prolongation of P-PA’ identifies people at high risk of development of AF. This study investigated echocardiographic variables (including P-PA’ measured with Colour TDI) which may identify dogs which developed AF within 6 months.

All dogs with AF were retrospectively reviewed. Those that developed a new-onset AF within 6 months after previous echo were included in the AF group. Dogs with underlying cardiac disease that did not develop AF within 6 months after echo were also reviewed and included in the non-AF group. The non-AF group were selected to have similar body weight (BW) and left atrial dilatation (2D LA:Ao) to the AF group. P-PA’ durations were measured offline from archived colour TDI images by placing the region of interest over the interatrial septum (colour P-PA’IAS) and lateral left atrial wall (colour P-PA’lateral). P-PA’ durations and echo variables of 2D, M-Mode and pulsed-wave TDI (S’, E’ and A’ velocities) were compared between groups. Receiving operator characteristic curves were used to identify the best AF predictor.

Sixty-five dogs were included (22 AF; 43 non-AF). Degenerative mitral valve disease and dilated cardiomyopathy were the most frequent cardiac diseases in both groups. Risk of new-onset AF was not associated with a specific breed, gender, neutering status, or cardiac disease. BW, LA:Ao and colour P-PA’IAS were not significantly different between groups. The AF group had significantly greater left-ventricular (LV) end-diastolic (ED) and end-systolic (ES) volumes, M-Mode LV ED and ES diameters, LV ES diameter indexed for body weight, LV ES volume indexed to body surface area (ESVi), LA maximal diameter (LAm) and colour P-PA’lateral. The variables with highest area under the curve (AUC) were P-PA’lateral (0.8), LAm (0.73), and ESVi (0.70). A colour P-PA’lateral cut-off of 81.3 ms had a specificity of 81% and sensitivity of 65%.

Colour P-PA’lateral duration was superior to other echo variables at predicting AF development within 6 months. LAm had the second highest AUC despite similar LA:Ao between groups. Absolute LA size appears to play a more important role in AF than relative atrial dilation. Clinically useful cut-offs and intra/inter-observer variability need to be confirmed in a prospective study.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)
J. Neves
University of Liverpool
Neston, UK

URL: http://www.vin.com/doc/?id=8172680
ECG-Gated Computed Tomography Angiography of Patent Ductus Arteriosus in 25 Dogs

N.J. Beijerink; E. Newfield; G.P. Nicolson; H. Laurendet; M.A. Makara
Sydney School of Veterinary Science, University of Sydney, Camperdown, NSW, Australia

Patent ductus arteriosus (PDA) is one of the most common congenital cardiac diseases in dogs. ECG-gated computed tomography angiography (CTA) can be a complementary minimally-invasive way in early planning of interventional occlusion. The aim of this prospective observational study was to report CTA findings associated with PDA.

A total of 25 dogs diagnosed with PDA aged 2 to 54 months and weighing 2.5 to 38.1 kg were enrolled: all dogs were planned to undergo possible interventional occlusion under the same anaesthetic directly after CTA. The contrast medium injection protocol was individually tailored with total injection time equaling the sum of diagnostic scan delay and scan duration. First, 1 ml/kg undiluted contrast medium (370 mgI/ml) was administered for two thirds of the total injection time, directly followed by 2 ml/kg of 1:1 diluted contrast medium for one third of the total injection time. The CT scan was triggered manually under a single breath hold when the contrast bolus reached the descending aorta. Scanning was commenced regardless of the heart rate.

Image reconstruction was performed during mid-diastole (70% of the R-R interval). In 2 dogs the heart rate was too high (>140 BPM) to allow image reconstruction. In the other 23 dogs the sagittal plane of the images was optimized for visualization of the PDA. The minimal ductal diameter at the pulmonary ostium (median 3.4 mm, range 1.7–11.6 mm), ampulla diameter (median 7.0 mm, range 3.7–13.2 mm), ampulla length (median 10.7 mm, range 6.8–18.9 mm), angle between PDA and aorta (median 149 degrees, range 134–155 degrees) and Miller type PDA morphology (type I, n=5; type 2A/B, n=16; type III, n=2) were determined. A total of 23 dogs (all except the 2 dogs with a type III PDA morphology) subsequently underwent successful interventional occlusion, and in all dogs with available CTA images the suspected PDA morphology could be confirmed with fluoroscopy.

In conclusion, despite fluoroscopy remaining the gold standard for accurate sizing of the PDA prior to interventional occlusion, CTA is a complementary diagnostic method that may provide additional relevant information for planning of catheter-based intervention, potentially shorten surgery time and reduce the amount of radiation to which the clinician is subjected.

DISCLOSURES

No disclosures to report.


SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

N.J. Beijerink
University of Sydney
Sydney School of Veterinary Science
Camperdown, Australia

URL: http://www.vin.com/doc/?id=8172681
Transcatheter embolization of a patent ductus arteriosus (PDA) is a commonly performed minimally invasive cardiovascular intervention in dogs. Prophylactic antibiotics are routinely administered in the perioperative period to prevent implant-related bacterial endocarditis. Because of the worldwide increasing issue of antibiotic resistance, the question arises whether routine administration of prophylactic antibiotics is evidence-based.

The present retrospective case series included client-owned dogs that underwent a transcatheter embolization of their PDA at the author's clinic between 2004 and 2016. Further inclusion criteria were that the author had to be either the primary or the supervising surgeon, at least 3 months of follow-up information had to be available, at least one metal implant had to be delivered in the PDA, and no local or systemic antibiotics were given on the day of the intervention and the week thereafter. Follow-up information was gained either via telephone interview with the owner or with the referring veterinarian, or via re-check examinations at the author’s clinic.

In total 54 dogs fulfilled the inclusion criteria. The occlusion devices were detachable coils in 18 dogs, Amplatz canine ductal occluders (ACDO) in 35 dogs and a human Ampatzer duct occluder in 1 dog. All coils and ACDOs were implanted via the femoral artery with the dogs under general anesthesia under fluoroscopic guidance. The median age of the dogs at surgery was 4 months (range 2–95 months) and their median weight was 7.5 kg (range 1.9–35.7 kg). An immediate closure of the PDA was reached in 36 dogs. The median length of the procedure was 100 minutes (range 45–192 minutes). The median length of the follow-up was 25 months (range 3–157 months).

None of the dogs developed clinical signs that could be compatible with bacterial endocarditis within 3 months after the PDA-occlusion.

The most important weakness of the present study is its retrospective nature. Another weakness is that in the majority of cases the follow-up information was gained via telephone interview. However, bacterial endocarditis is a life-threatening condition, which would not cause only mild symptoms. Though the 3 months follow-up might look arbitrarily chosen, several veterinary and humans studies use the same cut-off. Moreover, a longer incubation period is very unlikely, if bacteria are assumed to enter the circulation during surgery.

The findings of the present study are in line with the most recent human recommendations, which do not recommend the routine use of prophylactic antibiotics at transcatheter PDA-embolization.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
V. Szatmári
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172682
Biological Variability of N-Terminal Pro-B-Type Natriuretic Peptide in Fifty-Three Healthy Labrador Retrievers Over an 8 Month Period

K. Borgeat¹; S. Gomart¹; M. Harrison²; A. Colyer²; F.J. Glen¹; J.R. Payne¹; M.J. Hezzell¹; D. Allaway²

¹Langford Vets, Bristol, UK; ²WALTHAM Centre for Pet Nutrition, Melton Mowbray, UK

Short-term biological variability of, and breed differences in, N-terminal pro-B-type natriuretic peptide (NTproBNP) that might influence interpretation of test results have been reported. This study aimed to assess the variability of plasma NTproBNP measurements over 8 months in healthy Labrador Retrievers, and also to investigate correlation between urine NTproBNP:creatinine ratio (UBNP-C) and plasma NTproBNP concentration.

Fifty-three Labrador Retrievers (median age 5.2 years, range 2.3–8.2 years) were maintained at WALTHAM in housing and with study procedures complying with the Animals (Scientific Procedures) Act 1986 (UK), and residual samples were used for this study. All dogs were healthy and echocardiographically normal. Serial sampling of fasted plasma and urine were performed (weeks 0, 8, 16, 24, and 32) including assessment of NTproBNP, measured in residual plasma and urine (latter indexed to creatinine).

The log_{10} (plasma NTproBNP) was analysed by a linear mixed model (REML) to allow for repeated measures on each dog over time, with a random effect of dog and categorical fixed effects of diet, week, and their interaction. Changes from baseline to weeks 8, 16, 24, and 32, and the changes between each week, were analysed. Percentage variability from baseline of plasma NTproBNP was calculated. An average plasma NTproBNP for each dog over the 5 study points was calculated (AV-BNP). NTproBNP standard deviation (SD-BNP) was also assessed. Spearman's correlation analysis was performed to investigate correlation between UBNP-C and plasma NTproBNP.

Clinically important values in plasma NTproBNP were detected, with wide intra-individual variability (70–130%). There was no association between percentage variability of plasma NTproBNP, SD-BNP or AV-BNP and any other measured variable, other than a mild, positive correlation between age and AV-BNP (r=0.429, p=0.002). A weak positive correlation between UBNP-C and plasma NTproBNP (rho 0.368, p<0.001).

Plasma NTproBNP measurements in clinically healthy Labradors are frequently outside laboratory reference intervals, creating false positive tests, compounded by significant measurement variability. UBNP-C has questionable clinical utility; further studies are necessary to validate this measurement.

DISCLOSURES

Disclosures to report.

Allaway, Harrison, and Colyer are employees of WALTHAM, a division of Mars Petcare Ltd. Reduced cardiac biomarker fees were provided by IDEXX Laboratories for this study.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

S. Gomart
Langford Vets
Bristol, UK

URL: http://www.vin.com/doc/?id=8172683
Clinical Use of a Patient-Side Feline NT-ProBNP ELISA Test in 281 Cats in General Practice

F. Glen¹; J.R. Payne²; M.J. Hazlett¹; K. Borgeat¹

¹Langford Vets, University of Bristol, Bristol, UK; ²Highcroft Veterinary Referrals, Bristol, UK

Although the utility of a patient-side NT-proBNP ELISA (BNP-POC) has been described in cats screened for cardiomyopathies, its usefulness in populations with potentially lower disease prevalence is unknown. This retrospective study aimed to describe general practice BNP-POC use and to estimate a positive predictive value (PPV) for echocardiographic evidence of cardiomyopathy in apparently healthy cats.

Clinical records from cats undergoing BNP-POC (March 2015–March 2017) were reviewed. Signalment, history, examination findings, and other clinical data were recorded, along with the veterinarian’s stated reason for test performance, test result (normal/abnormal), and echocardiographic findings (where available). Left ventricular wall thickness ≥6 mm classified cats as HCM, left atrial enlargement (LAE) was present where LA:Ao>1.5, LA diameter long-axis >16 mm).

BNP-POC was recorded in 281 cats: 155 were male and median age was 11.5 years (0.2–20.0). A murmur was detected in 207/281, a gallop in 24/281 and arrhythmias in 12/281. The most frequent reasons for testing were: auscultated abnormalities (61.6%), pre-anaesthetic assessment (14.9%), and possible cardiac-related signs (13.1%).

Results were abnormal in 93/281 cats (33%). Excluding those with clinical signs (n=37) or an unknown reason for testing (n=7) 81/237 apparently healthy cats tested abnormal: 39/81 underwent echocardiography. Of these, 23/39 (59%) had HCM, with 17/39 (44%) having LAE. No cats were diagnosed with other classes of heart disease.

In a general practice population of apparently healthy cats, BNP-POC had an estimated PPV for HCM of 59%, and for LAE of 44%. Prospective studies are needed to validate this test in a larger population.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

F. Glen
Langford Vets, University of Bristol
Bristol, UK

URL: http://www.vin.com/doc/?id=8172684
Diagnostic and Prognostic Utility of Surface ECG in Cats with Left Ventricular Hypertrophy

G. Romito¹; C. Guglielmini²; A. Diana¹; M.O. Mazzarella¹; M. Cipone¹; M. Baron Toaldo¹
¹University of Bologna, Ozzano Emilia, BO, Italy; ²University of Padova, Padova, Italy

In human cardiology, surface electrocardiography (ECG) is used for the risk stratification of patients affected by cardiomyopathies. The aim of the present study is to assess if ECG can show similar usefulness in cats with left ventricular hypertrophy (LVH).

Fifty-five privately owned cats (20 clinically healthy and 35 with LVH) were retrospectively selected. Complete physical examination, indirect measurement of arterial blood pressure, echocardiography, 2-minutes peripheral 6-lead ECG, and standard blood work, including serum thyroxine concentration were available. ECG measurements included: detection of any type of arrhythmia, heart rate, amplitude and duration of P wave and QRS complex, ST segment elevation or depression, mean electrical axis of P and T wave, and QRS complex, and PQ, QRS, QT, and QT corrected for heart rate (QTc) duration. In cats with LVH, outcome data and cause of death were annotated, when available.

Sinus rhythm was diagnosed in all healthy and in 24/35 (68.6%) cats with LVH. The remaining cats with LVH showed different types of rhythm disturbance, including third degree atrioventricular block (AVB) (2/35, 5.7%), sinus rhythm with isolated atrial (2/35, 5.7%) or ventricular ectopic complexes (2/35, 5.7%), sinus bradycardia (1/35, 2.9%), sinus rhythm associated with both first degree and second degree AVB (1/35, 2.9%), sinus rhythm associated with second degree AVB (1/35, 2.9%), accelerated idioventricular rhythm (1/35, 2.9%) and ventricular tachycardia (1/35, 2.9%). The presence of any type of arrhythmia had sensitivity of 31%, specificity of 100%, negative predictive value of 45%, and positive predictive value of 100%, in identifying LVH. ECG measurements were performed in all healthy cats and in 29/35 cats with LVH. Only QT and QTc were statistically different between healthy cats and cats with LVH (p<0.007 for both variables). Among the healthy cats, the highest values for QT and QTc were 180 ms, and 200 ms, respectively. Survival data were available for 23/29 cats with LVH where ECG measurements were performed. Of these 10/23 died for cardiac related cause. Median survival time was 58 days and not measureable for cats with QT>180 ms and QTc≥180 ms, respectively, and 125 days and not measureable for cats with QTc<200 ms and QTcs<200 ms, respectively. Both QT>180 ms and QTc<200 ms were predictors of death for cardiac related causes (p=0.042 and p=0.017, respectively).

Surface ECG seems to provide useful diagnostic and prognostic information in cats with LVH.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

G. Romito
University of Bologna
Ozzano Emilia, BO, Italy

URL: http://www.vin.com/doc/?id=8172685
Notched QRS Complexes in Dogs With and Without Structural Cardiac Disease: 85 Cases

R.L. Winter; R.M. Bates; S. Jung
Auburn University, Auburn, AL, USA

The objectives of this study were to describe the signalment and cardiac disease diagnosis in dogs with notched QRS complexes of normal duration, as well as to describe the specific leads and number of leads with notched QRS complexes on ECG. Medical records and ECGs from 85 dogs with notched QRS complexes in at least 1 ECG lead were evaluated. A retrospective review of digitally stored ECGs and associated medical records of dogs with a recorded ECG as part of routine clinical evaluation was performed. Medical records were reviewed for signalment and cardiac disease diagnosis in dogs with notched QRS complexes identified. The age at time of ECG recording was 9.15 ± 3.38 years for the 85 dogs with notched QRS complexes in at least 1 ECG lead. Most dogs (78.8%) had 3 or less ECG leads with notched QRS complexes. Most dogs (69.4%) with notched QRS complexes in at least 1 lead had cardiac disease. The odds ratio of a dog having cardiac disease if more than 1 lead was identified with notched QRS complexes was 3.97. The most common cardiac disease identified was chronic atrioventricular valvular degeneration (CVD), and the majority of these dogs (80%) had 2 or less leads with notched QRS complexes. In conclusion dogs with and without cardiac disease can have notched QRS complexes, and the likelihood of a dog having cardiac disease that has more than 1 ECG lead with notched QRS complexes is significant which should warrant diagnostic evaluation.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.L. Winter
Auburn University
Auburn, AL, USA

URL: http://www.vin.com/doc/?id=8172686
Poster Presentations

Reliability of Vena Contracta for Staging Degenerative Chronic Mitral Valve Disease in Dogs  A. Caro-Vadillo
Retrospective Analysis of Pulmonary Hypertension in Cats with Left-Sided Congestive Heart Failure  T. Vezzosi
Frequency of Mitral Valve Prolapse in Adult Healthy Dachshund Dogs  M.H.M.A. Larsson
Prevalence of Pulmonary Hypertension in Dogs Naturally Infected with Angiostrongylus Vasorum  E. Darnis
Symmetric Dimetyl-Arginine in Dogs with Myxomatous Mitral Valve Disease With and Without Pulmonary Hypertension  M. Berlanda
Left Ventricular Hypertrophy in Dog: An Echocardiographic Study  C. Locatelli
Pulmonary Vein to Pulmonary Artery Ratio in Healthy and Cardiomyopathic Cats  V. Patata
Comparative Analysis of a Portable Smartphone-Based Electrocardiograph (D-Heart®) Versus Standard 6-Leads Electrocardiograph in the Canine Patient  A.S. Savarese
Use of Graphic Organisers in an Elective Veterinary Cardiology Course  J.L. Ward
Frequency of Heart Murmur in 69 Healthy Adult Dachshunds  C.T. Amaral
Choline Concentration as a New Potential Biomarker to Distinguish Pleural Effusions from Heart Base Tumours and Cardiomyopathy in Dogs  P.L. Levent
Utility of the SNAP Feline N-Terminal Pro-B-Type Natriuretic Peptide Test in Detecting Asymptomatic Hypertrophic Cardiomyopathy: A Prospective Study in 61 Cats  C. Damoiseaux
Reliability of Vena Contracta for Staging Degenerative Chronic Mitral Valve Disease in Dogs

A. Caro-Vadillo¹; E. Pintado-Carretero², A. Casasússolea³

¹Complutense Veterinary School, Madrid, Spain; ²Centro Veterinario Asís, Alcazar De San Juan (CR), Spain; ³Servicio Veterinario de Ecografía de Alejandro Casasús, Madrid, Spain

It is important to obtain an accurate quantification of mitral regurgitation severity. This fact is especially important in order to identify B2 patients - ACVIM classification - that can benefit from starting medication or to prevent congestive heart failure. The vena contracta is the narrowest portion of a jet downstream from the regurgitant orifice. The objective of the present study is to prove if the vena contracta could be used as criteria for classification in dogs with DCMVD.

One hundred and thirteen dogs suffering from DCMVD in different phases according to ACVIM classification, have been included: B1, n=54; B2, n=51 and C, n=8. The vena contracta was measured from the parasternal left apical four-chamber long axis view. Three measurements were obtained for each dog and the average was obtained. The results showed a statistically significant difference between stages for end-diastolic left ventricular index (EDVI), end-systolic left ventricular index (ESVI) and vena contracta (Kruskal-Wallis for independent samples test). The differences were significant between B1 dogs and B2 dogs (p=0.022) and between B1 and C dogs (p=0.035) for vena contracta. The differences were significant between B1 dogs and B2 dogs (p<0.0001) and between B1 and C dogs (p<0.001) for EDVI. The differences were significant between B1 dogs and B2 dogs (p=0.044) and between B1 and C dogs (p=0.032) for ESVI.

There were no differences for these values between B2 and C dogs. The vena contracta appears to be useful to differentiate between early phases of DCMVD and congestive phase of DCMVD but it seems less useful to differentiate between B2 dogs and C dogs. It is important to remember that this measurement is not useful if multiple jets are present, which is common in dogs with DCMVD. The vena contracta has an ellipsoidal shape so the measurements could vary depending on the plane of acquisition. Due to the fact that the vena contracta usually is small (typically less than 0.5 cm), slight measurement errors could lead to large mistakes and misclassifications. In humans, it is recommended to measure the vena contracta from the right parasternal long axis. All of these factors must be taken into consideration from a critical point of view in the face of the present results.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Caro-Vadillo
Complutense Veterinary School
Madrid, Spain

URL: http://www.vin.com/doc/?id=8172695
Retrospective Analysis of Pulmonary Hypertension in Cats with Left-Sided Congestive Heart Failure

T. Vezzosi¹; K.E. Schober²

¹University of Pisa, San Piero a Grado (PI), Italy; ²Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, USA

Pulmonary hypertension (PH) is present in approximately 70–80% of dogs with left-sided congestive heart failure (L-CHF) and contributes to clinical signs and outcome. Anecdotal evidence suggests that PH in cats with L-CHF is much less frequent. However, data on the prevalence of PH in cats with L-CHF is not available. This study addresses the general hypothesis that PH secondary to L-CHF is uncommon in cats and that echocardiographic findings in cats with PH are different compared to dogs.

This retrospective observational study included 56 healthy cats and 131 cats with L-CHF imaged between 2004 and 2016 at the Veterinary Medical Center, Ohio State University. Key diagnostic variables included tricuspid regurgitation (TR) peak velocity, right atrial (RA) size, right ventricular (RV) size and function, RV wall thickness, pulmonary artery (PA) size, Doppler-derived systolic time intervals of PA flow (STIs), presence of septal flattening, and variables characterizing left atrial size and left ventricular size and function. PH was identified if TR peak velocity was >2.7 m/s (estimated systolic PA pressure >35 mm Hg). Parametric and non-parametric statistical test procedures were used to compare normal cats to cats with L-CHF, and cats with and without PH.

Tricuspid regurgitation was present in 57/131 (44%) of cats with L-CHF. Pulmonary hypertension was present in 22/131 of cats with L-CHF (17%). In 15/22 cases PH was associated with cardiomyopathy, in 5/22 cases with congenital heart disease, and in 2/22 cases to other causes. All cats with PH (22/22, 100%) had subjectively-assessed right-sided enlargement, with larger RA and RV diameters (p<0.0001), thicker RV wall thickness (p<0.05) and higher prevalence of septal flattening (6/22, 27%, p<0.0001) in comparison to cats without PH. Pulmonary artery size and Doppler-derived STIs were not statistically different between cats with and without PH. Maximum right atrial diameter (>21.5 mm; Sensitivity [Sn] 0.82, Specificity [Sp] 0.42) and RV ventricular diameter (>7.8 mm; Sn 0.91, Sp 0.64) had the most accurate cutoff to predict PH compared to other variables. Method reproducibility (measurement variability) was good, with most coefficients of variation <15%.

Compared to dogs, PH is not a common finding in cats with L-CHF. Right-sided enlargement is the main finding in cats with PH, and right-heart dimensions should be used to suspect PH if TR is absent or difficult to measure. Further studies are needed to identify reasons and mechanisms for the obvious differences between dogs and cats.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Vezzosi

University of Pisa
San Piero a Grado, PI, Italy

URL: http://www.vin.com/doc/?id=8172700
Frequency of Mitral Valve Prolapse in Adult Healthy Dachshund Dogs

P.H. Itikawa; G.T. Goldfeder; A.M. Gimenes; P.S. Backschat; S.L. Oliveira; D.P.S. Oliveira; C.A.B. Lorigados; M.H.M.A. Larsson

School of Veterinary Medicine and Animal Science, University of São Paulo, Sao Paulo, Brazil

Dachshunds are affected by chronic mitral valve disease (CMVD) which is the most often heart disease in dogs. CMVD develops mainly in small animals, but in chondrodystrophic breeds is more common. Dachshunds are predisposed to develop mitral valve prolapse (MVP) which is a systolic displacement of one or both mitral leaflets beyond the mitral valve annulus. The MVP is associated with marked sinus arrhythmia in Dachshunds. The hypothesis is that adult healthy Dachshund dogs are predisposed to exhibit MVP before mitral regurgitation. We performed a prospective study with client-owned animals that were screened by physical examination, thoracic radiography, electrocardiography, systolic blood pressure measurement, echocardiography, and laboratory tests (CBC, biochemical blood urea, and creatinine). A complete echocardiographic examination with electrocardiogram monitoring was performed. We enrolled 69 Dachshund healthy dogs (28 [40.6%] males and 41 [59.4%] females); from 18 months to 10 years-old, weighting 8.4±2.3 kg. No heart diseases were observed, including mitral regurgitation. Mild MVP was present in 28 (40.58%). Of these, 24 (85.71%) with sinus arrhythmia, 3 (10.71%) with normal sinus rhythm and 1 (3.57%) with sinus tachycardia. In addition, those with sinus arrhythmia, 17 (70.83% with mild) and 7 (29.16% with marked) sinus arrhythmia. Therefore, healthy adult Dachshund dogs may present MVP associated with marked sinus arrhythmia that can be a predisposing factor to develop mitral regurgitation in the future.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.H.M.A. Larsson
School of Veterinary Medicine and Animal Science
University of São Paulo
Sao Paulo, Brazil

URL: http://www.vin.com/doc/?id=8172701
Prevalence of Pulmonary Hypertension in Dogs Naturally Infected with *Angiostrongylus Vasorum*

E. Darnis; K. Gommeren; C. Clercx; K. McEntee; A.C. Merveille
Liège University, Liège, Belgium

Pulmonary hypertension (PH) has been reported in dogs infected with *Angiostrongylus vasorum*. Moderate to severe PH was identified in a small portion of dogs, associated with shorter survival time in a retrospective study. Only mild PH was identified in experimentally infected dogs. The objective of this study was to determine the prevalence and severity of PH in dogs presented to a university clinic with *A. vasorum* infection and to describe associated echocardiographic changes in these dogs.

Dogs presented between November 2013 and February 2017 with confirmed *A. vasorum* infection based on positive Baermann coproscopy, Ag detection in blood, or PCR in BALF were retrospectively included. Diagnosis of PH was based solely on radiography (group 1) or plus echocardiography (group 2). In group 2, PH severity was determined by tricuspid regurgitation velocity (TRmax), pulmonic insufficiency velocity (PRmax). When no regurgitation was measurable, indirect signs of PH such as, right heart remodeling, main pulmonary artery dilation (PA/Ao), acceleration time to ejection time (AT/ET), tricuspid annular plane systolic excursion (TAPSE), and pulmonary vein diameter-to-pulmonary artery diameter ratio (PV/PA) were taken into account.

Thirty-six dogs were included (group 1: 16; group 2: 20). Median age at the time of diagnosis was 4.5 years (3 months to 10 years). Chronic cough, dyspnea, and exercise intolerance were the main clinical complaints.

In group 2, 40% of dogs (8/20) had severe PH, 7/8 displaying a right apical systolic heart murmur, and 3/8 being in right-sided congestive heart failure. Prevalence of moderate and severe PH in group 2 was 65% (13/20), two dogs displaying only indirect signs of PH. In these dogs, median TRmax and PRmax were respectively 4.65 m/s (3.93–6.28), and 2.75 m/s (2.03–3.73). Median AT/ET, PA/Ao, PV/PA were 0.295 (0.178–0.49), 1.05 (0.64–1.28), and 0.7 (0.4–1.3), respectively. Right ventricular dilation was observed in 11/13 dogs and was considered as severe in all dogs with severe PH. However, TAPSE was within confidence interval for all dogs.

In group 1, only 25% of dogs had evidence of PH with mild enlargement of pulmonary arteries. However, in group 2, two dogs with severe PH had normal pulmonary vasculature on x-ray, questioning the sensitivity of thoracic radiography for PH.

In conclusion, based on Doppler-echocardiography, the prevalence of moderate and severe PH in dogs naturally infected with *A. vasorum* seems more important than previously described. Systematic ultrasound scanning of dogs infected with *A. vasorum* is advised to evaluate presence and severity of PH.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Darnis
Liège University
Liège, Belgium

URL: http://www.vin.com/doc/?id=8172702
Symmetric Dimethyl-Arginine in Dogs with Myxomatous Mitral Valve Disease With and Without Pulmonary Hypertension

H. Poser; M. Berlanda; S. Graziotto; T. Badon; B. Contiero; C. Guglielmini
University of Padua, Legnaro, Italy

The symmetric dimethyl-arginine (SDMA) is produced by protein metabolism and eliminated by renal clearance. In the recent years, it has been used as a marker of kidney disease as it correlates with the glomerular filtration rate. In humans, SDMA is increased in patients with cardiovascular disease and has a negative prognostic value. The aim of the study is to assess the SDMA in dogs with myxomatous mitral valve disease (MMVD) at various disease stages, to evaluate the effect of pulmonary hypertension (PH) and the possible influence of cardiovascular therapies.

Dogs visited between May-2014 and September-2016 were retrospectively recruited if they had a diagnosis of MMVD after complete cardiovascular assessment (physical examination, thoracic radiogram, ECG, trans-thoracic echocardiography), CBC, biochemistry profile, and a sample of serum stored at -20°C (n=45). A control group of healthy dogs was also included (n=8). Dogs with MMVD were divided according to the ACVIM guidelines in stage B1 (n=9), B2 (n=11), C+D (n=17). Dogs in the ACVIM-groups were further subdivided into treated (n=0, 3, and 14,) and non-treated (n=9, 8, 3) for groups B1, B2, and C+D respectively. Dogs were considered affected by PH if they had tricuspid regurgitation with peak velocity >3 m/s and no right ventricle outflow tract obstruction (n=11). SDMA was determined by a referring laboratory using a routinely available immunoassay. Selected echocardiographic, CBC, biochemical parameters, and SDMA were compared among ACVIM-groups using Kruskal-Wallis test; the same test was used to assess the combined effect of therapies and ACVIM-group on serum urea nitrogen (BUN), creatinine, and SDMA. Correlations between SDMA and echocardiographic, CBC, and biochemical variables were assessed using Pearson’s test. Man-Whitney test was used to assess differences of SDMA between PH-groups.

SDMA was increased in ACVIM-group C+D compared to group B1 (p=0.035) and B2 (p=0.021); BUN was increased in group C+D compared to healthy (p=0.01), B1 (p=0.007), and B2 (p=0.009), while creatinine was not significantly different among groups. SDMA was positively and significantly correlated with BUN (r=0.55; p<0.001), creatinine (r=0.529; p<0.01), sodium (r=0.448; p=0.003), left-atrium to aorta ratio (r=0.335; p<0.025) and mitral valve e-wave velocity (r=0.334, p=0.27). Treatment did not significantly affect SDMA, BUN, or creatinine in any ACVIM-group. No significant difference of SDMA was observed between PH-groups.

Increased SDMA is observed in the advanced stages of canine MMVD and likely reflects reduced renal function better than BUN and creatinine. Therapies and PH do not seem to affect SDMA in dogs with MMVD.

DISCLOSURES

Disclosures to report.

SDMA was determined by IDEXX Laboratories and the cost of the analysis was partially reduced.

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

M. Berlanda
University of Padua
Legnaro, Italy

URL: http://www.vin.com/doc/?id=8172703
Left Ventricular Hypertrophy in Dog: An Echocardiographic Study

C. Locatelli¹; A. Savarese¹; P.G. Brambilla¹; I. Spalla²

¹University of Milan, Milan, Italy; ²Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, UK

The assessment of the severity of left ventricular (LV) hypertrophy in human medicine consists of three main cardiac parameters: LV wall thickness, LV mass (LVM), and LV geometry. The latter is assessed either by LVM/body surface area (BSA) and relative wall thickness, RWT. Based on LV geometry, the LV is classified as normal if LVM/BSA and RWT are within reference ranges, concentric remodelling as normal LVM and increased RWT, concentric hypertrophy as increased LVM and RWT and eccentric hypertrophy as normal/decreased RWT and increased LVM. Data about normal values for LVM and RWT are scant in dogs.

The aims of this retrospective study were: 1) to determine normal values for LVM/BSA e RWT (M-mode derived) in healthy dogs, 2) to evaluate the effect of sex, age, and breed on these echocardiographic parameters and 3) to compare LVM/BSA e RWT in healthy (>7 years) and hypertensive dogs.

The clinical archive (2015–2016) of the cardiology unit of DIMEVET (University of Milan, Italy) was searched for all dogs with a complete echocardiographic examination and systemic blood pressure determination. Dogs were grouped into healthy (based on no cardiac, metabolic, or renal disease) or hypertensive (according to ACVIM guidelines). From the digitally stored echocardiographic M-mode data, LVM/BSA and RWT were calculated. LVM was derived from geometric formula and indexed to BSA. RWT was calculated as the ratio between 2x posterior wall thickness and LV internal diameter at end diastole.

Eighty-three healthy dogs (48 female/35 male) and 26 hypertensive dogs were included in the study. The mean (SD) LVM/BSA and RWT were respectively 151g/m² (57) and 0.53 (0.10) in healthy dogs. No difference in sex and age (dogs >7 years vs. <7 years) was found. Sighthound dogs (n=20) showed a statistically larger LVM/BSA (221 g/m² vs. 129 g/m², p=0.00) with similar RWT than non-sighthound dogs (n=63) (0.54 vs. 0.53, p=0.74). Hypertensive dogs showed otherwise a statistically different RWT (0.69 vs. 0.55 p=0.011) from healthy dogs >7 years with similar LVM (153 vs. 132 g/m², p=0.098).

The results of our study suggest that these echocardiographic parameters may be of help in routinely classifying the hypertrophy pattern/LV geometry in dogs. In contrast with human findings, no sex difference was found in LVM/BSA. Sighthound dogs tended to show greater LVM/BSA values, likely to represent physiologic hypertrophy (normal RWT with increased LVM/BSA). Dogs with systemic hypertension had increased RWT with normal LVM and this could represent the first response of the LV to pressure overload.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Locatelli
University of Milan
Milan, Italy

URL: http://www.vin.com/doc/?id=8172704
Pulmonary Vein to Pulmonary Artery Ratio in Healthy and Cardiomyopathic Cats

V. Patata1; D. Caivano2; M. Rishniw3; H. Poser4; O. Domenech2; F. Marchesotti2; M.E. Giorgi2; F. Spina2; F. Birettini2

1Istituto Veterinario di Novara, Novara, Italy; 2Department of Veterinary Medicine, University of Perugia, Perugia, Italy; 3Veterinary Information Network, Davis, CA, USA; 4Department of Cardiology, Istituto Veterinario di Novara, Novara, Italy; 5Department of Animal Medicine, Production & Health, University of Padua, Padua, Italy

Recognition of congestive heart failure (CHF) in dyspnoeic cats is crucial for correct intervention. The pulmonary vein (PV) to pulmonary artery (PA) ratio (PV/PA) has been proposed as an index that might help discriminate dogs in CHF but has never been studied in cats. We sought to determine reference intervals for various, previously published, PV and PA variables in healthy cats. We then examined these variables in cats with subclinical and clinical (CHF) cardiomyopathies to determine the diagnostic utility in identifying CHF.

We prospectively enrolled 99 cats: 51 healthy cats, 24 subclinical cardiomyopathic cats, and 24 cardiomyopathic cats with CHF. PV and PA were measured at the minimal and maximal diameters from M-mode images obtained from a modified right parasternal long axis view. Aorta and left atrium were measured from the right parasternal short axis just after the end of systole.

Median PVmin/PAmin in healthy cats was approximately 0.51 and PVmax/PAmax was 0.67. The median distensibility of the vessels was 23% for ΔPA and 41% for ΔPV. Several variables (PVmax/PAmax, PVmax/Ao and PVmin/Ao) increased incrementally between all 3 groups (p<0.0001). Cats with CHF had a larger PVmin/PAmin than subclinical and healthy cats (p<0.0001). When evaluating diagnostic performance of these variables (using only cardiomyopathic cats with or without CHF), PVmin/PAmin and PVmin/Ao had 100% specificity and 84% and 80% sensitivities, respectively. By comparison, LA/Ao had 71% specificity and 88% sensitivity.

Our study provides reference values for PV and PA variables in cats. Moreover, PV/PA variables performed better than LA/AO in discriminating cardiomyopathic cats with and without CHF.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Patata
Istituto Veterinario di Novara
Novara, Italy

URL: http://www.vin.com/doc/?id=8172705
Comparative Analysis of a Portable Smartphone-Based Electrocardiograph (D-Heart®) Versus Standard 6-Leads Electrocardiograph in the Canine Patient

A.S. Savarese¹; C.L. Locatelli¹; N.M. Maurizi²; N.B. Briante³; P.G.B. Brambilla¹

¹University of Milan, Milan, Italy; ²Dept. of Clinical and Experimental Medicine, University of Florence, Florence, Italy; ³D-Heart srl, Genova, Italy

Electrocardiogram (ECG) is an essential tool for diagnosing and monitoring cardiac arrhythmias in veterinary medicine. However, a low-cost, user-friendly, 6-leads, smartphone-based electrocardiograph is still lacking.

D-Heart® is a portable, smartphone-based device, which streams the tracing via Bluetooth to any smartphone, enabling the acquisition of an ECG on multiple leads, currently used in human cardiology.

The aim of this study was to determine the accuracy of D-Heart® tracings, compared with the gold standard non-portable 6-lead electrocardiograph in dogs.

Standard 6-lead ECGs and D-Heart® ECGs were subsequently acquired in conscious dogs in right lateral recumbency. Each tracing was saved with an anonymous ID. Two experienced observers, independent and impartial, performed data analysis. In case of disagreement, a third impartial observer adjudicated the tracing.

The sample was described, for continuous variables, by mean and standard deviation or median and interquartile range (IQR), when appropriate, and for categorical variable by proportion. The concordance between the ECG methods was assessed by weighted kw-Cohen index, with its relative significance, taking as the end point variable the standard 6-lead ECG group. The Bland-Altman method with a 95% confidence level was applied for P, PR, QRS, T, and QT interval measurements. Since differences between the two measurements did not follow a normal distribution, a non-parametric approach (median value and IQR) was used to determine the limits of agreement. P values were considered significant at the 0.05 level. Amplitude of the waves was not considered in this preliminary analysis because currently the software doesn't allow voltage variation.

One hundred fifteen dogs of different weights and breeds admitted to the cardiology service of DIMEVET were enrolled. Mean age of dogs was 7.5±4 years. Most were intact males (45%, n=51). The most represented breed were mongrels (27%, n=32).

Weighted Cohen's kappa (kw) test between ECGs demonstrated an excellent concordance of 0.989 (p<0.001) in the evaluation of the heart rhythm, of 0.991 (p<0.001) for ST segment morphology and of 0.838 (p=0.040) for T wave morphology. There was a 100% concordance among P morphology assignment. P, PR, QRS, T, and QT intervals comparison with Bland-Altman method showed an extremely good concordance for D-Heart® measurements (95% limit of agreement ±0.9 ms for P, ±10 ms for PR, ±35 ms for QRS, ±5 ms for T wave). Less concordance resulted for QT (±80 ms).

D-Heart® proved effective accurate recording of ECG comparable to standard 6-lead ECG, opening new perspectives to improve diagnostic tools in veterinary cardiology.

DISCLOSURES

Disclosures to report.

This project was funded by D-Heart. Niccolò Maurizi and Nicolò Briante are the co-founders of the social innovative start-up D-Heart.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.S. Savarese
University of Milan
Milan, Italy

URL: http://www.vin.com/doc/?id=8172706
Use of Graphic Organisers in an Elective Veterinary Cardiology Course

J.L. Ward¹; S.B. Marcketti²

¹College of Veterinary Medicine, Iowa State University, Ames, IA, USA; ²Center for Excellence in Learning and Teaching, Iowa State University, Ames, IA, USA

Effective teaching methods are critical for veterinary student learning of complex subjects such as cardiology. Graphic organizers (GO) are visual and spatial displays, such as tables or charts, that facilitate learning by making conceptual relationships between content more apparent. We hypothesized that, in an elective veterinary cardiology course, study aids in the form of GOs would lead to improved learning outcomes (higher post-test scores), improved study efficiency (less time spent studying), and higher student satisfaction compared to traditional outline (OUT) format.

This study was a mixed-method prospective randomized crossover design. Study participants (n=31) were 3rd year veterinary students at the Iowa State University, College of Veterinary Medicine enrolled in an elective veterinary cardiology course. Participants completed a comprehensive pre-test and were randomized into two groups (A and B). All students received identical cardiology content presented by the instructor via live weekly in-class lectures. Following 8 pre-designated "experimental" lectures, students were given instructor-prepared study aids summarizing the lesson material, presented in either GO or OUT format. The following week, students completed a post-test of content knowledge for that lesson only, and indicated the amount of time they spent studying for that lesson. Crossover occurred such that Group A and Group B alternated between receiving GO and OUT for each experimental lesson. Qualitative data were collected in the form of in-depth pre-course and post-course surveys.

Groups were comparable at baseline in terms of demographic data, academic achievement, pre-course survey results, and pre-test scores. Post-test scores did not differ (p>0.05) based on type of study aid provided to students for that lesson (GO versus OUT). Students spent an average of 10 minutes (17%) less time studying per lesson when using GO compared to OUT (p=0.05). Student satisfaction with both study aid formats was high, but students preferred GO over OUT in terms of study efficiency (p=0.002), visual appeal (p<0.001), ease of use (p<0.004), and likelihood of referencing the study aid in the future (p<0.001). In conclusion, in an elective veterinary cardiology course, use of GO compared to OUT format study aids resulted in equivalent higher study efficiency and student satisfaction, while resulting in equivalent short-term learning outcomes.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.L. Ward
College of Veterinary Medicine
Iowa State University
Ames, IA, USA

URL: http://www.vin.com/doc/?id=8172707
A physiological heart murmur (PHM) can be identified in animals with no structural abnormalities of the heart and great vessels. It is a sound produced by blood flow, usually detected in puppies, but can be commonly observed in healthy young adult dogs. PHM may be a result of an increased sympathetic tone, and is possible to be secondary to anxiety. It has been described in some breeds and in athletic dogs during adulthood. A cross-sectional study was performed with 69 healthy Dachshunds, including 28 males (40.6%) and 41 females (59.4%), aged between 18 months to 10 years-old and weighting 8.4 ± 2.3 kg. The dogs underwent through physical examination, blood testing, echocardiogram, electrocardiogram, blood pressure measurement, and thoracic radiography. No abnormalities were found. Systolic heart murmurs were detected in 36 dogs (52.2%): 32 (46.4%) with grade II/VI and 4 (5.8%) with grade III/VI (Levine/Freeman Scale). Murmurs were mostly located in mitral valve area (72.2%). Heart murmurs in adult dogs are frequently indicative of pathological conditions. However, none of the 36 dogs had structural heart abnormalities or systemic disturbances. Therefore, this study shows a high prevalence of PHM in healthy adult Dachshunds.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C.T. Amaral
School of Veterinary Medicine and Animal Science
University of São Paulo
Sao Paulo, Brazil

URL: http://www.vin.com/doc/?id=8172696
Choline Concentration as a New Potential Biomarker to Distinguish Pleural Effusions from Heart Base Tumours and Cardiomyopathy in Dogs

P.L. Levent¹; Z. Yilmaz¹; M.C. Cansev²

¹Uludag University Faculty of Veterinary Medicine, Bursa, Turkey; ²Department of Pharmacology, Uludag University Faculty of Medicine, Bursa, Turkey

Research of new biomarkers in body fluids to detect the primary problem is crucial in human and veterinary medicine. Although serum choline is suggested as emerging biomarkers in humans and dogs with myocardial ischemia, there is no available data on usefulness of choline levels for predicting cardiac events. Therefore, this study was aimed to evaluate the use of choline concentration as a potential biomarker for distinguishing pleural effusions due to heart base tumours (HBT) and dilated cardiomyopathy (DCM), and determine whether there was a correlation between pleural and serum choline levels in dogs.

Dogs with pleural effusion due to DCM (n=11) and HBT (n=8) were used as materials. Pleural effusions were diagnosed by clinical, radiological, and ultrasonographic (US) examinations along with US-guided thoracentesis. DCM was diagnosed based on the sum of the scores (≥6 points) recommended by European Society of Veterinary Cardiology taskforce. Pre-operative diagnosis of HBTs was confirmed by histopathological evaluations showing mesothelioma, chemodectoma, hemangiosarcoma, and aortic body tumours. Healthy age- and breed-matched dogs (n=10) were used as controls. Serum free-choline concentration of each sample was analyzed by high performance liquid chromatography in triplicate and results were expressed as micromolar (µM).

Serum choline concentrations in dogs were (median [range]) 14.8 (6.5–19.2) µM for healthy dogs, 14.7 (7.9–28.4) µM for DCM and 8.7 (5.0–13.9) µM for HBTs (but not significant between groups). There was a statistically significant difference (p<0.05) on choline concentration (Mean ± SEM) in pleural fluids between dogs with DCM and HBTs; 13.5 ± 3.9 µM and 23.1 ± 8.5 µM, respectively. Choline level was higher (p<0.05) in pleural fluid, compared to that of serum in dogs with HBTs, whereas there was not statistically significant difference between them in dogs with DCM. In all dogs (n=19), choline level in pleural effusions (24.9 ± 6.3 µM) was higher (p<0.001) than its serum level (10.6 ± 1.2 µM). There were no significant relationships (Pearson correlation) between choline levels in serum and pleural fluids in dogs with DCM and HBT.

These data suggest that pleural fluid choline concentration, rather than its serum concentration, might be used as a new potential biomarker for distinguishing from DCM and HBTs in dogs.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

P.L. Levent
Faculty of Veterinary Medicine
Uludag University
Bursa, Turkey

URL: http://www.vin.com/doc/?id=8172697

C. Poissonnier1, E. Bomassi2, V. Gouni3, C. Jamin1, C. Damoiseaux1, M. Lavennes1, J.L. Pouchelon1, L. Desquilbet1, V. Chetboul1

1National Veterinary School of Alfort, Maisons-Alfort, France; 2Centre Hospitalier Vétérinaire des Cordeliers, Meaux, France; 3INSERM U 955, Créteil, France

Ebstein anomaly (EA) is a rare type congenital heart disease characterized by an apical displacement of the tricuspid valve leaflets in the right ventricle (RV), causing dilation of the right atrium (RA) and decrease in the functional RV size. Few studies have been dedicated to canine EA. The objective of this retrospective study was to characterize the epidemiological, clinical, and echocardiographic findings associated with canine EA, as well as survival.

The case records of dogs diagnosed with EA by use of echocardiography (2002–2017) were reviewed. The study population consisted of 40 dogs with EA (median age at diagnosis=15 months [IQR 7–36], male-to-female ratio=1.5). Only medium to large breeds were represented, the most common breed being Labrador Retriever (24/40, 60%). Eight dogs (20%) had a hemodynamically compromise concurrent heart disease (n=7) or respiratory disease (n=1), and were therefore excluded from subsequent analysis.

A right apical systolic heart murmur (median grade=5 [IQR 4–5]) was detected in all dogs, and 13/32 dogs (41%) presented clinical signs related to EA. Dilation of the RA was moderate to severe in most dogs (median RA to left atrium [LA] ratio=1.45 [IQR 1.29–1.72]). Several echocardiographic indices used in human pediatrics to evaluate EA were calculated, including the displacement index (distance from the hinge point of the anterior mitral leaflet to that of the delaminated septal leaflet divided by body surface area: median=17.4 mm/m² [IQR 12.0–21.9]) and the Celermajer index (ratio between the RA area and the sum of the areas of the RV, LA and left ventricle, median=1.0 [IQR 0.5–1.3]).

Follow-up was available for 25/32 dogs. Death of cardiac origin was reported in 4/25 dogs (16%) and all-cause death in 8/25 dogs (32%); median age at all-cause death was 73 months. Median time to all-cause death was 74 months after the diagnosis of EA. Median time to cardiac death (CD) could not be calculated, due to the high proportion of dogs still alive at the end of study. It is estimated that 72% dogs [95% CI, 50–86%) did not present CD 160 months after the diagnosis of EA. Univariate analyses showed that time from diagnosis to CD was associated with the presence of ascites, clinical signs, a RA:LA ratio ≥2, the presence of a right thrill, and a Celermajer index ≥1.

In conclusion, RA enlargement is significantly associated with decreased survival time of dogs with EA although most may live years and may not die from CD.

DISCLOSURES

Disclosures to report.

C. Poissonnier: Fondation Un Coeur/Vetoquinol sponsoring for clinical projects unrelated to this study.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Poissonnier
National Veterinary School of Alfort
Maisons-Alfort, France

URL: http://www.vin.com/doc/?id=8172698
Utility of the SNAP Feline N-Terminal Pro-B-Type Natriuretic Peptide Test in Detecting Asymptomatic Hypertrophic Cardiomyopathy: A Prospective Study in 61 Cats

C. Damoiseaux¹; C. Poissonnier²; M. Rospabé¹; E. Trehicou-Sechi¹; R. Tissier³; O. Sarret²; V. Chetboul¹

¹Unité de Cardiologie d’Alfort, Ecole Nationale Vétérinaire d’Alfort, Maisons Alfort, France; ²IDEXX Laboratories, Saint Denis, France; ³Unité de Pharmacie-Toxicologie, Maisons Alfort, France

Hypertrophic cardiomyopathy (HCM) is the most common feline heart disease. Currently, echocardiography is the gold standard to diagnose feline HCM, including occult forms of the disease. However, this imaging technique requires expertise to interpret the data and represents a financial cost for the owner, thus limiting its widespread use for screening “apparently healthy” cats. Therefore, a rapidly assessed biomarker, such as a pet-side test able to identify asymptomatic HCM cats would be of interest.

Previous studies showed that the circulating cardiac biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) is significantly increased in cats with moderate to severe occult HCM, as compared to healthy cats. The aim of this prospective study was to determine the sensibility (Se) and specificity (Sp) of the Idexx SNAP Feline proBNP Test to diagnose HCM in asymptomatic adult cats.

MATERIAL AND METHODS

The study population consisted of prospectively recruited “apparently healthy” adult cats (2015–2017), with or without heart murmurs. Cats with congenital heart diseases, with other cardiomyopathy than HCM, with current or past diagnosis of congestive heart failure, and with gallop rhythm, were not included in the study. All cats underwent a complete physical examination, blood pressure measurement, serum urea and creatinine measurements, and conventional echocardiography. Total T4 was also assessed in cats >6 years old. Plasma NT-proBNP concentration was measured using EDTA-potassium samples and a commercially available feline specific assay. A Snap Feline NT-proBNP was also performed (positive detection limit: 200 pmol/L), according to the manufacturer's instructions.

RESULTS

The study population consisted of 61 “apparently healthy” cats (29 males and 32 females; median age: 4.9 years [1.1–16.6]; body weight: 4.6 kg [2.5–10.5]): 31 normal cats with both normal cardiac auscultation and echocardiography and 30 asymptomatic cats with a left apical systolic heart murmur either related to HCM (n=9, 6 diffuse HCM forms and 3 segmental HCM forms with hypertrophy of the sub-aortic interventricular septum) or to a minor to mild mitral valve regurgitation without any other echocardiographic abnormality (MVR; n=21). The SNAP test distinguished asymptomatic HCM cats from other “apparently healthy” cats (i.e., normal cats or cats with minor to mild MVR) with 64% sensibility (Se) and 100% specificity (Sp), the negative and positive predictive values were 93% and 100% respectively and when only considering diffuse HCM forms with 100% Se and 100% Sp.

In conclusion, the SNAP Feline NT-proBNP Test may help identifying diffuse HCM forms in asymptomatic cats.

DISCLOSURES

Disclosures to report.

Study financed by IDEXX's laboratories.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Damoiseaux
Unité de Cardiologie d’Alfort
Ecole Nationale Vétérinaire d’Alfort
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8172699
Scientific Programme

**Pharmacotherapy of Human Heart Failure**  Faiez Zannad, MD, PhD, INSERM

**Device Therapy for Human Heart Failure**  Faiez Zannad, MD, PhD, INSERM

**Minimally Invasive Repair of the Mitral Valve in Dogs: Is It a Feasible Option?**  Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)

**The LOOK Mitral Study: Is There Any Standard Treatment for Dogs with Mitral Valve Disease?**  Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)

**Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study**  Sonya Gordon, DVM, DVSc, DACVIM (Cardiology), Adrian Boswood, DVC, MA, MRCVS, VetMB, Jens Häggström, DVM, DECVIM (Cardiology)

**Evolution of a New Hybrid Technique for Treating Pulmonic Stenosis in Dogs**  Simon Swift, MA, VetMB, CertSAC, DECVIM-CA (Cardiology), MRCVS
Much progress has been accomplished over the last 30 years in the pharmacotherapy of human heart failure (HF). However, this is mainly limited to chronic HF with reduced ejection fraction (HFrEF). Evidence of benefit in HFrEF is of high level and based on multiple outcome trials (Level of evidence A), leading to strong grade of recommendations (Grade 1) in international guidelines. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) will soon be replaced by valsartan-sacubitril, a hybrid therapy comprising an ARB and a neprylisin inhibitor, which is shown to be more effective than ACEi (enalapril) in a recent landmark trial (PARADIGM-HF). Beta-blockers are the second pillar of therapy in HFrEF, and mineralocorticoid receptor antagonists (MRA) the third one, all based on high level of evidence for reducing CV mortality and HF admission. Ivabradine, a heart rate slowing agent, is grade II b level on the recent set of guidelines. However, despite being class IA guideline therapies, excessive perceived concern about safety hinders seriously optimal use in daily practice, depriving patients from such life saving therapy. Education, home monitoring and disease management programs are essential and help improve effective implementation and outcome.

Unfortunately, treatment of HF with preserved ejection fraction (HFpEF), which prevalence is ever rising as to become higher than that of HFrEF, is still empirical, relying only on better management of co-morbidities and risk factors, such as better control of hypertension and diabetes. All trials, with therapies effective in HFrEF, have been negative so far in HFpEF. One exception may be the MRA spironolactone, where some evidence suggests that it might be beneficial.

Another disappointing area is acute HF leading to hospital admission, the most common cause of admission in subjects more than 65 years of age and, together with cardiovascular death, source of the highest disability and socio-economic burden. None of the many trials is positive. Few medications add little to the decongesting effect of diuretic and nitrate vasodilator therapy. No therapy is associated with morbidity - mortality benefit. Therefore, the best treatment of acute HF is preventing it by the optimal use of chronic HF therapy.

Heart failure remains a very fertile area of investigation. Currently, many innovative compounds with various mechanisms of action are undergoing an extensive trial program.

Key References

Faiez Zannad, MD, PhD, INSERM
Centre d'Investigations Cliniques, Université de Lorraine, France

URL: http://www.vin.com/doc/?id=8172709
Device therapy in heart failure (HF) is a fertile area of investigation and progress. All therapies are being developed for HF with reduced ejection fraction (HFrEF), and most target severe HF. However cardiac resynchronisation therapy (CRT), targeting HFrEF with large ECG QRS (and mainly patients with left bundle branch block) is proven to be effective as early as NYHA class II, beyond and on top of pharmacotherapy, and receives a high grade of guidelines recommendation (1A) for improving survival and reducing the rate of HF admission. Implantable cardiac defibrillator (ICD) is effective in reducing sudden death in patients with EF below 35%. It is usually combined with CRT in patients with large QRS. Questionable cost effectiveness issues make the use of ICD and CRT limited and more so, to wealthy countries.

In more advanced HFrEF, left ventricular assist device (LVAD) is effective in prolonging survival and decreasing disability and is mainly used as a bridge to heart transplant. It tends now also to be used as destination therapies in patients unlikely to receive a heart transplant.

A large array of other device therapies, based on a much lower level of evidence is currently competing for an increasing segment of HF population (i.e., patients remaining symptomatic despite optimal medical therapy). Penetration is still anecdotal. Autonomic modulation therapy is being tested with disappointing findings with vagal nerve modulation and renal sympathetic denervation and promising results with baroreceptors stimulation.

An even larger array of innovative technologies is being tested, culminating with the total artificial heart. This area is receiving a high level of interest by large and smaller Medtech companies and is very competitive. It is also facing increasing regulatory requirements of safety, efficacy and cost effectiveness, potentially limiting enthusiasm and investment in research and development.

**KEY REFERENCES**


**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Faiez Zannad, MD, PhD, INSERM
Centre d'Investigations Cliniques
Université de Lorraine, France

URL: [http://www.ven.com/doc/?id=8172710](http://www.ven.com/doc/?id=8172710)
Minimally Invasive Repair of the Mitral Valve in Dogs: Is It a Feasible Option?
Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)
Dept. Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA

KEYNOTE MESSAGE
Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs, and the principal cause of congestive heart failure (CHF) in this species. Dogs affected by MMVD are currently treated medically in order to control clinical signs of CHF. Although drug therapy was demonstrated to reduce mortality, the underlying cause of clinical signs, mitral regurgitation, is not specifically addressed by medical therapies and the disease is progressive. In humans, standard care of patients with MMVD is surgical mitral valve repair, but the invasiveness, complexity, and high cost of this procedure has limited its implementation in veterinary medicine. Therefore, minimally invasive mitral valve repair/replacement represents an appealing alternative to the open heart surgery in veterinary medicine. In this session, current options for mini-invasively repair or replace the mitral valve will be critically reviewed. Moreover, preliminary results of minimally invasive mitral valve repair performed at our institutions will be discussed.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)
Dept. Small Animal Clinical Sciences
Virginia-Maryland College of Veterinary Medicine, Virginia Tech
Blacksburg, VA, USA

URL: http://www.vin.com/doc/?id=8172711
The LOOK Mitral Study: Is There Any Standard Treatment for Dogs with Mitral Valve Disease?
Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)
Dept. Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA

KEYNOTE MESSAGE
Current common medical treatment for chronic mitral valve disease due to myxomatous mitral valve degeneration (MMVD) includes diuretics, pimobendan, ACE-I, and spironolactone. However, although current guidelines for the diagnosis and treatment of MMVD in dogs provide some recommendations about medical therapy at different stages of the disease, decision on when to start the treatment, and which drugs should be used, remains mainly a choice of the clinician. A recent study suggests that pimobendan is able to delay onset of congestive heart failure in dogs with MMVD and advanced cardiac remodelling. The Longitudinal Outcome Of Canine Mitral valve disease (LOOK-mitral) study is a multicenter prospective longitudinal study intended to:
1. Assess the natural history of canine MMVD in a large referred population
2. Assess the prevalence and effects of co-morbidities on the natural history of the disease
3. Identify risk factors for disease progression and death

The study was initiated in October 2015 and represents a collaborative research project between the Virginia-Maryland College of Veterinary Medicine and the CVCA Cardiac Care for Pets group in USA. Inclusion criteria for study enrollment is a diagnosis of MMVD confirmed by echocardiographic exam. Dogs are enrolled in the study at the time the diagnosis is confirmed by a cardiology specialist. Collected data include physical exam, radiographic findings, ECG findings, echocardiography, co-morbidities, laboratory results, and treatment. Data are collected at each reevaluation until the termination of the study (October 2020) or until the death of the dog. To date, the database contains clinical information from 2,156 dogs of 104 different breeds. Follow-up examination data are available for approximately 30% of the dogs. In this session, current recommendation for medical treatment of dogs affected by MMVD will be critically appraised. Moreover, preliminary data about treatment of dogs enrolled in the LOOK-Mitral study will be presented.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Michele Borgarelli, DVM, PhD, DECVIM-CA (Cardiology)
Dept. Small Animal Clinical Sciences
Virginia-Maryland College of Veterinary Medicine, Virginia Tech
Blacksburg, VA, USA

URL: http://www.vin.com/doc/?id=8172712
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Adrian Boswood¹, DVC, MA, MRCVS, VetMB; Sonya Gordon², DVM, DVSc, DACVIM (Cardiology); Jens Häggström³, DVM, DECVIM (Cardiology)

¹Royal Veterinary College, Hertfordshire, UK; ²Texas A&M, College Station, TX, USA; ³Swedish University of Agricultural Sciences, Uppsala, Sweden

KEYNOTE MESSAGE
Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs. Pimobendan has been shown to increase survival in dogs with MMVD and signs of congestive heart failure (stage C). Furthermore, pimobendan was recently shown in the EPIC trial to prolong the preclinical period in dogs with MMVD and cardiomegaly, but with no signs of CHF (stage B2). No previous prospective study has described the change of clinical, laboratory, and heart size variables in a large cohort of dogs as they progress from stage B2 to stage C MMVD. The EPIC trial offers a unique opportunity to study the effects of pimobendan and disease progression on these variables in the short and long term in stage B2 MMVD dogs. Furthermore, the EPIC trial data allow characterization of the changes that occur as dogs progress from the preclinical stage of the disease into CHF. The results of the longitudinal data of the EPIC trial will be presented for the first time during this session.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Sonya Gordon, DVM, DVSc, DACVIM (Cardiology)
Texas A&M
College Station, TX, USA

Adrian Boswood, DVC, MA, MRCVS, VetMB
Royal Veterinary College
Hertfordshire, UK

Jens Häggström, DVM, DECVIM (Cardiology)
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172713
Evolution of a New Hybrid Technique for Treating Pulmonic Stenosis in Dogs
Simon Swift, MA, VetMB, CertSAC, DECVIM-CA (Cardiology), MRCVS
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA

KEYNOTE MESSAGE

Canine valvular pulmonic stenosis has been categorised based on the degree of leaflet thickening, leaflet fusion, and pulmonary artery hypoplasia. Dogs with mild and moderate disease have normal life expectancies but those with severe disease die prematurely. Balloon dilation is often successful in severe cases with thin fused leaflets, resulting in decreased clinical signs and increased life expectancy. Dogs with thickened, dysplastic valves and pulmonary artery hypoplasia show limited response to balloon dilation. Larger dogs may respond better to a double balloon technique and higher burst pressure/cutting balloons have been used. However, there is a subset of dogs that do not show a significant decrease in gradients. For these, implantation of a bare metal stent in the right ventricular outflow tract can relieve the obstruction. Case examples will be used to illustrate the procedure and discuss the medium-term outcome. However, the catheters required for stent implantation are large and a novel hybrid technique to implant the stent allowing the procedure to be performed in small dogs will be shown.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Simon Swift, MA, VetMB, CertSAC, DECVIM-CA (Cardiology), MRCVS
Dept of Small Animal Clinical Sciences
College of Veterinary Medicine, University of Florida
Gainesville, FL, USA

URL: http://www.vin.com/doc/?id=8172714
Oral Presentations

Plasma Metabolomics Reveals Lowered Carnitine Concentrations in Overweight Labrador Retriever Dogs  J.J. Söder
Silica Urolithiasis in a Dog - A Case Report  B. Kiefer-Hecker
Knowing the Total Amount of Phosphorus in a Diet Is Not Enough - Different Sources Have Different Effects  B. Dobenecker
The prevalence of dog obesity is increasing and a better understanding of the metabolism of overweight dogs is needed to improve obesity prevention and treatment. This study aims to detect and quantify plasma metabolites during a feed challenge-test in dogs and to identify alterations in the metabolism related to overweight. Twenty-eight healthy intact male Labrador retriever dogs were included, 12 of which were classified as lean (body condition score (BCS) 4–5 on a 9-point scale) and 16 as overweight (BCS 6–8). After overnight fasting, plasma samples were collected and dogs were fed a high-fat meal. Postprandial plasma samples were collected hourly for 4 hours. Nuclear magnetic resonance (NMR) was conducted and 41 plasma metabolites were statistically evaluated. The results showed that all postprandial time points differed from the fasting time point in multivariate discriminant analysis (cross-validated ANOVA: p=0.00014). Eleven specific metabolites with peak concentrations mainly at 2 or 3 hours postprandially contributed to the separations. Carnitine was identified as a metabolite related to overweight at all time points in stepwise logistic regression analysis (p=0.03) and overweight dogs had lower carnitine response in a mixed model repeated measures analysis (p=0.005). Notably, the fasting carnitine concentration in overweight dogs (mean±SD, 9.4±4.2 mM) was very close to a proposed reference limit for carnitine deficiency. These findings demonstrate that NMR is suitable for metabolic evaluations in feed-challenges in dogs. The lowered carnitine concentration in overweight dogs warrants further investigation as it could indicate carnitine deficiency and an altered lipid metabolism in overweight dogs.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**J.J. Söder**

Swedish University of Agricultural Sciences

Uppsala, Sweden

URL: [http://www.vin.com/doc/?id=8172850](http://www.vin.com/doc/?id=8172850)
Silica-containing uroliths in dogs occur very infrequently (≤0.5% of analysed uroliths) in Europe,\textsuperscript{1,2} although Schenk et al. (2010)\textsuperscript{3} observed a peak of 13\% in 2009 in Switzerland. The affected dogs were predominately male (88–93\%)\textsuperscript{4} and between 7.2 to 8.6\textsuperscript{3,4} years old.

A 10-year-old neutered male terrier mongrel (BCS 3/5) with a history of pancreatitis was examined for abdominal pain. During an abdominal ultrasonic examination that revealed no abnormalities of the pancreas but hyperechoic structures in the bladder the dog urinated. The urine sediment was positive for bacteria, erythrocytes and leucocytes but not crystals. Antimicrobial treatment was started. The pancreatic lipase was within the reference range. Two weeks later a urine sample collected by the owner contained numerous struvite crystals; another sample obtained one week later by cystocentesis revealed no crystals and no signs of inflammation and a urine pH of 7.1. The ultrasonographic examination of the bladder a few days afterwards showed multiple uroliths. Twenty stones were removed surgically and the analysis revealed 100\% silica.

It is hypothesised that silica uroliths may be related to silica intake by plants or plant by-products with diet or by consumption of soil (>90\% silica) secondary of diet-associated pica.\textsuperscript{5} In this case the dog was fed a commercial gastrointestinal lowfat dry diet for 1 year. Additionally, the dog regularly consumed faeces of feral rabbits on its daily walks since more than 2 years. The analysis of a sample of such faeces showed that it contained high amounts of insoluble ash (7\% of fresh matter or 12.3\% vs. 4\% dry matter in pet rabbits). The intake of such faeces together with soil sticking to it might have caused silica uroliths in this case, since no signs of dysuria or abnormal ultrasonographic examinations of the bladder or urinalysis did recur after the dog was kept from consuming rabbit faeces for more than three months.

**DISCLOSURES**

No disclosures to report.

**References**


**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

B. Kiefer-Hecker
Ludwig-Maximilians-Universität München
Oberschleissheim, Germany

URL: [http://www.vin.com/doc/?id=8172851](http://www.vin.com/doc/?id=8172851)
The restriction of phosphate (P) intake is crucial in patients with chronic renal insufficiency (CRI), especially in case of hyperphosphatemia. Major sources of P are proteins, bones and cartilages as well as inorganic supplements for nutritional and technical purposes. To date, the total amount of P in a diet is used to assess the daily load of P for the patient. Besides, P excess is suspected to play a role also in the pathogenesis of CRI.\textsuperscript{1,2,3} The aim of this study was to test the effects of different P sources on the body based on a different availability of the mineral.

In 8 adult Beagles the aD of P and calcium (Ca) was determined after feeding a control diet (0.5% P/DM) for 18 d (13 d adaptation, 5 d balance). This was repeated aiming at 2.2% P/DM by adding different phosphates (CaHPO\textsubscript{4}, NaH\textsubscript{2}PO\textsubscript{4}, poultry meal, Na\textsubscript{5}P\textsubscript{3}O\textsubscript{10}, Ca(H\textsubscript{2}PO\textsubscript{4})\textsubscript{2}, bone meal, KH\textsubscript{2}PO\textsubscript{4}, K\textsubscript{4}P\textsubscript{2}O\textsubscript{7}, Ca(H\textsubscript{2}PO\textsubscript{4})\textsubscript{2}, bone meal, KH\textsubscript{2}PO\textsubscript{4}, K\textsubscript{4}P\textsubscript{2}O\textsubscript{7}) while adjusting the Ca/P ratio to \(\sim 1.3/1\) using CaCO\textsubscript{3} (exceptions diet poultry meal: Ca/P 1.7/1; diet Na\textsubscript{5}P\textsubscript{3}O\textsubscript{10}:1.5% P/DM due to low acceptance) with wash-out periods of \(\geq\)10 d. Serum P, Ca and PTH was determined at d 18 pre- and 2 h postprandially. Pre- and postprandial urine was analysed for creatinine and P. Statistics: ANOVA (Bonferroni) or Kruskal Wallis (Tukey) according to data distribution.

Compared to control aD P was reduced in diet CaHPO\textsubscript{4}, pentaphosphate, poultry and bone meal. In postprandial urine P/creatinine increased significantly in all diets but control, poultry and bone meal. The same was true for postprandial serum P concentrations with levels even above reference range in NaH\textsubscript{2}PO\textsubscript{4}, Na\textsubscript{5}P\textsubscript{3}O\textsubscript{10}, Ca(H\textsubscript{2}PO\textsubscript{4})\textsubscript{2}, KH\textsubscript{2}PO\textsubscript{4}, K\textsubscript{4}P\textsubscript{2}O\textsubscript{7} and Ca(H\textsubscript{2}PO\textsubscript{4})\textsubscript{2} causing mean concentrations near or above reference range.

For the first time this study demonstrated in dogs systematic differences in P digestibility and metabolism between different P sources often used in petfood. Because of the relevance of P in renal diets but also because of the potentially harmful effects of elevated serum P and PTH levels on skeleton, cardio-vascular system and kidneys in healthy animals, the intake of highly soluble P compounds such as Na and K phosphates have to be assessed differently. The knowledge of the total amount of P in a diet does not suffice to decide about adequacy or potential harm.

**DISCLOSURES**

No disclosures to report.

**References**


**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

B. Dobenecker
Ludwig Maximilians University
Oberschleissheim, Germany

URL: http://www.vin.com/doc/?id=8172852
A Randomised Double-Blind, Placebo Controlled Study Evaluating the Effects of Short-Chain Fructo-Oligosaccharides (scFOS) on Cat Stools Odors  
F.A. Allaert

Increased Dietary Long-Chain Polyunsaturated Fatty Acids Alter Plasma Fatty Acid Concentrations and Lower Risk of Urine Stone Formation in Cats  
D.E. Jewell

Foods Enriched with Bioactive Ingredients Including Fish Oil Increase Circulating (N-3) Fatty Acid Concentrations, Decrease PGE\textsubscript{2}, and Increase Lean Body
Mass in Cats  
D.E. Jewell

Studies in a New Body Condition Scoring by Morphometric Method in Dogs  
A.K. Koizumi

Validation of a Modified 9-Integer-Unit Body Condition Score System and a Computer-Based Modelling Tool to Estimate Body Condition in Pet Dogs  
A.J. German

Clinical Thiamine Deficiency in Cats in the UK Associated with the Feeding of a Defective Commercial Dry Food Diet  
A. Stewart
A Randomised Double-Blind, Placebo Controlled Study Evaluating the Effects of Short-Chain Fructo-Oligosaccharides (scFOS) on Cat Stools Odors

F. Herpin; F.A. Allaert
CEN Nutrition Animal, Dijon, France

OBJECTIVES
The main objective was to evaluate the effects of the addition of short-chain fructo-oligosaccharides (scFOS) to the daily cat feed ration on the intensity of unpleasant odors of cat faeces. The secondary objectives were to evaluate the digestive tolerance of the product and the cat owner’s satisfaction.

METHODS
The study was a randomized, double blind, placebo controlled study conducted on 2 parallel arms. The experimental products were dry cat food with 1% scFOS (Profeed®, TEREOS) or without scFOS. The inclusion criteria were: healthy cats living in naturalistic conditions at the owner’s home, 1–15 years old, using cat litter and whose owners were complaining of their intense bad smells. Cats recently or currently under treatment were excluded. The main criterion was the intensity of the odor of the faeces evaluated by owners on a 7-point Likert scale (0: no odor, 6: unbearable). The digestive tolerance was evaluated by the consistency of stools on a faecal score scale and the satisfaction criterion was evaluated on a Likert scale. These criteria were daily collected during 2 weeks at the beginning of the study and after about 30 days of feeding.

RESULTS
The study covers 57 cats aged of 4.3±3.4 among which 54.4% were female: 27 cats were included in the verum group and 30 in the placebo group. Their characteristics and past history were similar. The intensity of the odor of the faeces were similar in both groups at inclusion (verum 3.5±0.7 vs placebo 3.3±0.6; p: 0.2767). The comparison between the two groups showed that the reduction of the faeces odor was greater in the verum group than in the placebo group, 2.25 more (p:0.06) for a reduction described in absolute values (-0.9±0.9 vs. -0.4±1.1) and 2.5 more (p:0.05) when described as a percentage (-26.9±29.8 vs. -10.4±31.7). The percentage of owners who were very satisfied or extremely satisfied with the improvement of the odor was significantly greater in the verum group than in the placebo group (53.8% vs. 43.3%) and in particular the percentage of very satisfied owners (19.2% vs. 0.0%). Stool consistency remained stable in both groups, confirming that scFOS are well tolerated by cats.

CONCLUSIONS
Adding scFOS into the daily cat feed ration is beneficial in order to reduce unpleasant odors of cats’ stools without altering digestive tolerance.

DISCLOSURES
Disclosures to report
CEN Nutrition Animal has received research grants from Tereos.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

F.A. Allaert
CEN Nutrition Animal
Dijon, France

URL: http://www.vin.com/doc/?id=8172854
Increased Dietary Long-Chain Polyunsaturated Fatty Acids Alter Plasma Fatty Acid Concentrations and Lower Risk of Urine Stone Formation in Cats

D.E. Jewell¹; J.A. Brockman¹; S. Davidson¹; J.L. MacLeay¹; J.A. Hall²

¹Hill's Pet Nutrition, Topeka, KS, USA; ²Oregon State University, Corvallis, OR, USA

Increasing concentrations of dietary (n-3) polyunsaturated fatty acids (PUFA), e.g., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), relative to (n-6) FA, e.g., arachidonic acid (AA), have been shown to increase plasma concentrations of EPA and DHA and reduce AA concentrations. The purpose of this study was to investigate the effects of increasing dietary PUFA concentrations on urine characteristics. We have recently shown that lifespans of cats with non-obstructive kidney stones is shortened compared with control cats indicating a need to prevent stone formation and decrease the rate of chronic kidney disease progression.

Domestic short hair cats (n=12; mean age 5.6 y, range 2 to 9 y) were randomized into two groups and fed one of two diets for 56 d and then crossed over to the other diet for another 56 d. The protocol was reviewed and approved by the Institutional Animal Care and Use Committee, Hill's Pet Nutrition, Inc. For 30 d before study initiation, cats consumed a pretrial (control) food that contained 0.07% AA and no measurable EPA or DHA. After 30 d, cats were split into two groups. Group 1 continued eating control food for 56 d. Group 2 was fed test food for 56 d, which contained 0.16 % AA, and 0.27% EPA and DHA combined. After 56 d, Group 1 cats were fed test food and Group 2 cats were fed control food for another 56 d. Serum was analyzed for FA concentrations at baseline and after each feeding period. Concurrently, urine was analyzed for urine specific gravity (USG), calcium concentration, and relative super saturation for struvite crystals. In addition, a urine calcium oxalate titrimetric test (COTT) was performed.

After consuming test food, cats had increased (all p<0.01) plasma concentrations of AA (36%), EPA (352%) and DHA (200%) compared with cats consuming control food. In addition, urine from cats fed test food had decreased USG (p=0.04), decreased calcium concentration (p=0.03; -9%), decreased struvite super saturation (p=0.03; -51%) and enhanced titratability to added oxalate before forming calcium oxalate crystals (p=0.06; -26%). Resistance to oxalate crystal formation was negatively correlated with blood calcium concentration (r=0.41; p<0.01) and this relationship was unaffected by test food. However, feeding test food decreased USG, decreased urine calcium concentration, and increased resistance to oxalate crystal formation. These data show that there could be significant urinary tract benefit for cats, i.e., reduced urine stone formation, by increasing dietary AA, EPA and DHA.

DISCLOSURES

Disclosures to report.
D.E. Jewell, J.A. Brockman, S. Davidson, J.L. MacLeay are all employees of Hill's Pet Nutrition, Inc. J.A. Hall has received grant money from Hill's Pet Nutrition, Inc.

REFERENCES

D.E. Jewell
Hill's Pet Nutrition
Topeka, KS, USA

URL: http://www.vin.com/doc/?id=8172855
Foods Enriched with Bioactive Ingredients Including Fish Oil Increase Circulating (N-3) Fatty Acid Concentrations, Decrease PGE\textsubscript{2}, and Increase Lean Body Mass in Cats

D.E. Jewell\textsuperscript{1}; M.I. Jackson\textsuperscript{1}; J.A. Hall\textsuperscript{2}

\textsuperscript{1}Hill's Pet Nutrition, Topeka, KS, USA; \textsuperscript{2}Oregon State University, Corvallis, OR, USA

Increasing concentrations of dietary (n-3) polyunsaturated fatty acids (PUFA), e.g., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), relative to (n-6) FA, e.g., arachidonic acid (AA), have been shown to increase plasma concentrations of EPA and DHA and reduce AA concentrations. The purpose of this study was to investigate the effects of enriching food with bioactive ingredients, including EPA and DHA, on body composition, and concentrations of circulating fatty acids and the inflammatory biomarker prostaglandin E\textsubscript{2} (PGE\textsubscript{2}). Domestic short hair cats (n=81; mean age 11.1 y, range 6 to 14 y) were fed a pretrial food for 30 d, randomized into three groups, and then fed one of three diets for 180 d. The protocol was reviewed and approved by the Institutional Animal Care and Use Committee, Hill's Pet Nutrition, Inc. The pretrial food contained 33.4\% protein, 0.12\% arachidonic acid (AA) and negligible EPA and DHA. The control food contained 32.6\% protein, 0.10\% AA, 0.03\% EPA, and 0.02\% DHA. Test food 1 (TF1) and Test food 2 (TF2) contained 31.8\% and 30.2\% protein, respectively, as well as 0.04\% AA, 0.095\% EPA, and 0.06\% DHA. Both TF1 and TF2 contained additional bioactive food factors (from broccoli, tomatoes, oats, and peas), with TF2 having increased bioactive ingredient concentrations compared with TF1. Serum was analyzed for FA and PGE\textsubscript{2} concentrations initially, and at 45, 90 and 180 d. Concurrently, body composition was determined by dual energy x-ray absorptiometry. After consuming food for 180 d, lean body mass (LBM) was unchanged in cats fed control food (42±30 g), whereas cats fed TF1 (73±30 g; p=0.02) and TF2 (197±31 g; p<0.01) had increased LBM. Body fat was unchanged in cats fed control food (-11±43 g), but decreased in cats fed TF1 (-124±42 g; p<0.01) and TF2 (-185±43 g; p<0.01). PGE\textsubscript{2} concentrations were decreased in cats fed control and TFs, and were positively correlated to the ratio of (n-6) to (n-3) FA in serum (r=0.31; p<0.01) and negatively correlated to the sum of (n-3) FA (r=0.30; p<0.001). Cats consuming foods containing plant bioactives and fish oil had reduced concentrations of the inflammatory biomarker PGE\textsubscript{2} and enhanced lean body composition, which together may aid in offsetting inflammation and adiposity associated with aging in cats.

DISCLOSURES

Disclosures to report.

D.E. Jewell, and M.I. Jackson are employees of Hill's Pet Nutrition, Inc. J.A. Hall has received grant money from Hill's Pet Nutrition, Inc.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

D.E. Jewell

Hill's Pet Nutrition

Topeka, KS, USA

URL: http://www.vin.com/doc/?id=8172856
Studies in a New Body Condition Scoring by Morphometric Method in Dogs
A.K. Koizumi; R. Aihara; M. Sakurada; H. Asakawa; K. Otsuji
Teikyo University of Science, Tokyo, Japan

Body condition scoring (BCS) is the method that many clinical veterinarians adopt as a nutritional assessment method. However, the BCS assessment can be inconsistent because of its subjective method. Therefore we developed a BCS palpation model to improve the precision of the BCS assessment. Furthermore, we studied a new BCS assessment by the morphometric method to further improve the precision of BCS assessment. BCS is assessed by measuring body length and the current body weight in this method.

Thirty-nine dogs which varied in their BCS levels were used. Breed, gender and age were neglected for the selection of the dogs. Measurement of body fat percentage: the deuterium water dilution method was used. After the blood collection, deuterium water of 0.2 g/kg was subcutaneously injected and the blood samples were collected 3 hours after the administration. The concentration of deuterium water in the blood was analyzed by radio isotope mass-spectrometry. Body length: the length between the scapula and ilium (BLs-i) and between the scapula and base of tail (BLs-b) was measured. Calculation of the body weight corresponding to each BCS: ideal body weight (IBW) was calculated as the body weight at the body fat percentage of 20%. The body weight corresponding to each BCS was calculated as follows: BCS of 5: more than IBW x 1.21, BCS of 4: IBW x 1.11–1.20, BCS of 3: IBW x 0.91–1.1, BCS of 2: IBW x 0.81–0.9., and BCS of 1: IBW x 0.80 or less.

The results suggest that the correlation coefficient between BLs-b and IBW was r=0.8355, p<0.01 and higher than the correlation coefficient between BLs-i and IBW. This means that measuring the length of BLs-b is more accurate than measuring the length of BLs-i. The results suggest that the IBW of each dog could be estimated by measuring the BLs-b. The correlation coefficient between the BLs-b and IBW in 5 long-bodied dogs (Miniature Dachshund, Welsh Corgi, etc.) was higher than it in the all subject dogs. This suggests that it is better to divide dogs into following three types: standard shape, long and square bodied dogs for the morphometric BCS assessment. In addition, individual BCS can be calculated from an estrangement percentage between IBW and current weight by using above formula. This morphometric method is simpler and more objective than the conventional method.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.K. Koizumi
Teikyo University of Science
Tokyo, Japan

URL: http://www.vin.com/doc/?id=8172857
Validation of a Modified 9-Integer-Unit Body Condition Score System and a Computer-Based Modelling Tool to Estimate Body Condition in Pet Dogs

W. Saengsoi1; E. Morel2; M.A. Hours2; E.J. Comerford1; S. Tew1; V. Biourge2; A.J. German1

1University of Liverpool, Neston, UK; 2Royal Canin Research Center, Aimargues, France

Body condition scoring (BCS) is the most widely accepted clinical method for estimating body fat mass in dogs. The 9-point system is preferred but, since visual characteristics are depicted with only 5 silhouette images from a single breed, assessment of visual characteristics of dogs of different size and body shape is challenging.

Two modifications to the original 9-point BCS system were developed with reference to an image archive of almost 3799 photographs from 155 dogs attending the Royal Canin Weight Management Clinic, University of Liverpool (Gant. BMC Veterinary Research 2016, 12:18). Body fat mass (measured by dual-energy X-ray absorptiometry [DEXA]) and BCS was known for all dogs, and owners gave written permission for use of these photographs (VREC50). The first modification was a paper-based system that used a set of 5 size-specific BCS charts, for small, medium, large, and giant breeds, respectively. The written descriptions for each category were identical, but different images were included for the different size categories. The second was a computer-based system whereby visual characteristics were modelled on-screen by altering body shape in 5 different zones (chest, abdomen, back, thigh, and pelvis), with the computer software then calculating the body condition score automatically using an algorithm.

Thirty dogs of a range of breeds were used to validate both systems, all of which had been referred for surgical treatment of cranial cruciate ligament disease at Small Animal Teaching Hospital, University of Liverpool. Owners had consented to their participation in a separate research study (VREC192), involving body fat measurement by DEXA (under the same anaesthetic used for diagnostic and therapeutic procedures). One author (WS) assessed the BCS for all dogs, under the supervision of a second author experienced in body condition scoring (AJG). The computer system was used first, followed by the paper-based system.

Median BCS was 6/9 (3/9–8/9) and median body fat was 35% (range 8–52%). There was a strong positive correlation between body fat measured by DEXA and BCS for both the paper- (R²=0.74, p<0.001) and computer-based (R²=0.80, p<0.001) systems. Both systems also correlated strongly with each other (R²=0.97, p<0.001), and agreement was almost perfect (Cohen's kappa 0.89, p<0.001).

These findings demonstrate that both the modified paper-based and computer-based BCS systems correlate with body fat mass measured by DEXA and can be considered for use with clinical cases.

DISCLOSURES

Disclosures to report.
Alex German's academic post is funded by Royal Canin. This author has also received financial remuneration and gifts for providing educational material, speaking at conferences, and consultancy work. Elodie Morel, Marie-Anne Hours, and Vincent Biourge are all employees of Royal Canin.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.J. German
University of Liverpool
Neston, UK

URL: http://www.vin.com/doc/?id=8172858
Clinical Thiamine Deficiency in Cats in the UK Associated with the Feeding of a Defective Commercial Dry Food Diet

A. Stewart1; H. Covey1; E. Beltran1; L. Garosi2; A. Hibbert3; A. Kathrani3

1Royal Veterinary College, Hertfordshire, UK; 2Davies Veterinary Specialists, Herts, UK; 3Bristol University, Bristol, UK

Thiamine (vitamin B1) is a water-soluble vitamin functioning as an essential cofactor in carbohydrate metabolism. Cats require high levels of thiamine in their diets for normal metabolic function, and exclusive feeding of a thiamine-deficient diet can lead to clinical signs of deficiency within four weeks that can be rapidly fatal if left untreated. Here we describe four cases of clinical thiamine deficiency in cats in the United Kingdom associated with exclusive feeding of a defective commercial dry kibble. Cats ranged between 1.5 and 6 years of age, and were all exclusively fed the defective diet for at least four weeks prior to onset of acute neurologic signs. Neurological examination variably revealed depressed mental status, mydriasis, severe generalized ataxia, delayed postural reaction in all four limbs, decreased menace response in both eyes, positional nystagmus and cervical ventroflexion. MRI scans of the brain in all cats revealed bilateral symmetrical lesions at the level of the caudal colliculi and caudate nuclei that were T2W and FLAIR hyperintense, T1W isointense and non-contrast enhancing, consistent with a metabolic encephalopathy. Analysis of the diet at an external laboratory confirmed severely low thiamine levels (1.2–3.8 mg thiamine/kg dry matter basis; the NRC RA for adult feline maintenance is a minimum of 5.6 mg of thiamine/kg dry matter). Rapid clinical improvement was documented in all cases within 24 hours of initiating parenteral thiamine administration. All four cats survived, but one has significant persistent neurologic deficits and another has mild behavioral abnormalities reported by the owner six months post diagnosis that are suspected to now be permanent.

The cases described above represent only the second reported major outbreak of clinical thiamine deficiency occurring due to defective dry cat food as opposed to canned. In contrast to this previously reported outbreak, all cats here presented with acute neurologic signs as the initial presenting complaint rather than nonspecific GI signs initially. Full reporting of the number of affected cats is still pending analysis by the company, but they have indicated that numerous other clinical cases have been identified thus far and none of the primary care veterinarians assessing these patients had thiamine deficiency considered as a potential differential diagnosis upon review of the records. Increased awareness of the clinical presentation of thiamine deficiency will hopefully help raise diagnostic rates for this condition in the future.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Stewart
Royal Veterinary College
Hertfordshire, UK

URL: http://www.vin.com/doc/?id=8172859
Scientific Programme

Dietary Management of Urolithiasis in Dogs and Cats - The Latest Research Insights  Nadine Paßlack, Dr. med. vet.
Advancing the Nutritional Management of Chronic Enteropathies - What's at the Cutting Edge?  Aarti Kathrani, BVetMed (Hons), PhD, DACVIM, DACVN, MRCVS
Critical Review About the Role of Vitamin D in Health and Disease  Annette Liesegang
Nutritional Management of Dermatological Diseases in Dogs and Cats - The Latest Research Insights  Christine Iben, DECVCN
Dietary Management of Urolithiasis in Dogs and Cats - The Latest Research Insights
Nadine Paßlack, Dr. med. vet.
Institute of Animal Nutrition, Freie Universität Berlin, Berlin, Germany

**Keynote Message**

Urinary stones are a common disease in dogs and cats. However, its pathogenesis has not been fully investigated. For the treatment and prevention of urinary stones, specific dietary strategies are required. The recommended diet strongly depends on the stone composition and is still in the focus of current research. In particular, the impact of qualitative and quantitative mineral and protein supply on urine characteristics has recently been investigated, and the results provide new insights for the dietary management of urinary stones in dogs and cats. In this session, the latest research findings for the dietary treatment of urolithiasis will be discussed. Dietary recommendations will be provided for the use of commercial and home-prepared diets and will be demonstrated based on clinical cases.

**Key References**


**Speaker Information**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Nadine Paßlack, Dr. med. vet.
Institute of Animal Nutrition
Freie Universität Berlin
Berlin, Germany

URL: [http://www.vin.com/doc/?id=8172861](http://www.vin.com/doc/?id=8172861)
Advancing the Nutritional Management of Chronic Enteropathies - What's at the Cutting Edge?
Aarti Kathrani, BVetMed (Hons), PhD, DACVIM, DACVN, MRCVS
School of Veterinary Sciences, University of Bristol, Bristol, UK

KEYNOTE MESSAGE

Chronic enteropathy in a companion animal can be subcategorised retrospectively depending on effective response to treatment. Therefore, the term food-responsive enteropathy describes a group of diseases resulting in chronic gastrointestinal signs that is responsive to dietary management alone; the underlying etiology of these diseases is unknown but likely encompasses immune-mediated and non-immune-mediated causes. Although there is no standard acceptable criterion, the author considers companion animals that fail to respond to at least two appropriate commercial therapeutic diet trials and a limited-ingredient home-cooked diet as likely not having a food-responsive enteropathy. Currently, there are three categories of commercial therapeutic diets that are available for the diagnosis and management of food-responsive enteropathy in dogs and cats: hydrolysed diets, limited-ingredient novel protein diets, and gastrointestinal diets. In humans, exclusive enteral elemental nutritional therapy is the only dietary intervention that has been rigorously tested and shown to induce remission of Crohn's disease. Several studies and a meta-analysis compared elemental diets with corticosteroids in paediatric patients with active Crohn's disease and found no significant difference in remission rates between the two forms of therapy. Similar remission rates have also been reported in adults with newly diagnosed Crohn's disease. In this session, the definition, diagnosis, and dietary treatment of chronic enteropathies in companion animals will be discussed. In addition, insights into the dietary management of human inflammatory bowel disease will be reviewed.

Key References
The synthesis of vitamin D (vitD) in the skin was demonstrated for many species such as human, rat, cattle, sheep, goat, guinea pig, rabbit, and recently for pigs and hens. In contrast to these species, cats and dogs are mainly dependent on dietary vitD sources (Dittmer and Thompson 2011). Vitamin D's relation to the regulation of bone metabolism and skeletal health is well known, but interestingly many non-skeletal tissues express the vitamin D receptor. This leads to the assumption that vitamin D's role is far beyond of what we already know about it. In human medicine, many diseases are linked to Vitamin D deficiency: cancer, autoimmune, infectious and cardiovascular disorders. Vitamin D is involved in cell differentiation and immunomodulatory aspects (Dittmer and Thompson 2011). Little is known about the role of vitamin D in the physiology of non-skeletal tissues in cats and dogs and only a few studies on this issue exist. However, these studies show that also in companion animal disorders, vitamin D metabolism is changed and shows abnormalities. However, the physiological role of vitamin D in companion animals is still very scarce and this talk tries to summarise some studies which will lead to a better understanding of vitamin D homeostasis in cats and dogs. The literature on vitamin D metabolism and a wide range of diseases in companion animals and humans is a high trend at the moment. The problem about many studies is to find the true reason of what is directly linked to the onset, the development, and the outcome of these non-skeletal disorders or if vitamin D is simply a marker for these diseases or the outcome of these diseases, respectively. Especially in humans there is a wide range of studies on the role of vitamin D in the aetiology of diseases or even mortality (Kupferschmidt 2012). In the focus of these studies is the role of the supplementation of vitamin D, especially in the development of infections, autoimmune diseases or neoplasms (Kupferschmidt 2012). Some studies now show the effect of vitamin D in the development and treatment of different diseases in dogs and cats. In addition, it is important to avoid over-supplementation of vitamin D, since there are some reports that it may cause hypercalcaemia (Mellanby et al. 2005; Wehner et al. 2013).

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Annette Liesegang
Institute of Animal Nutrition, Vetsuisse Faculty
University of Zurich, Zurich, Switzerland

URL: http://www.vin.com/doc/?id=8172863
Nutritional Management of Dermatological Diseases in Dogs and Cats - The Latest Research Insights
Christine Iben, DECVCN
Institute of Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine Vienna, Vienna, Austria

KEYNOTE MESSAGE

There are three categories to group dermatological diseases in dogs and cats due to nutritional interventions: Food intolerance or hypersensitivity, malnutrition or excess nutrition with certain nutrients (e.g., protein, vitamins, trace elements) including responsive skin diseases, and, finally, nutritional support of dermatological diseases independent of the reason.

Food Intolerance and Food Hypersensitivity:
A recent thesis determined the prevalence of nutritional skin diseases in cats from 2010 to 2015 at the veterinary hospital of the University of Veterinary Medicine Vienna. Considering all cats, including those with the suspicious nutritional causes of skin diseases, only 0.84% had the diagnosis or suspicious diagnosis to suffer from a nutrition-related skin disease. In less than half of the suspicious cases, the diagnosis nutrition-related skin disease could be verified.

The presentation will focus on the diagnoses of food intolerance and compare the state of the art in veterinary and human medicine. An overview about the properties of commercially available diets will be given as well.

Under- and Overnutrition and the Nutritional Support of Skin Diseases:
The role of nutrition due to the health of coat and skin and possibilities to support the therapy of dermatological diseases are shown and illustrated with case examples.

Obesity and nutrient deficiencies as a possible reason for skin and coat alterations will be discussed. Finally, also zinc- and vitamin A-responsive dermatitis will be presented.

References


SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Christine Iben, DECVCN
Institute of Animal Nutrition and Functional Plant Compounds
University of Veterinary Medicine Vienna, Austria

URL: http://www.vin.com/doc/?id=8172864
Oral Presentations

Pre- and Postoperative D-Dimer Concentration in Dogs: Changes in D-Dimer Concentration in Dogs Following Soft Tissue and Orthopaedic Surgery  
I. Aroch

Evaluation of Haemostatic Changes in Dogs With Parvoviral Enteritis Before and After Fluid Resuscitation Using Thromboelastography  
Z. Whitehead

Analytical and Clinical Validation of a Human Enzyme-Linked Immunosorbent Assay (ELISA) for Measurement of Canine Angiopoietin-2  
M.L. König

Plasma Angiopoietin-2 (Ang-2) Is Elevated in Dogs with Sepsis and/or Systemic Inflammatory Disease Syndrome (SIRS) and Is Associated with Severity of Disease and Outcome  
M.L. König

Investigation of Interleukin-6 (IL-6) as Prognostic Marker  
S. Neumann

Comparison of Serum Amyloid A and Fibrinogen to Other Inflammatory Biomarkers in Cats  
V. Leynaud

Identification of ILF2 Autoantibodies as a Promising Biomarker for Autoimmune Disease in Dogs  
H.D. Bremer

Serum Histones as Biomarkers of the Severity of Heatstroke in Dogs  
I. Aroch

Pleural Effusion Lactate Dehydrogenase (LDHp) Concentration and Serum Total Protein (TPs) Concentration Versus Traditional Veterinary Classification Method in the Discrimination Between Transudates and Exudates: A Cross-Sectional Study in 100 Dogs with Pleural Effusion  
A. Zoia

The Site of Bone Marrow Acquisition Affects the Myeloid to Erythroid Ratio in Apparently Healthy Dogs  
R.K. Burchell

Acute Myeloid Leukemia in Retrovirus-Negative Cats: A Case Series of 16 Patients  
B.Y. Cuq
Pre- and Postoperative D-Dimer Concentration in Dogs: Changes in D-Dimer Concentration in Dogs Following Soft Tissue and Orthopaedic Surgery

I. Aroch, G. Segev, J. Milgram, N. Shalev, A. Shipov
Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel

Surgical procedures may lead to activation of the coagulation cascade and to clot formation, complicating the interpretation of postoperative increases in D-dimer concentration in dogs. This study aimed to examine whether D-dimer concentrations increase following different surgical procedures in dogs. Dogs presented for elective neutering (castration or ovariohysterectomy), elective orthopaedic and post-traumatic orthopaedic surgeries were enrolled. Plasma D-dimer concentration, measured immediately prior to, immediately after, and 24 hours after surgery (T0, T1 and T24, respectively), were compared within and among the study groups. The study included 45 dogs (15 in each group). All dogs recovered uneventfully from surgery. D-dimer was >250 ng/mL in 8 dogs (18%) preoperatively, in 9 (20%) at T1 and in 5 (11%) at T24. At T1 and T24, only 2 dogs had D-dimer concentration >500 ng/mL, and it was <750 ng/mL in all dogs. There was no difference in the proportion of abnormally increased D-dimer concentration (>250 ng/mL) among the time points (p=0.29), and no differences in median D-dimer concentration among the different time points, excluding the neuter group (p=0.029). Post hoc analysis showed that D-dimer concentration in the neuter group was higher at T1 vs. T0 (161 ng/dL; range 71–727 vs. 122 ng/mL; range, 43–353, respectively) and lower at T24 vs. T1, but both differences were insignificant (p=0.065 and p=0.31, respectively). The results suggest that surgery per se is unlikely to induce increased D-dimer concentration in dogs, regardless of its type; therefore, any postoperative abnormally increased D-dimer concentration should be regarded as clinically potentially important.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

I. Aroch
Koret School of Veterinary Medicine
Hebrew University of Jerusalem
Rehovot, Israel

URL: http://www.vin.com/doc/?id=8172867
Evaluation of Haemostatic Changes in Dogs With Parvoviral Enteritis Before and After Fluid Resuscitation Using Thromboelastography

Z. Whitehead; A. Goddard; W.J. Botha; P. Pazzi
Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa

Canine parvoviral (CPV) enteritis is associated with severe inflammation and the possible development of sepsis. Inflammation and sepsis are associated with activation of systemic haemostasis with subsequent hypercoagulability, previously described in 9 dogs with CPV enteritis. The effect of crystalloid fluid resuscitation on haemostasis in dogs with CPV has to date not been investigated.

The aims of the study were to: a) confirm a hypercoagulable state in dogs with CPV enteritis at admission, compared to healthy control dogs; b) assess the change in haemostatic status after treatment with crystalloid resuscitation fluids in dogs with CPV enteritis; and c) determine if haemostatic changes before and after fluid resuscitation are correlated to inflammatory markers and specific coagulation variables.

This prospective study included 27 client-owned dogs with naturally occurring CPV enteritis and 15 healthy control dogs. Blood samples were collected in all the dogs at admission, as well as immediately after fluid resuscitation in the CPV group. The volume of resuscitation fluid for each case was recorded.

Thromboelastography (TEG), antithrombin (AT) activity, fibrinogen concentration, haematocrit (HCT), and platelet count were measured.

For the TEG variables, the median maximum amplitude (MA) was significantly increased (p<0.001), reaction time (R) and clotting time (K) significantly longer (p<0.05), and the angle significantly smaller (p<0.05) in the CPV group compared to the controls. Fibrinogen was significantly increased in the CPV group compared to the controls (p<0.001). There was a significant increase in MA, angle and platelet count and a significant decrease in R, K, HCT, and AT after fluid resuscitation (p<0.05 for all). MA was moderately correlated to the platelet count at admission (r_s=0.464, p<0.05), as well as after fluid resuscitation (r_s=0.448, p<0.05) in the CPV group. R was moderately correlated with AT activity at admission (r_s=0.405, p<0.05). The decrease in HCT after fluid resuscitation correlated moderately (r_s=0.431, p<0.05) with the volume of fluid administered. The decrease in AT activity correlated strongly with the volume of fluid administered (r_s=0.754, p<0.001).

In conclusion, based on MA, CPV enteritis is associated with a hypercoagulable state at admission, compared to healthy control dogs, that is exacerbated after crystalloid fluid resuscitation.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Z. Whitehead
Faculty of Veterinary Science
University of Pretoria,
Pretoria, South Africa

URL: http://www.vin.com/doc/?id=8172870
Analytical and Clinical Validation of a Human Enzyme-Linked Immunosorbent Assay (ELISA) for Measurement of Canine Angiopoietin-2

M.L. König; E. Marti; J. Mirkovitch; S.C. Lettry; M. Wyder; S. Schuller
University Bern, Bern, Switzerland

Angiopoietin-2 is a novel marker of endothelial dysfunction and vascular leakage. The aim of this study was to validate a human Enzyme-linked Immunosorbent Assay (ELISA) for measurement of angiopoietin-2 (Ang-2) in canine plasma and to evaluate the effect of SIRS/sepsis on plasma Ang-2 concentrations in dogs. Ethical approval for collection of blood samples from healthy dogs and dogs with SIRS/sepsis was obtained (26425 BE38/15). The assay was validated using canine plasma samples, canine recombinant Ang-2 and supernatants from quiescent and stimulated canine aortic endothelial cells. Dilution linearity and parallelism, accuracy, precision, and reproducibility of the assay were determined. The association of age, sex, weight, and sepsis with Ang-2 plasma concentration were analysed.

The ELISA had excellent dilution linearity, parallelism, accuracy, precision, and reproducibility for measurement of Ang-2 concentrations in canine plasma and endothelial cell supernatants. Median plasma Ang-2 concentration was significantly higher in septic dogs (25.5; IQR, 19.9–69.9 ng/ml) than in healthy dogs (6.7; IQR, 5.9–9.8 ng/ml). Ang-2 concentration in supernatant of canine macrovascular endothelial cells was significantly higher after stimulation with tumour necrosis factor a (TNF-a) compared to unstimulated cells.

The tested human ELISA is able to measure canine Ang-2. Data suggests that Ang-2 is increased in plasma of dogs with sepsis and released from endothelial cells upon stimulation with TNF-a, similar to what has been described in human medicine. This data provides the basis for future studies using Ang-2 as a marker of endothelial cell activation in dogs.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.L. König
University Bern
Bern, Switzerland

URL: http://www.vin.com/doc/?id=8172871
Plasma Angiopoietin-2 (Ang-2) Is Elevated in Dogs with Sepsis and/or Systemic Inflammatory Disease Syndrome (SIRS) and Is Associated with Severity of Disease and Outcome

M.L. König1; A. Nentwig2; E. Marí1; J. Mirkovitch1; S. Schuller1

1University Bern, Bern, Switzerland; 2ENNETSeeKLINIK für Kleintiere, Hühnenberg, Switzerland

Ang-2 is a novel marker of endothelial dysfunction and inflammation. Ang-2 is released from endothelial cells upon stimulation and exerts its effect via the endothelial-specific Angiopoietin-Tie ligand-receptor system. Ang-2 destabilizes endothelial barrier function and acts as pro-inflammatory molecule. It is therefore, an interesting molecule to study in the context of vascular leakage syndromes, such as sepsis and SIRS and has received considerable attention in human medicine as a diagnostic and prognostic marker and a potential treatment target. The aim of this study was to assess Ang-2 concentrations in plasma of canine patients with SIRS with and without sepsis and to examine whether this parameter correlates with disease severity and outcome. Ethical approval was obtained for the study protocol. Plasma was collected from healthy dogs (n=18), and dogs with SIRS (n=31) with or without sepsis (n=28) presented to a veterinary referral hospital. Dogs were included into the SIRS group if they fulfilled the SIRS criteria by Hauptmann JG et al. (1997) at admission. Dogs were considered septic if an underlying bacterial infection was identified. The APPLE5 score, a five-variable model based on glucose, albumin, mentation score, platelet count, and lactate, was used as an objective measure of disease severity. Plasma Ang-2 was measured using a previously validated commercial human Ang-2 ELISA. Ang-2 was compared between healthy dogs and dogs with SIRS with or without sepsis, as well as between survivors and non-survivors using the Kruskal-Wallis Test. Correlations between Ang-2 and other clinically relevant parameters including C-reactive protein (CRP), white blood cell count and bilirubin were determined using linear regression analysis. There was no significant difference between groups with regards to age, sex, and breed distribution. Median Ang-2 was significantly higher in dogs with SIRS (16.2; ICR, 8.9–34.5 ng/ml) and sepsis (21.1; ICR, 15.1–29.8 ng/ml) compared to healthy dogs (8.0; ICR, 6.7–10.7 ng/ml). Ang-2 was significantly higher in non-survivors (24.1; ICR, 11.9–50.0 ng/ml) than dogs alive at discharge (11.0; ICR, 7.5–21.5 ng/ml). Dogs with an APPLE5 score ≤25 (low severity grade) had significantly lower Ang-2 levels compared to dogs with an APPLE5 score >25 (high severity grade). Plasma Ang-2 did not correlate with CRP, white blood cell count, or bilirubin. Ang-2 may represent a useful additional prognostic marker in dogs with SIRS with or without sepsis.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.L. König
University Bern
Bern, Switzerland

URL:  http://www.vin.com/doc/?id=812572
Investigation of Interleukin-6 (IL-6) as Prognostic Marker

S. Neumann, J. Schuettler, S. Fischer
University of Goettingen, Goettingen, Germany

The assessment of the disease course is essential to make a prognosis and important part of daily veterinary and human clinical practice. Different parameters are used with different success. IL-6, a pro-inflammatory cytokine, may have some prognostic value which was showed by some human studies. The mechanism why IL-6 is elevated in cases of bad prognosis is still unknown. We investigated the prognostic value of IL-6 in dogs, cats, and cattle.

Twenty-nine dogs, patients of a critical care unit were included in this study. The dogs suffered from different severe life-threatening diseases like pancreatitis or sepsis. IL-6 was measured at first consultation. The patients were treated with disease specific treatment and the clinical course was observed. Finally, clinical outcome and IL-6 concentration were compared.

Eight cats suffering from chronic kidney disease in an advanced stage were treated and the clinical outcome was compared with the IL-6 serum concentration at the time of hospitalization.

In cattle 20 calves suffering from diarrhea were investigated. Here the recovering period was compared with the incoming IL-6 serum concentration. None of these calves died.

IL-6 was measured with species specific ELISA according to manufactures instructions.

The dogs could be differentiated into survivors (20) and non-survivors (9). The IL-6 serum concentration in the group of non-surviving dogs was significantly elevated compared to surviving dogs (p<0.001).

Cats with chronic kidney disease which do not survive the treatment showed significantly higher IL-6 serum concentration compared to surviving cats (p<0.001).

At the beginning of diarrhea, the IL-6 concentration was significantly higher in calves with an extended recovering period compared with those that recovered 7 to 10 days after the onset of diarrhea (p<0.05).

To get information about the outcome of a life-threatening disease can be important to give the owners some advice and to make treatment decisions. IL-6 which is mainly known as pro-inflammatory cytokine and which is elevated in sepsis and inflammatory response syndrome, was successfully assessed as prognostic marker in humans. In our studies, we have proved that IL-6 is also useful in dogs and cats suffering from life threatening inflammatory and non-inflammatory diseases and can give information about the disease outcome. In calves, we could show that the recovering period can also be predicted by IL-6.

So, in conclusion, IL-6 seems to be a valuable prognostic marker in different species with different diseases.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

S. Neumann
University of Goettingen
Goettingen, Germany

URL: http://www.vin.com/doc/?id=8172873
Comparison of Serum Amyloid A and Fibrinogen to Other Inflammatory Biomarkers in Cats

V. Leynaud¹; C. Trumel²; J.P. Braun²

¹National Veterinary School of Alfort, Maisons-Alfort, France; ²National Veterinary School of Toulouse, Toulouse, France

Inflammatory diseases are hard to evaluate in veterinary patients and clinical criteria can be misleading. Thus, biomarkers of inflammation can be of high value. Unfortunately, classical hematological and biochemical parameters used to evaluate inflammation lack sensitivity, especially in cats.

There is a growing interest in acute phase proteins (APP) in veterinary medicine, in both diagnosis and treatment response monitoring of inflammatory diseases.

The aim of this study was to compare APP to classical parameters for evaluating inflammation in cats.

Thirty-five cats with various inflammatory diseases were prospectively enrolled with owner consent along with 16 healthy cats. White blood cell (WBC) count, neutrophil count, total proteins, albumin, albumin/globulin ratio, band cell count (BCC), neutrophil toxicity score (NTS), fibrinogen, and serum amyloid A (SAA) were measured for each of them.

The sensitivity of APP - fibrinogen and SAA (97% [CI 91–100%] and 94% [CI 86–100%], respectively) - was much higher than blood smear criteria - BCC and NTS (80% [CI 66–94%] and 86% [CI 73–99%], respectively) - and blood parameters such as total proteins (46% [CI 29–63%]), albumin (34% [CI 18–50%]), WBC count (37% [CI 21–53%]), and neutrophil count (34% [CI 18–50%]).

The specificity was perfect for several parameters: 100% for WBC count, neutrophil count, albumin, fibrinogen, and NTS - and very good for the others: SAA (94% [CI 82–100%]), BCC (83% [CI 53–100%]) and total proteins (82% [CI 62–100%]).

This study shows that APP are very sensitive for evaluating inflammation in cats compared to other biomarkers.

Disclosures

Disclosures to report.

The study was sponsored by SCIL Laboratories but they did not interfere in the interpretation of the results.

Speaker Information

(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Leynaud

National Veterinary School of Alfort
Maisons-Alfort, France

URL: http://www.vin.com/doc/?id=8172874
Identification of ILF2 Autoantibodies as a Promising Biomarker for Autoimmune Disease in Dogs

H.D. Bremer1; N. Landegren2; R. Sjöberg3; Å. Hallgren2; G. Andersson1; I. Lilleyhöök1; O. Kämpe2; K. Lindblad-Toh4; H. Hansson-Hamlin1

1 Swedish University of Agricultural Sciences, Uppsala, Sweden; 2 Karolinska Institute, Stockholm, Sweden; 3 Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden; 4 Broad Institute of Harvard and MIT, Cambridge, MA, USA

Autoantibodies are one important characteristic of autoimmune disease and can be used as diagnostic biomarkers. Protein arrays, containing thousands of full-length proteins, have successfully been used to identify antigens targeted by autoantibodies in human autoimmune disease but has not previously been used in dogs. Autoantibodies are often directed against proteins that are well conserved between species and we hypothesized that the human protein arrays could be used to identify novel autoantigens in dogs with autoimmune disease.

Sera from 21 Nova Scotia Duck Tolling Retrievers (NSDTRs), a dog breed predisposed to autoimmune disease, were included. Twelve of the dogs had clinical signs consistent with immune-mediated rheumatic disease (IMRD), an autoimmune disease characterized by chronic pain and stiffness from multiple joints, and nine were healthy controls. All the IMRD dogs were positive on the indirect immunofluorescence (IIF) antinuclear antibody (ANA) test, which is the standard test used to identify autoantibodies. Nine displayed a speckled ANA pattern on IIF and three a homogenous pattern.

Human proteins arrays (HuProtTM v2 Human Proteome Arrays, Cambridge Protein Arrays, Cambridge, UK) were incubated with sera from the IMRD affected and healthy dogs, followed by incubation with Alexa Fluor® 647 conjugated rabbit anti-dog IgG. Signal intensities, representing autoantibody levels, were measured in a microarray scanner. Potential autoantigens were identified by introducing a cut off based on the healthy controls (mean + 3SD, log-transformed data).

Interleukin enhancer binding factor 2 (ILF2) was identified as the most promising autoantigen. ILF2 is a transcription factor involved in regulation of T-cells, and is particularly important for expression of IL-2, a cytokine involved in immune response and immune regulation. ILF2 antibodies were present in seven of the twelve IMRD dogs. The seven dogs displayed a speckled staining pattern on IIF.

To validate the findings, presence of autoantibodies against ILF2 was investigated in a larger group of NSDTRs as well as in dogs of other breeds, using a radioligand binding assay. ILF2 autoantibodies were present in 27 out of 29 IMRD affected NSDTRs displaying a speckled ANA pattern, and in various dogs of other breeds with a speckled ANA pattern. ILF2 antibodies were not present in any sera from 141 control dogs.

This study describes the use of human protein arrays for autoantigen discovery in dogs, and also identifies autoantibodies against ILF2 as a promising biomarker candidate in diagnostics development for autoimmune disease in dogs.

DISCLOSURES

Disclosures to report.

The study was founded by the Swedish Research Council FORMAS, the Swedish Kennel Club, and Agria Research Foundation. Hanna Bremer has been awarded a travel grant from Knut and Alice Wallenberg Foundation.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

H.D. Bremer
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172875
Serum Histones as Biomarkers of the Severity of Heatstroke in Dogs

I. Aroch¹; G. Segev¹; Y. Avital¹; I. Ginsburg²; A. Merisa³; M. Horowitz³; Y. Bruchim¹

¹Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel; ²Faculty of Dental Medicine, Hadassah Medical Center, The Hebrew University of, Jerusalem, Israel; ³Laboratory of Environmental Physiology, Faculty of Dental Medicine, Hadassah, Jerusalem, Israel

Canine heatstroke is a systemic inflammatory response syndrome (SIRS), often leading to multiple organ dysfunction, encephalopathy, and death. Currently, there is no specific treatment to decrease the hyperthermia-induced inflammatory, and haemostatic derangements. Histones are highly conserved, positively-charged nuclear proteins, serving as the chromatin basic structure block unit. They leak from damaged cells, exhibiting toxic, pro-inflammatory, pro-thrombotic properties. Histones can be targeted pharmacologically, thereby offering a potential therapeutic target in SIRS. Serum histone concentration (sHs) was measured in 16 dogs with naturally-occurring heatstroke at presentation and in 7 healthy controls using a commercially available ELISA. Median sHs was significantly (p=0.043) higher in the heatstroke group vs. the control group (13.2 vs. 7.3 ng/mL, respectively), in those with severe haemostatic derangement vs. the other dogs (median 19.0 L, range 4.6–40 vs. median 7.0, range 4.6–34.6 ng/mL, respectively; p=0.038), and in non-survivors vs. survivors of heatstroke (21.4, range 4.2–40.0 vs. median 8.16, range 2.8–19.0 ng/mL, respectively; p=0.049). sHs was significantly correlated with serum urea (r=0.8) and total CO2 (r=0.7) concentrations and creatine kinase activity (r=0.7) at presentation, and with prothrombin time at 12 hours post-presentation (r=0.9). The area under the ROC curve of sHs concentration as a predictor of death was 0.72, (cutoff point, 13.7 ng/mL; sensitivity, 60%; specificity 88%). sHs are measurable in dogs by ELISA. The correlations between sHs and other biomarkers of disease severity, and its increase in severely affected dogs (i.e., the non-survivors), suggest a role of sHs in the inflammation and haemostatic derangement in canine heatstroke.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

I. Aroch
Koret School of Veterinary Medicine
Hebrew University of Jerusalem
Rehovot, Israel

URL: http://www.vin.com/doc/?id=8172876
Pleural Effusion Lactate Dehydrogenase (LDHp) Concentration and Serum Total Protein (TPs) Concentration Versus Traditional Veterinary Classification Method in the Discrimination Between Transudates and Exudates: A Cross-Sectional Study in 100 Dogs with Pleural Effusion

A. Zoia1; M. Peilini1; D. Righetti1; M. Caldin2; M. Drigo3

1San Marco Veterinary Clinic, Padova, Italy; 2Laboratorio d’Analisi Veterinarie San Marco, PA, Italy; 3Department of Animal Medicine, Production and Health, Veterinary Padua University, Legnaro, Italy

Traditional veterinary classification divides PEs in transudates (resulting from decreased colloid-osmotic pressure [COP]), modified transudates (resulting from increased hydrostatic pressure [HP]) and exudates (resulting from increased vascular permeability) based on effusion total protein (TPp) and total nucleated cell count (TNCCp). In humans, PEs are divided in transudates or exudates based on Light’s criteria (LDHp, PE/serum LDH ratio, and TPp/TPs ratio). If a transudate is found, TPs determine whether it results from an increased HP or a decreased COP. Subsequently, LDHp resulted to be the test of Light’s criteria with the best performance. The aim of this study was to compare, in dogs with PEs, the diagnostic accuracy of LDHp-TPs in distinguishing exudates (i.e., LDHp >2/3 of the upper serum reference interval) from transudates (TPs ≥4.0 g/dL for HP-transudates; TPs <4.0 g/dL for COP-transudates) in comparison to the traditional veterinary classification method (adopting textbook TPp-TNCCp cut-off values).

PEs were classified, based on pathophysiology of formation, in decreased COP-transudates, increased HP-transudates, and exudates. The disease causing the PE was used as gold standard for establishing the underlying pathophysiology. For both classification methods sensitivity, specificity, and accuracy were calculated and frequency of agreement between these methods and the true nature of the PE was compared (McNemar Chi–square test with Yates’ correction).

One-hundred PEs were studied: 7 COP-transudates, 18 HP-transudates, and 75 exudates. The LDHp-TPs method correctly classified 73/75 exudates (2 misclassified as HP-transudate; sensitivity = 97%; specificity = 93%; accuracy = 98%), 7/7 COP-transudates (100% sensitivity, specificity, and accuracy), and 18/18 HP-transudates (sensitivity = 100%; specificity = 98%; accuracy = 98%). The traditional veterinary classification misclassified 30/75 exudates: 14 as HP-transudates, two as COP-transudates, and 14 were unclassifiable (i.e., discordant information deriving from TPp and TNCCp), (sensitivity = 60%; specificity and accuracy undeterminable due to the presence of unclassifiable PEs). Of the 18 HP-transudates, TPp and TNCCp misclassified 12 effusions: seven as COP-transudates and five were unclassifiable (sensitivity = 33%; specificity and accuracy undeterminable [see above]). All the 7 COP-transudates were correctly classified using the traditional veterinary classification (sensitivity = 100%; specificity and accuracy undeterminable [see above]). The overall accuracy (i.e., the number of correctly classified PE) was 98% (95% CI, 95–100%) for the LDHp-TPs method and 58% (95% CI, 48–68%) for the traditional veterinary classification. The frequency of agreement between the LDHp-TPs and the traditional veterinary classification with the true nature of the PEs was significantly different (98% versus 58%, respectively; p<0.0001).

In conclusion, LDHp-TPs has an excellent diagnostic accuracy in discriminate canine PE exudates versus HP-transudates and COP-transudates while the traditional veterinary classification fails.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Zoia
San Marco Veterinary Clinic
Padova, Italy

URL: http://www.vin.com/doc/?id=8172877
The Site of Bone Marrow Acquisition Affects the Myeloid to Erythroid Ratio in Apparently Healthy Dogs

R.K. Burchell1, A. Worth1, N. Lopez-Villalobos1, J. Marshall1, A.L. Macneill2, A. Gal1

1Massey University, Palmerston North, New Zealand; 2Colorado State University, Fort Collins, CO, USA

Bone marrow (BM) cytology and histopathology are complementary tools used to investigate haematological diseases. Site of acquisition is normally based on clinician preference. The purpose of this study was to investigate if there are significant site-dependent differences in the diagnostic quality of samples from different locations. In this study diagnostic concordance, between histology and cytology, and at different acquisition sites was tested in 18 dogs euthanised for reasons other than haematological diseases. Sequence of acquisition of the samples was randomised. BM was collected for cytology and histology from both humeri and ileal crests immediately after euthanasia. Cytology and histology was interpreted independently by a board-certified pathologist and clinical pathologist respectively. Data was analyzed using a linear mixed model that included fixed effects for site, method and the interaction between site and method, with a random effect for dogs. The myeloid:erythroid ratio (MER) was log transformed for symmetry. Site of BM acquisition did not affect sample quality or diagnosis by cytology or histology. In general, the MER from the ileal crest was larger than the MER from the humeri, and there were significant differences in the MER between histology and cytology. Pairwise comparisons found significant differences in cytological MER between the left humerus and left ileal crest and left ileum and right humerus. In conclusion, differences in MER between different BM sites in apparently healthy dogs did not affect the overall interpretation of the BM, but this may not apply to sick dogs.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.K. Burchell
Massey University
Palmerston North, New Zealand

URL: http://www.vin.com/doc/?id=8172868
Acute myeloid leukemia (AML) is a myeloproliferative neoplasm that arises in the bone marrow. AML is associated with high morbidity and mortality. AML in cats has often been associated with infection by feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV). However, few patients have been reported to develop AML without FIV or FeLV infection. This abstract reports presentation, hematology, cytology, histopathology, and outcomes in retrovirus-negative cats diagnosed with AML.

Sixteen patients were diagnosed with AML based on bone marrow cytology, histology, or post mortem: 8 castrated males, 1 intact male, and 7 spayed females. Eleven cats were domestic shorthair, 1 domestic longhair, 1 Siamese, 1 Ragdoll, 1 Norwegian Forest, and 1 Egyptian Mau. Thirteen cats were anemic (median HCT 17% [7–37]) at presentation and 12 cats were thrombocytopenic (median PLT 54 x 10^9 L [4–202]). Leukopenia (median WBC 3.5 x 10^9 L [0.4–27.3]) consisting of neutropenia was present in 12 cats. Leukocytosis due to neutrophilia was present in 1 patient. Blast or atypical cells were identified on the blood smear in 14 patients, and red blood cell agglutination in 6 cats. Treatments included antibiotics, immunosuppression or chemotherapy with highly variable outcomes. Among the cats receiving immunosuppression 6 were euthanized within a week; 4 others lived 1, 4, 6, and 12 months, and one is alive after 1 year. Two cats receiving antibiotics were euthanized within 2 weeks. Three cats received chemotherapy, one lived 5 months and two are currently being treated. AML should be considered in retrovirus-negative cats with cytopenias.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B.Y. Cuq
Ontario Veterinary College
University of Guelph
Guelph, ON, Canada

URL: http://www.vin.com/doc/?id=8172869
Poster Presentations

Blood Reference Ranges for Rabbits from Routine Diagnostic Samples  M. Weiss
Urine Protein Analysis by Capillary Electrophoresis in Healthy Dogs  P.F. Navarro Martinez
Detection and Stability of MicroRNAs in Urine from Healthy Cats  L.N. Nielsen
Preliminary Evaluation of Protein Carbonyl Group in Canine Serum Using a Western Blotting Technique  B. Ruggerone
Age Dependent Correlation of Mutation C,118G>A in the SOD1 Gene to Clinical Signs of Degenerative Myelopathy in Hovawart Dogs  H. Bauer
Reproducibility of Urinary Sediment Examination: Stain versus Bright Field and Phase Contrast  M. Giraldi
The establishment of reliable reference ranges is a central prerequisite for the diagnostic evaluation of blood results. Such reference ranges should be established based on an adequate animal population and using identical techniques. The purpose of this retrospective study was to establish laboratory reference ranges for pet rabbits (*Oryctolagus cuniculus*) from routine diagnostic samples, sent to Laboklin between January 2015 and January 2017. Clinical chemistry parameters were determined using the cobas® c701 analyzer (Roche Diagnostics, Germany). Haematological parameters were determined using the Sysmex XT-2000i (Sysmex Deutschland GmbH, Germany). The statistical evaluation was performed using the Reference Limit Estimator 20151017. This tool calculates reference ranges from patients with unknown health status using an algorithm that excludes presumably non-healthy individuals by decreasing the statistical error based on a high number of data sets. Rabbit chemistry and hematology parameters were calculated from data sets of 937 to 2039 values resulting in lower, consistent, or, in some cases, higher reference ranges compared to reference ranges derived from the literature. Our results demonstrate that it is possible to calculate reference ranges based on data from routine diagnostic samples, enabling laboratories to establish their own reference ranges given an adequate amount of data. The program is accredited by the German Society of Clinical Chemistry and Laboratory Medicine for human medicine. To our knowledge, this was the first time that Reference Limit Estimator 20151017 was used to calculate reference ranges for blood parameters in rabbits.

**DISCLOSURES**

Disclosures to report.

Employee of Laboklin GmbH and Co. KG, a commercial veterinary laboratory.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**M. Weiss**  
Laboklin GmbH & Co. KG  
Bad Kissingen, Germany

URL: [http://www.vin.com/doc/?id=8172879](http://www.vin.com/doc/?id=8172879)
Urine Protein Analysis by Capillary Electrophoresis in Healthy Dogs

P.F. Navarro Martínez; L. Gil Vicente; S. Fernández-Barredo del Amo

1Universidad Católica de Valencia, San Vicente Mártir, Valencia, Spain; 2Centro Diagnóstico Veterinario, CEDIVET, Valencia, Spain

Serum protein analysis by capillary electrophoresis (CE) is a well-established laboratory method used for the diagnosis and follow up of infectious, inflammatory, immune mediated, and neoplastic conditions in human and veterinary medicine. Recently in human medicine, the analysis of urine by CE has been proved as a good technique to identify renal biomarkers in healthy and pathological samples. To these author's knowledge, there are no data about reference values in normal urine electrophoresis in dogs, and there are very few studies in veterinary medicine that relate different kinds of urine proteins with pathological conditions. The aim of this study is to use CE, as a laboratory method to establish normal urine electrophoretic patterns in healthy dogs.

Prospectively, 15 urine samples from healthy dogs with physical examination apparently normal were analyzed. These dogs were tested for a complete blood analysis and Leishmania infantum, Ehrlichia canis and Rickettsia conorii serology. Animals with abnormal results or positive serologies were discarded. Owners were asked to collect the first urine of the morning as a sample. Urine was stored at 4°C until analysis (less than 12 hours). Previously to CE, a complete urinalysis that included, specific gravity, pH, leukocytes, glucose, ketones, bilirubin, urobilinogen, blood, nitrates, microscopic examination, urine culture, and urine protein to creatinine ratio (UPC) was performed. To prepare the urine to the CE, four milliliters (ml) of urine were used to concentrate the proteins in each sample. After several washes and final dialysis, a suitable urine sample for CE was obtained.

The result obtained was 15 similar urine electrophoretic patterns. All the tested urines showed a very similar pattern with protein fractions distributed in a similar way to the serum samples of the same animal. No monoclonal peaks were observed, albumin was recorded as the most abundant protein in all the specimens, and other peaks were detected corresponding with transferrin in less quantity.

The conclusion is that the use of CE to evaluate urinary electrophoresis in healthy dogs, results in comparable patterns that can be used as a reference range of normality.

DISCLOSURES

Disclosures to report.

ECVIM-CA Congress - Abstract disclosures - The authors have the following disclosures related to their presentation: Employee/salary: - Gil L. (Senior lecturer, Universidad Católica Valencia) - Navarro PF. (PhD Student, Universidad Católica Valencia) - Fernández-Barredo S. (Director in Cedivet, analysis reference laboratory).

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

P.F. Navarro Martínez
Universidad Católica de Valencia San Vicente Mártir
Valencia, Spain

URL: http://www.vin.com/doc/?id=8172880
Detection and Stability of MicroRNAs in Urine from Healthy Cats
S. Cirera; L.N. Nielsen; R. Langhorn; L.R. Jessen
University of Copenhagen, Frederiksberg C, Denmark

MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression in a variety of physiological processes. Several studies have documented a diagnostic potential of circulating miRNAs in different neoplastic and inflammatory conditions in both humans and animals. Recently, also urinary miRNAs have been investigated in humans. Urinary miRNAs could potentially be useful non-invasive biomarkers in various urological disease conditions in cats.

The objective of this study was to; 1) investigate if miRNAs can be detected in feline urine; 2) evaluate the performance of different extraction kits for the best miRNA yield and sample purity; 3) assess stability of urinary miRNAs during different storage conditions.

Five cats were characterized as healthy based on clinical examination, hematology and biochemistry, urinalysis. Urine samples were obtained by cystocentesis. Three samples were collected from each cat: one immediately frozen at -80°C, one at -20°C, one refrigerated for 24 hours (+4°C) and subsequently frozen at -20°C. Two methods for RNA isolation were investigated (microRNA purification kit [Norgen Biotek Corp.] and miRNeasy mini kit [Qiagen]). Expression levels of 3 miRNAs (let-7a, miR-16, and miR-23a) were tested by quantitative real-time PCR and normalised to a spiked-in synthetic miRNA. Data was processed and statistically analysed by GenEx 6 Pro program (MultiD). An Anova test was applied to compare storage temperatures.

It was possible to detect the investigated miRNAs in urine from healthy cats. The miRNeasy mini kit performed markedly better with less contaminants following cDNA synthesis. No significant difference in miRNA levels could be detected among storage temperatures (range of fold change for each miRNA at +4°C, -20°C, -80°C: (let-7a: 4.91–5.64; 0–6.25; 5.67–6.51), (miR-16:3.61–6.54; 0–9.32; 4.02–8.99), miR-23a: 3.7–5.21; 0–5.21; 4.78–5.37).

miRNAs are stably expressed in urine from healthy cats independently of storage temperature. Further studies are needed to assess the value of miRNAs as diagnostic biomarkers in urogenital conditions in cats.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

L.N. Nielsen
University of Copenhagen
Frederiksberg C, Denmark

URL: http://www.vin.com/doc/?id=8172881
Preliminary Evaluation of Protein Carbonyl Group in Canine Serum Using a Western Blotting Technique

B. Ruggerone; G. Colombo; S. Paltrinieri
Università degli Studi di Milano, Milan, Italy

In human medicine, protein carbonyls (PCOs) are widely used biomarkers to detect oxidized proteins in serum and are significantly higher in septic patients.

The aim of this study was to detect PCOs in canine serum by using a western blotting technique and to assess their possible role as a novel marker of sepsis.

The technique described by Levine was used. After the separation by SDS-page of serum, samples were blotted onto nitrocellulose membrane and labelled with 2, 4-dinitrophenylhydrazine (DNPH). DNPH can react with PCOs by producing the dinitrophenyl group (DNP), that can be detected and quantified; a two-step incubation with anti-dinitrophenyl-KLH antibodies (rabbit IgG fraction) and secondary goat anti-rabbit IgG, HRP conjugate, was followed by PCO quantification with western blotting. The signal developed with enhanced chemoluminescence.

Oxidized sera from healthy, fasted, and privately-owned dogs were analysed in order to evaluate the linearity and the coefficient of variation (CV) of this method and to build a calibration curve.

Then, PCOs were evaluated in serum of 13 privately-owned dogs divided in 3 groups based on clinical and laboratory findings: 4 healthy dogs (A), 5 septic dogs with pyelonephritis (B), and 4 septic dogs with pyometra (C). The differences between the three groups were statistically evaluated and the possible practical utility of the method was estimated on the basis of the CV previously obtained.

The western blot technique showed an evident band of apparent MW of 69 kDa, consistent with carbonylated dog serum albumin. The obtained CV varied between 24% and 36%.

Results of sick dogs (groups B + C = 2.063 ± 0.719 mmol/L, min-max: 0.710–2.920) were significantly higher (p<0.05) than those of healthy dogs (0.975 ± 0.440 mmol/L, min-max: 0.320–1.260) while no significant differences were found between dogs of group B (2.052 ± 0.614 mmol/L, min-max: 1.320–2.920) and C (2.078 ± 0.935 mmol/L, min-max: 0.710–2.970).

The western blotting method employed in this study may identify PCOs in canine serum but has a high intrinsic variability in terms of CVs. Hence, despite statistically significant differences found between healthy and septic dogs this high variability suggests that misinterpretation of values close to the maximum values of the healthy dogs may occur in routine practice. Further studies on a higher caseload are needed to confirm PCOs as a reliable marker of sepsis.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B. Ruggerone
Università degli Studi di Milano
Milan, Italy

URL: http://www.vin.com/doc/?id=8172882
Canine degenerative myelopathy (DM) is a progressive neurodegenerative impairment of the spinal cord in many dog breeds. Usually clinical signs are not apparent in dogs younger than 8 years. DM is strongly correlated with a mutation c.118G>A in the superoxide-dismutase-1-gene (SOD1).

Numerous breeds including the Hovawart are known to be affected.

We report on statistical data regarding allele frequency of the mutation c.118G>A in the Hovawart breed in samples tested in the years 2009 to 2016.

Over 1500 samples of Hovawart dogs of any age were analysed. The mutant allele was present in the population at a frequency of 39.8%. This is concordant with published data. Forty point eight percent were heterozygous, respectively 19.4% were homozygous for the SOD1:c.118A genotype.

For an unbiased approach of monitoring frequency and age of disease onset in dogs with the homozygous high-risk genotype SOD1:c.118A we revised dogs above the age of 9 years which were under the age of 7 years at time of testing. Veterinary surgeons respectively breeders were asked to evaluate onset of disease and clinical signs.

Out of 13 dogs meeting the criteria 7 reports on health status were obtained. All 7 dogs showed clear symptoms of DM with onset at age 7 to 10 and a median of 8.5 years for this event. Out of these, 6 cases of DM were diagnosed by veterinarians. At the time of evaluation 6 out of 7 dogs were euthanized due to symptoms related to DM, all of them lacking post-mortem confirmation though. The median age of euthanization was 9.5 years. Shortest interval between diagnosis and euthanasia was 2 months.

We conclude that the prevalence of developing symptoms of DM is strongly correlated with the homozygous genotype SOD1:c.118A in Hovawart dogs. Frequency of symptoms within the homozygous group may be higher than reported in random breed dogs earlier. Despite the limited number of cases, our data suggest that the homozygous genotype SOD1:c.118A displays extremely severe symptoms of DM in Hovawart dogs.

DISCLOSURES

Disclosures to report.

All authors are employed at the diagnostic laboratory LABOKLIN GmbH & Co. KG.

SPAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

H. Bauer
Laboklin GmbH & Co. KG
Bad Kissingen, Germany

URL: http://www.vin.com/doc/?id=8172883
Reproducibility of Urinary Sediment Examination: Stain versus Bright Field and Phase Contrast
M. Giraldi; P. Rossetti; T. Vitiello; P. Scarpa
University of Milan, Milan, Italy

The aim of this study was to determine the intra-operator, inter-operator, and inter-method reproducibility and concordance of semiquantitative evaluation of urinary leukocytes examined in bright field, phase contrast, and stained sediment.

Forty urine samples were prospectively collected for diagnostic purposes from client-owned dogs irrespective of underlying disease. Urines (10 mL) were centrifuged at 450 G for 5 minutes and sediments were resuspended in 0.5 mL. From each sample, sediment examination was performed combining bright-field microscopy (BFM), phase-contrast microscopy (PCM), or stained sediment (SS) with microscope slide (SL) or counting chamber (CC). SS was prepared adding 8 µL of stain (modified Sternheimer-Malbin stain) to 80 µL of resuspended sediment. SL was prepared placing 50 µL of sediment or stained sediment on a slide covered by 24 x 32 mm coverslip. CC was prepared placing 10 µL of sediment (or stained sediment) in a counting chamber. Three operators with different experience (expert technician, PhD student, and undergraduate student) quantified with each method the number of leukocytes in 10 fields at 400 x magnification in a blind fashion and the mean was used for statistical analysis. Results of SS + SL and SS + CC were normalized for the stain dilution before analysis. For each sample, coefficient of variation (CV) of the 10 fields interpreted by the expert operator with all the methods were calculated. Friedman and Cohen's k tests were used to compare the difference and the concordance, respectively, between methods for each operator (intra-operator) and between operators for the six methods (inter-operator). The difference between methods was also calculated with Friedman test.

Among the 40 samples, mean ± SD of leukocytes in the six methods were 6.4±8.2, 7.0±9.0, 7.7±12.5, 9.9±14.1, 10.0±13.6, and 9.9±14.1. Mean CV obtained by the expert operator were 90.1%, 99.3%, 92.2%, 77%, 78.8%, and 83.8%. No significant difference was found between methods for each operator. Significant difference between operators was found with BFM+SL (p=0.008) and PCM+SL (p=0.009). No significant difference was found between methods. The lowest intra-operator concordance was found with SS+SL (k coefficient between 0.70 and 0.79) whereas for all the operators lower concordances were found between PCM+SL and SS+SL.

SS yielded lower variability among different operators but it tended to have lower concordance. All methods were reliable for expert operators. However, BFM yielded higher concordance and lower CV. BFM is preferred according to results of this study and given the inexpensiveness and easiness of this method.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Giraldi
University of Milan
Milan, Italy

URL: http://www.vin.com/doc/?id=8172884
Scientific Programme

Haemopoietic Neoplasms in Dogs and Cats  Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS

Infectious Diseases Affecting the Bone Marrow in Dogs and Cats  Mathios E. Mylonakis, DVM, PhD

A Case-Based Approach to Bone Marrow Cytology  Mathios E. Mylonakis, DVM, PhD , Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS
Haemopoietic Neoplasms in Dogs and Cats
Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS
Dick White Referrals, Newmarket, Suffolk, UK

KEYNOTE MESSAGE

Haemopoietic neoplasms are clonal disorders of haemopoietic cells and include myeloid and lymphoid leukaemia, lymphoma, and plasma cell tumours. Acute myeloid leukaemia (AML) is a neoplastic proliferation of early non-lymphoid haemopoietic precursors with minimal or absent maturation. The diagnosis rests on a marrow blast count exceeding 20% of all nucleated cells, although this is often much higher. The blast cells may be identifiable with light microscopy or may be poorly differentiated, in which case cell lineage is confirmed with flow cytometric immunophenotyping using myeloid-specific markers such as myeloperoxidase, MAC-387 and CD14, as well as CD34 (a marker of haemopoietic precursors). Acute lymphoid leukaemia (ALL) is characterised by the presence of lymphoblasts in the marrow and blood with cytopenias of one or more major cell lines and an absence of substantial lymphadenopathy. The cells have B or T cell immunophenotype and may express CD34 whilst MHCII expression is often absent. In acute undifferentiated leukaemia, the blast cells do not express any lineage-specific markers although do express CD45 and often CD34. The prognosis for acute leukaemia is poor with much shorter remission times than is seen with high-grade lymphoma.

Lymphoma is a heterogenous group of diseases with different prognoses, and it is increasingly recognised that lymphoma should be classified using a combination of morphology and immunophenotype, according to the WHO or updated Kiel classification scheme. Lymphoma can infiltrate the bone marrow and blood, but affected animals usually have marked lymphadenopathy, in contrast to the absent, mild or moderate lymphadenopathy seen in acute leukaemia. The lymphoid cells in various types of high-grade lymphoma (HGL) are often larger and have more prominent nucleoli than in ALL, although morphology alone often cannot distinguish ALL and HGL. A combination of clinical presentation, morphology, and flow cytometry is required. Case examples will be used to illustrate how a combination of morphology and immunophenotype is used to classify various haemopoietic neoplasms.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS
Dick White Referrals
Newmarket, Suffolk, UK

URL: http://www.vin.com/doc/?id=8172886
Infectious Diseases Affecting the Bone Marrow in Dogs and Cats
Mathios E. Mylonakis, DVM, PhD
School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

KEYNOTE MESSAGE
Canine and feline rickettsial (Ehrlichia canis), protozoal (Leishmania infantum), viral (canine and feline parvoviruses, feline retroviruses), and fungal (Histoplasma capsulatum) agents may affect the bone marrow, resulting in a range of haematological abnormalities of various severity and duration. The nature of bone marrow injury in these diseases has yet to be fully elucidated and one or more pathogenetic mechanisms may underlie the bone marrow pathology. Acute or chronic refractory aplasia is the major bone marrow disorder, associated with the myelosuppressive (chronic) canine monocytic ehrlichiosis (Ehrlichia canis), feline and canine parvoviral infections, feline leukaemia virus (FeLV), and feline immunodeficiency virus infections. Marrow necrosis, myelofibrosis, pure red cell aplasia, myelodysplastic syndromes, and myelophthisic diseases may also be associated with FeLV infection. Histiocytic inflammation, along with erythroid hypoplasia and mild-to-moderate multilineage myelodysplastic changes are the major cytopathological changes in leishmaniosis, while an intense granulomatous inflammation has been documented in histoplasmosis. Importantly, however, none of the aforementioned bone marrow disorders is disease-specific and they can be induced by numerous non-infectious diseases. In this session, the pathogenesis of bone marrow injury associated with common canine and feline infectious diseases will be updated. Moreover, the disease-specific haematological abnormalities will be discussed, aiming to enhance the ability to make evidence-based diagnostic recommendations in the clinical setting.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Mathios E. Mylonakis, DVM, PhD
School of Veterinary Medicine
Aristotle University of Thessaloniki
Thessaloniki, Greece

URL: http://www.vin.com/doc/?id=312847
A Case-Based Approach to Bone Marrow Cytology

Elizabeth Villiers1, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS; Dick Mathios2, DVM, PhD

1White Referrals, Newmarket, Suffolk UK; 2School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

KEYNOTE MESSAGE

Bone marrow (BM) aspiration cytology is a cost-effective diagnostic tool, which provides excellent morphological detail of cells and infectious agents. The major indications for BM aspiration include unexplained clinical manifestations (e.g., fever, lameness), persistent hematological or biochemical abnormalities (e.g., non-regenerative anemia, persistent neutropenia or extreme leucocytosis, pancytopenia, hyperglobulinemia), diagnosis and/or staging of malignancies (e.g., lymphoma, mast-cell tumor), diagnosis of infectious diseases such as leishmaniosis and canine monocytic ehrlichiosis (CME), and evaluation of canine iron stores. It is very important to correlate BM findings with a complete blood count taken at or very near the time of BM sampling. A systematic approach to examination should be adopted, evaluating one cell series at a time, checking for orderly maturation and for any morphological abnormalities which could suggest dysplasia. A 500-cell differential count is ideal, although sometimes 200 or 300 are counted. Intra-marrow causes of isolated non-regenerative anemia include non-regenerative immune-mediated hemolytic anemia (NRIMHA), pure red cell aplasia, erythroid hypoplasia, myelofibrosis, and myelodysplasia (subtype refractory anemia). Isolated neutropenia may be due to increased consumption at a focus of inflammation, margination or reduced production. The latter can result from immune-mediated neutropenia in which the target may be the neutrophil, or less commonly, an earlier neutrophil precursor. Bi- or pancytopenias may result from aplastic anemia (myelosuppressive CME, feline and canine parvoviral infections, feline leukemia virus infection, idiopathic), BM necrosis, myeloplastic syndromes (acute leukemias, myeloproliferative neoplasms, stage V lymphoma, metastatic neoplasms, severe granulomatous inflammation in histoplasmosis), myelodysplastic syndromes, and rarely myelofibrosis and NRIMHA. In this session, selected neoplastic and non-neoplastic BM diseases will be addressed and illustrated with case examples.

Key References


SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Mathios E. Mylonakis, DVM, PhD
School of Veterinary Medicine
Aristotle University of Thessaloniki
Thessaloniki, Greece

Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS
Dick White Referrals
Newmarket, Suffolk, UK

URL: http://www.vin.com/doc/?id=8172888
ESVE - European Society of Veterinary Endocrinology

Oral Presentations

Poster Presentations

Scientific Programme
Oral Presentations

Agreement of Two Pre-Pill Cortisol Measurements in Dogs with Hypercortisolism Treated with Trilostane  N. Sieber-Ruckstuhl
Sterol-O-Acyl Transferase 1 (SOAT1) Expression in Canine Cortisol-Secreting Adrenocortical Tumours: Providing the Basis for a Future Treatment Option  G.J. van Staaldhuinen
CYP17 Inhibitor Abiraterone Acetate as a Promising Future Treatment for Canine Hyperadrenocorticism: In Vitro Investigations  W.L. de Wit
Molecular Prognostic Markers in Canine Cortisol-Secreting Adrenocortical Tumours  K. Sanders
The Use of Chromogranin A Epitopes Vasostatin and Catestatin as Biomarkers for Catecholamine-Producing Tumours in Dogs  J.M. Hanson
Pilot Study Assessing the Use of Cabergoline in the Management of Diabetic Acromegalic Cats  C.J. Scudder
Serial Changes in Insulin-Like Growth Factor 1 and Impact on Hypersomatotropism-Screening in Feline Diabetes Mellitus  V.L. Woolhead
Ultrastructural Characterisation of Pancreatic Beta-Cells in Cats with Diabetes Mellitus  E. Zini
The Diabetic Clinical Score (DCS): Evaluation of a Simple Standardised Quantification Tool to Allow Rapid Description of Clinical Signs in Diabetic Dogs  S.J.M. Nissen
Thyroid and Renal Function in Cats Post Low-Dose Radioiodine Therapy  N.C. Finch
Evaluation of Symmetric Dimethylarginine (SDMA) in Dogs with Primary Hypoadrenocorticism Under Long-Term Mineralocorticoid Replacement Therapy  J.I. Casado Diaz
A Comparison of the ACTH Concentrations in Dogs with Stable Hypoadrenocorticism Being Treated with Either Fludrocortisone or Desoxycortone Pivalate and Prednisolone  S. Spence
Prevalence of Hyperaldosteronism and Hypertension in Cats with Chronic Azotaemia  A.C. Hagblom
The Use of a TRH Stimulation Test, with Measurement of Plasma Concentrations of Growth Hormone and Thyroid Stimulating Hormone, to Differentiate Between Primary Hypothyroidism and Non-Thyroidal Illness in Dogs  T. Pijnacker
Interrelation Between Thyroid Function and Sex Hormones in Female German Shepherd Dogs  P. Scarpa
Agreement of Two Pre-Pill Cortisol Measurements in Dogs with Hypercortisolism Treated with Trilostane

N. Sieber-Ruckstuhl1; C. Musella1; W. Burkhardt1; B. Riond2; C.E. Reusch1; F.S. Boretti1

1Clinic for Small Animal Internal Medicine, Zürich, Switzerland; 2Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Zürich, Switzerland

The ideal method to monitor trilostane therapy in dogs with hypercortisolism (HC) is still controversial. Lately, determination of the pre-trilostane (pre-pill) serum cortisol concentration has been shown to be more repeatable than either post-trilostane or post-ACTH stimulation cortisol. Therefore, the pre-pill cortisol concentration may be superior to other cortisol measurements for monitoring purposes.

As it is well known that cortisol concentrations can fluctuate and are influenced by certain circumstances (e.g., stress), the aim of this study was to investigate the agreement of two pre-pill cortisol measurements in dogs with HC during trilostane therapy.

Client owned dogs with HC treated with trilostane twice daily were prospectively enrolled. Cortisol concentrations were measured two times 1 hour apart just before the next trilostane dose (pre-pill 1 and 2). Each value was assigned to one of three groups according to the control of cortisol release: excessive (<41 nmol/l), adequate (41–138 nmol/l) or inadequate (>138 nmol/l). The Wilcoxon signed rank test was used to examine for significant differences between the paired measurements and the spearman rank correlation was calculated. The degree of agreement between group assignments was quantified by kappa.

A total of 47 cortisol pairs of 16 dogs with HC were included. Pre-pill 1 and 2 did not differ significantly (p=0.18). There was a significant correlation between the two values (p<0.0001, r=0.73). Compared to pre-pill 1, pre-pill 2 was higher in 17, equal in 5 and lower in 25 pairs. Group agreement between pre-pill 1 and 2 was 70% (moderate agreement - weighted kappa 0.5). In 30% of the pairs group assignment disagreed, which would have led to a different therapeutic decision. In some dogs, certain circumstances (e.g., excessive barking during hospitalization, difficulties during blood collection) were identified as potential factors explaining the discrepancy between pre-pill 1 and 2.

In conclusion, in a substantial number of dogs there was a large difference between the two pre-pill values, which was ascribable to certain events during hospitalization in some dogs. Recording of any incident during handling that might affect cortisol release seems important. Whether the measurement of two pre-pill values is of true benefit compared to the determination of only one has to be evaluated in further studies.

DISCLOSURES

Disclosures to report.

NSR has been a member of the Vetoryl novel monitoring meeting 2017 organized by Dechra Veterinary Products Ltd. CR was a consultant for Boehringer Ingelheim and Novartis Animal Health and is currently a consultant for Dechra Limited. She has received financial support for her endocrine research from various companies such as Nestlé Purina, Hills, Provet, Antlia SA, Glycemicon, and from the clinical studies fund of the ECVIM-CA, and from the Society of Comparative Endocrinology.

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

N. Sieber-Ruckstuhl
Clinic for Small Animal Internal Medicine
Zürich, Switzerland

URL: http://www.vin.com/doc/?id=8172814
Sterol-O-Acyl Transferase 1 (SOAT1) Expression in Canine Cortisol-Secreting Adrenocortical Tumours: Providing the Basis for a Future Treatment Option

G.J. van Staalduinen; K. Sanders, D.M. Peterson; M.C.M. Uijens; A. Slob; S. Galac
Utrecht University, Utrecht, Netherlands

Current medical treatment options in dogs with cortisol-secreting adrenocortical tumors (ATs) are trilostane or mitotane. However, trilostane is a palliative treatment and has no effect on the tumor itself, while mitotane does have adrenocorticolytic activity, but can cause serious adverse effects. ATR-101, a new orally available drug, is known to have selective adrenocorticolytic activity in guinea pigs, dogs, monkeys, and humans, and is currently being tested in a phase II clinical trial for ATs in humans. ATR-101 is a selective and potent sterol-O-acyltransferase 1 (SOAT1) inhibitor, which leads to the accumulation of free cholesterol in adrenocortical cells, resulting in endoplasmic reticulum stress and ultimately leading to apoptosis. Inhibition of SOAT1 could be an interesting therapy option in dogs with ATs, but can only be useful if canine ATs express SOAT1.

The aim of this study was to determine whether the use of a selective SOAT1 inhibitor such as ATR-101 could have potential in the treatment of canine ATs. To this end, we evaluated the SOAT1 mRNA expression with RT-qPCR in 59 ATs (44 carcinomas and 15 adenomas) and 12 normal adrenals (NAs), and protein expression with immunohistochemistry (IHC) in 47 ATs (36 carcinomas and 11 adenomas) and 4 NAs. Slides were stained with polyclonal rabbit-anti-human antibody and antibody specificity was confirmed with western blot. A semiquantitative H-score for SOAT1 protein expression was calculated by multiplying the area of positive staining with the staining intensity grading score.

SOAT1 mRNA was detectable with RT-qPCR in all samples tested. No significant differences were found between NAs (mean fold change 1.05±0.31), adenomas (1.17±0.60) and carcinomas (1.76±1.39), but expression was more variable in ATs and in particular in carcinomas. No significant differences were found in protein expression between NAs (H-score 5.97±1.82), adenomas (5.41±2.03) and carcinomas (5.54±3.26), but carcinomas again showed more variable expression and three carcinomas had low to absent SOAT1 protein expression (H-score lower than one).

In conclusion, SOAT1 mRNA was present in all and SOAT1 protein in 94% of our samples, providing a solid base that a selective SOAT1 inhibitor could have great potential as a future treatment in canine ATs. To determine the effect of ATR-101 in canine ATs, further studies are warranted.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

G.J. van Staalduinen
Utrecht University
Utrecht, Netherlands

URL:  http://www.vin.com/doc/?id=8172821
CYP17 Inhibitor Abiraterone Acetate as a Promising Future Treatment for Canine Hyperadrenocorticism: *In Vitro* Investigations

W.L. de Wit; K. Sanders; J.W. Hesselink; J.A. Mol; S. Galac

Utrecht University, Utrecht, Netherlands

Cushing’s disease or pituitary-dependent hypercortisolism (PDH) is a common endocrine disorder in dogs. At present, medical management of canine PDH consists of either trilostane or mitotane therapy. Both treatments have disadvantages associated with the induction of hypoadrenocorticism. Therefore, a more specific inhibition of glucocorticoid synthesis is desirable. Our recent studies indicate that the steroidogenic enzyme cytochrome P-450c17 (CYP17) could be an interesting target for selective inhibition of cortisol production without impeding the synthesis of aldosterone. Abiraterone acetate (AA), a highly selective irreversible CYP17-inhibitor, is already available on the market and successfully used for the treatment of castration-resistant prostate cancer in humans. In addition, the registration for human application will probably enable a relatively straightforward implementation into veterinary clinical practice. As side effects of AA are mostly related to hypocortisolism, this approach seems interesting as a novel medical treatment option for canine hypercortisolism.

The aim of this study was to determine the effects of AA on cortisol synthesis; on mRNA expression of steroidogenic genes encoding for CYP17, 3β-hydroxysteroid dehydrogenase (3β-HSD) and Ki67, a cellular marker for proliferation; and on adrenocortical cell viability.

Canine primary adrenocortical cell cultures from adrenal glands of seven healthy dogs were incubated with various concentrations of AA. PDH was mimicked by co-incubation with synthetic ACTH (Synacthen®). After 48 hours of incubation, RNA was isolated to evaluate gene expression using real-time quantitative PCR (RT-qPCR). Culture medium was removed for measurement of cortisol after 72 hours of incubation. In addition, cell viability was assessed using alamarBlue® assay.

AA dose-dependently decreased cortisol concentration in ACTH-stimulated adrenocortical cells with an IC50 value of 24.2 nM (p<0.0001). At the highest AA concentration of 10 µM, the average suppression of cortisol synthesis was 92.5% (SEM±3.5). The mRNA expression of CYP17, 3β-HSD and Ki67 was not significantly altered after incubation with AA. Finally, AA did not significantly affect adrenocortical cell viability.

We conclude that AA is effective in reducing cortisol synthesis *in vitro* without affecting adrenocortical cell viability and proliferation. Therefore, AA seems to be a promising future treatment option in the medical management of canine Cushing’s disease. To ascertain this, further *in vivo* studies are warranted.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

W.L. de Wit

Utrecht University

Utrecht, Netherlands

URL: [http://www.vin.com/doc/?id=8172822](http://www.vin.com/doc/?id=8172822)
Assessment of malignancy in canine cortisol-secreting adrenocortical tumors (ATs) remains challenging. No previous studies have linked molecular markers to survival times in dogs after adrenalectomy, making it difficult to give a reliable prognosis. The aim of this study was to identify molecular prognostic markers in a large cohort of canine ATs. This could not only enhance insight in individual prognosis, but could also provide potential future treatment targets.

Fifty-nine dogs with hypercortisolism due to an AT that underwent adrenalectomy between 2002 and 2015 at the authors’ institution and of which follow-up information was available, were included in this study. Three classes of potential prognostic factors were reviewed: firstly clinical data, including body weight, age at time of surgery, gender, neuter status and tumor size; secondly immunohistochemical Ki67 labeling index; and thirdly mRNA expression of factors associated with proliferation of ATs, including SF-1, PTTG1, PBX1, VAV2, RRM2, TOP2A, Ki67, CCND1, MC2R and BCL2. Univariate analysis was performed with the Cox proportional hazards model for continuous variables and the Log Rank test for bivariate variables. Multivariate analysis was performed using multiple linear regression with forward selection.

Median survival time was 63.6±9.4 months. In the univariate analysis, significant prognostic factors were tumor volume in cm$^3$ ($p=0.015$, hazard ratio [HR]=1.004), maximal diameter of tumor in cm ($p=0.047$, HR=1.284), Ki67 labeling index ($p<0.001$, HR=1.220) and mRNA expressions of SF-1 ($p=0.021$, HR=60.244), PTTG1 ($p=0.024$, HR=12.321), PBX1 ($p=0.005$, HR=8.714), and TOP2A ($p=0.035$, HR=7.191). Forward stepwise multivariate analysis identified Ki67 labeling index ($p=0.024$, HR=1.574) and SF-1 mRNA expression ($p=0.044$, HR=1.936×10$^6$) as independent predictors of poor survival.

In conclusion, most important predictors of poor survival are Ki67 labeling index and SF-1 expression. These results show the importance of including Ki67 staining in histopathological assessment of canine ATs. Moreover, since pharmacological manipulation of SF-1 is possible, the considerable impact of SF-1 expression on prognosis indicates great potential of SF-1 as a treatment target in canine ATs in the near future.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

**K. Sanders**

Utrecht University

Utrecht, Netherlands

URL: [http://www.vin.com/doc/?id=8172823](http://www.vin.com/doc/?id=8172823)
The Use of Chromogranin A Epitopes Vasostatin and Catestatin as Biomarkers for Catecholamine-Producing Tumours in Dogs

O.V. Höglund1; O. Yoshida2; K. Asano2; K. Ishigaki2; M. Stridsberg3; J.M. Hanson1

1Swedish University of Agricultural Sciences, Uppsala, Sweden; 2Nihon University, Fujisawa, Japan; 3Uppsala University, Uppsala, Sweden

Pheochromocytomas may be difficult to differentiate from adrenocortical tumors in dogs until diagnosis with histopathology is obtained. Fine-needle aspiration biopsy of adrenal masses is an invasive technique, with risk for complications. Measurement of urine catecholamine metabolites necessitates acidification of the urine with hydrochloric acid and associated handling risks. Ideally, a blood marker that reliably can differentiate between catecholamine-producing tumors and adrenocortical tumors, would be preferable. However, direct measurement of plasma catecholamines and their metabolites are less reliable than measurement of urine catecholamine metabolites in dogs. Measurement of serum inhibit concentrations is useful in gonadectomized dogs only. In human medicine, chromogranin A (CgA) is an established marker for neuroendocrine tumors (NETs). Chromogranin A is stored in secretory granules of neuroendocrine tissues and co-secreted with epinephrine and norepinephrine at sympathetic stimuli. The metabolites of CgA are more stable in plasma than are the catecholamines. The aim of the present study was to measure and compare serum concentrations of the CgA epitopes vasostatin and catestatin in serum collected before surgery from dogs with histologically confirmed catecholamine-producing tumors and dogs with adrenocortical tumors.

Serum samples were collected before surgery from 23 dogs with adrenal tumors and in one dog with an extra-adrenal neuroendocrine tumor. All tumors and their tissue origin were confirmed by histopathology. There were 12 catecholamine-producing tumors (11 pheochromocytomas, 1 extra-adrenal tumor), and 12 adrenocortical tumors. Serum concentrations of vasostatin and catestatin were analyzed by a radioimmunoassay (RIA) that has previously been validated for the use in dogs. Statistical analysis was performed with a non-parametric test using the software R version 3.0.2.

In the dogs with catecholamine-producing tumors, the median serum vasostatin concentration was 0.82 nmol/l (IQ range, 0.52 to 1.60 nmol/l). In the dogs with adrenocortical tumors, the median serum vasostatin concentration was 0.50 nmol/l (IQ range, 0.34 to 0.59 nmol/l). Serum vasostatin concentrations were significantly higher in dogs with catecholamine-producing tumors, than in dogs with adrenocortical tumors (Wilcoxon signed rank test, independent groups, p<0.05). There was no statistically significant difference in serum catestatin concentrations between the two groups.

Based on the results from this study, it can be concluded that the serum CgA epitope vasostatin may be a valuable serum biomarker to differentiate catecholamine-producing tumors from adrenocortical tumors.

DISCLOSURES

Disclosures to report:

The research was financed by a grant from Ture F and Karin Forsbergs Foundation. Dr. Stridsberg developed the method in the department’s laboratory at Uppsala University for research purposes only. For other research purposes Dr. Hanson has received the European Society Endocrinology/Dechra Veterinary Products, travel grant for researchers in veterinary endocrinology, and financial support from the Foundation for Research, Agria Insurance Company, the Swedish Research Council.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.M. Hanson
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172824
Cabergoline is a dopamine 2 receptor (D2R) agonist which is a second line medical therapy for human acromegalic patients. Pasireotide, a somatostatin analogue, is the only effective medical management option for feline acromegaly but its cost is a limiting factor for many owners. Our work has demonstrated dopamine receptors within the feline acromegalic pituitary and we hypothesised that cabergoline would improve diabetic control and IGF-1 concentrations of diabetic acromegalic cats.

This was a prospective cohort study of client-owned diabetic acromegalic cats, Ethics approval URN 2016 1604. Enrolment criteria were: a diagnosis of diabetes mellitus, an IGF-1 concentration >1000 ng/ml and owners declining alternative treatment options for acromegaly. Patients were admitted to the hospital on day 0, underwent pituitary imaging and started cabergoline therapy (Kelactin, Kela N.V.) on day 1. Cats were monitored in hospital until day 4 and were discharged to continue treatment at home. Serum IGF-1 and fructosamine were measured on day 0, day 4 and month 1. Any possible medication side effects were recorded. Descriptive statistics and non-parametric tests were used to analyse the data.

Six cats were enrolled. The first three cats received 5 µg/kg q24h PO and the second three cats received 10 µg/kg q24h PO of cabergoline. The median IGF-1 concentration at day 0 was 1797 ng/ml (range 890–>2000) which was not statistically different to day 4 and month 1 (1884 ng/ml and 1754 ng/ml, respectively). The median fructosamine concentration on day 0 was 551 µmol/l (range 454–887) which was not statistically different from day 4 and month 1 (551 to 569, respectively). All cats were receiving PZI insulin (ProZinc, Boehringer) and the median dose on day 0 (1.1 units/kg q12h) was not different to day 4 and month 1 (1.1 and 1.2, respectively). Three patients experienced a single gastrointestinal upset event (inappetence, diarrhoea) which resolved within three days. One of the six cats experienced an improvement of diabetic control (fructosamine day 0 was 454 µmol/l and month 1 was 288 µmol/l while insulin dose on day 0 was 1 unit/kg q12h and month 1 was 0.2 units/kg q12h) although there was no decrease of IGF-1 concentration (day 0: 890 ng/ml; month 1:929 ng/ml).

Cabergoline therapy, using the investigated dose and duration, was not associated with a reduction in IGF-1 concentration in the tested diabetic acromegalic cats; glycaemic control improved in one. Additional cases, alternative dosing regimens and longer-term follow-up are being assessed.

DISCLOSURES

Disclosures to report:
The diabetic remission clinic is supported by Nestle Purina and Boehringer Ingelheim.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
C.J. Scudder
Royal Veterinary College
Hatfield, UK

URL: http://www.vin.com/doc/?id=8172825
Serial Changes in Insulin-Like Growth Factor 1 and Impact on Hypersomatotropism-Screening in Feline Diabetes Mellitus

V.L. Woolhead; L. Teo Whee Wen; C. Scudder; R. Gostelow; G. Harman; Y. Forcada; D.B. Church; S.J.M. Niessen
Royal Veterinary College, North Mymms, UK

Hypersomatotropism [HS] is the underlying cause of diabetes mellitus in a substantial number of diabetic cats. Serum insulin-like growth factor-1 [IGF-1] measurement is currently the test of choice, with concentrations greater than 1000 ng/ml having a 95% positive predictive value. Therefore, all commercial laboratories currently use this value as a cut-off to indicate likely HS presence. However, endogenous insulin availability affects IGF-1 synthesis, thereby possibly reducing test sensitivity, especially in newly insulin-treated diabetic acromegalics.

This study's two main questions were: 1. How many newly diagnosed and treated diabetic cats demonstrate serum IGF-1 initially not suggestive to subsequently become suggestive of HS using this cut-off (1000 ng/ml)? 2. How strong is the correlation between endogenous insulin and IGF-1 concentrations in untreated diabetic cats?

Serial blood samples of diabetic cats were prospectively recruited from first opinion UK veterinary practices within 180 days of initiating insulin treatment. Serum IGF-1 and basal serum endogenous insulin were evaluated using a validated and commercially offered RIA and ELISA, respectively; the latter in untreated diabetic cats only. Mann Whitney test was used to compare groups and Spearman rank correlation coefficient to assess correlation between endogenous insulin and IGF-1; p<0.05 was considered significant. Serial blood samples of 219 cats were recruited (two samples: 103 cats; three: 55; four: 44; ≥five: 17). Sixty-two (28.3%) cats had at least one IGF-1 measurement >1000 ng/ml (median 1576 ng/ml, range 1001–>2000); a median of 0.6 units/kg/injection insulin (range 0–2.4) was administered. Of the cats with IGF-1 >1000 ng/ml, 20 (9.1%) initially showed IGF-1 <1000 ng/ml; therefore, the attending clinician could have discarded the possibility of HS in these patients. Median subsequent IGF-1 increase was 594 ng/ml (range 71–1495), having initially received a median of 73 days of insulin treatment (range 25–154). Basal endogenous insulin in untreated diabetic cats with IGF-1 <1000 ng/ml (n=106; median 29.0 ng/l, range 9.2–791) was significantly lower than in those with IGF-1 >1000 ng/ml (n=15; median 64.2 ng/l, range 9.2–490; p=0.024). A moderate positive correlation (r_s=0.42, p<0.0001) was detected between endogenous insulin and IGF-1 in untreated cats. In this study, approximately 1 in 10 newly diagnosed diabetic cats with an IGF-1 suggestive of underlying HS, based on the currently advocated cut-off, will initially show a negative value using this cut-off. Lower endogenous insulin, which moderately correlates with IGF-1, and/or suboptimal current cut-off value advice, could be contributing factors.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V.L. Woolhead
Royal Veterinary College
North Mymms, UK

URL: http://www.vin.com/doc/?id=8172826
Ultrastructural Characterisation of Pancreatic Beta-Cells in Cats with Diabetes Mellitus

E. Zini1; S. Dalla Riva2; L. Cavicchioli2; E. Salesov1; L. Vignato2; M. Oslo1; F. Fracassi3; R. Chiocchetti2; M. Valente2; T.A. Lutz4; C.E. Reusch1; M. Della Barbera2

1Clinic for Small Animal Internal Medicine, Zürich, Switzerland; 2University of Padua, Padua, Italy; 3University of Bologna, Bologna, Italy; 4Institute of Veterinary Physiology, Zürich, Switzerland

Dysfunctional pancreatic beta-cells are crucial in the pathophysiology of diabetes. Based on light microscopy, diabetic cats have reduced number of beta-cells but whether secretory granules and mitochondria, which are central to cellular function and viability, have abnormal morphology is unknown. Furthermore, a recent investigation questioned the role of islet amyloid in the pathogenesis of diabetes in cats since its amount did not differ between diabetic and age-matched control cats. However, intracellular aggregation of amylin into oligomers, rather than extracellular amyloid, may be the principle of beta-cell toxicity in type 2 diabetes. Therefore, the aims of the study were to characterize ultrastructural lesions of beta-cells in diabetic cats with emphasis on granules, mitochondria and intracellular amylin aggregation.

Pancreases of diabetic and control cats euthanized for any disease were prospectively collected. Samples were harvested within 1 hour from death and glutaraldehyde-fixed. Control cats were selected to be matched for age, sex and body weight. Sections were prepared for electron microscopy and immunogold labelling by using anti-insulin and anti-amylin antibodies. Beta-cell morphology was assessed, including beta-cell granule area, eccentricity (minimum-to-maximum diameter ratio), granule number, as well as beta-cell mitochondrial area, number and inter-cristae distance. Intracellular accumulation of amylin-positive material outside the granules was explored. Non-parametric tests were used for statistical analysis.

Five diabetic cats and 5 controls were included. Diabetic cats had beta-cells with clearer cytoplasm than control cats. The median area of beta-cell granules was higher in diabetic than controls [0.144 \( \mu \text{m}^2 \) (0.047–0.252) vs. 0.035 \( \mu \text{m}^2 \) (range: 0.027–0.046); \( p<0.05 \)] and their median number lower [0.5/\( \mu \text{m}^2 \) (0.3–2.8) vs. 5.6/\( \mu \text{m}^2 \) (range: 3.9–7.8); \( p<0.05 \)]; eccentricity did not differ. The median inter-cristae distance of mitochondria was higher in diabetic than controls [0.064 \( \mu \text{m} \) (0.052–0.075) vs. 0.034 \( \mu \text{m} \) (range: 0.032–0.043); \( p<0.05 \)]; their area and number did not differ. Mitochondria of diabetic cats appeared swollen. Amylin-positive material outside the granules was observed in the cytoplasm of 3 diabetic cats and in none of the controls.

In conclusion, the reduced number of granules might suggest that the remaining pool of beta-cells in diabetic cats is less functional or exhausted by the excessive workload. The reason behind the larger granule size is uncertain. The increased inter-cristae distance of mitochondria in diabetic cats, as well as their swollen appearance, might suggest increased permeability and loss of function. The appearance of amylin-positive material outside of granules suggests intracellular aggregation of amylin monomers to oligomers, which may possibly contribute to beta-cell death.

DISCLOSURES

Disclosures to report:

Claudia Reusch was consultant for Boehringer Ingelheim and Novartis Animal Health and is currently consultant for Dechra Limited. She has received financial support for her endocrine research from various companies such as Nestlé Purina, Hills, Provet, Antlia SA, Glycemicon and from the clinical studies fund of the ECVM-CA and from the Society of Comparative Endocrinology.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Zini
Clinic for Small Animal Internal Medicine
Zurich, Switzerland

URL: http://www.vin.com/doc/?id=8172827
The Diabetic Clinical Score (DCS): Evaluation of a Simple Standardised Quantification Tool to Allow Rapid Description of Clinical Signs in Diabetic Dogs

S.J.M. Niessen¹; K. Hazuchova¹; E. Bowles¹; R. Gostelow¹; C. Scudder¹; V. Woolhead¹; H. Darcy¹; Y. Forcada¹; A. Popp²; F. Venzon Varela²; E. Furrow³; L. Fleeman⁴; D.B. Church¹

¹Royal Veterinary College, North Mimms, UK; ²Universidade Federal do Rio Grande do Sul, Brazil; ³College of Veterinary Medicine, University of Minnesota, MN, USA; ⁴Animal Diabetes Australia, Melbourne, VIC, Australia

Glycaemic parameters, such as fructosamine, glycosylated haemoglobin and serial glucose measurements (SGMs), are always to be interpreted in light of the clinical signs being exhibited by diabetic pets. Sample artefacts, assay-issues, inter-day variation and stress can yield deceiving laboratory results. Likewise, the clinical history suffers from inter-person variation, due to varying ways of asking or answering questions, interpreting non-standardised language, forgetting questions and lack of quantification. The aim of this study was to evaluate the newly designed simple Diabetic Clinical Score (DCS) in diabetic dogs. The DCS was previously validated for use in diabetic cats.

Diabetic dog owners were asked to choose the specific severity (ranging from none/normal, mild, moderate to severe) of specific diabetic clinical signs (polyuria and polydipsia, polyphagia, attitude/activity). The extent of possible weight loss was established by weighing (none; mild: <5%; moderate: 5–10%; severe: >10%). The severity was subsequently converted into a score ranging from 0 (none/normal) to 3 (severe), yielding a summarised total score (DCS) for all signs combined ranging from 0 (no clinical signs) to 12 (maximum clinical signs). The DCS was correlated with one or more of following objective parameters obtained at the same visit: fructosamine, average blood glucose during SGMs (AvBG) or water intake diary. Appropriate descriptive and correlation statistics used.

Sixty-seven diabetic dogs were assigned a DCS (median 4; range 0–10). A significant correlation was present between the AvBG (n=16, Spearman's rho: 0.656, p<0.001), daily water intake (n=32, Spearman’s rho: 0.605, p<0.0003) and the DCS. A significant correlation between the DCS and fructosamine (n=38, Spearman's rho: 0.340, p<0.04) was also present though only when dogs with concurrent hyperadrenocorticism, hyperlipidemia, hypothyroidism and diabetic ketoacidosis were removed from the analysis. Seventy-nine percent of owners reported the questions to be clear/completely clear.

The DCS proved easy to comprehend by dog owners. The significant correlation between DCS and objective clinical parameters suggests it could represent a simple objective tool to describe, communicate and quantify the clinical signs encountered in diabetic dogs in clinical practice and research settings. Differences between the DCS and objective parameters should be further investigated.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

S.J.M. Niessen
Royal Veterinary College
North Mimms, UK

URL: http://www.vin.com/doc/?id=8172828
Thyroid and Renal Function in Cats Post Low-Dose Radioiodine Therapy

N.C. Finch1; J. Stallwood1; S. Tasker1; A. Hibbert2

1University of Bristol, Bristol, UK; 2The Feline Centre, Langford Vets, Bristol, UK

Iatrogenic hypothyroidism can develop post-radioiodine treatment for feline hyperthyroidism; its incidence may be dose-dependent. Cats that develop iatrogenic hypothyroidism have a greater incidence of development of azotaemia than cats that remain euthyroid. Dogs with experimentally induced hypothyroidism have both decreased glomerular filtration rate (GFR) and endogenous creatinine production. This suggests that using creatinine as a marker of kidney function in hypothyroid cats could underestimate the incidence of development of kidney disease. This longitudinal study evaluated thyroid and renal function in cats post low-dose (111 MBq) radioiodine therapy.

Hyperthyroid cats presented for low-dose radioiodine treatment to The Feline Centre, Langford Vets were prospectively enrolled into the study. At baseline, one, six and 12 months post-radioiodine treatment, thyroid and renal function were evaluated via total thyroxine (TT4) and thyroid stimulating hormone (TSH), and via serum creatinine concentration (Scr) and GFR (corrected slope-intercept ioxohol clearance), respectively. Cats were categorized as overt hypothyroid (TT4<15 nmol/l, TSH>0.15 ng/ml), subclinical hypothyroid (TT4<15–60 nmol/l, TSH>0.15 ng/ml), euthyroid (TT4≤60 nmol/l, TSH≤0.15 ng/ml) and hyperthyroid (TT4>60 nmol/l) at each timepoint. Decreased GFR was defined as <0.92 ml/min/kg and azotaemia as Scr>175 µmol/l.

Twenty-seven cats were recruited into the study with 21 completing the 12-months follow-up; two were lost at one month and four at 12 months. Two cats (8%) remained persistently hyperthyroid, of which one underwent repeat radioiodine treatment. Five cats (20%) remained hyperthyroid at one-month but were euthyroid by 6 months. Seven cats (28%) developed overt hypothyroidism over the 12 months (2/7 at one-month, 4/7 at 6 months and 1/7 at 12 months) of which two were preceded by subclinical hypothyroidism and none of these cats regained normal thyroid function by 12 months. One cat had subclinical hypothyroidism at 12 months with no further follow-up available. No cats developed transient overt or subclinical hypothyroidism. Of the cats that developed overt hypothyroidism, 4/7 (57%) developed decreased renal function by 12 months. Decreased GFR preceded azotaemia development in 2/4 (50%) of these cats.

Twenty-eight percent of cats developed overt hypothyroidism that could be documented up to 12 months post treatment. This highlights the importance of continued monitoring of thyroid function post treatment even for cats receiving low-dose radioiodine therapy. Reduced renal function was documented in 57% of overtly hypothyroid cats, with GFR detecting decline in renal function earlier than Scr, suggesting GFR may be more useful to monitor renal function in cats post radioiodine therapy. However, the study is limited by the small number of cats developing overt hypothyroidism and further studies evaluating the optimal method for detecting early decline in renal function are required.

DISCLOSURES

Disclosures to report:

This study was funded by a Petsavers grant and by Langford Vets clinical research fund NC Finch. Currently receives direct research support from Boehringer Animal Health, Petsavers, Langford Vets clinical research fund, Wellcome Trust. Currently receives indirect research support from Zoetis and IDEXX. Previously received direct support from Agria pet insurance. Previously received indirect support from MSD Animal Health. Salary is currently funded by the Wellcome Trust. Currently a member of the Governing Council of the Cat Fancy Veterinary Advisory Committee. Previously has received honorarium for speaking for not-for-profit organisations, and occasionally for pharmaceutical industries and for articles published in peer and non-peer reviewed publications (S. Tasker [ST]). In the past ST has received financial support for haemoplasma research from Zoetis Animal Health and for vector-borne disease research from Bayer Animal Health. ST receives financial support for current infectious disease research from BSAVA Petsavers, Langford Trust, Petplan Charitable Trust, Morris Animal Foundation, Dogs Trust, South West Biosciences DTP, MSD Animal Health and Langford Vets Clinical Research Fund. ST has also received financial support for infectious disease research in the past from the Elizabeth Blackwell Institute of the University of Bristol, ECVM Clinical Studies Fund, the University of Bristol Campaigns and Alumni Fund, the RCVS Trust Fund Blue Skies and The Wellcome Trust. ST is a member of the World Forum for Companion Animal Vector Borne Diseases, supported by Bayer Animal Health. ST is a member of the European Advisory Board on Cat Diseases, which is supported by Merial. ST works for the Molecular Diagnostic Unit, Langford Vets, University of Bristol, which carried out the PCRs described in the study. ST has been paid for providing continuing professional development for not-for-profit organisations, and occasionally for commercial companies, around the world. A. Hibbert (AH) has received financial support for feline hyperthyroid disease research from BSAVA Petsavers, TOSOH Bioscience, Langford Vets and the Langford Trust. AH has been paid for providing continuing professional development for not-for-profit organisations, and occasionally for commercial companies, around the world.
Evaluation of Symmetric Dimethylarginine (SDMA) in Dogs with Primary Hypoadrenocorticism Under Long-Term Mineralocorticoid Replacement Therapy

J.I. Casado Diaz¹; N. Sieber-Ruckstuhl¹; F.S. Boretti¹; F. Fracassi²; C.E. Reusch¹

¹Vetsuisse-Faculty, University of Zürich, Zürich, Switzerland; ²Department of Veterinary Medical Sciences; University of Bologna, Bologna, Italy

In the majority of dogs with primary hypoadrenocorticism (PH), the disease is characterized by an absolute deficiency of glucocorticoids and mineralocorticoids. Consequently, those patients require life-long replacement of both hormones. Since application of the respective drugs do not restore physiological hormone levels and biorhythm, overdose may be possible during long-term management. Unlike to glucocorticoid excess, overdose of mineralocorticoids may go clinically unnoticed. Due to their role as key mediators for renal damage and progression of kidney disease, mineralocorticoid overdose represents a matter of concern.

The aim of the study was to investigate kidney function by means of SDMA and creatinine (Cr) in dogs with PH during long-term mineralocorticoid therapy.

Twenty-seven client-owned dogs with PH receiving either desoxycorticosterone pivalate (DOCP) or fludrocortisone acetate (FC) for a minimum of 12 months were included in the study. Concentrations of Cr had been measured during regular re-evaluations and were retrieved from the medical records retrospectively. SDMA was measured using the validated immunoassay at the reference laboratory (IDEXX Diavet).

Treatment time ranged from 12–146 months (median 47). Nine dogs had been treated with FC, 8 dogs with DOCP and in 10 dogs FC had been changed to DOCP because of poor response or adverse effects. At the time of diagnosis 3 dogs had elevated SDMA whereas Cr was elevated in 8 dogs, both parameters normalized after starting therapy. Two dogs developed persistent elevated SDMA 18 and 32 months after starting therapy with FC and DOCP respectively, followed by an elevated Cr 14 and 4 months later. Clinical signs and further work up were consistent with chronic kidney disease (CKD) in both dogs. Although SDMA was within the reference interval in all other dogs, 3 dogs showed an elevated Cr, being permanent in one of them. A significant correlation between SDMA and Cr was demonstrated (r=0.35; p=0.0013). There was no statistical evidence of any differences in Cr or SDMA between the FC and the DOCP groups.

In conclusion, selected dogs may develop CKD during long-term mineralocorticoid therapy. The prevalence of CKD in PH might be higher than in the general dog population, however this has to be verified in a larger number of dogs. The significance of an elevated Cr with normal SDMA is unclear, possibly reflecting prerenal azotemia or early kidney dysfunction.

DISCLOSURES

Disclosures to report:
CR was consultant for Boehringer Ingelheim and Novartis Animal Health and is currently consultant for Dechra Limited. She has received financial support for her endocrine research from various companies such as Nestlé Purina, Hills, Provét, Antlia SA, Glycemicon and from the clinical studies fund of the ECVIM-CA and from the Society of Comparative Endocrinology. NSR has been member of the Vetoryl novel monitoring meeting 2017 organized by Dechra Veterinary Products Ltd.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
J.I. Casado Diaz
Vetsuisse-Faculty
University of Zurich
Zürich, Switzerland

URL: http://www.vin.com/doc/?id=8172816
A Comparison of the ACTH Concentrations in Dogs with Stable Hypoadrenocorticism Being Treated with Either Fludrocortisone or Desoxycortone Pivalate and Prednisolone

S. Spence; S. Fowlie; E. Roberts; I. Ramsey
University of Glasgow, Glasgow, UK

Desoxycortone pivalate (DOCP) (Zycortal®, Dechra) is a pure mineralocorticoid and so concurrent doses of glucocorticoids need to be individually titrated; currently this is done on the basis of clinical signs. In contrast, most dogs treated with fludrocortisone (a mixture of mineralocorticoid and glucocorticoid) do not receive additional glucocorticoid supplementation following stabilisation. The objective of this study was to compare the ACTH concentrations in dogs treated with fludrocortisone with the same dogs when treated with DOCP and prednisolone.

A prospective, cross-over trial was performed using 33 dogs with hypoadrenocorticism who had been previously stabilised on fludrocortisone. Each dog was randomly allocated to one of two groups, each of which were treated with 3 months of fludrocortisone then 3 months of DOCP and prednisolone (or vice versa). The prednisolone dose was adjusted according to clinical signs. Two dogs failed to complete the trial. Three patients received prednisolone concurrently for at least part of the fludrocortisone phase and the data from these dogs in this phase were removed from further analysis. ACTH levels were measured at the start and end of each treatment phase using an immunoradiometric assay (NationWide Laboratories). Tests for normality were performed and Mann-Whitney U tests were used to compare the various ACTH concentrations and the prednisolone doses at the start and end of the DOCP phase. A Pearson correlation was used to compare the final prednisolone dose and ACTH concentrations at the end of the DOCP phase.

There was a significant difference between the ACTH concentrations after DOCP (median=2.5 pg/ml) compared to those after fludrocortisone (median=150 pg/ml) or before starting DOCP (median=128 pg/ml). There was also a significant reduction in prednisolone dose during the DOCP phase from a median starting dose of 0.22 mg/kg to 0.13 mg/kg. After 3 months of treatment with DOCP and prednisolone 21 out of 31 dogs had ACTH concentrations less than 10 pg/ml (suggesting suppression of the ACTH secretion). No significant correlation was found between the final prednisolone dose and the ACTH concentration at the end of the DOCP phase. In contrast, 18 of the 31 dogs had ACTH concentrations more than 100 pg/ml (possibly suggesting inadequate glucocorticoid supplementation) following 3 months of treatment with fludrocortisone.

It is concluded that in many dogs with hypoadrenocorticism being treated with DOCP, the dose of prednisolone has the potential to be further reduced based on ACTH concentrations.

DISCLOSURES

Disclosures to report:

The lead author's position was previously funded by Dechra Ltd, the manufacturer of Zycortal. This study was funded by Dechra.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

S. Spence
University of Glasgow
Glasgow, UK

URL: http://www.vin.com/doc/?id=8172817
Prevalence of Hyperaldosteronism and Hypertension in Cats with Chronic Azotaemia

A.C. Hagblom; J.M. Hanson
Swedish University of Agricultural Sciences, Uppsala, Sweden

Primary hyperaldosteronism (PHA) is suggested to be more common in cats than previously thought. Because of its profibrotic and proinflammatory effects, aldosterone may contribute to the progression of hypertension and kidney damage.

The aim of the present study was to perform a pilot study on the plasma aldosterone concentration (PAC), plasma renin activity (PRA), and hypertension in cats with chronic azotemia in Sweden.

Twenty-one cats with chronic azotemia were included in the study. Blood samples were collected into pre-chilled EDTA tubes and centrifuged at +4°C. The separated plasma was stored at -80°C until transport at -70°C to the commercial laboratory for analysis. PAC was measured with an ELISA, PRA with a radioimmunoassay, and blood pressure (BP) with high-definition oscillometry. Statistical analysis was performed with non-parametric tests with the free software R version 3.3.2.

In the 21 cats, median PAC was 21 pmol/L (range, <20 to 127 pmol/L; reference range, 87 to 224 pmol/L). In seventeen cats the PAC was below reference range; in 10 of these the PAC was below detection limit (20 pmol/L). Median PRA was 0.30 ng/ml/hr (range, 0.0 to 4.5 ng/ml/hr; reference range, 0.14 to 3.85 ng/ml/hr). Five of the 21 cats had a PRA below the reference range. Median aldosterone-to-renin activity ratio (ARR) was 86 (range, 14 to 4300). Eleven of the 21 cats were hypertensive (BP≥160 mm Hg). Median PAC in hypertensive cats was 43 pmol/L (range, <20 to 127). Median PAC in normotensive cats was <20 pmol/L (range, <20 to 77). There was no statistical difference in PAC or PRA between hypertensive and normotensive cats (Mann-Whitney-Wilcoxon test, p=0.09 and p=0.10, respectively).

Five of the 6 cats with a PAC >70 pmol/L were hypertensive. Four of the 5 hypertensive cats had a PRA below or in the lower reference range. The ARR in these 4 cats was 513, 673, 720, and 1200. One cat (ARR 1200) was euthanized. Histopathological examination revealed a mixed diffuse and nodular hyperplasia of the z. glomerulosa of the right adrenal gland, and bilaterally chronic to active interstitial nephritis. The remaining two cats had an ARR of 23 and 122.

The results of the present study indicate presence of renin-independent aldosterone secretion in 19% of the cats with chronic azotemia. A surprisingly high proportion of the cats had a subnormal PAC. This is an observation that needs further investigation, before conclusions are drawn.

DISCLOSURES

Disclosures to report:

A scholarship from the Foundation of Elsa Paulssons memorial fund was granted to finance a part of the costs of this study. Dr Hanson has received European Society Endocrinology/Dechra Veterinary Products travel grant for researchers in veterinary endocrinology, and financial support from the Foundation for Research, Agria Insurance Company, the Swedish Research Council, and Thure F and Karin Forsbergs Stiftelse.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.C. Hagblom
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172818
The Use of a TRH Stimulation Test, with Measurement of Growth Hormone and Thyroid Stimulating Hormone, to Differentiate Between Primary Hypothyroidism and Non-Thyroidal Illness in Dogs

T. Pijnacker; C.F. Vermeulen; M. van der Vinne; H.S. Kooistra; J.A. Mol
Utrecht University, Utrecht, Netherlands

Hypothyroidism is one of the most common endocrinopathies in dogs. The diagnosis of hypothyroidism relies upon measurement of basal plasma concentrations of total thyroxine (T₄) and thyroid stimulating hormone (TSH). A low plasma T₄ combined with a high plasma TSH points to primary hypothyroidism. However, 30%–38% of hypothyroid dogs have TSH values within the reference range. Consequently, a low plasma total T₄ concentration in combination with a plasma TSH concentration within the reference range does not distinguish between dogs with hypothyroidism and dogs with non-thyroidal illness (NTI). A potential interesting observation from previous studies (Lee et al., 2001, and Diaz-Espiñeira et al., 2008) is that hypothyroidism in dogs is associated with increased release of growth hormone (GH).

The aim of this study was to evaluate whether a TRH stimulation test can differentiate between dogs with NTI and dogs with hypothyroidism that have a plasma TSH concentration within the reference range, by measuring plasma concentrations of GH and TSH.

Twenty-one dogs with clinical signs consistent with hypothyroidism, a plasma TT₄ concentration below the reference interval (19–46 nmol/l), and a plasma TSH concentration within the reference interval (<0.60 µg/l) were included in this study. Thyroid scintigraphy was performed to classify dogs as having hypothyroidism or NTI. All dogs underwent a TRH stimulation test in which plasma concentrations of TSH and GH were measured twice before intravenous administration of 10 µg/kg TRH (t=-15 and t=0) and 30 and 45 minutes after TRH administration.

Eleven of the 21 dogs were classified as hypothyroid and 10 dogs as having NTI by thyroid scintigraphy. There were no differences in baseline characteristics between the groups except for gender. The plasma TSH concentration did not change significantly in the hypothyroid dogs after administration of TRH, whereas it significantly increased in the NTI dogs (p<0.001). In contrast, the plasma GH concentration increased significantly in the hypothyroid dogs after TRH administration (p=0.009), whereas it did not change in the NTI dogs.

The TRH stimulation test with measurement of circulating concentrations of TSH and GH could be used to differentiate between hypothyroid dogs and NTI dogs that have clinical signs of hypothyroidism, a low basal TT₄ concentration and a basal TSH concentration within the reference interval. This is a promising test which might be of valuable use in primary veterinary practice.

DISCLOSURES

Disclosures to report:

This study was partially funded by a grant from the American Kennel Club.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Pijnacker
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172819
Interrelation Between Thyroid Function and Sex Hormones in Female German Shepherd Dogs

P. Scarpa; F. Iavazzo; M. Beccaglia; A. Monino; P. Dri; G. Milite

1University of the Study of Milan, Milan, Italy; 2Ambulatorio Veterinario Beccaglia, Lissone (MB), Italy; 3Animal Care SRL, Martignacco (UD), Italy

In veterinary literature, data about the interaction between thyroid gland and female reproductive status are lacking. Furthermore, previous studies have often referred to male dogs and few data are available about thyroid influence on different phases of the bitch oestrus cycle.

The aim of this study was to determine the influences of the different phases of oestrous cycle on thyroid hormones in German Shepherd bitches.

Seventeen clinically healthy German Shepherd bitches (9 months to 6 years old) were monitored during a complete oestrus cycle (proestrus, oestrus, diestrus, anestrus); the different phases were determined by vaginal cytology. Two blood samples were collected by cephalic vein in each phase, between 11 am and 2 pm, after 12h–24h fasting. Thyroid hormones (TT4, fT4, TT3, fT3), TSH, progesterone, 17-ß-estradiol, serum triglycerides and cholesterol were assessed in each blood samples. At the beginning and at the end of the study a complete haematological and biochemical evaluation was also performed. Seven bitches were bred during the study, and hormone concentrations were also evaluated during pregnancy.

Data were statistically analysed: correlation test was performed between thyroid and pituitary hormones with age, between the different hormones assessed (thyroid, pituitary and sexual hormones) and between estradiol and cholesterol. One-way ANOVA was used to compare the averages of each parameter (thyroid/pituitary) in different phases of the cycle and in diestrus gravidarum and not gravidarum.

Effect size (Cohen's d) or root mean square standardized effect were calculated to measure the magnitude and strength of the statistically significant research findings.

A significant negative correlation between age and TT4 (r=-0.367; p<0.05), fT4 (r=-0.266; p<0.05), fT3 (r=-0.335; p<0.05) was found.

One way ANOVA showed that TT4 concentration during estrus and diestrus phase, was significantly higher than in proestrus and anestrus phase (p=0.0332). TSH concentration during diestrus and pregnancy was not significantly different by two tails T-test (p=0.0507), even though a higher TSH concentration during pregnancy was evident.

TT4 (r=0.40289; p<0.001) and fT4 (r=0.260; p=0.0067) were positively and significantly associated with progesterone.

TSH was positively and significantly correlated with 17-ß-estradiol (r=0.2; p=0.0388), while TT4 was negatively and significantly correlated with 17-ß-estradiol (r=-0.3179; p=0.0008).

Cholesterol was negatively and significantly correlated with 17-ß-estradiol (r=-0.3355; p=0.0001) and was significantly higher during diestrus (r=-0.3355; p=0.0001). There was no significant correlation between total triglycerides and 17-ß-estradiol.

Results showed an influence of reproductive status on thyroid function, especially during progesterone-prevalent phase (diestrus) and especially relating to TT4 concentration.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Scarpa
University of the Study of Milan
Milan, Italy

URL: http://www.vin.com/doc/?id=8172820
Poster Presentations

Safety and Efficacy of Dapagliflozin, a Novel Antidiabetic Drug, in Healthy Cats  R.K. Burchell
Evidence for Regional Variation of Patient Characteristics in Dogs with Hyperadrenocorticism  K.F.A. Langner
Symmetric Dimethylarginine (SDMA) in Hyperthyroid Cats  A. Corsini
Low Thyroxine Concentrations After Controlled Feeding of Bovine Thyroid Gland to Dogs  M. Schmicke
C-reactive Protein in Dogs Diagnosed with Hyperadrenocorticism  J.G. Lyngby
Systemic Hypertension in Diabetic Cats: Does It Really Matter?  P. García San José
Systemic Hypertension in Dogs with Diabetes Mellitus  M.D. Pérez Alenza
Canine Electrolyte Analysis in Dogs with Hypoadrenocorticism - A Comparison of Two In-house Analysers with a Reference Laboratory  S.J. Fowlie
Concurrent Pituitary and Adrenocortical Tumors in Dogs with Spontaneous Hypercortisolism  K.L. van Bokhorst
Prevalence of Neurological Signs in Hypothyroid Dogs at Diagnosis  S. González Sanz
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Dogs  F. del Baldo
Serum Symmetric Dimethylarginine (SDMA) in Dogs with Hypothyroidism  G. Carotenuto
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Cats  E. Malerba
Safety and Efficacy of Dapagliflozin, a Novel Antidiabetic Drug, in Healthy Cats

R.K. Burchell; A. Gal; S.E. Burton; N.J. Cave
Massey University, Palmerston North, New Zealand

Renal sodium glucose transporter type 2 (SGLT2) inhibitors are a novel class of drug developed for the management of type-2 diabetes (T2DM) in humans. Inhibition of SGLT2 induces profound renal glucosuria reducing blood glucose and lowering insulin requirements in man. Adverse effects are uncommon. These drugs have not been evaluated in cats to the authors’ knowledge. In this study 3 healthy cats were sequentially dosed with 5, 10, 15 and 20 mg of dapagliflozin for 5 days per treatment with a 2-week washout between each regimen. Cats were housed in individual cages. Haematology, serum biochemistry and urinalysis were performed before and after each trial. Daily food, water intake, urine production and 24-hour urinary glucose excretion were measured for the duration of each trial. Data was analysed using a mixed linear model with a fixed effect of ‘dose’ and ‘day’, and the random effect of ‘cat’. Dapagliflozin induced significant glucosuria at all doses used, which persisted for 5 days after the last dose for each regimen. The 10 mg dose induced the most significant increase in daily urine glucose output with a concomitant decrease in daily urine output. One cat developed a mild hyperglobulinaemia and leukocytosis, but no other adverse effects were noted. The cats lost weight during each of the trials, which is one of the touted benefits of the drug in human diabetics. Polydipsia/polyuria were not observed, nor were urinary tract infections detected during the trial. In conclusion, dapagliflozin appeared safe and is effective in inducing glucosuria.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R.K. Burchell
Massey University
Palmerston North, New Zealand

URL: http://www.vin.com/doc/?id=8172830
Evidence for Regional Variation of Patient Characteristics in Dogs with Hyperadrenocorticism

K.F.A. Langner¹; B.C. Duff²; S. Foster²

¹Murdoch University Australia, Perth, WA, Australia; ²Vetnostics, North Ryde, Sydney, NSW, Australia

Patient signalment and pathological causes of canine hyperadrenocorticism have been largely derived from studies on North American dog populations. It is has been suggested that these findings are not necessarily applicable to other countries.

This retrospective study assessed 200 consecutive records of Australian dogs between 2006–2009 that had samples submitted to an accredited laboratory for measurement of endogenous adrenocorticotropic hormone (ACTH) by radioimmunoassay. Adrenal ultrasonography was not easily available for most general veterinary practices at this time and the endogenous ACTH assay was routinely used for differentiation of pituitary from adrenal dependent disease. Clinical and clinicopathologic data were obtained from the laboratory submissions and/or submitting practitioner patient records. A total of 175 dogs met the inclusion criteria for a confirmed diagnosis of hyperadrenocorticism. This subset was evaluated for age, body weight, sex, breed and lesion location (pituitary versus adrenal).

Median age of the assessed dogs was 11 years and median body weight was 8.17 kg. Sixty-one percent of the dogs were female and 39% male. The most commonly affected breeds were crossbred dogs (32.6%) and Maltese (20.6%). Maltese crossbreds and Maltese purebreds together comprised 31.4% of the study population. Other commonly identified breeds included Australian Cattle Dog, Jack Russell Terrier (3.4% each), Poodle, Miniature Fox Terrier, Shi Tzu and Bichon Frise (2.9% each). Pituitary dependent hyperadrenocorticism was identified in 171 dogs (97.7%). A functional adrenal tumour was found in 3 dogs (1.7%) and suspected in a fourth dog.

The results demonstrated that Australian dogs with hyperadrenocorticism have a lower median body weight and a higher prevalence of pituitary dependent disease when compared to the North American data. In addition a striking percentage of the study population were Maltese dogs and their crosses. These findings have implications for investigation and therapy of canine hyperadrenocorticism in Australia. They also highlight that regional differences in hyperadrenocorticism should be recognised by veterinarians worldwide.

DISCLOSURES

Disclosures to report:

This study was a population study and involved no conflict of interest by the authors. One of the authors (BD) is employed by the accredited laboratory that was the source of the raw data. One of the authors (SF) is a consultant to the same laboratory. The study was an independent collaborative retrospective study. It was not performed for any commercial benefit and was not funded by any person or entity.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

K.F.A. Langner
Murdoch University Australia
Perth, WA, Australia

URL: http://www.vin.com/doc/?id=8172836
Symmetric Dimethylarginine (SDMA) in Hyperthyroid Cats
A. Corsini¹; S. Crosara¹; G. Carotenuto²; F. Fracassi²
¹Parma University, Parma, Italy; ²Department of Veterinary Sciences, Bologna, Italy

Hyperthyroidism leads to a decrease in serum creatinine (Crea) by increasing glomerular filtration rate (GFR) and decreasing body muscle mass. This can mask a concurrent chronic kidney disease that might become evident after the onset of treatment. Symmetric dimethylarginine (SDMA) is a novel, early, renal biomarker independent of body muscle mass, therefore it might be a useful marker of renal disease in hyperthyroid cats. In humans is not clear if hyperthyroid state could influence SDMA.

Aim of this study was to evaluate SDMA in hyperthyroid cats at the time of diagnosis and after treatment.

This was a retrospective observational study. Nineteen hyperthyroid cats (TT4>40 mmol/L) with normal Crea (<1.8 mg/dl) were included. Eighteen healthy cats, older than 7 years, with normal TT4 and Crea <1.8 mg/dl were enrolled as control group. Data about physical exam, emogram, serum biochemistry and serum TT4 concentration were evaluated. SDMA was measured on serum left over from previous analyses and stored at -80°C. SDMA measurement was performed in serum samples collected at the time of diagnosis of hyperthyroidism and after methimazole treatment when TT4 normalized, between 10 to 90 days after initiation of the treatment. Follow-up was available for 8/19 hyperthyroid cats; SDMA was measured using a validated immunoassay (IDEXX SDMA test).

Hyperthyroid cats were older (p=0.0005) and had a lower weight (p<0.0001) than control cats. In hyperthyroid cats Crea at diagnosis was positively correlated with SDMA (r=0.47, p=0.04) and negatively correlated with TT4 (r=-0.46, p=0.04). No correlation was found between SDMA and TT4 at diagnosis (p=0.10). In hyperthyroid cats weight was positively correlated with creatinine (r=0.51, p=0.004) but not with SDMA (p=0.39). There was no difference for Crea between hyperthyroid cats and controls at diagnosis (p=0.3). Creatinine significantly increased (p=0.03) after treatment despite body weight did not (p=0.13). No difference was found when comparing SDMA in hyperthyroid and control cats at diagnosis (p=0.11) nor after treatment (p=0.86). Five hyperthyroid cats had SDMA value higher than reference range at diagnosis. Follow-up after treatment was available for 2/5 only; in these 2 cats when TT4 was normal Crea was still normal and SDMA was increased in one. 2/5 cats showed increased creatinine when TT4 normalized, but none of them had high SDMA at diagnosis.

Based on this preliminary study hyperthyroidism seems not to influence SDMA concentration.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
A. Corsini
Parma University
Parma, Italy

URL: http://www.vin.com/doc/?id=8172837
Low Thyroxine Concentrations After Controlled Feeding of Bovine Thyroid Gland to Dogs

L. Steinhoff; B. Ruhmann; A. Mösseler; M. Schmicke

1Endocrinology, Clinic for Cattle, University of Veterinary Medicine Hannover, Hannover, Germany; 2Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Hannover, Germany

Feeding of biologically appropriate raw food (BARF) including gullet is popular. Due to the close anatomical position of the thyroid gland and the respective muscle tissue such diets are likely to be contaminated with thyroid gland tissue and may cause alimentary thyrotoxicosis. However, as controlled studies are missing, it is unclear which effect the absorbed total thyroxine (T4) and triiodothyronine (T3) may have on the thyroid hormone status. Because T4 levels are still routinely checked in the elderly dog and commonly in dogs suspicious of behavioral issues it would be of high diagnostic interest, if potential thyroid gland feeding may interfere with the diagnostic approach. Therefore, the present study aimed in investigating the short term effect of thyroid gland feeding on the thyroid hormone concentration in dogs. Bovine thyroid gland from the slaughterhouse (0.5 g/kg body weight) was fed after 12 h fasting together with a complete dry diet. Blood samples were taken 19 days before the experiment in order to verify euthyroidism in the healthy beagle dogs (n=5). On the day of the feeding experiment blood was taken before (0 and 4, 8, 24, 52 h as well as 6 days after feeding. In the samples T4-, free T4-, T3 and thyroid stimulating hormone (TSH) as well as thyroglobulin autoantibodies (TgAA) were measured either using an automated chemiluminescence immunoassay (Immulite® 1000 System, Siemens Diagnostics, USA) or a commercially available TgAA assay (Oxford Laboratories, MI, USA). No dog had TgAA. After feeding thyroid gland there was an increase up to 7.8 fold basal levels of T4, free T4 and T3 serum concentrations. Serum levels returned to basal levels after 52 h, however, three of five dogs showed T4 and fT4 concentrations below the reference range 52 h and 6 days after single controlled thyroid gland feeding. TSH levels were suppressed after feeding for 52 h. None of the dogs showed any clinical symptoms of hyperthyroidism. Feeding of thyroid tissue to healthy dogs resulted in distinct effects on the thyroid hormone blood concentration. Initially single feeding of thyroid gland lead to considerably higher T4 levels but afterwards also to lower T4 and fT4 concentrations. Therefore, if euthyroidism should be diagnosed, administration of dog food containing thyroid gland should be carefully ruled out for the last seven days.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Schmicke
Endocrinology
Clinic for Cattle
University of Veterinary Medicine Hannover
Hannover, Germany

URL: http://www.vin.com/doc/?id=8172838
C-reactive protein (CRP) is a major acute phase protein and a marker of systemic inflammation in dogs. C-reactive protein, and indirectly the innate immune system, has not previously been evaluated in dogs with hypoadrenocorticism (HA). Accordingly, the aim of this study was to investigate if dogs with HA were able to mount an acute phase response assessed by an elevated CRP.

Medical records were reviewed for patients newly diagnosed with hypoadrenocorticism between May 2010 to March 2017. Dogs were considered having HA if both a pre- and post-ACTH stimulation cortisol were ≤55 nmol/L. Dogs were excluded if they were not newly diagnosed with HA, or had received treatment for either hypoadrenocorticism or hyperadrenocorticism, or if they did not have a CRP measured around the time of diagnosis.

Three hundred and twenty-two medical records from dogs with an ACTH stimulation performed were screened. Seventeen dogs with HA were identified. Of these, nine dogs with hypoadrenocorticism were included in this retrospective case series. The median age at time of presentation was 5.5 years and included three intact males, two neutered males, two intact females and two spayed females. The most prevalent clinical signs included vomiting (6/9), weight loss (6/9), and diarrhea (3/9), and all of the dogs had at least one of these clinical signs. Six of nine dogs had azotemia. The mean CRP was 62.2 mg/L, with an interquartile range: 20.45–89.66 mg/L (reference 0–25 mg/L). Seven out of nine dogs had an elevated CRP. Interestingly, the two dogs with normal CRP were non-azotemic and clinically stable at the time of presentation.

In conclusion, dogs with hypoadrenocorticism are able to induce CRP production. This could indicate that at least part of the innate immune response is functional. Dogs with HA often have a normal neutrophil count, making neutrophils unreliable as marker of inflammation in HA. C-reactive protein could therefore be a useful biomarker for acute inflammation in patients with HA when other markers of inflammation are not reliable.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**J.G. Lyngby**

University of Copenhagen

Frederiksberg, Denmark

URL: [http://www.vin.com/doc/?id=8172839](http://www.vin.com/doc/?id=8172839)
Hypertension in diabetic humans is common (prevalence 40 to 80%) and related with hyperglycemia, duration of the disease and several complications. In diabetic cats, previous studies shown that hypertension is not present or it is uncommon. The aims of this study were to determine prevalence of hypertension in feline diabetes mellitus (DM) and its potential relation with different parameters (age, body condition score [BCS], BCS previous to diagnosis, sex, glycemic control, time since diagnosis, concurrent diseases, chronic corticoid treatments, diabetic neuropathy and remission).

Thirty diabetic cats were assessed for the first time at the Veterinary Teaching Hospital Complutense between January 2013 and April 2016. Systolic blood pressure (SBP) was measured using Doppler methodology. Hypertension was defined as ≥160 mm Hg, and subclassified following the ACVIM consensus and the ISFM guidelines. BCS was categorized from 1 to 9, being 5 the ideal weight. No cat was receiving anti-hypertensive treatment.

Age ranged from 3 to 16 years, 23/30 males and 7/30 females; all neutered excepting one male. At diagnosis 12/30 (40%) of the cats were underweight. Previous to diagnosis no cat was underweight, in fact 83% (25/30) were overweight.

Prevalence of hypertension was 30% (9/30) and 4/30 had severe hypertension (≥180 mm Hg). Concurrent diseases known to be associated with hypertension were present in 9/30 cats (30%).

Hypertension and SBP values were not correlated with age, time since diagnosis, sex, glycemic control, corticoid excess, remission or diabetic neuropathy. BCS previous to diagnosis was negatively correlated with SBP (p=0.039). None of the overweight cats previous to diagnosis were hypertensive (p=0.008). Also, underweight cats at diagnosis shown a higher prevalence of hypertension than those with a BCS≥5 (50% and 25% respectively; p=0.038).

Prevalence of hypertension was different in diabetic cats without concurrent diseases (0%), diabetic cats with a disease not associated with hypertension (29%) and those with a disease known to increase SBP (56%)(p=0.023).

Remission was present in 11/27 cats (41%) with a median time of 4.2±3.5 months. Remission was positively correlated with the presence of diabetic neuropathy at first visit (p=0.052).

Hypertension seems to be infrequent in diabetic cats as previously reported, and it is positively correlated with concurrent diseases associated with hypertension and negatively correlated with BCS before diagnosis. The relation between hypertension, obesity and diabetes in cats is not similar to observed in humans. In hypertensive diabetic cats, it is recommended to search for other diseases causing the elevated blood pressure.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. García San José
Hospital Veterinario Complutense
Madrid, Spain

URL: http://www.vin.com/doc/?id=8172840
Systemic Hypertension in Dogs with Diabetes Mellitus

P. Casals Canal; P. García San José; I. Clares Moral; S. González Sanz; R. García del Real Torralva; M.D. Pérez Alenza

1Hospital Veterinario Complutense, Madrid, Spain; 2Departamento de Medicina y Cirugía Animal, Universidad Complutense, Spain

The relationship between diabetes mellitus (DM) and hypertension is complex. In humans, DM is associated with hypertension, but information on blood pressure in diabetic dogs is scarce. It has been reported in diabetic dogs, that males and dogs with longer duration of diabetes have higher blood pressure (BP) values. Furthermore, obesity is associated with increases in BP in a variety of species but its role in dogs is unclear. Aims of this study were to identify the frequency of hypertension in dogs with DM, and characterize the relationship between hypertension and age, sex, reproductive status, duration of DM, body condition score, concurrent diseases and treatment with corticoids.

Medical records of all diabetic dogs presented to the Internal Medicine Service of the Veterinary Teaching Hospital Complutense Madrid from July 2013 to March 2017 were reviewed. BP using a Doppler device was assessed at the first visit. Hypertension was defined as a systolic blood pressure (SBP) ≥160 mm. Dogs receiving antihypertensive medication at this moment were excluded. Following the ACVIM guidelines, hypertensive animals were sub-classified according to the risk of target organ damage and antihypertensive treatment was administered if deemed appropriate. Good control of DM was considered with fructosamine values <350 micromol/l, glucose curve values ranging from 90 to 250 mg/dl and absence of DM clinical signs.

Fifty-three dogs were included, 25 females (12/25 intact and 13/25 neutered), and 28 males (15/28 intact and 13/28 neutered). Ages ranged from 0.2 to 13.7 years. At first visit in our hospital, 44/53 dogs did not have a good control of DM.

Twenty-five dogs were considered hypertensive (25/53; 47%). Hypertension was significantly positively correlated to age (p=0.009). No significant correlation between hypertension and sex, reproductive status, concurrent diseases, time since DM diagnosis or obesity was observed. Hypertension was not significantly correlated with the control of DM; however, none of the dogs considered as in good control of the diabetes had severe hypertension (p=0.067).

Hypertension was significantly associated with chronic corticoid excess, due to hyperadrenocorticism or exogenous administration (12/19) (p=0.05).

Hypertension was present in 47% of diabetic dogs (similar to the prevalence reported in previous studies), and age and corticoid excess were significantly related to it. Obesity in diabetic dogs was not related to hypertension as it has been observed in non-diabetic dogs.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.D. Pérez Alenza
Departamento de Medicina y Cirugía Animal
Universidad Complutense
Spain

URL: http://www.vin.com/doc/?id=8172841
Canine Electrolyte Analysis in Dogs with Hypoadrenocorticism - A Comparison of Two In-house Analysers with a Reference Laboratory

S.J. Fowlie; S. Spence; E. Roberts; I. Ramsey
University of Glasgow, Glasgow, UK

Dogs receiving treatment for hypoadrenocorticism are typically monitored by analysis of their serum sodium (Na⁺) and potassium (K⁺) concentrations and the Na⁺:K⁺ ratio alongside their clinical signs. There is a desire for veterinarians to be able to measure these concentrations in-house, allowing same day dose changes as opposed to waiting for the results from a reference laboratory.

The aim of this study was to compare these electrolyte concentrations and Na⁺:K⁺ ratios obtained from two in-house electrolyte analysers (IDEXX Catalyst Dx® and IDEXX Vetstat®) with a reference laboratory (Olympus AU600) in a cohort of dogs with hypoadrenocorticism.

Cases (n=33) were prospectively enrolled into a clinical trial comparing fludrocortisone to DOCP in the treatment of hypoadrenocorticism. All dogs had multiple electrolyte measurements taken at various time points during treatment. A total of 343 samples were tested by the reference laboratory using the Olympus AU600 analyser. Of these, 280 samples were also tested using the Catalyst Dx® analyser and 61 by the Vetstat® analyser. Some samples were tested using all three analysers.

The Catalyst Dx® and Vetstat® showed good correlation to the Olympus AU600 for Na⁺ and K⁺ concentrations and Na⁺:K⁺ ratio. For the Catalyst Dx® these were r=0.714, 0.830 and 0.858, respectively, all with a p<0.0001. For the Vetstat® these were r=0.816, 0.955 and 0.959, all with a p<0.0001. The mean difference (Bland-Altman plot) for Na⁺ was -5.84 mmol/L with a standard deviation of 3.69 for the Catalyst Dx® and -11.67 mmol/L and 2.46 for the Vetstat®. The mean difference and standard deviation for K⁺ was -0.15 mmol/L and 0.36 respectively for the Catalyst Dx® and 0.01 mmol/L and 0.17 for the Vetstat®. Finally, the mean difference and standard deviation for the Na⁺:K⁺ ratio was -0.20 and 2.90, respectively, for the Catalyst Dx® and -3.07 and 1.83 for the Vetstat®.

Both in-house analysers displayed good correlation with the reference laboratory for the electrolytes measured. However, both analysers persistently recorded higher Na⁺ concentrations. Analysis of K⁺ concentrations was closer to the reference laboratory but the effect of the increased Na⁺ resulted in the Na⁺:K⁺ ratio also being higher. This could have clinically significant effects in the management of dogs with hypoadrenocorticism and care should be taken when using target ranges based on a reference analyser when using results from in-house electrolyte measurements.

DISCLOSURES

Disclosures to report:

The lead author's position and this study are jointly funded by Dechra Ltd and the University of Glasgow.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

S.J. Fowlie
University of Glasgow
Glasgow, UK

URL: http://www.vin.com/doc/?id=8172842
Concurrent Pituitary and Adrenocortical Tumors in Dogs with Spontaneous Hypercortisolism

K.L. van Bokhorst; S.A.E.B. Boroffka; H.S. Kooistra; S. Galac
Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands

Spontaneous hypercortisolism or Cushing's syndrome in dogs is due to a pituitary tumour (PT) or an adrenocortical tumour (AT), but concurrent PT and AT have also been reported. The objective of this retrospective study was to analyse the clinical and computed tomographic (CT) imaging data of a large group of dogs diagnosed with spontaneous hypercortisolism to report for concurrent PT and AT.

The clinical records of 202 dogs with spontaneous hypercortisolism, referred to the authors' institution, were reviewed. Diagnosis was based on physical and biochemical changes suggestive of hypercortisolism and confirmed by endocrine function tests. Endocrine tests revealing dexamethasone resistance in combination with an endogenous plasma ACTH concentration <40 ng/ml was interpreted as functional AT. In all dogs, pre- and postcontrast CT of both the pituitary gland and the adrenal glands was performed. A pituitary/brain (P/B) ratio >0.31 was interpreted as enlarged, consistent with a PT. Heterogeneous adrenal structure, asymmetric shape, and adrenal width >15 mm were consistent with an AT. Adrenal expansion into blood vessels greatly supported the diagnosis of an AT.

In dogs with suppressible hypercortisolism (122/202), 78 dogs (64%) showed an enlarged pituitary gland (median P/B ratio 0.43, range 0.32–1.21) on CT. Two of these 78 dogs were diagnosed with a concurrent AT. In the remaining dogs with suppressible hypercortisolism (44/122; 36%) a pituitary microadenoma (median P/B ratio 0.27, range 0.07–0.31) was diagnosed.

In the non-suppressible group (80/202), 47 of the 80 dogs (59%) had an enlarged pituitary gland (median P/B ratio 0.57, range 0.35–1.50) and in 8 of the 80 dogs (10%) a concurrent AT was present. In the remaining 33 dogs (41%) from this group, the pituitary gland was not enlarged (median P/B ratio 0.23, range 0.09–0.30). Among them, a pituitary microadenoma was diagnosed in 6 dogs. In the other 27 dogs, ATs (2 bilateral, 25 unilateral) were diagnosed and confirmed by a plasma ACTH concentration <40 ng/ml in all cases and by histopathology in 21/27 cases.

We conclude that concurrent adrenal and pituitary lesions are present mainly in dogs with non-suppressible hypercortisolism. Results of this study show that CT evaluation of both the pituitary and the adrenal glands should always be included in the diagnostic work-up of dogs with hypercortisolism to provide optimal treatment and prognosis.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

K.L. van Bokhorst
Faculty of Veterinary Medicine
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172831
Prevalence of Neurological Signs in Hypothyroid Dogs at Diagnosis

S. González Sanz1; R. García del Real Torralva1; P. García San José1; I. Clares Moral1; P. Casals Canal1; M.D. Pérez Alenza2

1Hospital Veterinario Complutense, Madrid, Spain; 2Departamento de Medicina y Cirugía Animal, Universidad Complutense, Spain

Neurological signs (NS) can occur in canine hypothyroidism and sometimes, they are the unique manifestation of this disease. The objective of the present retrospective study was to evaluate the frequency of NS, including seizures, among hypothyroid dogs at diagnosis. Fifty-nine dogs newly diagnosed with hypothyroidism at The Veterinary Teaching Hospital Complutense Madrid between October 2011 and March 2017 were reviewed.

Age ranged between 2.3 and 6.5 years, 24/59 females, 37/59 males, 29/59 intact and 30/59 neutered. Duration of clinical signs before diagnosis ranged from 1 to 24 months (mean 9±6.7 months). Clinical signs, body condition score (BCS), concurrent diseases, body weight, total-thyroxine (TT4), free-thyroxine (fT4), thyroid stimulating hormone (TSH) and cholesterol levels were recorded.

Neurological signs were present in 17/59 dogs (29%), being seizures the most common (13/17), while 4/17 dogs presented other NS (vestibular deficits, megaesophagus, head bobbing syndrome and peripheral neuropathies).

No association was observed between seizures and age, sex, BCS, duration of signs before diagnoses, TT4 and fT4 levels, reproductive status or other NS. Mean plasma TSH in dogs without seizures (2.0±1.7 ng/ml) was significantly higher than in dogs without this NS (1.3±2.2 ng/ml) (p=0.04). Among the 13 dogs that presented seizures, 7/13 (54%) had normocholesterolemia and 6/13 (46%) hypercholesterolemia; including one dog (8%) with plasma cholesterol levels above 620 mg/dl. However, in the group of dogs without seizures, only 4/29 (14%) presented normal cholesterol levels and 25/29 (85%) hypercholesterolemia, including 12/29 (41%) with plasma cholesterol levels above 620 mg/dl (p=0.01)

Prevalence of seizures at diagnosis was higher in dogs with clinical evidence of myxoedema (4/9; 44%) compared with dogs without this clinical sign (9/50; 18%) (p=0.078)

Neurological signs have been described to occur in 7.5% of hypothyroid dogs. However, in the present study, 29% of hypothyroid dogs had NS, and among them, 76.5% presented seizures. Probably, our diagnostic protocol used for convulsive patients, were thyroid hormones testing is always included before anticonvulsive treatment is administered, is related with this finding. Different mechanisms have been proposed to explain the development of NS in hypothyroid dogs, including alterations in axonal transport and ischemia. Hypercholesterolemia and atherosclerosis and consequent hypoxia of central nervous system has been observed and proposed as a cause of NS; however, in the present study hypercholesterolemia is definitely not related to seizures. Clinical evidence of myxoedema though seems to be related with seizures.

DISCLOSURES

No disclosures to report.
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Dogs

F. del Baldo; E. Malerba; S. Corradini; I. Rovatti; A. Zeppi; F. Dondi; F. Fracassi
University of Bologna, Ozzano dell’Emilia, Italy

Nowadays only few portable blood glucose meters (PBGMs) have been developed specifically for use in dogs and cats. Recently one glucometer (Gluco Calea, WellionVet; GC) and one glucose-ketones meter (Belua, WellionVet; BE) have been developed for use in veterinary medicine. The aims of this study were to assess the accuracy and precision of these devices in canine venous and capillary blood samples based on ISO 15197:2013 and to evaluate packed cell volume (PCV) interferences.

Samples were obtained from 45 non-anemic dogs (PCV 37–54%) and 10 anemic dogs (PCV<37%) divided into three glycemic ranges: high (>140 mg/dl), medium (90–139 mg/dl), and low (<90 mg/dl). Paired measurements of glucose and 3-β-hydroxybutyrate (3-HB) from capillary and venous blood samples were determined using the two devices and compared with the results of reference methods (enzymatic hexokinase and 3-HB-dehydrogenase, respectively) obtained by an automated chemistry analyzer (Beckman-Coulter AU480). Linear regression, Bland Altman plots and the Parkes error grid analysis (EG) were used to assess the accuracy. PCV interferences for glucose measurement were assessed comparing the differences between PBGMs readings and reference method values in anemic and non-anemic dogs. To assess within-run precision, glucose concentrations obtained from 12 samples, belonging to the three glycemic ranges, were measured 10 times within 10 minutes. Between-day precision was assessed by testing each manufacturer’s glucose control solution over 10 consecutive days. P<0.05 was considered significant.

Mean differences (mg/dl) between measurements of each PBGM on capillary and venous blood and values measured by the reference method were: GC 37.8±24.2, 44.1±27.2, BE 20.4±28.6 and 10.2±25.1 respectively. A positive significant correlation between all paired samples was found for both devices (r>0.89). However neither PBGMs fulfilled ISO requirements: 82.21% and 84.08% of glucose values measured respectively on capillary and venous blood using GC fell in zone A+B of EG; 86.7% and 97.8% of glucose values measured respectively on capillary and venous blood by BE fell in zone A+B of EG. Within-run and between-day precision were adequate. The effect of PCV was significant and higher results with lower PCV were observed.

The correlations between capillary and venous 3-HB and reference 3-HB were r=0.48 and r=0.59, respectively. Mean differences between capillary and venous 3-HB and reference method were 0.05 (±0.57) and -0.07 (±0.79) respectively; within-run precision was adequate.

Our results show that both GC and BE are not sufficiently accurate and safe for clinical use in dogs.

DISCLOSURES

Disclosures to report:

Devices and test strips were provided by manufacturers (WellionVet).

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

F. del Baldo
University of Bologna
Ozzano dell’Emilia, Italy

URL: http://www.vin.com/doc/?id=8172633
Canine hypothyroidism is associated with decreased glomerular filtration rate (GFR), while serum creatinine (SCr) concentrations are rarely increased above the reference interval (RI) in hypothyroid dogs. Symmetric dimethylarginine (SDMA) is considered a biomarker for early detection of renal dysfunction and resulted strongly correlated with GFR in dogs. In humans, SDMA is significantly higher in hypothyroid compared to healthy people. The aim of this study was to evaluate the SDMA concentrations in a population of hypothyroid dogs (HD) at the time of diagnosis (T0) and after treatment (T1). Fourteen dogs affected by spontaneous hypothyroidism and 20 healthy dogs (control group) were included. The diagnosis of hypothyroidism was based on consistent clinical signs, laboratory findings, including serum total T4 and cTSH concentrations below and above the RI, respectively. In dogs with normal cTSH, rhTSH stimulation test was performed to confirm the diagnosis. SCr was measured for diagnostic or check-up purposes and SDMA was measured afterwards from surplus of serum stored at -20°C. In HD such measurements where performed at T0 an after 15 to 112 days (median 64.5) of treatment (T1) with levothyroxine (10–15 µg/kg q12h PO). SDMA was measured using a validated immunoassay (IDEXX SDMA test). HD had a median age of 4 years (4–15), median body weight (BW) of 37.5 kg (7.9–53), 7/14 were male (1 castrated) and 7/14 female (3 spayed). There were no significant differences regarding signalment and BW between HD and control group. Median SDMA concentrations (RI<14 µg/dl) were 10 µg/dl (6–17), 13.5 µg/dl (7–20) and 10.5 µg/dl (5–17) in healthy dogs, HD at T0 and T1, respectively. SDMA concentrations were significantly higher in HD at T0 in comparison with healthy dogs (p<0.029) and HD at T1 (p<0.031). Among HD, 7/14 had SDMA above the RI at T0 and only 1/14 (7%) at T1. At T0, 4/14 HD had SCr above the RI (>1.35 mg/dl). SCr concentration was significantly higher in HD at T0 compared to HD at T1 (p<0.0082), and in one dog SCr was above the RI at T1. No significant correlation was observed between SDMA and T4, and SDMA and SCr in the HD at T0 and T1.

This study shows that in HD SDMA concentrations are frequently above the RI at diagnosis and normalize after treatment. The GFR modifications that are present in canine hypothyroidism may be better detected with SDMA compared to SCr.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

G. Carotenuto
University of Bologna
Ozzano dell'Emilia, Italy

URL: [http://www.vin.com/doc/?id=8172834](http://www.vin.com/doc/?id=8172834)
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Cats
E. Malerba; F. del Baldo; S. Corradini; A. Zeppi; I. Rovatti; F. Dondi; F. Fracassi
University of Bologna, Ozzano dell'Emilia, Italy

Numerous portable blood glucose meters (PBGMs) have been developed during the last decade, the majority of which is designed for use in humans. Recently one glucometer (Gluco Calea, WellionVet; GC) and one glucose-ketones meter (Belua, WellionVet; BE) have been developed for use in veterinary medicine. The aims of this study were to assess the accuracy and precision of these devices in feline venous and capillary blood samples based on ISO 15197:2013 and to evaluate packed cell volume (PCV) interferences.

Samples were obtained from 29 non anemic cats (PCV 30–47%) and 18 anemic cats (PCV<30%) divided into three glycemic ranges: high (>140 mg/dl), medium (90–139 mg/dl) and low (<90 mg/dl). Paired measurements of glucose and 3-β-hydroxybutyrate (3-HB) from capillary and venous blood samples were determined using the two devices and compared with the results of reference methods (enzymatic hexokinase and 3-HB-dehydrogenase, respectively) obtained by an automated chemistry analyzer (Beckman-Coulter AU480). Linear regression, Bland Altman plots and the Parkes error grid analysis (EG) were used to assess the accuracy. PCV interferences for glucose measurement were assessed comparing the differences between PBGMs readings and reference method values in anemic and non-anemic cats. To assess within-run precision, glucose concentrations obtained from 14 samples, belonging to the three glycemic ranges, were measured 10 times within 10 minutes. Between-day precision was assessed by testing each manufacturer’s glucose control solution over 10 consecutive days. p<0.05 was considered significant.

Mean differences (mg/dl) between measurements of each PBGM on capillary and venous blood and values measured by the reference method were: GC 30.7±35.4, 35.6±40.5, BE 15.5±35.5 and 15.0±24.1 respectively. A positive significant correlation between all paired samples was found for both devices (r>0.89). However neither PBGMs totally fulfilled ISO requirements, but 100% of glucose values measured on venous blood using BE fell in zone A+B of EG. Within-run and between-day precision were adequate. The effect of PCV was significant (higher results with lower PCV) only for BE.

The correlations between capillary and venous 3-HB and reference 3-HB were r=0.66 and r=0.82 respectively. Mean differences between capillary and venous 3-HB and reference method were -0.07 (±1.15) and -0.30 (±1.48) respectively; within-run precision was adequate.

Our results show that GC is not sufficiently accurate while the superior performances of BE supports its clinical use in cats.

DISCLOSURES

Disclosures to report:

Devices and test strips were provided by manufacturers (WellionVet).

SPONSOR INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Malerba
University of Bologna
Ozzano dell'Emilia, Italy

URL: http://www.vin.com/doc/?id=8172835
Scientific Programme

Iatrogenic Hypothyroidism - Should It Affect How We Treat Hyperthyroidism?  Harriet M. Syme, BSc, BVetMed, PhD, FHEA, DACVIM, DECVIM-CA, MRCVS

Canine Immune-Mediated Endocrinopathies: An Immunologist’s View  Brian Catchpole, BVetMed, MSc(VetEd), PhD, FRCVS

Can We Trust Numbers? Daunting Lessons from the ESVE Laboratory Quality Assurance Scheme  Peter A. Graham, BVMS, PhD, CertVR, DECVCP, MRCVS

Weight Regulation by the Immune System and the Influence of Thyroid Hormones  Donal O'Shea, MD, FRCPI, FRCP(UK)
Iatrogenic Hypothyroidism - Should It Affect How We Treat Hyperthyroidism?
Harriet M. Syme, BSc, BVetMed, PhD, FHEA, DACVIM, DECVIM-CA, MRCVS
Department of Clinical Science and Services, Royal Veterinary College, London, UK

Iatrogenic hypothyroidism is common following treatment for hyperthyroidism. Until recently, this fact has been largely ignored, primarily because the patients are usually clinically well and do not demonstrate overt manifestations of hypothyroidism. Cats with iatrogenic hypothyroidism are more likely to be azotaemic than those that remain euthyroid following treatment. Furthermore, as might be anticipated, restoring euthyroidism in cats with iatrogenic hypothyroidism results in decreases in creatinine concentration in the majority, and resolution of azotaemia in a proportion. It has been observed that while in hyperthyroid cats overall, development of azotaemia following treatment for hyperthyroidism does not alter prognosis, this does make a difference in cats with iatrogenic hypothyroidism with those cats with both hypothyroidism and azotaemia having shortened survival times. This has led to interest in tailoring treatment to avoid development of iatrogenic hypothyroidism. Unfortunately, with this approach there may be a trade-off with an increased risk of unsuccessful/incomplete treatment of hyperthyroidism.

In this session, we will discuss whether approaches to avoid iatrogenic hypothyroidism are justified and also whether or not they are likely to be successful. This will be considered for all treatment modalities (medical, diet, surgery and I-131). Criteria for confirming the diagnosis of iatrogenic hypothyroidism will be discussed, and recent literature reviewed to consider whether iatrogenic hypothyroidism is likely to be transient or permanent, and the implications of this on the decision whether or not treatment is indicated.

Key References

Speaker Information
Harriet M. Syme, BSc, BVetMed, PhD, FHEA, DACVIM, DECVIM-CA, MRCVS
Department of Clinical Science and Services
Royal Veterinary College
London, UK

URL: http://www.vin.com/doc/?id=8172844
**Canine Immune-Mediated Endocrinopathies: An Immunologist's View**

Brian Catchpole, BVetMed, MSc(VetEd), PhD, FRCVS
Dept. Pathobiology & Population Sciences, Royal Veterinary College, London, UK

**Key Message**

Immune-mediated destruction of endocrine tissue is likely to be involved in the pathogenesis of several canine endocrinopathies, leading to hormone deficiency. Such immune-mediated endocrine diseases are relatively common in dogs and human beings, although there are some differences in terms of the evidence and nature of the autoimmune response. There seem to be some common immunogenetic factors associated with autoimmunity, some of which are likely to be involved in determining breed susceptibility. In hypothyroidism (lymphocytic thyroiditis), thyroid peroxidase is a major autoantigen in humans, although in dogs, thyroglobulin seems to be the major target. In hypoadrenocorticism (Addison's disease) autoantibodies directed against 21hydroxylase predominate in humans, but the evidence for similar autoantibodies in dogs is conflicting, and there is evidence for P450 side-chain cleavage enzyme and 3 beta hydroxysteroid dehydrogenase as autoantigens. Canine diabetes mellitus has a more complex and heterogeneous pathogenesis, with primary immune-mediated destruction of pancreatic beta cells likely present in only a subpopulation of dogs, with autoantibodies against insulin and the 65 kDa isoform of glutamic acid decarboxylase (GAD65) demonstrated in some cases. Several genetic studies in different canine endocrinopathies have shown associations with immune-response genes, including dog leukocyte antigen (DLA), cytotoxic T lymphocyte antigen 4 (CTLA4) and various cytokines, although the specific variants involved might differ from breed to breed and other (non immunological) genetic factors are also likely to contribute. In this session, a comparative approach will be taken to focus on canine endocrinopathies in terms of the underlying immunopathogenesis, the genetic factors that are likely to be important, and the evidence for autoantibody and cell-mediated immune responses against endocrine tissue antigens.

**Key References**


**KEYNOTE MESSAGE**

Whether or not we trust our endocrine results is really a matter of whether they are fit for purpose. That is, whether or not clinical management decisions based on those results are appropriate or inappropriate. Clinical management decisions include confirming diagnoses, ruling out diagnoses, and making dose adjustments in long-term therapy.

There are factors which will affect the analytical accuracy of an endocrine result including method choice and analytical interferences and there are those which will affect the interpretation of endocrine results including physiological and pre-analytical ones.

The effect of method choice on results can be assessed by appropriate validation and quality control and by periodic checks of internal consistency and precision. External quality assessment (EQA) also helps determine how local results may differ from international results. Since 2012, the European Society of Veterinary Endocrinology (ESVE) has run an international EQA program sending out aliquots of a single sample to more than 50 labs twice a year. So far the scheme has resulted in the correction of reporting units and discontinuation of some methods. Furthermore, it has identified an unexpected spread in cortisol and fructosamine results, demonstrated that some insulin methods cannot detect low concentrations, and confirmed difficulty in reaching consensus on oestradiol. In analytes where consensus was unexpectedly poor (e.g., cortisol and fructosamine), there was no relationship between the reference limits reported by the labs and the results obtained, that is, not only does there need to be caution in interpreting common endocrine results against textbook reference intervals and decision thresholds, but also in some cases when comparing them to local lab reference limits. By providing this EQA scheme, the ESVE aims to improve the international consistency of endocrine laboratory results and accuracy of endocrine diagnoses.

Key References

1. ESVE EQA Reports and Participant Lists: [http://www.esve-payments.org/esve/eve-qas](http://www.esve-payments.org/esve/eve-qas)

**SPEAKER INFORMATION**

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

Peter A. Graham, BVMS, PhD, CertVR, DECVCP, MRCVS
SVMS, University of Nottingham
Sutton Bonington, UK

URL: [http://www.vin.com/doc/?id=8172846](http://www.vin.com/doc/?id=8172846)
Obesity is now accepted to be a most important condition in humans and pets. It is linked to a range of chronic diseases including cancer, dementia, and diabetes. The reality is that weight gained is 90% irreversible for 90% of people who successfully adopt lifestyle change, pharmacotherapy may increase this to 20% weight reduction in 20% of individuals, and gastric surgery enables up to 30% weight loss.

There is a recognition that the simple "energy in - energy out" equation is no longer fit for purpose in understanding weight regulation. The explosion in extreme obesity and childhood obesity demands a fuller understanding of just how the body controls weight - and in particular defends against weight loss. Each individual handles a kilocalorie differently thanks to among other factors, the gut microbiome and that individual's rate of energy burn. It is now emerging that the innate immune system is a fundamental and dynamic player in the regulation of thermogenesis.

This talk will outline the way that the immune system regulates weight and will show how hormones regulate this. This is relevant for a range of hormones that are known to regulate weight including thyroid hormone.

Key References

**Speaker Information**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Donal O’Shea, MD, FRCPI, FRCP(UK)
St. Vincent's University Hospital, Elm Park, Dublin, Ireland
University College Dublin, Ireland

URL: [http://www.vin.com/doc/?id=8172847](http://www.vin.com/doc/?id=8172847)
ESVIM - European Society of Veterinary Internal Medicine

Speaker List

Oral Presentations

Poster Presentations
<table>
<thead>
<tr>
<th>Oral Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calibrated Automated Thrombography to Evaluate Thrombin Generation in Dogs with Immune-Mediated Hemolytic Anaemia B.Y. Cuq</td>
</tr>
<tr>
<td>Effect of Immune-Suppressive Treatment on Cytokine Production in Healthy Dogs J.R.S. Dandrieux</td>
</tr>
<tr>
<td>Identification of Antinuclear Antibodies in Dogs Using Immunodiffusion H. Hansson-Hamlin</td>
</tr>
<tr>
<td>Short- and Long-Term Morbidity and Mortality in Dogs and Cats Following Cardiopulmonary Arrest L. Brown</td>
</tr>
<tr>
<td>Feline Primary Erythrocytosis: A Multicentre Retrospective Case Series (18 Cases) H. Darcy</td>
</tr>
<tr>
<td>Investigation of a Fungal Aetiology in Canine Idiopathic Pulmonary Fibrosis E. Roels</td>
</tr>
<tr>
<td>Clinical Features of 70 Cases of Canine Idiopathic Eosinophilic Lung Disease S. Keegan</td>
</tr>
<tr>
<td>Therapy and Long-term Follow-up of 70 Cases of Canine Idiopathic Eosinophilic Lung Disease D. Casamían-Sorrosal</td>
</tr>
<tr>
<td>Development of Respiratory Dysbiosis as Cats Transition from Healthy to Asthmatic Airways A.I. Vientos-Plotts</td>
</tr>
<tr>
<td>Documenting Silent Reflux and Microaspiration Events Using Nuclear Sцинтиigraphy in Healthy Dogs M.E. Grobman</td>
</tr>
<tr>
<td>Diagnosis of Pulmonary Angiostrongylosis in Dogs with Negative Non-invasive Tests (Baermann Analysis and AngioDetect™) A.M. Canonne</td>
</tr>
<tr>
<td>Discrimination Between Cough and Non-cough Behaviours Using Acoustic Wave Recordings M.E. Grobman</td>
</tr>
<tr>
<td>Tracheal Stent in Dogs: Outcome Prediction and Owner Satisfaction Assessment E. Robin</td>
</tr>
<tr>
<td>Meticulous Debridement as Sole Management for Successful Outcome in 6 Dogs with Sinonasal Aspergillosis (SNA) C. Stengel</td>
</tr>
</tbody>
</table>
Calibrated Automated Thrombography to Evaluate Thrombin Generation in Dogs with Immune-Mediated Hemolytic Anaemia

B.Y. Cuq1; S.L. Blois1; R.D. Wood1; A.C. Abrams-Ogg1; C. Bédard2; G.A. Wood1

1Ontario Veterinary College, University of Guelph, Guelph, ON, Canada; 2Faculty of Veterinary Medicine, University of Montreal, St Hyacinthe, QC, Canada

Up to 60% of the mortality in dogs with immune-mediated hemolytic anemia (IMHA) is associated with thrombosis or disseminated intravascular coagulation. No conventional hemostatic test is accurate to evaluate the risk for hypercoagulability. Viscoelastic testing has been proven to be influenced by anemia, and might not reliably assess hemostasis in IMHA patients. Calibrated automated thrombography (CAT) is a thrombin generation (TG) assay that has been validated in clinically healthy dogs. The objective of the study was to assess the suitability of TG in the assessment of hypercoagulability in IMHA patients. IMHA was determined by the presence of anemia, spherocyte and positive slide agglutination test or positive Coomb's Test. CBC, coagulation profile and CAT parameters (lag time, time to peak, peak, endogenous thrombin potential) were performed in all IMHA patients, at the time of diagnosis and then at 48 and 96 h. Lag time was prolonged for IMHA patients at day 0 (D0) and D2; and time to peak was higher on D0 but not statistically different on D2 or D4 compared to healthy dogs. Peak was higher in dogs with IMHA at D0, D2 and D4. There was no statistical difference in the endogenous thrombin potential between IMHA and healthy dogs. No correlation between the CAT parameters and blood cell count, coagulation parameters or the likelihood for the patient to be discharged. Prolonged lag time and time to peak indicate hypocoagulation in IMHA dogs early in the disease onset; however, based on peak value, IMHA patients appear to generate more thrombin once coagulation is initiated compared to normal dogs. TG was not useful in predicting patient outcomes.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B.Y. Cuq
Ontario Veterinary College
University of Guelph
Guelph, ON, Canada

URL: http://www.vin.com/doc/?id=8172929
Effect of Immune-Suppressive Treatment on Cytokine Production in Healthy Dogs

J.R.S. Dandrieux1; T.M. Archer2; L. Narayanan2; R. Wills2; C.S. Mansfield1

1University of Melbourne, Werribee, Melbourne, VIC, Australia, 2College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, USA

Immunosuppressive drugs are the cornerstone of treating immune-mediated diseases in dogs. Currently, dosage adjustments are often based on resolution of clinical signs and monitoring for adverse effects. Recently, a validated pharmacodynamic assay (PD) has been used to monitor dogs treated with cyclosporine by assessing interleukin-2 (IL-2) and interferon-gamma (INFγ). There is no study to date looking at cytokine secretion and detection in dogs receiving other immunosuppressive drugs.

The aim of this study was to evaluate multiple immunosuppressive drugs and determine individually whether they affected secretion of IL-2, IL-6, IL-10, INFγ or tumour necrosis factor alpha (TNFα) in healthy dogs using a multiplex assay.

Blood was obtained from healthy adult Walker hounds before and after immunosuppressive treatment at standard doses using a randomised crossover study design. Treatments included azathioprine, cyclosporine, mycophenolate mofetil, leflunomide, or prednisone. Blood was sampled prior to and following 7 days of treatment. Four dogs were tested for each drug with a minimum wash out period of three weeks. Whole blood was activated with either phorbol 12-myristate 13-acetate and ionomycin (PMA/I) or lipopolysaccharide (LPS). Cytokines in the supernatant were analysed using a multiplex assay. The Kruskall-Wallis test was used to test for carryover effects of the drugs. The Wilcoxon signed-rank test was used to assess each activator effect on cytokine production.

Pre-treatment, stimulation of blood with PMA/I significantly increased INFγ, IL-10, and TNFα, whereas stimulation with LPS significantly increased IL-6, IL-10, and TNFα production (p<0.001 for all cytokines). There was no significant increase in IL-2 with either activator. No significant carry over effect was detected for any of the drugs used.

Azathioprine, leflunomide, and mycophenolate treatments did not reliably change cytokine production for any of the cytokines tested. Dogs treated with cyclosporine had no detectable IL-10, TNFα, and INFγ after treatment when blood was stimulated with PMA/I. All dogs treated with prednisone had marked reduction in their TNFα production (<30% of pre-treatment concentration) after PMA/I stimulation. All dogs, and 3 out of 4 dogs, had a reduction of at least 80% in TNFα and IL-6 concentrations respectively after LPS stimulation.

Specific patterns of cytokine suppression may be useful to monitor efficacy of immunosuppression in dogs treated with cyclosporine and prednisone. No clear trend was seen with the other immunosuppressive drugs tested.

DISCLOSURES

Disclosures to report:
Funding from the co-authors include funding from the Australian research Council, Canine Health Foundation, Canine Research Foundation, Hills Pet Nutrition, NexVet Biologics and PlassVacc. None of this funding is directly related to this project. None of the authors have shares, receive consulting fees or have financial interests with any company. Neither do family members.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.R.S. Dandrieux
University of Melbourne
Werribee, Melbourne, VIC, Australia

URL: http://www.vin.com/doc/?id=8172936
Circulating antinuclear antibodies (ANAs) are commonly present in the systemic autoimmune disease systemic lupus erythematosus (SLE) and in other SLE-related diseases, in humans as well as in dogs. Certain canine breeds, such as German shepherd dogs and Nova Scotia duck tolling retrievers (NSDTRs), have been shown to be overrepresented for autoimmune diseases.

The indirect immunofluorescence (IIF)-ANA test is the standard method for detecting ANAs. Further testing for ANA specificities with different techniques, such as ELISAs, immunoblot or immunodiffusion, is routinely performed in humans, but not in dogs, to aid in the diagnosis of disease. Several specific ANAs identified in humans have been identified also in suspected canine SLE or SLE-related disorders but in many cases the main antigen targeted by the antibodies cannot be identified. IIF-ANA positive dogs are usually divided into two subgroups depending on their fluorescence pattern, a speckled pattern with no chromosomal reactivity or a homogenous pattern with chromosomal reactivity. Previous studies have shown that only dogs with a speckled IIF-ANA pattern are positive on immunodiffusion.

Our aim was to investigate if the immunodiffusion (ID) technique, using sera from IIF-ANA positive dogs, may identify specific ANAs of relevance in human patients and also identify different subgroups of unknown antigens.

Sera from 32 IIF-ANA positive dogs with speckled fluorescence pattern were part of the study (21 German shepherd dogs, three NSDTRs and eight dogs of seven other different breeds). Ten healthy dogs of different breeds were used as controls. Thirty-one of the 32 IIF-ANA positive dogs were positive on immunodiffusion. Twenty-nine of the positive dogs could be further divided into three separate groups based on their reactions on immunodiffusion. Group 1 (n=4) and group 2 (n=16) had reactivity to unknown antigens (different between the groups). Group 3 (n=9) had antibodies directed to RNP. A breed associated ANA specificity was observed in both NSDTRs and German shepherd dogs. All NSDTRs belonged to group 1, while group 2 consisted only of German shepherd dogs.

The ID technique thus shows that IIF-ANA canine sera may be divided into subgroups reflecting the same specific ANA reactivity. In most of the dogs the specific ANA reactivity could not be identified, which might indicate dog-specific autoantigens. Further investigations of canine sera are needed in order to identify the specific antigen reactivity of these ANAs.

DISCLOSURES
No disclosures to report.
The RECOVER initiative has generated interest regarding the poor prognosis for veterinary patients suffering cardiopulmonary arrest (CPA) and produced evidence-based guidelines for their care. There is, however, scant documentation of post-discharge outcomes for animals that survive. This study aimed to describe mortality associated with in-hospital CPA, determine median survival time of dogs and cats that survive CPA, and examine the incidence and persistence of acquired neurological deficits. Medical records of animals that underwent cardiopulmonary resuscitation (CPR) at a referral centre were reviewed. Factors examined included species and age, managing department, location in hospital of arrest, primary disease process, closed versus open CPR, return of spontaneous circulation (ROSC), time to death, and cause of death. Where survivors to discharge were identified, the animal's primary care veterinarian was contacted for provision of medical records following discharge. A total of 241 animals underwent CPR (196 dogs and 45 cats) with 116 (48%) animals achieving ROSC and 29 of 41 (12%) surviving to discharge. Complete medical records were obtained for 79% (23/29) of survivors. Five of 29 (17%) had neurological deficits including depressed mentation, ataxia, circling and blindness on leaving hospital. All had either complete resolution or significant improvement of neurologic deficits within one month. Eight animals (35%) died following discharge prior to completion of the study period, however two were excluded from analysis as they were discharged explicitly for a palliative visit. The remaining six animals had a median survival time of 1284 days (502–1508 days). Fifteen animals (65%) were alive on completion of the study, with a median of 1362 days following discharge (162–2901). The proportion of animals surviving to discharge was similar to that reported in the veterinary literature. Whilst the immediate prognosis for animals undergoing CPA is poor, for animals surviving to discharge life expectancy is reasonable and the prognosis good for improvement of acquired neurological deficits.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

L. Brown
Murdoch University
Murdoch, WA, Australia

URL: http://www.vin.com/doc/?id=8172938
Feline primary erythrocytosis (PE) is a rare myeloproliferative disorder causing excessive increase in packed cell volume (PCV). Veterinary literature is sparse with isolated reports and minimal information regarding prognosis. We evaluated a retrospective multicentre case series of feline PE, with the aim of increasing understanding of disease progression to guide management and prognostication. Theories of possible underlying genetic causes were evaluated by comparing the natural history of feline PE to human polycythaemia vera (PV).

Cases required documentation of increased PCV (>48%), sufficient investigation to exclude relative and secondary erythrocytosis, and follow-up data for at least twelve months or until death.

Eighteen cats from five UK veterinary hospitals were included. No significant trends in signalment were noted. Seizures and mentation changes were the most common presenting signs (both n=10). Median PCV and total protein were 70% and 76 g/l, respectively, with no other consistent blood cell changes. Sixteen cats survived to discharge. Phlebotomy was performed initially in 15/16 cats and after discharge in 10/16. Six cases eventually required no further phlebotomies. Hydroxyurea was the most common adjunctive therapy (n=10). Fourteen patients were alive at the time of writing (survival time >12 months).

This case series demonstrates that management of feline PE is generally well-tolerated with evidence of prolonged survival times. Disease characteristics are similar to a subset of human PV caused by mutations in exon 12 of the Janus kinase 2 gene, representing a possible future therapeutic target.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

H. Darcy
Royal Veterinary College
Potters Bar, UK

URL: http://www.vin.com/doc/?id=8172939
Investigation of a Fungal Aetiology in Canine Idiopathic Pulmonary Fibrosis

E. Roels¹; C. Barrera²; L. Millon²; M.M. Rajamäki³; J. Talbot⁴; C. Clercx¹; V. Barrs⁴

¹University of Liège, Liège, Belgium; ²Department of Mycology, UMR6249 Chrono-Environment, University Hospital, Besançon, France; ³Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, Helsinki, Finland; ⁴Faculty of Science, Sydney School of Veterinary Science; Marie Bashir Institute, Sydney, NSW, Australia

Canine idiopathic pulmonary fibrosis (CIPF) is a progressive parenchymal lung disease of unknown origin and poorly understood pathophysiology that mainly occurs in old West Highland white terriers (WHWTs). Computed tomographic and histopathological findings of CIPF share characteristics of both human usual intestinal pneumonia (UIP) (typical pattern of IPF in humans) and non-specific interstitial pneumonia (NSIP) patterns. In humans, a NSIP pattern is commonly observed in hypersensitivity pneumonitis. This inflammatory pulmonary syndrome results from sensitization to inhaled antigens such as fungal particles and can cause irreversible lung fibrosis in chronic stages. Given that no aetiologies have been identified for CIPF, the objective of this study was to investigate a potential fungal cause. A conventional pan-fungal PCR assay targeting the conserved rDNA gene internal transcribed spacer (ITS) regions of fungi, using two primer pairs (ITS1-ITS2, ITS1-ITS4) was performed using DNA extracted from lung tissue samples from WHWTs affected with CIPF (n=26) and age-matched unaffected controls (n=14). DNA of soil Aspergillus fumigatus isolates were included as positive controls. Water samples were tested as negative controls. Additionally, serum samples from 8 WHWTs affected with CIPF and 8 age-matched unaffected WHWTs were tested for precipitins against 10 species of environmental fungus using electrosyneresis on cellulose acetate. Fungal ITS1-ITS2 and ITS1-ITS4 sequences were not amplified from any lung sample, suggesting that invasive fungal infection or heavy colonization is unlikely in CIPF. On the other hand, results of the serological assay revealed the presence of ≥2 arcs of precipitins (indicative of a positive result) in 55 of the 160 reactions tested (35 positive results in CIPF population vs. 20 in controls, p=0.013), supporting an increased prevalence of environmental fungal exposure in CIPF dogs compared with controls. For Lichtheimia corymbifera, a commonly involved antigen in human farmer's lung hypersensitivity pneumonitis, the number of precipitin arcs was significantly higher in CIPF dogs in comparison with controls (p=0.04). Whether this finding reflects a lung sensitization to fungal allergens and is involved in the pathogenesis of CIPF warrants further investigation.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Roels
University of Liège
Liège, Belgium

URL: http://www.vin.com/doc/?id=8172940
Records of all cases diagnosed between 2004–2016 with eosinophilic bronchitis (EB) or idiopathic eosinophilic bronchopneumopathy (EBP) at four university hospitals in the UK were reviewed. Cases were excluded if full records were not available or if other pulmonary disease such as neoplasia or parasitic pneumonitis was identified. The following information was retrieved: breed, age, sex, weight, clinical signs, presence of eosinophilia, thoracic imaging findings, bronchoscopy results (classified as mild; moderate; severe), BALF cytology results (eosinophilic pleocytosis classified as mild 10–25%; moderate 25–50%; severe >50%), infectious disease screening and concurrent disease processes. The following subgroups were created: acute (<1 month of clinical signs) vs chronic (>1 month of clinical signs); EB1 (no radiographic changes or bronchial/peribronchial pattern) vs EBP1 (interstitial/alveolar patterns) and EB2 (no radiographic changes) vs EBP2 (any pulmonary pattern). Group comparisons by chi-square or Fisher's exact test were carried out in regards to age, weight, bronchoscopy score, presence of eosinophilia or bronchiectasis and degree of eosinophilia in BALF.

The inclusion criteria were met by 70 cases. Median age was 4 years (IQR 1–6). Females (63%; 44/70) and cross-breed dogs (17%;17/70) were most commonly affected. The commonest clinical sign was cough (94%; 66/70). There were 69% (48/70) classified as chronic and 32% (22/70) as acute. EB1 group was 46% (32/70) vs EBP1 group 54% (38/72) and EB2 group was 81% (57/70) vs EBP2 group 19% (13/70). Circulating eosinophilia occurred in 36% (25/70) and bronchiectasis in 14% (10/70) of cases. Bronchoscopy score was mild (38%; 25/68), moderate (54%; 37/68) and severe (9%; 6/68). BALF results were mild in 10% of patients (7/70); moderate in 29% (20/70) and severe in 61% (43/70). EB cases (EB1 [p=0.003] and EB2 [p=0.002]) were less likely to have eosinophilia. EB2 cases had higher degree of eosinophilic pleocytosis on BALF (p=0.006) and no EB2 case suffered from bronchiectasis. There was no difference (p>0.05) in any of the other clinical variables between EB vs EBP groups or between acute and chronic cases.

The conclusions of this study include: dogs with eosinophilic lung disease (ELD) in general and EBD in particular were more commonly young to adult and female and cross-breed dogs were commonly affected. EB dogs without radiographic changes represent a different ELD population with less severe eosinophilic pleocytosis in BALF and absence of bronchiectasis and eosinophilia. Unlike the situation in human medicine, there are no obvious clinical or diagnostic differences between acute and chronic ELD in dogs.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

S. Keegan
University of Bristol
Langford, UK

URL: http://www.vin.com/doc/?id=8172941
Therapy and Long-term Follow-up of 70 Cases of Canine Idiopathic Eosinophilic Lung Disease

S. Keegan¹; P. Silvestrini²; Y. Martinez-Pereira³; P. Watson⁴; J. López-Alvarez³; R. Blake³; A. Kortum⁴; D. Casamí-Sorrosal⁶

¹University of Bristol, Langford, UK; ²School of Veterinary Medicine; University of Liverpool, UK; ³School of Veterinary Science; University of Edinburgh, UK; ⁴School of Veterinary Medicine; University of Cambridge, UK; ⁵Canis Mallorca & HCV Barcelona, Spain; ⁶Dick White Referrals, UK

Records of 70 cases (2004–2016) diagnosed with idiopathic eosinophilic bronchitis (EB) or idiopathic eosinophilic bronchopneumopathy (EBP) were reviewed. Total response (TR) or partial response (PR) was resolution or improvement of clinical signs, respectively. Remission or long-term remission was absence of respiratory signs following discontinuation of therapy for more than one or six months respectively. Relapse was reoccurrence of clinical signs during remission. The following subgroups were established: acute (<1 month of clinical signs) vs chronic (>1 month of clinical signs); EB1 (no radiographic changes or bronchial/peribronchial pattern) vs EBP1 (interstitial/alveolar patterns); EB2 (no radiographic changes) vs EBP2 (any pulmonary pattern); prednisolone dose (<or=1 mg/kg/day; antiinflammatory-A) vs >1 mg/kg/day; immune-mediated-I). These groups were compared for achievement of remission and long-term remission with chi-square or Fisher's exact test. Probability of achieving remission and long-term remission was evaluated by Kaplan Meier curves/long rank test.

Oral prednisolone was administered to 96% (67/70) of cases (4% received single-inhaled therapy) and 37% (25/67) of those also received combined inhaled fluticasone (no difference between subgroups; p<0.05). Immunosuppressive or antiinflammatory prednisolone was started in 46% (31/67) or 54% (36/67) of cases respectively (no difference between subgroups; p<0.05). In 5% (2/36) of the latter an increase to an immunosuppressive dose to control the clinical signs was required. The 1-, 2-, and 4-year survival to death/euthanasia due to respiratory disease was 95%, 95%, and 91%, respectively. TR and PR occurred in 93% (65/70) and 7% (5/70) of cases respectively. Remission and long-term remission was achieved in 60% (42/70) and 41% (24/58) of cases, respectively. Relapse occurred in 24% (10/42) of cases during remission and in 4% (1/24) during long-term remission. Achievement of TR, PR, remission or long-term remission and the probability of achieving remission or long-term remission was not different (p>0.05) between subgroups although a possible trend towards increased likelihood of achieving long-term remission for the I vs A group was observed.

The conclusions of this study include: Idiopathic eosinophilic lung disease rarely leads to euthanasia or death and clinical response is achieved in all dogs. Unlike the situations in humans we found no evidence that dogs with EB vs EBP or dogs with acute vs chronic disease differ in outcome. Many dogs achieved a total response and remission with anti-inflammatory dose of prednisolone (plus/minus inhaled therapy). However, whether dogs in which an immunosuppressive dose is not used are less likely to achieve long-term remission warrants further studies.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

D. Casamí-Sorrosal
Dick White Referrals
UK

URL: http://www.vin.com/doc/?id=8172942
In humans, deviation from a core airway microbiota is thought to predispose to development, exacerbation or progression of respiratory diseases. Our objective was to describe changes in the airways and fecal microbiota as cats transitioned from healthy (day 0) to asthmatic, in the early (6 weeks) and chronic (36 weeks) stages. The gut microbiota influences microbial communities at distant sites. However, as asthma is a localized disease, we hypothesized that it would result in decreased richness and diversity of the lower airway microbiota, contributing to a state of dysbiosis, while the fecal microbiota would remain unaffected.

Fecal, oropharyngeal (OP), and bronchoalveolar lavage (BAL) samples were collected from eight healthy research cats before (day 0) and at 6, 12, 24 and 36 weeks after experimental asthma induction using Bermuda grass allergen. Extracted DNA underwent PCR of the 16S rRNA gene. Once sequenced, richness, diversity, and relative abundance of representative operational taxonomic units (OTUs) were determined via RM ANOVA on ranks (p<0.050). Principal component analysis (PCA) was used to visualize relatedness of samples. Differences in community composition between timepoints were tested using PERMANOVA of Bray-Curtis similarity indices.

Feces had decreased richness between day 0 and 6 weeks (p<0.001) only. In OP samples, richness increased at 6 and 36 weeks versus day 0 (p=0.036 and 0.02, respectively). No significant change in relative abundance of predominant taxa was found in fecal or OP samples over time. In BAL, richness significantly decreased from day 0 to 6 and 36 weeks (mean #OTUs 96, 47 and 21, respectively; p<0.001). Relative abundance of Pseudomonadaceae decreased from day 0 to 36 weeks (68% to 0.12%; p<0.001) with increases in Sphingobacteriaceae and Bradyrhizobiaceae (from 0.08% to 52.16% and from 0.40% to 32.58%; p<0.001). Within BAL, PERMANOVA detected significant differences (p<0.001) in diversity between samples collected at day 0 and week 36 compared to all other time-points.

Upper and lower airway communities differ from each other and from the fecal microbiota. In upper airways, increased richness without change in relative abundance of predominant taxa was noted after asthma induction. In contrast, lower airway microbiota undergo significant changes in early and chronic stages of asthma. Decreases in relative abundance of organisms associated with healthy airways supports the concept of airway dysbiosis. Knowledge of changes in asthmatic airway microbial populations opens the door to investigation of modulation of airway microbiota to attenuate disease.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.I. Vientos-Plotts
College of Veterinary Medicine
University of Missouri
Columbia, MO, USA

URL: http://www.vin.com/doc/?id=8172930
Documenting Silent Reflux and Microaspiration Events Using Nuclear Scintigraphy in Healthy Dogs

M.E. Grobman; C.A. Maitz; C. Reinerino
College of Veterinary Medicine, University of Missouri, Columbia, MO, USA

Aspiration-related respiratory syndromes are well recognized in humans. About half of healthy adults aspirate without apparent clinical consequence. Understanding the frequency and severity of reflux and microaspiration in healthy individuals is critical to determining their role in respiratory disease pathogenesis. In dogs, analogous information is lacking. The objective of this pilot study is to use scintigraphic reflux studies to investigate frequency, location, and duration of reflux and aspiration events in healthy dogs.

Healthy dogs without aero-digestive symptoms within the preceding 6 months were fed a meal containing (3mCi) colloidal 99m-technetium phytate (99mTcP). Time activity curves (TACs) were quantified over the pharynx and three esophageal zones at 5 and 30 minutes post-ingestion. Static images of the lungs were obtained at 2 and 18 hours to evaluate for aspiration. Reflux was characterized by counts exceeding background activity by 200%. Data were reported descriptively as median and range.

Five healthy adult dogs (median 4 yrs, range 3–9 yrs) were enrolled. All dogs had >1 reflux event (median 3, range 2–4, total 15) over the 5 minute dynamic collection period. Reflux was limited to distal esophageal reflux with rising (n=1; reflux with failure of clearance) and falling (n=14; reflux with appropriate clearance) TACs. Pharyngeal contamination was identified in one dog. Aspiration was not observed in any dog.

In dogs, scintigraphic reflux studies can document reflux and may complement videofluoroscopic swallow studies and esophageal pH monitoring. Reflux, but not aspiration, is common in healthy dogs and must be considered during interpretation of results in clinically affected dogs.

DISCLOSURES

Disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.E. Grobman
College of Veterinary Medicine
University of Missouri
Columbia, MO, USA

URL: http://www.vin.com/doc/?id=8172931
Diagnosis of Pulmonary Angiostrongylosis in Dogs with Negative Non-invasive Tests (Baermann Analysis and AngioDetect™©)

A.M. Canonne¹; F. Billen²; I. Peters³; C. Clercx²
¹National Veterinary School of Alfort, Maisons Alfort, France; ²Faculty of Veterinary Medicine, University of Liège, Liège, Belgium; ³2TDDS Laboratories, University of Exeter, UK

Canine angiostrongylosis is now considered as an emerging condition in Belgium. The gold standard for the diagnosis is based on the detection of first-stage larvae by Baermann faecal analysis. However, the imperfect sensitivity is the main disadvantage of this test. Alternative methods including serological or molecular assays have been developed to improve diagnosis. Detection of circulating antigens seems to enable diagnosis before patency; however, sensitivity in naturally-infected dogs with negative Baermann analysis has not been documented. PCR on bronchoalveolar lavage fluid (BALF) has recently been reported as valuable tool and helpful in dogs with negative Baermann analysis.

Comparative usefulness of faecal or serological tests and BALF analysis has not been investigated in naturally-infected dogs. The aim of this study was to report and compare results of the rapid test detecting circulating antigens, Baermann analysis and PCR on BALF in a small series of dogs with angiostrongylosis.

Dogs with suspected angiostrongylosis based on clinical findings, for which results of three different diagnostic methods were available, were retrospectively included. The three methods were PCR, performed on BALF, the rapid blood test (AngioDetect™©, Idexx Laboratories) and Baermann analysis, performed on three faecal samples.

Seven dogs were selected. Owners reported cough and dyspnoea of variable severity from 2 weeks to 2 months’ of duration. PCR on BALF was positive in all dogs while the rapid test was negative in 4 dogs and uninterpretable in another one. Among the 4 dogs with negative rapid test, Baermann analysis was also negative in 3 dogs. Bronchoscopy and PCR on BALF were thus essential for diagnosis in 3 dogs, which presented moderate-to-severe clinical signs from 2 to 4 weeks. If PCR on BALF is considered as gold standard, relative sensitivities of the rapid test and Baermann analysis would be of 29% and 42%, respectively.

In conclusion, even though Baermann analysis and the rapid test should be used as first-line tools because of their availability, cost-effectiveness and non-invasiveness, they might be of lower sensitivity than BALF PCR analysis in early cases. Based on this small descriptive series, bronchoscopy and PCR on BALF may be considered in clinically-suspected dogs in which both rapid test and Baermann analysis are negative. Further studies including ELISA assays for antigens or antibodies are warranted to help select the most appropriate diagnostic tests in canine angiostrongylosis.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

A.M. Canonne
National Veterinary School of Alfort
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8172932
Discrimination Between Cough and Non-cough Behaviours Using Acoustic Wave Recordings

M.E. Grobman¹; T.E. Lever²; C. Reinero¹

¹College of Veterinary Medicine, University of Missouri, Columbia, MO, USA; ²Department of Otolaryngology, University of Missouri, Columbia, MO, USA

Cough is a protective mechanism, promoting clearance of the respiratory tract, while also contributing to pathology of clinical disease; as such, it is a both a marker for and target of therapeutic intervention. Cough assessment in dogs is subjective, generally based on owner's perceptions. An objective method of evaluation is needed. In humans, acoustic cough monitoring provides objective data on cough number and intensity by examining acoustic waveforms. We hypothesized that healthy dogs would demonstrate cough waveforms which could be distinguished from other acoustic behaviors (AB); whine, bark, growl, lick, drink, chew and throat-clear. Data were obtained from 10 healthy employee-owned dogs with informed consent. Acoustic behaviors were recorded using a CTA-laryngeal-microphone and analyzed using RavenPro© bioacoustics analysis software for AB duration, peak amplitude and frequency, time to peak amplitude and frequency, power, and energy. Inter- and intra-group statistical analysis was performed using a one-way ANOVA on ranks with p<0.05 being significant. With the exception of throat-clear, cough was distinguished from every other evaluated AB by one or more of the analyzed waveform parameters (p<0.001). No between-subject differences were identified between cough and throat-clear groups for any waveform parameter. All other behaviors showed statistically significant within-group variation (p<0.001). Cough and throat-clear (a clinically similar mechanism to protect the airways) have repeatable acoustic features that are distinguishable from other common AB and are consistent between dogs. Acoustic monitoring may provide an objective means for evaluating cough in dogs with respiratory disease and assessing response to therapeutic intervention.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.E. Grobman
College of Veterinary Medicine
University of Missouri
Columbia, MO, USA

URL: http://www.vin.com/doc/?id=8172933
Tracheal stenting is indicated for dogs with refractory tracheal collapse. Information regarding clinical improvement and owner satisfaction following stenting is scarce. The objectives of this study were to (1) screen for clinical, radiographic, and endoscopic predictors of improvement and survival after tracheal stenting, and (2) assess long-term owner satisfaction.

Dogs treated by tracheal stenting from 2011 to 2016 were retrospectively identified. Only dogs that had survived for ≥ 100 days after stenting were included. Data extracted from medical records and thoracic radiograph review were assessed as potential clinical improvement and survival predictors via univariate and multivariate analyses. Clinical improvement was studied via 4 parameters (coughing, respiratory distress, noisy breathing, and fatigability) ranked by owners based on severity before and after stenting using a subjective 10-point scale. Owner satisfaction was measured via a 10-point scale.

Twenty-seven dogs were included. Median survival time after stenting was 560 days (range 104–1837). No predictors of clinical improvement after stenting were identified. Age at stenting (p=0.036), fatigability score improvement (p=0.007), noisy breathing score improvement (p=0.044), total clinical score improvement (p=0.019), and owner satisfaction (p=0.001) were significantly associated with survival after stenting on univariate analysis. Age at stenting (p=0.01), noisy breathing score improvement (p=0.028), and owner satisfaction (p=0.002) remained significant survival predictors on multivariate analysis. The median satisfaction score was 7.5 (range 0–10) and 85% of owners would redo the procedure.

Based on these results, age at stenting, owner satisfaction, and noisy breathing improvement are prognostic factors after tracheal stenting. Owner satisfaction was overall good.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Robin
CHV Fregis
Arcueil, France

URL: [http://www.vin.com/doc/?id=8172934](http://www.vin.com/doc/?id=8172934)
We have shown that topical antifungal medication with meticulous debridement results in an overall success rate for SNA in 58 of 62 (94%) dogs (J Am Vet Med Assoc 2017;250:309). It is well known, however, that fungal hyphae do not invade the mucosa but can only be found at the mucosal surface and within material collected from the nasal cavity (J Comp Pathol 2005;132:283). Consequently, meticulous debridement alone might be successful to clear SNA.

Dogs with nasal discharge were prospectively enrolled if CT and endoscopic findings were indicative of SNA and fungal culture and PCR was positive for *A. fumigatus*. Trephination of frontal sinus was performed if involvement was seen on CT and it could not be reached endoscopically. Fungal plaques were loosened with a curette and removed from the affected frontal sinus by suction or with flushing using copious amounts of balanced electrolyte solution (up to 5 L). If no trephination was performed, fungal plaques and necrotic material in the sinus were loosened with forceps under endoscopic guidance and then flushed out. Once there was no evidence of fungal material left in the frontal sinus, flushing and suction were continued in the nasal cavity. This procedure of flushing and suctioning, lasting up to 2 hours, was performed until all visible fungal material and necrotic tissue were removed. No antifungal drugs were used. Recheck endoscopy with sinonasal flushing was repeated 3–5 weeks later. Resolution of SNA was defined as absence of visible fungal plaques with no or negligible amounts of necrotic material present during the second flushing and no clinical signs 4 months later based on telephone communication.

So far 9 dogs were enrolled, 6 (mean 6.5 years old) with >4 months re-evaluation. 1 dog died unrelated to SNA 2 months after enrolment. Trephination was performed in 4/6 dogs. No fungal material was seen in any of the 6 dogs at the recheck endoscopy (after median 26 days) and all owners confirmed no nasal discharge at the telephone communication (after median 204 days).

This preliminary study suggests that antifungal drugs are not needed for the treatment of canine SNA if debridement is performed meticulously and absolutely all fungal material is removed.

**DISCLOSURES**

No disclosures to report.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Stengel
Tierklinik Hofheim, Hofheim, Germany

URL: [http://www.vin.com/doc/?id=8172935](http://www.vin.com/doc/?id=8172935)
<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchoalveolar Lavage Analysis Using Urea Dilution Standardisation in Diagnosis of Respiratory Diseases in Dogs</td>
<td>A.E.H. Paul</td>
</tr>
<tr>
<td>Prevalence of Degenerative Joint Disease in Mature Indoor Cats</td>
<td>H.P. Huang</td>
</tr>
<tr>
<td>Oral Carica Papaya in the Supportive Care of Infectious Thrombocytopenia in Bleeding Dogs</td>
<td>B. Rengaswamy</td>
</tr>
<tr>
<td>Methaemoglobinemia Caused by Cytochrome b5 Reductase Deficiency: Genetic Studies and Long-term Treatment with Oral Methylene Blue</td>
<td>J. Jaffey</td>
</tr>
<tr>
<td>Prevalence of Gait Abnormalities in Pugs: A Questionnaire-Based Survey</td>
<td>C. Rohdin</td>
</tr>
<tr>
<td>Comparing the Submaximal Exercise Test Results and Severity of Brachycephalic Obstructive Airway Syndrome in Pugs and French Bulldogs</td>
<td>M. Aromaa</td>
</tr>
<tr>
<td>Bronchiectasis in Irish Wolfhounds with Recurrent Bacterial Pneumonia</td>
<td>S.J. Viitanen</td>
</tr>
<tr>
<td>Investigation of the Nasal Microbiota in Healthy Dolichocephalic Dogs and Dogs with Sinonasal Aspergillosis (SNA)</td>
<td>E. Vangrinsven</td>
</tr>
<tr>
<td>Retrospective Study of Clinical Findings, Treatment and Outcome in Dogs and Cats Diagnosed with Dysautonomia</td>
<td>K.E. Clarke</td>
</tr>
<tr>
<td>Retrospective Study on 33 Cases of Canine Primary IMHA: Clinico-Pathological Features, Follow-up and Prognostic Factors</td>
<td>V. Marchetti</td>
</tr>
<tr>
<td>Diagnostic Accuracy of the Macro-endoscopic Bronchial Aspect for the Diagnosis of Eosinophilic Bronchitis</td>
<td>E. Benvenuti</td>
</tr>
<tr>
<td>Reflux Aspiration Can Be Detected in Lungs of Dogs with Respiratory Disease</td>
<td>M. Määttä</td>
</tr>
<tr>
<td>Clinical and Laboratory Alterations in 37 Dogs Diagnosed with Lungworm Infection: A Retrospective Study (July 2010–April 2017)</td>
<td>V.G. Greci</td>
</tr>
<tr>
<td>Comparison of Three Different Guidelines for Blood Transfusion Applied in a Population of Italian Feline Donors to Reduce the Risk of Transfusion Transmissible Infections</td>
<td>A. Miglio</td>
</tr>
</tbody>
</table>
Bronchoalveolar Lavage Analysis Using Urea Dilution Standardisation in Diagnosis of Respiratory Diseases in Dogs

A.E.H. Paul1; P. Irwin2; J. Stayt3; C.S. Mansfield4

1Anderson Moores Veterinary Specialists Ltd, Hursley, Winchester, UK; 2Murdoch University, Murdoch, Perth, WA, Australia; 3Vetpath Laboratory Services, Perth, WA, Australia; 4University of Melbourne, Parkville, Melbourne, VIC, Australia

Considerable variation has been reported in total cell counts and concentration of biochemical markers due to variable recovery of pulmonary epithelial lining fluid (PELF) in bronchoalveolar lavage (BAL) fluid. A number of chronic respiratory conditions can be difficult to diagnose definitively and accounting for dilution of PELF may allow us to better differentiate respiratory disease. Differentiation of various chronic respiratory diseases may be made via analysis of BAL fluid using urea concentration of BAL relative to blood urea concentration as a marker of dilution of PELF. Assessment of cell counts after adjusting for dilution may allow differentiation of the primary disease process in dogs presenting with respiratory signs.

Client-owned dogs presenting for investigation of respiratory disease were included. All dogs had a BAL performed and BAL cell counts were corrected after using urea as a marker for dilution and comparison of urea in blood to that of urea in BAL fluid. A final diagnosis of respiratory disease was made after retrospective analysis of all diagnostic investigations and response to treatment.

Seventy-two BAL samples from a total of 48 dogs were analysed and thirteen primary causes of respiratory disease identified based on diagnostic investigation including BAL cell cytology and treatment response. Respiratory diseases were also assigned to inflammatory, non-infectious, infectious, upper respiratory tract or respiratory neoplasia categories based on the disease diagnosed. There was no statistical difference in the adjusted total cell counts of BAL fluid (B AFL) from dogs with different respiratory diseases or disease groups. Mycoplasma spp had no effect on the total cell count in dogs with chronic bronchitis.

This study suggests total cell counts of BAL fluid corrected for dilution by urea concentration cannot be used to distinguish between different respiratory diseases. A larger number of cases and cross section of respiratory disease may further identify significant differences in total and differential cell counts of various different diseases.

DISCLOSURES

This study was funded by the Australian Companion Animal Health Foundation and supported by the Australian and New Zealand College of Veterinary Scientists Research Grant Amanda Paul and Jason Stayt also indicate that they have no affiliations or financial involvement with any organization or entity with a financial interest in, or in financial competition with, the subject matter or materials discussed in this article. Caroline Mansfield has funding for research provided by Australian Research Council, Canine Research Foundation (Australian Kennel Club), Comparative Gastroenterology Society, Nexvet Biologics, PlasVac, Blackmores, Hills Pet Nutrition. She is also provided an Honoraria for travel/speaking in 2017 provided by Nestle Purina, FSAVA. Peter Irwin has funding from the Australian Research Council, Canine Research Fund and Australian Companion Health Foundation for ongoing research projects.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.E.H. Paul
Anderson Moores Veterinary Specialists Ltd
Hursley, Winchester, UK

URL: http://www.vin.com/doc/?id=8172944
Prevalence of Degenerative Joint Disease in Mature Indoor Cats

H.P. Huang¹; T.C. Tai²; S.H. Chiu¹; Y.C. Wu²; Y.H. Lien²
¹National Taiwan University, Taipei, Taiwan; ²Azu Clinic for Animals, Taipei, Taiwan

The aims of this investigation were to report the radiographic prevalence of DJD and physical changes in the appendicular skeleton and its clinical relevance in mature indoor cats.

One hundred and sixteen apparently healthy mature client-owned cats were included (age ≥6 years). All cats were kept exclusively indoors. These owners reported no lameness was observed of these cats over the last six months. All cats underwent a full physical examination and orthopedic evaluation of the appendicular and axial skeleton (signs of pain, instability, effusion and crepitus, performed by the same assessor). Body condition score (BCS, 5-point system) was also assessed. Each cat was gently restrained for radiographic examination without sedation. Radiographs of both shoulders, elbows, carpi, coxofemoral joints, stifles, and tarsi were evaluated. Among 116 cats, 111 (95.7%) cats had at least one appendicular joint affected with radiographic osteoarthritis. The prevalence of DJD in shoulders, elbows, carpi, coxofemoral joints, stifles, and tarsi were 15/116 (12.9%), 86/116 (74.1%), 82/116 (70.7%), 17/116 (14.7%), 71/116 (61.2%), and 11/116 (9.5%), respectively. Results of multivariate general linear model analyses indicated that DJD in elbows and coxofemoral joints was associated with BCS (p=0.008 and p=0.014, respectively). DJD in hocks was associated with BCS, gender and neutering (p=0.039). Sixty-six (56.9%) cats had decreased mobility, and further discriminant analysis indicated that decreased mobility was associated with presence of DJD in hocks (p=0.014); whereas 21 (18.1%) cats hesitated to jump down, and further discriminant analysis indicated that hesitation of jump down was associated with presence of DJD in elbows (p=0.009). Presence of DJD and decreased mobility was not associated with age or body weight.

Based on this investigation, DJD was highly prevalent in indoor cats. The front limb joints were commonly affected with DJD. The living environment (exclusive indoors, flooring materials and limited access to exercise) might contribute to the high prevalence of DJD in this cohort.

DISCLOSURES

The study was self-funded. The authors declare that they have no competing interests. The study was carried out in accordance with the code of the Research Ethics Office of National Taiwan University: No ethical approval was needed if no trial therapy (tested medicine) was involved in the study. All owners of cats whose cases were included in this study signed up their written consent for agreement of participating in a research study.

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

H.P. Huang
National Taiwan University
Taipei, Taiwan

URL: http://www.vin.com/doc/?id=8172950
Carica papaya leaf extracts have been used orally to recover platelet counts and to control bleeding in human patients with Dengue fever. The active components of papaya carica extract have been proved earlier to inhibit immune-mediated platelet destruction and possible bone marrow suppression to fasten the natural course of recovery by increasing the platelet counts. In this report we studied the effect of *Carica papaya* in the treatment of infectious thrombocytopenia in dogs. During a one-year period 60 thrombocytopenic dogs with ehrlichiosis, babesiosis, and/or leptospirosis referred to Madras Veterinary College Teaching Hospital were studied. They had mild (platelets 50,000–100,000/µl) to severe (platelets 25,000–50,000/µl) thrombocytopenia and evidence of bleeding. In addition coagulation profiles, buccal mucosal bleeding times, saline agglutination tests, spherocyte reviews, direct Coombs’ (direct antiglobin) tests, von Willebrand Factor assays, platelet-associated antibody (PSAb) assays, bone marrow aspiration cytology, and DEA 1 typings were determined. Platelet-rich plasma or fresh whole blood were transfused in case of severe (platelets <20,000 cells/µl) thrombocytopenia and/or anemia and all dogs received doxycycline and prednisone for ehrlichiosis and leptospirosis, imidocarb for babesiosis. *Carica papaya* leaf extract was administered at 5 ml per 10 kg body weight twice a day for 3 weeks. Platelet counts increased significantly faster in dogs receiving *Carica papaya* from day 2–7 compared to those receiving only other treatments. Also the bleeding signs appear to improve more rapidly with *Carica papaya*, and no side effects were observed. In conclusion *Carica papaya* may be an inexpensive, easily available thrombopoietic supplement to more rapidly control thrombocytopenia and bleeding in dogs with haemoprotezoan diseases along with transfusions, specific infectious disease and immunosuppression.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B. Rengaswamy
Madras Veterinary College
Chennai, India

URL: http://www.vin.com/doc/?id=8172951
Methaemoglobinemia Caused by Cytochrome b5 Reductase Deficiency: Genetic Studies and Long-term Treatment with Oral Methylene Blue

J. Jaffey¹; M. Harmon¹; N. Villani¹; E. Creighton¹; G. Johnson¹; U. Giger²; J. Dodam¹

¹Veterinary Health Center, University of Missouri, Columbia, MO, USA; ²School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

Methemoglobin, which cannot carry oxygen due to oxidized iron, may accumulate when the cytochrome b5 reductase system is overwhelmed by toxins or genetically dysfunctional. We report here on the diagnostic study of hereditary methemoglobinemia of a dog and a novel long-term treatment.

A juvenile male mixed breed was presented for lethargy, exercise intolerance, and aggression. Cyanosis, tachycardia, and tachypnea were observed which persisted during oxygen supplementation. Arterial blood gas analysis by co-oximetry indicated increased methemoglobin concentration (27%; normal <2%) with normal arterial oxygen tension. After initial intravenous methylene blue (MB; 1 mg/kg) administration, the dog was treated long-term with oral MB (1.5 mg/kg, q48h). Both reduced the methemoglobinemia and resolved the clinical signs during the 63-day observation period.

The erythrocytic cytochrome b5 reductase activity, measured by NADH-ferricyanide reductase assay, was low (6% compared to control), while the cytochrome c reductase activity was normal. A whole genome sequence (36x) of this dog contained two heterozygous CYB5R3 missense mutations with a serine for glycine substitution predicted at codon 72 and a leucine for isoleucine substitution predicted at codon 190. Both missense mutations are very likely to be deleterious, suggesting that each was inherited from a different parent and that each contributed to the recessive methemoglobinemia in a compound heterozygous state.

This is the first molecular genetic report of CYB5R3 variants and long-term management with oral MB of hereditary methemoglobinemia of a dog with cytochrome b5 reductase deficiency. Further studies on other affected dogs are in progress.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Jaffey
Veterinary Health Center
University of Missouri
Columbia, MO, USA

URL: http://www.vin.com/doc/?id=8172952
Prevalence of Gait Abnormalities in Pugs: A Questionnaire-Based Survey

C. Rohdin¹; K. Hultin Jäderlund²; I. Ljungvall¹; K. Lindblad-Toh³; J. Häggström¹

¹Swedish University of Agricultural Sciences, Uppsala, Sweden; ²Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Oslo, Norway; ³Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala, Sweden

Abnormal gait can be the result of musculoskeletal and/or neuromuscular conditions. The Pug breed is predisposed for specific orthopedic conditions and neuromuscular problems in the Pug breed has become increasingly recognized in the last few years. Lameness, as the result of musculoskeletal problems, and spinal cord disorders, characterized by paresis and ataxia, were reported in a British study in 2.4% versus 1.4% of the Pugs attending primary veterinary care. The prevalence of spinal cord disorders presented from the United Kingdom poorly corresponds to a Swedish insurance data report suggesting a seven-fold increase in mortality rate for ataxia, paresis and collapse in Pugs compared to other breeds. Adding the attention ‘wobbly Pugs’ are given on the internet suggests a need to investigate the prevalence of gait abnormalities in the Pug in a systematic way. The aim of this prospective study was to investigate the prevalence of gait abnormalities in a cohort of Swedish Pugs by using an owner-based questionnaire targeting signs of gait abnormality and video footage showing the dog’s gait. The study also aimed at evaluating associated conditions of abnormal gait; including other health disorders prevalent in the breed. The owners reported gait aberrations in 20.2% of the Pugs with a prevalence increase with increasing age. Adding the Pugs that were reported to show indirect signs of gait abnormalities (wearing their nails and dorsal aspect of the skin on their paws) increased the prevalence of gait abnormalities in the breed from 20.2% to 30.7%. These results suggest gait abnormalities to be a more significant health problem than previously reported. Indeed, the single, listed, most common cause for death/euthanasia, reported by the owners, was a gait abnormality. In conclusion, gait abnormalities were a common finding in the Pug breed. Wearing of the nails and/or skin on the dorsum of the paws, predominately in the thoracic limbs, were frequently found and from a comparably young age. The result of the questionnaire and the video analysis suggest neurological disorders are predominately responsible for the high prevalence of gait abnormalities in the Pug breed. The prevalence of abnormal gait was significantly associated with age and with dyspnoea. The gait abnormalities were not associated with overt signs of pain but were associated with reluctance to go for walks.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Rohdin
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172953
Comparing the Submaximal Exercise Test Results and Severity of Brachycephalic Obstructive Airway Syndrome in Pugs and French Bulldogs

M. Aromaa; M.M. Rajamäki; L. Lilja-Maula
Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland

In addition to respiratory difficulties, exercise intolerance and impaired recovery are major signs of brachycephalic obstructive airway syndrome (BOAS). Therefore, we investigated the correlations of the 6 min walk test (6MWT) or the 1000 m walk test results with a veterinary assessment of BOAS severity in a group of prospectively recruited 1–5 years old Pugs (n=35) and French Bulldogs (FBs) (n=42). For severity of BOAS, dogs graded as having no or mild signs of BOAS were referred to as the BOAS- group and those having moderate or severe signs as the BOAS+ group based on veterinary physical examination findings. The BOAS- Pugs walked longer distance (p=0.002) in 6MWT (mean 584±33 m, range 505–630) and shorter time (p=0.006) in 1000 m walk test (mean 10.17±0.67 min, range 9.39–11.94) than BOAS+ Pugs (6MWT 517±64 m, range 400–585; 1000 m test 12.26±2.23 min, range 10.25–17.55). Similarly, the BOAS- FBs walked longer distance (p=0.063) in 6MWT (639±51 m, range 575–745) and shorter time (p=0.012) in 1000 m test (9.47±0.66 min, range 8.15–10.77), than BOAS+ FBs (6MWT 593±73 m, range 435–695; 1000 m test 10.72±1.25 min, range 8.42–12.15). BOAS- Pugs and FBs recovered also more quickly than BOAS+ Pugs and FBs (p=0.002; p=0.007). In conclusion, submaximal exercise test could be used as non-invasive tool for evaluation of severity of BOAS.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

M. Aromaa
Faculty of Veterinary Medicine
University of Helsinki
Helsinki, Finland

URL: http://www.vin.com/doc/?id=8172954
The development of bronchiectasis (BE), an irreversible dilation of the bronchi, is a well-established complication after bacterial or viral pneumonia in humans. BE leads to defects in the mucociliary clearance and predisposes to the development of new bacterial respiratory infections. BE has been described in dogs with variety of respiratory diseases, but the connection to recurrent bacterial infections has not been fully established. A breed predisposition to acute bacterial pneumonia (BP) has been described in the Irish wolfhound (IWH), but the etiology is largely undiscovered.

High resolution computed tomography (HRCT) was performed to 10 IWHs with recurrent BP (median age 6.0 years, range 0.8–7.7 years; median number of previous BPs 4, range 2–6). All dogs were examined when they were clinically healthy and not receiving antibiotics. HRCT findings comprised mild to severe bronchiectasis (9/10 dogs), mild to moderate local bronchointerstitial pattern (2/10), mild local interstitial pattern (1/10), parenchymal band (1/10), locally thickened pleura 1/10 and subpleural band (1/10). Bronchiectasis was detected in a single lung lobe in 3/9, in 2 lung lobes in 3/9 and in 3 lung lobes in 3/9 dogs. Left and right cranial lobes and the right middle lobe were most often involved.

In our study, BE was commonly detected in IWHs with recurrent BP. The development of BE is likely a post-infectious consequence of previous BPs. The presence of BE may further facilitate the development of new respiratory infections and may therefore act as a predisposing cause to recurrent BP.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

S.J. Viitanen
University of Helsinki
Helsinki, Finland

URL: http://www.vin.com/doc/?id=8172955
Investigation of the Nasal Microbiota in Healthy Dolichocephalic Dogs and Dogs with Sinonasal Aspergillosis (SNA)

E. Vangrinsven; B. Taminiau; E. Roels; A. Fastres; C. Auquier; F. Billen; G. Daube; C. Clercx
University of Liege, Angleur, Belgium

Sinonasal aspergillosis (SNA) most commonly affects middle-aged dolichocephalic dogs and is characterised by a destructive rhinitis and sinusitis, in the absence of fungal deeper tissue invasion. Pathogenesis of the disease is, to date, not fully understood. An uncontrolled and detrimental inflammatory response to commensal fungal colonization of the nasal cavities and sinuses has been suggested. In humans, a role of the bacterial microbiota in the regulation of host immune responsiveness to fungi has been hypothesised. Therefore, the objective of the present study was to identify and characterise the microbiota present in nasal cavities of client-owned dogs diagnosed with SNA compared with healthy age and breed-matched non-affected dogs.

Nine large-breed dolichocephalic dogs diagnosed with SNA (6 males, 3 females, mean age 5.5 years) and 10 healthy age-and breed-matched dogs (7 males, 3 females, mean age 5 years) were included. DNA was extracted from a sterile swab introduced in the distal third of the right nasal cavity under general anaesthesia. Metagenetic analysis was performed on V1-V3 hypervariable region of 16S rDNA after total bacterial DNA extraction from nasal specimens and sequencing on a MiSeq Illumina sequencer. Taxonomical assignation and microbiota community analysis were done with MOTHUR V1.35 with an OTU clustering distance of 0.03. Differences of population abundance between groups were assessed using multiple t tests with Holm-Sidak multi-test correction (significance <0.05).

Sequencing revealed that Proteobacteria and Firmicutes were the two most predominant phyla in both groups; representing together almost 80% of the total bacterial abundance. The remaining 20% were composed of Bacteroidetes and Fusobacteria in diseased dogs, and of Actinobacteria almost exclusively in healthy dogs. At family level, a significantly higher abundance of Lactobacillaceae were found in SNA dogs, while Moraxellaceae significantly predominated in controls. Analysis of diversity metrics revealed that bacterial species richness and diversity were significantly higher in SNA dogs compared with controls.

In conclusion, results of the present study demonstrated the presence of nasal microbiota alteration in dogs affected with SNA in association with an increased bacterial diversity. However, whether such changes are a cause or a consequence of the disease is unknown and warrants further investigation.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Vangrinsven
University of Liege
Angleur, Belgium

URL: http://www.vin.com/doc/?id=8172956
Dysautonomia is a disease characterised by degeneration of autonomic neurons. Previous retrospective case series have been small, single centre and indicate a grave prognosis. The aim of this study was to perform a retrospective, multicentre review of clinical data relating to dogs and cats diagnosed with dysautonomia and to evaluate the outcome in those patients. Cats and dogs with clinical signs consistent with dysautonomia were included in this retrospective study. A total of 34 cats and 19 dogs were included. Reported clinical signs included oesophageal, gastric and intestinal dysmotility and distension, urinary retention and dysuria, reduced or absent tear production, third eyelid protrusion and inappropriate mydriasis. Vomiting and regurgitation were commonly reported in both species (cats n=29/34, dogs n=17/19), while signs consistent with urinary retention were primarily reported in dogs (n=14/19) and third eyelid protrusion was more frequently reported in cats (n=20/34). Diagnostic imaging findings included aspiration pneumonia, megaoesophagus, gastrointestinal dilation with either fluid or gas and bladder distension. Oesophageal dilation was the most often identified diagnostic imaging finding in cats (n=20/34), while in dogs gastrointestinal distension was most commonly identified (n=5/19). Regularly instituted treatments included gastrointestinal prokinetics such as cisapride and metoclopramide, feeding tube placement (oesophageal and percutaneous endoscopic gastrostomy tubes) and medications to treat urinary retention such as bethanechol. The overall survival to discharge was 36%. The mortality rate prior to discharge was 71% in cats and 53% in dogs. Longer term survival (greater than two years) was seen in three dogs and six cats. In this retrospective study clinical signs, diagnostic imaging findings, treatment and prognosis were all similar to previous retrospective publications. This paper has illustrated that some individuals are able to survive this disease and can have a good long-term prognosis. Prospective studies are required to identify risk factors that indicate whether a patient is likely to survive and thus if it is worth embarking upon treatment.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

K.E. Clarke
Willows Veterinary Centre and Referral Service
Shirely, UK

URL: http://www.vin.com/doc/?id=8172957
Primary immune-mediated hemolytic anemia (pIMHA) is the most common immune-hematological disease in dogs, yet it still represents a prognostic and therapeutic challenge for many veterinarians. So far, only a limited number of prognostic indicators and outcome scores are accepted consistently.

Influence of treatments initiated by referring veterinarians on clinico-pathological features, disease severity, follow-up, and survival time were investigated from time of presentation (T0) to our referral center up to 4 months post presentation. CHAOS and Tokyo severity scores were applied to all cases and compared with the disease outcome. Furthermore, several clinico-pathological signs were studied as prognostic factors at time of discharge from the Veterinary Hospital (TD), at 30 days and 120 days after discharge.

Thirty-three cases of pIMHA (according to standard clinical and clinico-pathological criteria) collected between February 2010–2016 were included. Data regarding history, blood and urine laboratory tests, and immunosuppressive treatments was collected. Patients were divided into two groups (16 patients previously treated by the referring vets, group A, and 17 untreated, group B) and statistically compared.

In group A platelet count (p=0.002) and serum concentrations of alkaline phosphatase (p=0.010) were significantly higher than group B at T0. In group B serum concentrations of total protein (p=0.025), globulins (p=0.002), C-reactive protein (p=0.003), and lactate dehydrogenase (p=0.028), and urinary parameters as pigmenturia (p=0.0003) and bilirubinuria (p=0.041) were significantly higher than group A at T0 (Mann-Whitney test). CHAOS severity score was more predictive of outcome than Tokyo severity score at 30 and 120 days (odd ratio [OR], respectively, 15.1 and 10.7). In addition, a few clinico-pathological signs were statistically related with a worse prognosis (OR): urea concentration (>55 mg/dl) at TD, hyperbilirubinemia (>1.5 mg/dl) and number of nucleated RBCs (≥30/100 WBC) at T30 and T120, thrombocytopenia (<150x10⁹/L) at TD, T30 and T120. Group B dogs had higher mortality rate (47%) than group A dogs (13%) after 2 weeks from T0 (p>0.05, Kaplan-Meier curve).

In conclusion, previous immunosuppressive treatments by referring veterinarians may weaken the clinician's ability to properly assess patient's prognosis. This study confirmed some literature information regarding diagnosis, prognosis and survival times of dogs suffering of IMHA and it adds additional prognostic factors such as urea concentration, hyperbilirubinemia, circulating nucleated RBCs and thrombocytopenia.

DISCLOSURES

No disclosures to report.
Diagnostic Accuracy of the Macro-endoscopic Bronchial Aspect for the Diagnosis of Eosinophilic Bronchitis

E. Bottero¹; E. Benvenuti¹; P. Ruggiero¹; D. Falcioni¹; E. Mavilio¹; N. di Girolamo²

¹Associazione Professionale Endovet, Rome, Italy; ²Centro Veterinario Specialistico, Rome, Italy

Bronchoscopy is commonly used for to evaluate dogs with acute and chronic coughs. Our aim was to evaluate the diagnostic accuracy of the macroscopic endoscopic exam of the bronchial mucosa for the diagnosis of eosinophilic bronchitis. A retrospective multi-institutional diagnostic accuracy study was performed including all the dogs presenting with acute or chronic coughs and that underwent bronchial endoscopy by the Endovet Italian Group between January 2014 and December 2016. The reference standard was the cytological evaluation of the bronchoalveolar lavage. The primary outcome was sensitivity, specificity, positive predictive value, and negative predictive value of endoscopic visualization of nodules for the diagnosis of eosinophilic bronchitis. Of the 845 cases studied, a total of 781 dogs fulfilled the inclusion criteria with cytological evaluation of the bronchoalveolar lavage. The dogs ranged in age from 0.4 to 16 years (8.0 median, 4.0 SD), in body weight from 1.5 to 45 kg (13.0 median, 9.5 SD), and 325 (41.6%) were females. A final diagnosis of eosinophilic bronchitis was given for 113 (15.6%) cases, and 99 (13.6%) presented nodules during macroscopic endoscopy. In the final logistic regression model, detection of nodules during endoscopy, higher age, and lower body weight were associated with a diagnosis of eosinophilic bronchitis. Odds of having eosinophilic bronchitis were 34.4% (18.9 to 62.6; p<0.001) greater in dogs presenting nodules during endoscopy. The risk of eosinophilic bronchitis increased by 23% (14 to 32%; p<0.001) for a one-year increase in age, and by 3% (0 to 5%; p=0.048) for each kilogram decrease in body weight. Visualization of nodules during endoscopy had a sensitivity of 56.6% (47.0 to 65.9%), specificity of 94.3% (92.3 to 95.9%), positive predictive value of 62.7% (54.3 to 70.5%), and negative predictive value of 92.8% (91.2 to 94.1%). Based on the high specificity and high negative predictive value, visualization of nodules during endoscopy is highly indicative of eosinophilic bronchitis. However, the lack of visualization of nodules during endoscopy does not exclude the presence of eosinophilic bronchitis.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Benvenuti
University of Pisa
San Piero a Grado, Pisa, Italy

URL:  http://www.vin.com/doc/?id=817946
Reflux Aspiration Can Be Detected in Lungs of Dogs with Respiratory Disease

M. Määttä1; H.P. Laurila1; S. Holopainen1; L.I. Lilja-Maula1; M. Melamies1; S.J. Viltanen1; L.R. Johnson2; N. Koho1; M. Neuvonen1; M. Niemi1; M.M. Rajamäki1

1University of Helsinki, Helsinki, Finland; 2University of California, Davis, USA

Gastroesophageal reflux and microaspiration (MA) of small amounts of gastric juice have been associated with various human respiratory diseases, including idiopathic pulmonary fibrosis and asthma. MA can be documented by measuring proteins originating from the gastrointestinal tract in bronchoalveolar lavage fluid (BALF). In this study, bile acids were measured by mass spectrometry in BALF from West-Highland White Terriers (WHWTs) with canine idiopathic pulmonary fibrosis (CIPF, n=33), healthy WHWTs (n=13), dogs with bacterial pneumonia (BP, n=11), healthy Irish Wolfhounds (IWHs) with previous BPs (n=8), dogs with chronic bronchitis (CB, n=13), dogs with eosinophilic bronchopneumopathy (EBP, n=9), dogs with laryngeal dysfunction (LD, n=19), healthy English Bulldogs (EBs, n=26) and healthy Beagles (n=6).

Concentrations of 17 different bile acids were determined and total bile acid (TBA) concentration was calculated as a sum of these. TBA was above minimum detection limit in 79% of CIPF (26/33), 45% of BP (5/11), 54% of CB (7/13), 44% of EBP (4/9) and 63% of LD (12/19) dogs. In healthy dogs, bile acids in BALF were detected less commonly in IWHs (0%, 0/8), EBs (8%, 2/26) and Beagles (0%, 0/6) than in healthy WHWTs (54%, 7/13). Results suggest that MA occurs in various canine respiratory diseases. In healthy dogs bile acids were detected only in WHWTs which could be associated to the breed predisposition of CIPF.

DISCLOSURES

Disclosures to report:


SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Määttä
University of Helsinki
Helsinki, Finland

URL: http://www.vin.com/doc/?id=8172947
Clinical and Laboratory Alterations in 37 Dogs Diagnosed with Lungworm Infection: A Retrospective Study (July 2010–April 2017)

V.G. Greci
Ospedale Veterinario Gregorio VII, Roma, Italy

Lungworm infection is a potentially life-threatening parasitic infection in the canine species. Most common clinical presentation is respiratory distress and coughing; neurological manifestations and DIC have also been reported.

The aim of this study is to report the clinical and laboratory alterations in 37 dogs diagnosed with lungworm infection.

The mean age was 46.7 months (2–156 months); 24 dogs were male (21 intact; 3 neutered) and 13 dogs were female (6 intact; 7 spayed). Seven dogs were mixed-breed; the others belonged to different breeds. Fifteen dogs had a history of risk exposure.

Main duration of clinical signs was 11.4 days (1–60 days) with coughing (23 dogs) and dyspnea (16) the main symptoms. Five dogs had acute occurrence of neurological sign and one dog developed neurological signs few days after diagnosis. Thoracic radiographs were characterized by a mild (4) to diffuse moderate (8) or severe (25) mixed alveolar-bronchial-interstitial pattern.

CBC-count was performed in 33 dogs and showed anemia (15/33), leukocytosis (16/33), neutrophilia (15/33), eosinophilia (16/33), monocytosis (12/33), basophilia (5/33), lymphocytosis (3/33) and low PLT count (14/33). Biochemistry was performed in 29 dogs and showed increase in total protein count (13/29), globulin count (16/29), CPK (17/29), amylase (14/29), C-reactive protein (22/29), phosphorus (11/29) and urea (9/29). Protein serum electrophoresis was available in 14 dogs and showed increased in the β1 fraction and in the β2 fraction in 11 and 13 dogs respectively. Urinalysis was available in 4 dogs and PU/CU was increased in 2 dogs. Coagulative profile was performed in 17 dogs and was suggestive of DIC in 13 dogs, eleven of these dogs had a mean hematocrit of 24% (17.1–30.1%).

Twenty dogs were positive on fecal examination and two were negative; one of these dogs was positive for Angiostrongylus vasorum (IDEXX Angio-detect-test). Twenty-two dogs were positive on the IDEXX Angio-detect-text and one was negative but positive on fecal examination but lungworm typing was not submitted. One dog was diagnosed on BAL. Three dogs were diagnosed post mortem, two had A. vasorum infection and the other dog had a mixed infestation with A. vasorum and Filaroides ostrii. Overall seven dogs died; the others recovered.

Lungworm infection should be included in the differential diagnosis of dog presenting with respiratory disease and acute onset of neurological signs. Though hematological alteration are non-specific, presence of DIC, increase globulin count with increase in the β fraction should aware the clinician of a possible undergoing lungworm infection.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

V.G. Greci
Ospedale Veterinario Gregorio VII
Roma, Italy

URL: http://www.vin.com/doc/?id=8172948
Comparison of Three Different Guidelines for Blood Transfusion Applied in a Population of Italian Feline Donors to Reduce the Risk of Transfusion Transmissible Infections

A. Miglio¹; M.L. Marenzoni¹; S. Lauzi²; M. Coletti¹; S. Paltrinieri²; M.T. Antognoni¹

¹Department of Veterinary Medicine, Perugia, Italy; ²Department of Health, Animal Science and Food Safety (VESPA), University of Milan, Milan, Italy

The increased demand for blood transfusion in animals causes the need to have an adequate number of donors. At the same time, a high level of blood safety must be guaranteed and different guidelines (GLs) deal with this topic.

Aim of the present study was to evaluate the appropriateness of different GLs in preventing transfusion-transmissible infections (TTI) in Italian feline blood donors.

Blood samples were collected from 31 cats enrolled as blood donors by owner's voluntary choice at an Italian blood bank during approximately 1 year. Possible risk factors for TTI were recorded. Based on Italian, European and American GLs, specific TTI, including haemoplasmas, feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), Anaplasma phagocytophilum, Ehrlichia spp., Bartonella spp., Babesia spp., Theileria spp., Leishmania donovani sensu lato and feline coronavirus (FCoV), were screened. Rapid antigen and serological and biomolecular investigations (PCR) were used. Several PCR protocols were compared to detect haemoplasma and FeLV DNA.

The presence of at least a recognized risk factor for TTI was reported in all cats. They resulted negative for FIV and FeLV, whereas 5 (16.1%) positive for FCoV antibodies using rapid tests. PCR were negative for all tested microorganisms, except 4 cats (12.9%) positive for haemoplasma DNA and one (3.2%) for FeLV provirus. However, this latter resulted positive only with the most sensitive PCR protocol applied, but not with the others.

Since the different GLs recommend different protocols and that they can differently classify a candidate donor as suitable or not, a harmonization of recommendations, especially on the main TTI to screen and on the choice of the best sensitive serological or molecular tests, with possible variations according to the local epidemiological situation, would be advisable to improve the general level of the veterinary blood safety. Moreover, considering the profile at high risk of TTI of blood donors and consequent costs and time of the procedures to guarantee blood safety, tools to select donors at low risk should be developed.

Appropriate recruitment strategies, currently not considered in GLs, questionnaire-based risk profile, educational courses for owners and the possibility to establish a permanent group of safe blood donors could improve the identification of suitable donors, reducing the necessity to perform a wide screening.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Miglio
Department of Veterinary Medicine
Perugia, Italy

URL: http://www.vin.com/doc/?id=8172949
<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of Meteorologic Data to Predict Parasite Spreads, Should We Expect More in the Future?</td>
<td>Eric R. Morgan, MA, VetMB, PhD, DEVPC, MRCVS</td>
</tr>
<tr>
<td>Factors Influencing Geographical Spread of Angiostrongylus vasorum Through Europe?</td>
<td>Eric R. Morgan, MA, VetMB, PhD, DEVPC, MRCVS</td>
</tr>
<tr>
<td>Feline Lungworms: What Are We Missing?</td>
<td>Donato Traversa, DVM, PhD, DEVPC</td>
</tr>
<tr>
<td>Are Dirofilaria Infections Really Spreading Throughout Europe?</td>
<td>Claudio Genchi, DVM, PhD, DEVPC</td>
</tr>
<tr>
<td>Epidemiology, Clinical Concerns and Prevention</td>
<td>Roger K. Prichard, BSc, PhD, DHC, HDipEVPC</td>
</tr>
<tr>
<td>The Emergence of Macroyclic Lactone Resistance in Dirofilaria immitis; Identification and Risk Assessment</td>
<td>Roger K. Prichard, BSc, PhD, DHC, HDipEVPC</td>
</tr>
<tr>
<td>What Have Dirofilaria and Wolbachia Taught Us About Endosymbiotic Relationship?</td>
<td>Claudio Genchi, DVM, PhD, DEVPC</td>
</tr>
<tr>
<td>Microcirculation and the Glycocalyx: Does It Matter?</td>
<td>Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC</td>
</tr>
<tr>
<td>Colloids in Small Animals - What's the Evidence?</td>
<td>Katja-Nicole Adamik, Dr. med. vet., DACVECC, DECVECC</td>
</tr>
<tr>
<td>Fluid Status and Responsiveness: What's New?</td>
<td>Kris Gommeren, PhD, DECVIM-CA</td>
</tr>
<tr>
<td>Initial Stabilisation via Early Goal-Directed Fluid Therapy</td>
<td>Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC</td>
</tr>
<tr>
<td>Feline Transfusion Therapy - Blood Compatibility and Xenotransfusion</td>
<td>Urs Giger, DECVIM-CA, DECVC, DACVIM-SAIM</td>
</tr>
<tr>
<td>Canine Transfusion Therapy - Blood Compatibility Testing Considering New Kits and Blood Types</td>
<td>Urs Giger, DECVIM-CA, DECVC, DACVIM-SAIM</td>
</tr>
</tbody>
</table>
Use of Meteorologic Data to Predict Parasite Spreads, Should We Expect More in the Future?
Eric R. Morgan, MA, VetMB, PhD, DEVPC, MRCVS
School of Veterinary Sciences, University of Bristol, Bristol, UK

KEYNOTE MESSAGE

Increasing availability of weather data from surface and remote instrumentation, and better tools for collecting georeferenced data on animal disease, combine to create unprecedented opportunities to map and understand parasite spread. In this session, example attempts to respond to this opportunity will be presented, for parasites of large and companion animals. The strengths and limitations of different approaches will be discussed. In particular, the shortcomings of purely statistical models for parasite spread will be highlighted in the context of global climate change, and lack of unbiased data for companion animals. Awareness of these limitations is important for critical appraisal of increasingly popular climate change projections for disease. One solution is sounder mechanistic underpinning models, which can be validated by but not entirely calibrated on disease occurrence data. Models for the spread of heartworm, Dirofilaria immitis, provides examples of good practice in this area, but necessary biological data are often missing for companion animal parasites, and take time and funding to obtain. We should, therefore, expect more predictive models of parasite spread in future; but we should also expect more from them, including more transparent communication of model assumptions, and proper attempts to validate predictions. Practitioners should be suitably sceptical of predictions that fail to take these steps, and also have an important role in providing independent data to validate models. Better data collection and collation are needed if stronger models are to be developed; new technologies make this possible, but still require the will of practitioners who are often too busy to see the benefit.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Eric R. Morgan, MA, VetMB, PhD, DEVPC, MRCVS
School of Veterinary Sciences
University of Bristol
Bristol, UK

URL: http://www.vin.com/doc/?id=8172761
The cardiopulmonary nematode of dogs, *Angiostrongylus vasorum*, has apparently spread rapidly through Europe in the past couple of decades. This pattern has been partly driven by increased awareness of the parasite, new diagnostic tools, and investment in large prospective studies. Longitudinal studies in foxes on Great Britain, however, show that spread is real and not concocted, and anecdotal data elsewhere in Europe also suggest genuine spread. Climate seems to be a strong influence on observed global distribution, with exclusion from areas too cold in winter or too dry in summer. In Europe, it could be that the parasite is gradually expanding into its climatic envelope, and/or that the envelope is expanding as a result of global warming. This session will address climatic and other factors that might influence the spread of *A. vasorum* through Europe. Increasing urban fox populations in the wake of successful elimination of rabies, accelerating dog movements, and changes in communities of gastropod mollusc intermediate hosts are all hypothetically linked to range expansion and higher prevalence in endemic areas. Observed patchiness in distribution might be explained by mode of spread, or unequal sampling effort. Progress has been made in understanding the core climatic drivers of parasite transmission, but these are strongly modified by host factors; for example, recent data suggest that infection of snails drives changes in behaviour that subsequently alter parasite development rate. Integrating climatic and host drivers of transmission and spread provides a significant scientific challenge, which will take time to provide definitive answers. Forces leading to the emergence of *A. vasorum* could also vary locally, so a unified explanation might not be possible. Nevertheless, some general patterns are apparent and should guide practitioner strategies for managing the disease.

Key References

Parasitic nematodes infecting the respiratory tract of domestic cats are attracting increased attention in feline clinical practice. In addition to the most commonly recognised 'cat lungworm' *Aelurostrongylus abstrusus* and the well-known *Capillaria aerophila*, other parasites (e.g., *Troglostrongylus brevior*) have been recently acknowledged as important respiratory pathogens of cats. Feline lungworms are being increasingly diagnosed in various geographic areas and a continuous update on epizootiological modifications and advances in diagnosis, therapy, and control is of pivotal importance. In this talk, current knowledge of lungworms affecting cats will be summarised, along with a discussion of recent findings and insights into clinical and diagnostic features of the diseases they cause. The talk will also explore current and potential new avenues for management and control of feline parasitic respiratory diseases.

Key References


**Speaker Information**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**Donato Traversa, DVM, PhD, DEVPC**

University Veterinary Teaching Hospital
University of Teramo
Italy

URL: [http://www.vin.com/doc/?id=8172763](http://www.vin.com/doc/?id=8172763)
Are Dirofilaria Infections Really Spreading Throughout Europe? Epidemiology, Clinical Concerns and Prevention

Claudio Genchi, DVM, PhD, DEVPC
Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Italy

Key Reference Message

Dirofilaria immitis and D. repens are the most important filarial infections of the dog. Dirofilaria immitis is the causative agent of a very severe cardiopulmonary disease (heartworm disease), while D. repens is the agent of the subcutaneous dirofilariasis. Microfilaraemic dogs are the main reservoir (most infected cats are not microfilaraemic), able to infect the mosquito vectors. Both parasites are zoonotic; however, the number of D. repens human infections in Europe is much greater than that caused by D. immitis (more than 3,400 human cases vs. about 25, respectively). Since the last decades, both infections have spread from the endemic areas of southern Europe towards northern and northeastern regions as a consequence of changing climate and the movement of microfilaraemic dogs. This trend is much more noticeable in the case of subcutaneous dirofilariasis, as confirmed by the continuous increase of human infections, in some case causing severe conditions. The only way to decrease the risk for humans is the prevention and the control of the infection in dogs. On the contrary of heartworm infections, quite always symptomatic, D. repens is like a ghost. Most infections are subclinical, no specific signs of infection (sometimes nodules or alopecia) and no serological tests to assess the presence of the parasite. The only way for the diagnosis is the blood examination for circulating microfilariae (Knott test). A further problem is that not all the macrocyclic lactones currently used for the prevention of heartworm are fully effective against D. repens. Until now, only moxidectin has shown a complete efficacy in the prevention of patent infections, full efficacy against circulating microfilariae, and more than 90% of efficacy against the adult worms.

Key References

Speaker Information
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

Claudio Genchi, DVM, PhD, DEVPC
Department of Veterinary Medicine
Università degli Studi di Milano
Milano, Italy

URL: http://www.vin.com/doc/?id=8172764
The Emergence of Macrocyclic Lactone Resistance in *Dirofilaria immitis*: Identification and Risk Assessment

Roger K. Prichard, BSc, PhD, DHCH, DEVPC  
Institute of Parasitology, McGill University, Montréal, QC, Canada

**Keynote Message**

Concerns about cases of possible lack of efficacy (LOE) of macrocyclic lactone (ML) heartworm preventives emerged in USA about 15 years ago. However, it was initially unclear as to whether most or all of the LOE cases were due to a lack of compliance with monthly heartworm preventive treatment in endemic regions. However, detailed *in vivo* clinical studies, with heartworm preventives administered as recommended, have confirmed that ML resistance has emerged in *Dirofilaria immitis* in North America. The *in vivo* studies have been supplemented with genome-wide association studies in which ML-resistant populations of the parasite have been compared with susceptible populations in order to determine genetic markers which may be useful for confirming resistance and for epidemiological surveys. The confirmed resistant populations show a number of distinct genetic changes. Most of the confirmed resistance and LOE cases appear to be confined, at present, to the southern regions of the USA where dirofilariasis is hyperendemic. However, it has been shown that dogs can carry resistant parasites to other regions. To date, clear evidence of transmission of resistance in regions out of the southern USA has not been shown. As MLs are the only class of anthelmintics effective for prevention of heartworm disease, and all members of this class (ivermectin, milbemycin oxime, selamectin, moxidectin) are affected by the resistance, the emergence of ML resistance is of particular concern for preventing heartworm disease. Work is ongoing to develop an *in vivo* microfilarial reduction test as a surrogate for identifying cases of ML resistance, as well as to validate the genetic markers against more isolates confirmed as susceptible or resistant to ML heartworm preventives. Treatments to remove established adult infections, not involving "slow-kill" with ML anthelmintics, such as the use of Immiticide, or anti-*Wolbachia* therapy using doxycycline, appear to remain effective.

**Key References**


**Speaker Information**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Roger K. Prichard, BSc, PhD, DHCH, HDipEVPC  
Institute of Parasitology  
McGill University  
Montréal, QC, Canada

URL: http://www.vin.com/doc/?id=8172765
What Have *Dirofilaria* and *Wolbachia* Taught Us About Endosymbiotic Relationship?

Claudio Genchi, DVM, PhD, DEVPC
Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Italy

**KEYNOTE MESSAGE**

The history of bacterial endosymbiosis in *Dirofilaria* worms begins more than 30 years ago, when the presence of dense bodies within the reproductive organs and microfilariae of *D. immitis* was observed. Later, they were identified as intracellular, gram-negative microorganisms and it was found that such microorganisms were transovarially transmitted in adult worms. In 1995, these microorganisms were identified as bacteria belonging to the genus *Wolbachia* and subsequently, *Wolbachia* was observed in representatives of several filarial pathogenic genera and species (*Onchocerca, Brugia, Wuchereria*). These endosymbiont bacteria are phylogenetically close to rickettsiae and are transovarially transmitted to microfilariae. Because of the bacterial nature of the symbiont, antibiotic treatment is able to deplete bacteria from the worms leading to sterility of females, death of microfilariae, and eventually of adult worms. Furthermore, the discovery of *Wolbachia* endosymbiosis on filarial worms has opened the way to a new understanding of pathogenesis and immune response of filarial diseases, both in humans and animals. The immunopathology of filarial disease is extremely complex and the clinical manifestations of infection are strongly dependent, not only on the type of immune response elicited by the parasite, but also on the presence of *Wolbachia* in the infected host. Furthermore, the fact that adult parasites can survive for years in otherwise immune-competent hosts is likely a consequence of the *Wolbachia*-mediated parasite's ability to avoid/modulate the immune response. Current field and experimental studies have demonstrated that treating with antibiotic drugs in association with a macrocyclic lactone effective against heartworms is able to decrease the risk of thromboembolism caused by the inflammatory reaction mediated by the endosymbiont bacteria released by dying worms and that such a regimen is highly effective in eliminating adult worms.

**Key References**


**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Claudio Genchi, DVM, PhD, DEVPC
Department of Veterinary Medicine
Università degli Studi di Milano
Milano, Italy

**URL:** [http://www.vin.com/doc/?id=8172766](http://www.vin.com/doc/?id=8172766)
Microcirculation and the Glycocalyx: Does It Matter?
Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC
College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA, Australia

Keynote Message
The endothelial glycocalyx (EG) is a carbohydrate-rich scaffold of proteoglycans and glycosaminoglycans on the luminal surface of vascular endothelial cells. It maintains barrier function, prevents cellular adhesion by ‘hiding’ glycoproteins, and contains anticoagulants to maintain an anticoagulant phenotype. It is likely that shedding of the EG is one of the first steps in systemic inflammation and activation of coagulation, which then allows interactions between endothelial cells and circulating leucocytes and platelets. Systemic inflammatory diseases and various medical interventions, including IV fluid therapy, may damage the EG, compromising its function. Recently, it has been shown that fluid movement out of the vascular space is heavily influenced by the integrity of the EG rather than simple pressure dynamics (Starling's forces) and that damage to the EG promotes extravasation of fluid. This may be the preceding step to interstitial edema and organ compromise in critically ill patients. This lecture will review our understanding of the microcirculation and EG and make suggestions as to how this knowledge can be translated into our clinical practice.

Key References

Speaker Information
Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC
College of Veterinary Medicine, School of Veterinary and Life Sciences
Murdoch University
Murdoch, WA, Australia
URL: http://www.vin.com/doc/?id=8172767
Colloids in Small Animals - What’s the Evidence?
Katja-Nicole Adamik, Dr. med. vet., DACVECC, DECVECC
Small Animal Clinic, Vetsuisse-Faculty University of Bern, Bern, Switzerland

KEYNOTE MESSAGE

Until now, no official guidelines or consensus statement are available about the handling and use of hydroxyethyl starch (HES) or other synthetic colloids in small or large animals. However, according to an international survey in small animal medicine from May 2016 performed by the author, besides crystalloids, HES preparations were used by a high percentage of the respondents for fluid resuscitation and shock, as well as for colloid osmotic pressure support (unpublished data). Only a small percentage of veterinarians are using gelatin or dextran products. It is therefore of importance to elucidate the effects and side effects of HES in companion animals. The two most investigated side effects in small animals are impairment of global haemostasis and acute kidney injury (AKI).  

According to the available literature on haemostasis impairment, HES preparations lead to a significant impairment of platelet function and coagulation. By using viscoelastic methods in some of the studies, a better characterization of the specific effect on clot formation is possible, revealing a prolonged clot formation speed, a reduced fibrin polymerization, and a decreased clot strength. Notably, no effect beyond dilution with the comparator fluid could be demonstrated by some investigators, and in several in vivo studies the effects of HES were only short lived (some hours).

Studies investigating potential adverse renal effects of HES solutions are rare in dogs and cats. Most of them are retrospective and based on the evaluation of change in creatinine concentrations. Four retrospective studies could not demonstrate AKI after administration of 6% HES 130/0.4 in dogs or cats, whereas one study found HES therapy to be associated with increased risk of death or AKI in dogs receiving 10% HES-250/0.5

In this session, the existing evidence about synthetic colloids, mainly HES, will be discussed.

Keynote References


Prepared for ECVIM-CA 2017 Proceedings on August 28, 2017
Copyright 2017, 27th ECVIM-CA Congress and Authors - all rights reserved. Reproduction or bulk printing in whole or in part without permission is prohibited.
Fluid status and fluid responsiveness remain hot topics of debate in emergency and critical care. The concept of initial stabilisation using high volume boluses of crystalloids and/or colloids to improve tissue perfusion and oxygenation has become commonplace. However, not all shock patients will benefit from these large volumes (think of patients already having a normal volume status, or patients suffering from cardiac disease or dysfunction).

Moreover, even for patients in which a or some boluses improve cardiac output, tissue perfusion and hence oxygenation, the de-escalation and avoidance of overzealous crystalloid administration avoids destruction of the glycocalyx and helps to preserve the microcirculation. Therefore, proper evaluation of fluid responsiveness is essential to help improve patient outcome even further.

As proper use of fluids saves lives, some proper knowledge on how to monitor fluid status and fluid responsiveness is key to any practitioner confronted with ECC patients, and undoubtedly also to internists.

In this session, an overview of past, current, and future methods to assess volume status and volume responsiveness in human and veterinary medicine will be given. This session will then focus on the use of ultrasonography to guide fluid therapy and initial stabilisation in small animal medicine, and this technique will be illustrated with some clinical case scenarios.

Key References

Speaker Information
Kris Gommeren, PhD, DECVIM-CA
Small Animal Emergency and Critical Care
Liège University
Liège, Belgium
URL: http://www.vin.com/doc/?id=8172769
Initial Stabilisation via Early Goal-Directed Fluid Therapy
Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC
College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA, Australia

KEYNOTE MESSAGE

Early identification and treatment of shock is imperative to a successful outcome in affected patients. Treatment for shock aimed at improving oxygen delivery to the tissues should always be goal directed. Goal-directed resuscitation includes consideration of optimizing cardiac output by optimizing stroke volume, as well as arterial oxygen content. There is no single goal of successful resuscitation, rather a combination of parameters is monitored to guide when resuscitation has been adequate or to adjust resuscitation to meet the patients’ needs. For the majority of resuscitation efforts in veterinary medicine, our goals are restoration of normal physical exam perfusion parameters and improvement in easily measured indicators, such as blood pressure and lactate. Recent evidence in human medicine suggests that these goals may be adequate as long as the patient is continually reassessed and treatment adjusted accordingly. This lecture will review the literature regarding early goal-directed therapy in human medicine and more recent literature of pragmatic randomized clinical trials of fluid resuscitation, including a discussion of how evidence in the human literature can be applied to veterinary medicine.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC
College of Veterinary Medicine, School of Veterinary and Life Sciences
Murdoch University
Murdoch, WA, Australia
URL: http://www.vin.com/doc/?id=8172770
Cats are typically transfused for anaemia and far less commonly for coagulopathies. The AB blood group system is the major blood group system in cats. Type A is most commonly seen, while the type B frequency varies geographically and among breeds from 0 to 50%. The A allele is dominant over the B allele. Type AB appears to be generated by a separate allele and except for a few geographic areas and Ragdolls appears to be extremely rare. The function of the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) is responsible for the three types, albeit at the molecular level there is further heterogeneity. Simple and accurate typing and crossmatch kits are available to assure blood compatibility.

In contrast to canine transfusion therapy, the recruitment of feline donors has been hampered by their small size, occult infectious diseases, and need for sedation. Therefore, xenotransfusions with canine blood have been used, but studies have shown major blood incompatibilities and extremely short survival (<4 days) of transfused canine cells, and, therefore, cannot be recommended.

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Urs Giger, DECVIM-CA, DECVCP, DACVIM-SAIM
Section of Medical Genetics
University of Pennsylvania
Philadelphia, PA, USA

URL: http://www.vin.com/doc/?id=8172771
Canine Transfusion Therapy - Blood Compatibility Testing Considering New Kits and Blood Types

Urs Giger, DECVIM-CA, DECVCP, DACVIM-SAIM
Section of Medical Genetics, University of Pennsylvania, Philadelphia, PA, USA

Keynote Message

Blood transfusions have become an integral part in the support of anemic and bleeding. Veterinary clinicians and clinical pathologists play a key role in providing safe and effective transfusion therapy. Blood typing is clinically important to ensure blood compatibility and therefore is recommended for any dog in need of a transfusion or considered to become a blood donor. Dog erythrocyte antigen (DEA) 1 is considered the main blood group system with DEA 1- and weakly to strongly DEA 1+ dogs. Other typing is done on a more limited basis for DEA 3, 4, 5, & 7 and the more recently identified antigens Dal and Kai 1 & 2. The presence and clinically importance of naturally occurring anti-DEA 7 alloantibodies is being debated. However, all previously transfused dogs also should be crossmatched. Clinically acute haemolytic transfusion reactions have only been observed in previously transfused dogs and related to DEA 1, 4 and Dal. Simple and accurate typing and crossmatch kits are available to assure blood compatibility and are the focus of this presentation.

Key References

Speaker Information
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

Urs Giger, DECVIM-CA, DECVCP, DACVIM-SAIM
Section of Medical Genetics
University of Pennsylvania
Philadelphia, PA, USA

URL: http://www.vin.com/doc/?id=8172772
ESVNU - European Society of Veterinary Nephrology and Urology

Oral Presentations
Poster Presentations
Scientific Programme
Oral Presentations

Fibroblast Growth Factor 23 and Symmetric Dimethylarginine in Feline Chronic Kidney Disease  
H.J. Sargent

Immunohistochemical Staining of A-Klotho Protein in Feline Kidney Tissue  
D.H.N. van den Broek

Symmetric Dimethylarginine (SDMA) Compared to Creatinine for Detection of Decreased GFR in 97 Dogs with Stable Kidney Function  
L. Pelander

SDMA in Hyperthyroid Cats Before and After Treatment with Radioiodine  
E. Buresova

Interleukin 6 and Interleukin 18 as Markers of Kidney Injury in Dogs  
H. Chen

Symmetric Dimethylarginine (SDMA) Compared to Creatinine for Detection of Decreased GFR in 97 Dogs with Stable Kidney Function  
L. Pelander

Prevalence of Urinary Tract Infection in Dogs with Chronic Kidney Disease: A Retrospective Study of 201 Cases  
A. Lamoureux

Virulence and Antimicrobial Resistance of Escherichia coli Sequence Type 131 H30 and Other Human Pandemic Clones Spreading in Companion Animals  
C. Pomba

Urinary Biomarker Concentrations in Canine Urinary Tract Infections  
O.M. Russak

Evolution of Ionised Calcium Concentration Over Time in Cats with Ureteral Obstruction: 39 Cases  
Melanie Garcia

Urinary Findings Suggesting Early Renal Involvement in Cats with Feline Morbillivirus Infection  
P.E. Crisi

Effects of a Non-absorbent Litter on Urinalysis Results in Cats  
B.S. Reynolds

Determining the pH in Canine Urine: Comparing Visual and Automated Reading Variability of Urine Dipstick Analysis Within a Small Animal Teaching Hospital  
Marta Garcia

Assessment of Kidney Injury in Canine Parvoviral Infection by Comparing Novel Urinary Kidney Injury Biomarkers with Routine Renal Functional Parameters  
M.F. van den Berg
**Fibroblast Growth Factor 23 and Symmetric Dimethylarginine in Feline Chronic Kidney Disease**

H.J. Sargent; J. Elliott; Y.M. Chang; R.E. Jepson
Royal Veterinary College, London, UK

The diagnosis of chronic kidney disease (CKD) in cats is currently made using creatinine as an indirect marker of glomerular filtration rate (GFR), together with historical and clinical information and evaluation of urine concentrating ability. However, creatinine is recognised to be insensitive for the early decline in GFR. Symmetric dimethylarginine (SDMA) is a novel biomarker of GFR, with studies suggesting it may be more sensitive than creatinine in detecting this early decline. Fibroblast growth factor 23 (FGF-23) is a phosphaturic hormone known to increase with declining GFR and has been shown to be predictive of the onset of azotemia in cats >9 years, indicating disturbed phosphate homeostasis.

The introduction of SDMA, has led to the identification of cats where SDMA is increased but plasma creatinine remains within reference interval (RI). There is currently little understanding of the metabolic changes present in these cats. The aim of this study was to examine the relationship between plasma FGF-23 and SDMA concentrations in non-azotemic geriatric cats.

Clinicopathological information from cats (≥8 years) was sourced from the records of two first opinion practices. Cats with a current or historical diagnosis of azotemic CKD (creatinine >177 µmol/L), a serum thyroxine >40 nmol/L or other chronic disease were excluded. Cats were categorised into two groups: elevated SDMA (>14 µg/dl) and SDMA within RI (≤14 µg/dl). Stored samples were used to quantify FGF-23 in all cats. Data are presented as median [25th, 75th percentile]. Comparisons were made between groups using Mann-Whitney U tests and relationships between numerical variables were evaluated using Spearman's correlation.

Twenty-eight cats with elevated SDMA (17 [16, 19] µg/dl) and 61 cats with SDMA within reference interval (11 [10, 12] µg/dl) were included. Cats with elevated SDMA had significantly higher FGF-23 (377.7 [202.6, 610.9] pg/ml vs. 219.6 [143.2, 295.1] pg/ml, p= 0.003) and creatinine (156 [141.8, 171.5] µmol/L vs. 128 [109, 148] µmol/L, p< 0.001) concentrations. Phosphate concentration did not differ between groups (p = 0.593). A weak positive relationship was demonstrated between FGF-23 and SDMA (r_S=0.34, p=0.001) and between FGF-23 and creatinine (r_S=0.23, p=0.03).

Cats with elevated SDMA had higher FGF-23 concentrations than those with SDMA within RI suggesting the presence of alteration in phosphate homeostasis despite no significant difference in plasma phosphate concentrations. Further studies are required to identify factors influencing this relationship and the utility of FGF-23 concentration to inform management of cats with early stage CKD.

**DISCLOSURES**

Disclosures to report:

H.J. Sargent and Y.M. Chang have no conflicts of interest to declare. J. Elliott received funding from Consultancies: Elanco Ltd, CEVA Animal Health Ltd, Boehringer Ingelheim Ltd, Bayer Animal Health, Orion Incorp, Idexx Ltd, Nextvet Ltd, Waltham Centre for Pet Nutrition; grant funding from Elanco Ltd, Waltham Centre for Pet Nutrition, Royal Canin Ltd, Zoetis Ltd, CEVA Animal Health, Member of the International Renal Interest Society which receives a grant from Elanco Ltd. R. Jepson received funding from PetPlan, Feline Foundation for Renal Research, RVC Internal Grant, PetSavers, and consultancy agreements: Boehringer Ingelheim, Merial. Speaking honoraria: Boehringer Ingelheim, Hills Pet Nutrition.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

H.J. Sargent
Royal Veterinary College
London, UK

URL: [http://www.vin.com/doc/?id=8127717](http://www.vin.com/doc/?id=8127717)
Immunohistochemical Staining of A-Klotho Protein in Feline Kidney Tissue

D.H.N. van den Broek; J.S. Lawson; R. Chang; J. Elliott; R.E. Jepson
Royal Veterinary College, London, UK

Renal a-klotho functions as a co-receptor for fibroblast growth factor 23 (FGF-23) and therefore plays an important role in phosphate homeostasis. The transmembrane protein is primarily found in the renal tubules and its expression is reduced in patients with chronic kidney disease (CKD). In human studies and animal models, a-klotho deficiency has been associated with hyperphosphataemia, renal fibrosis, and increased mortality. Chronic kidney disease is a common disorder in ageing cats, with hyperphosphataemia and FGF-23 excess as important prognostic indicators, but the role of a-klotho has not been assessed in cats to date. Therefore, we aimed to localize renal a-klotho protein in feline kidney tissue.

Formalin-fixed paraffin-embedded sections of post-mortem kidney tissue from cats with varying kidney function were immunohistochemically stained using a rabbit polyclonal anti-a-klotho antibody (1:2000 dilution, anti-klotho antibody, ab203576, Abcam, Cambridge, UK) and visualized with an immunoenzymatic antigen detection system (rabbit specific HRP/DAB detection kit, ab64261, Abcam, Cambridge, UK). Mouse kidney sections were used as a positive control, and feline kidney sections incubated with isotype-specific immunoglobulins as a substitute for the primary antibody served as a negative control for staining specificity. Sections were counterstained with hematoxylin. Western blot analysis was performed on feline renal tubular cell lysate to assess molecular size of the antibody-bound protein.

Western blot analysis showed the primary antibody bound a single antigen of 120–130 kDa in size, which is the appropriate molecular size for a-klotho. No positive staining was detected in the negative isotype control sections, confirming the specificity of the staining for a-klotho. Alpha-klotho protein expression was identified immunohistochemically both in the proximal and distal tubules of murine and feline kidney tissue, with more intense staining of the distal tubules compared to the proximal tubules.

Renal a-klotho protein expression in cats shows similarities to its expression reported in other species. Further work is necessary to investigate if loss of a-klotho expression occurs in feline CKD and how this relates to renal fibrosis and mineral and bone disorder in cats with CKD.

DISCLOSURES

Disclosures to report:
D.H.N. van den Broek, J.S. Lawson and Y.-M. Chang have no conflicts of interest to declare. J. Elliott received funding from Consultancies: Elanco Ltd, CEVA Animal Health Ltd, Boehringer Ingelheim Ltd, Bayer Animal Health, Orion Incorp, Idexx Ltd, Nexvet Ltd, Waltham Centre for Pet Nutrition; grant funding from Elanco Ltd, Waltham Centre for Pet Nutrition, Royal Canin Ltd, Zoelis Ltd, CEVA Animal Health, Member of the International Renal Interest Society which receives a grant from Elanco Ltd. R. Jepson received funding from PetPlan, Feline Foundation for Renal Research, RVC Internal Grant, PetSavers, and consultancy agreements: Boehringer Ingelheim, Merial. Speaking honoraria: Boehringer Ingelheim, Hills Pet Nutrition.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

D.H.N. van den Broek
Royal Veterinary College
London, UK

URL: http://www.vin.com/doc/?id=8172724
Symmetric Dimethylarginine (SDMA) Compared to Creatinine for Detection of Decreased GFR in 97 Dogs with Stable Kidney Function

L. Pelander1; J. Hägström1; R. Heiene2; H. Syme3; J. Elliott3; I. Ljungvall1

1Swedish University of Agricultural Sciences, Uppsala, Sweden; 2Evidensia Norra Halland, Kungsbacka, Sweden; 3Royal Veterinary College, North Mymms, UK

Early detection of decreased glomerular filtration rate (GFR) in dogs is difficult. Current methods are insensitive and reference ranges are wide. More sensitive biomarkers are warranted. The aim of this study was to investigate the usefulness of the new marker symmetric dimethylarginine (SDMA) in comparison with creatinine for detection of decreased GFR in dogs with and without a stable diagnosis of chronic kidney disease (CKD).

Ninety-seven client-owned dogs were prospectively included into the study, 67 dogs with a diagnosis (or a strong suspicion) of CKD, and 30 healthy dogs. All dogs underwent physical examination, blood pressure measurements, urinalysis, hematology and blood biochemistry, cardiac and urinary ultrasound examinations, and scintigraphy for calculation of glomerular filtration rate (mGFR). Decreased mGFR was predefined as <30.8 ml/min/L and it was normalized to estimated extra-cellular plasma volume (ECFV) instead of body weight because of less dependency on hydration status of the dog. Estimation of ECFV was performed according to routine using the Rutland-Patokl plot, a mathematical model that describes the transfer of 99mTc-Technetium-DTPA from the blood compartment to the renal compartment.

Creatinine and SDMA were positively correlated (r=0.82). The reciprocal of creatinine and SDMA were both linearly correlated with GFR (R²=0.62 and 0.55, respectively). The sensitivity of creatinine and SDMA at their pre-specified cut-offs (46–115 µmol/L and 0–14 µg/dl, respectively) for detection of an abnormal GFR was exactly the same (89.7%) in the dogs of this study. The specificity was 89.7% for creatinine and 86.8% for SDMA.

In conclusion, the diagnostic performance of creatinine and SDMA, when using their pre-specified cut-offs, for detection of a decreased GFR in the dogs of this study was similar.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

L. Pelander
Swedish University of Agricultural Sciences
Uppsala, Sweden

URL: http://www.vin.com/doc/?id=8172725
Increased glomerular filtration rate (GFR) and decreased muscle mass make identification of chronic kidney disease (CKD) in hyperthyroid cats challenging. Symmetric dimethylarginine (SDMA) is a promising indirect renal biomarker that correlates closely with GFR in healthy geriatric and CKD cats. The aim of this study was to evaluate SDMA reliability as a renal biomarker in hyperthyroid cats. Forty-seven client-owned hyperthyroid non-azotemic (creatinine <168 μmol/l) cats were prospectively enrolled and treated with radioiodine ($^{131}$I). Antithyroid medication was discontinued 10 days prior to $^{131}$I treatment. Cats had to be free of any other medication at least for 14 days prior to $^{131}$I treatment and free of any other clinically relevant systemic disease. Creatinine and SDMA (IDEXX SDMATM Test) were determined before (T0) and 1 month after (T1) treatment. GFR (plasma exogenous creatinine clearance test) was measured at T0 and T1 in 10 of 47 cats. As expected, creatinine significantly increased ($p<0.001$) and GFR significantly decreased ($p<0.001$) after $^{131}$I treatment. SDMA did not significantly change over time ($p=0.37$). Only 1 cat became azotemic (creatinine >168 μmol/l) at T1 while having normal SDMA at both time points. SDMA was elevated (>14 μg/dl in 6 of 47 cats at T0 and normalised after treatment in 4 cats. GFR was available in 1 of these 6 cats and was within normal limits (SDMA normalised at T1). SDMA at T1 was increased above 14 μg/dl in 1 cat with borderline low GFR which was defined as GFR <1.9 ml/min/kg. Pearson correlation (n=10) between GFR and SDMA was moderate to low ($r=-0.48, p=0.16$ at T0 and $r=-0.36, p=0.31$ at T1) and correlation between GFR and creatinine was moderate ($r=-0.54, p=0.11$ at T0 and $r=-0.51, p=0.13$ at T1). Forty of forty-one cats with pre-treatment SDMA within reference interval remained non-azotemic post-treatment. However, not enough patients became azotemic post-treatment to evaluate if SDMA can predict post-treatment renal azotemia. Previous studies showed that SDMA is a promising renal biomarker but further studies are necessary to more fully assess its utility in feline hyperthyroidism.

DISCLOSURES
Disclosures to report:
This study was supported by Idexx laboratories.

SPAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

E. Buresova
Faculty of Veterinary Medicine
Ghent University
Merelbeke, Belgium

URL: http://www.vin.com/doc/?id=8172726
Available markers of acute kidney injury (AKI) lack sensitivity and specificity; consequently, diagnosis of AKI is delayed and Grade-I AKI is commonly unrecognized. We hypothesized that urinary interleukin (IL) 6 (IL-6) and 18 (IL-18) are sensitive and specific markers of AKI. Urine samples from healthy dogs, dogs with lower urinary tract disease (LUTD), chronic kidney disease (CKD), acute kidney injury (AKI) and at risk for AKI, were collected. Urine concentrations of IL-6 and 18 were measured using ELISA and corrected to urinary creatinine (uIL-6,18/uCr). Sixty-six dogs were included. There was a positive correlation between IL-6 and IL-18 (p<0.001, r=0.65). Median uIL-6/uCr of healthy, LUTD, CKD, AKI and dogs at risk were 0.026 pg/mg (range: 0.01–2.28), 0.04 pg/mg (range: 0.02–2.93), 0.08 pg/mg (range: 0.04–8.28), 0.46 pg/mg (range: 0.06–58.05) and 6.5 pg/mg (range: 0.04–19.74), respectively. Median uIL-18/uCr was 0.025 pg/mg (range: 0.01–0.14), 0.03 pg/mg (range: 0.02–0.26), 0.08 pg/mg (range:0.03–4.29), 0.32 pg/mg (range:0.01–5.38) and 0.12 pg/mg (range: 0.03–0.95), respectively. There was a significant difference in uIL-6/uCr and uIL-18/uCr among the study groups, with both higher in the AKI group compared with other groups, except uIL-18/uCr, which was not different between the AKI and CKD groups. Median uIL-6/uCr and uIL-18/uCr of dogs at risk for AKI, were higher compared with healthy dogs (p=0.034, p=0.045, respectively). ROC analysis of uIL-6/uCr and uIL-18/uCr as AKI predictors had an area under the curve of 0.85 and 0.78, respectively. uIL-6/uCr and uIL-18/uCr cut-off points of 0.11 and 0.13 were associated with sensitivity and specificity of 96% and 70%, respectively, and 83% and 70%, respectively. In conclusion, IL-6 and IL-18 are sensitive and specific markers of AKI.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

H. Chen
Koret School of Veterinary Medicine
Rehovot, Israel

URL: http://www.vin.com/doc/?id=8172727
Application of Novel Kidney-specific Biomarkers for Canine Kidney Diseases

G. Segev¹; I. Aroch²; F. Giosi²; J. Quinn³; M. Yerramilli³; A. Yochai²; M. Yerramilli³
¹Koret Scholl of Veterinary Medicine, Beit Hashmonai, Israel; ²Koret School of Veterinary Medicine, Israel; ³IDEXX Laboratories, Inc., Westbrook, ME, USA

AKI is associated with high mortality, partially due to its late recognition using available markers. Current research aims to identify new AKI biomarkers; however, their specificity is hampered when these are also expressed in extra-renal tissues. Recently, assays were developed for kidney-specific urinary clusterin (uClus) and serum and urine cystatin B (sCysB, uCysB, respectively). To assess their utility, 40 dogs were recruited and categorized to healthy controls, chronic kidney disease (CKD), AKI and UTI.

Median uClus/uCr was 40 ng/mg (range 3–157), 43 (12–6189), 1740 (391–11834) and 6964 (102–69855) in control, UTI, CKD and AKI groups, respectively. It differentiated control and AKI (receiver operating [ROC] area under curve [AUC] 0.96, CI95%, 0.88–1.00). ROC analysis applied to all dogs, had an AUC of 0.86, (CI95%, 0.72–0.97). A cut-off of 3380 ng/mg resulted in 80% sensitivity and 90% specificity. Median sCysB was 206 ng/ml (range 113–291), 608 ng/ml (200–1478) and 1763 ng/ml (604–4175), in control, CKD and AKI groups, respectively. It differentiated control and AKI (AUC 1.0, CI95% 1.00–1.00). ROC analysis applied to all dogs showed AUC of 0.91 (CI95% 0.79–1.00). A 700 ng/ml cut-off, gave 88% sensitivity and 86% specificity. ROC analysis of uCysB comparing AKI to all other groups gave an AUC of 0.87 (CI95% 0.74–1.00). A 485 ng/ml cut-off was associated with sensitivity and specificity of 79% and 83%, respectively.

In conclusion, these novel kidney-specific biomarkers differentiated AKI from healthy controls and other urinary tract conditions. Their specificity is a major advantage compared to previously reported biomarkers.

DISCLOSURES

Disclosures to report:

Farace, J. Quinn, M. Yerramilli, M. Yerramilli are Employees of IDEXX Laboratories, Inc., Westbrook, ME, USA

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

G. Segev
Koret School of Veterinary Medicine
Beit Hashmonai, Israel

URL: http://www.vin.com/doc/?id=8172728
Prevalence of Urinary Tract Infection in Dogs with Chronic Kidney Disease: A Retrospective Study of 201 Cases

A. Lamoureux¹; F. Da Riz²; J.L. Cadoré¹; E. Krafft¹; C. Maurey²

¹VetAgro Sup, Campus Vétérinaire de Lyon, Marcy l’Etoile, France; ²Université Paris Est, École Nationale Vétérinaire d’Alfort, Maisons Alfort, France

Studies have shown an increased prevalence of urinary tract infection (UTI) in cats with chronic kidney disease (CKD) but no information is available in dogs. The aims of our study were to determine the prevalence of UTI in a cohort of dogs with CKD and to investigate the impact of age, sex (including neuter status) and IRIS stage.

Dogs were retrospectively recruited from two veterinary teaching hospitals between January 2010 and June 2016 if they were diagnosed with CKD and had a culture performed on urine collected by cystocentesis. CKD was diagnosed in dogs with an increased blood creatinine concentration (≥125 µmol/L) and consistent clinical and/or ultrasonographic signs (azotemic dogs); and in dogs with a creatinine concentration <125 µmol/L but having renal proteinuria, minimally concentrated urine with ultrasonographic signs of CKD or abnormal renal histology (IRIS stage 1). Azotemic dogs were categorized in IRIS stages 2 to 4 if they had creatinine values measured at least two weeks apart, others were left unstaged. Dogs with diseases which could predispose to UTI or receiving treatment which could impact urinary specific gravity were excluded. Differences between groups were assessed using the Chi-square or the Mann-Whitney tests with statistical significance defined as p<0.05.

Two hundred and one dogs were included and 32% of them had a UTI. *Escherichia coli* was identified in 73% of them. Lower urinary tract signs were only reported in 9% of dogs with a UTI. Sixty-one azotemic dogs could not be staged and 41% of them had a UTI. Twenty-eight percent of dogs with stage 1, 44% of dogs with stage 2, 30% of dogs with stage 3 and 9% of dogs with stage 4 CKD had a UTI. Dogs with stage 4 had significantly less UTI than dogs in stage 2 or 3 (p=0.005 and 0.046, respectively). There was no significant difference between the other groups. No significant difference was found in the prevalence of UTI with age or neutering, but the prevalence of UTI was higher in females (46%) than in males (21%) (p=0.0003).

The prevalence of UTI in this population of dogs with CKD was 32% but most of them were asymptomatic. As already described, females were overrepresented. Because of this high prevalence, a urine culture could be recommended in any dog with CKD regardless of its age, sex and IRIS stage; even though the true clinical impact of this finding is currently unknown.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Lamoureux
VetAgro Sup
Campus Vétérinaire de Lyon
Marcy l’Etoile, France

URL: http://www.vin.com/doc/?id=8172729
Whole Genome Sequencing of *Escherichia coli* Isolated from the Urinary Tract of Individual Dogs Over Time

T. Johnstone; D. Bulach
Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, VIC, Australia

Phylogeny and antibiotic resistance profile (resistome) of urinary *E. coli* isolated from individual dogs at different time points were investigated to gain a better understanding of recurrent or persistent *E. coli* UTI. The microbiology database of the U-Vet Werribee Animal Hospital was screened for urinary *E. coli* isolated from dogs with at least two positive urine cultures. Comorbidities on the date of the respective urine culture were retrieved from the dogs’ medical records. *E. coli* strains were recovered from frozen storage banks and subjected to whole genome sequencing. The core genome of study strains was compared to reference strain ABU83097 and multi-locus sequence types (MLST) were identified. Strain resistomes were determined by searching genomes for 38 known antibiotic resistance genes. Seventy-six *E. coli* strains from 19 dogs were analysed. All dogs had conditions that predisposed to UTI and were treated with antibiotics after positive urine cultures. The number of examined *E. coli* strains per individual dog ranged from 2 to 8 (median 3.5); they had originally been recovered over a median time span of 146.5 days (range 9–2450 days). Overall, *E. coli* were phylogenetically diverse; 25 different MLST were recorded. Core genomes were 73.9–95.2% similar to the reference. None of the *E. coli* isolated had identical core genomes. However, in 18/19 dogs, 2 to 6 (median 2.5) *E. coli* with highly similar core genomes (with single nucleotide differences ranging from 25 to 457) were identified. These highly similar *E. coli* had originally been cultured from urine of affected dogs over a median time span of 84 days (range 7 to 602 days) and in 15/18 cases, all highly similar strains had identical resistomes over time. In 10 dogs, at least one strain that was phylogenetically different was also present; in 3 dogs, these strains were cultured between episodes with 2 highly similar strains. Thirty-five of 76 strains (46%) were phenotypically multi-drug-resistant (MDR). Up to 13 different antibiotic resistance genes (median 2.5) were identified. There was no apparent correlation between time point of strain isolation (i.e., late or early in disease) and MDR status. Results of this study suggest that the majority of *E. coli* isolated from the urine of dogs with comorbidities either belong to one evolving lineage, or that several highly similar lineages co-exist in any given dog. Changes in resistome were uncommon.

**DISCLOSURES**

Disclosures to report:

Dr Bulach is affiliated with Doherty Applied Microbial Genomics, The Doherty Institute, Melbourne, Australia. The laboratory work for this abstract was performed at the Doherty Institute, which is affiliated with the University of Melbourne.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Johnstone
Faculty of Veterinary and Agricultural Sciences
University of Melbourne
Werribee, VIC, Australia

URL: http://www.vin.com/doc/?id=8172730
Virulence and Antimicrobial Resistance of *Escherichia coli* Sequence Type 131 H30 and Other Human Pandemic Clones Spreading in Companion Animals

A. Belas; C. Marques; A. Franco; C. Pomba
Faculty of Veterinary Medicine, CIISA, University of Lisbon, Lisbon, Portugal

The fluoroquinolone-resistant (FQR) O25b-H30 subclone of *E. coli* sequence type 131 (ST131-O25b-H30), with its nested ESBL (CTX-M-15)-associated H30Rx subset, is the most global disseminated virulent B2 group *E. coli* multidrug-resistant lineage causing infection in humans. Within phylogenetic group D, the sequence type 648 complex (STc648) is another human increasingly resistance-associated *E. coli* lineage. This study aimed to detect and evaluate the prevalence of human pandemic clones among *E. coli* strains causing urinary tract infection in companion animals and to characterize their virulence and antimicrobial resistance.

For this study 298 *E. coli* (1999–2014) isolated from companion animals with urinary tract infection were studied regarding clonal background, virulence and antimicrobial resistance. Susceptibility towards sixteen antimicrobial agents was done by the disk diffusion. PCR-based assays were used to detect the phylogroup (A, B1, B2 and D), Pathogenicity associated-islands (PAIs) (n=8), urovirulence genes (n=8), antimicrobial resistance genes (n=13), the human pandemic *E. coli* ST131-O25b, O25b-H30, O25b-H30Rx and O16 lineages. Furthermore, all third-generation cephalosporin (3GC) resistant *E. coli* were typed for MLST in order to detect *E. coli* sequence type 648 complex. Regarding phylogenetic background the isolates were predominantly from group-B2 (55.4%, n=165/298), followed by group-A (16.1%, n=48/298), group-B1 (14.8%, n=44/298) and group-D (13.8%, n=41/298).

The group-B2 ST131-O25b and O16 lineages represented 10% (n=30/298) of all the uropathogenic strains and ST131-O25b-H30 was the most common 25.0% (n=7/28), all were MDR and FQR. The ST131-O25b-H30 most common pathogenicity and virulence-associated genes profiles were PAI I\text{cft073}-PAI IV\text{i536}-PAI II\text{cft073} (28.6%, n=2/7), ecp-papEF\text{eucD} (27.3%, n=3/7). About 43% of ST131-O25b-H30 strains (n=3/7) were the FQR H30Rx–\text{bla}_{CTX-M-15} producer subclone. Among the 3GC-resistant *E. coli* phylogroup D, the most represented lineage was the ST648 71.4% (n=10/14), followed by ST405, ST1775, ST57 and ST354 (7.1%, n=1/14 each). All ST648 isolates were MDR, \text{bla}_{CMY-2} producers and one had also \text{bla}_{CTX-M-9}. ST648 PAIs and virulence genes profiles belonged mostly to PAI I\text{cft073}-PAI IV\text{i536} (40.0%, n=4/10), PAI II\text{i536}-PAI I\text{cft073}-PAI IV\text{i536} (30.0%, n=3/10), and ecpA-papEF (70%, n=7/10), respectively.

In this study we report for the first time the detection of the worldwide-disseminated ST131-O25b-H30 virulent, MDR and FQR human clone and its CTX-M-15-H30Rx subclone in companion animals. The detection of human high-risk pandemic *E. coli* lineages causing UTI in companion animals besides the animal health problem is a great public-health concern.


DISCLOSURES

Disclosures to report:

With financial support of CIISA and FCT through Project UID/CVT/00276/2013. AB and CM hold FCT PhD grants SFRH/BD/113142/2015 and SFRH/BD/77886/2011.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Pomba
Faculty of Veterinary Medicine
CIISA
University of Lisbon
Lisbon, Portugal

URL: [http://www.vin.com/doc/?id=8172731](http://www.vin.com/doc/?id=8172731)
Diagnosis of canine urinary tract infections (UTI) is based on a positive urine culture and inflammatory sediment. In practice, culture and/or sediment analysis are not always performed prior to using antibiotics; which is at odds with rational prescribing. In-clinic measurement of biomarkers to specifically test for a UTI, would therefore be of great value. In humans, the concentration of a number of urinary biomarkers increases in UTI. As yet, these have not been evaluated in dogs to determine if they behave similarly.

Aim: to determine whether measuring inflammatory biomarkers in canine urine could correctly identify bacterial infection.

Hypothesis: CRP, IL-6, procalcitonin and lactoferrin concentrations in canine urine with confirmed infections are significantly increased compared with controls.

Specific canine ELISAs were developed for CRP, IL-6, procalcitonin and lactoferrin. These were selected given their association with UTI in human medicine. Assays underwent comprehensive validation prior to initiating this study.

The above biomarkers were measured in residual urine samples following routine urinalysis, from a cohort of dogs with confirmed UTI (n=25) and from a control cohort without UTI (n=26). Inclusion criteria for the UTI group was a positive urine culture and inflammatory urine sediment. Control samples had an inactive sediment and sterile culture. This study was approved by the establishment's ethical review committee.

For comparing non-parametric datasets, Mann-Whitney tests were performed; for multiple comparisons between non-parametric datasets, the Kruskall Wallis test was used.

There was a significant increase in CRP (p<0.009) and lactoferrin (p<0.018) concentrations between UTI samples and controls. Enterococci significantly increased CRP concentrations compared with Coliforms (p<0.008) and mixed bacterial populations (p<0.03). Enterococci significantly increased IL-6 concentrations compared with Coliforms (p<0.03). Enterococci significantly increased procalcitonin concentrations compared with mixed bacterial populations (p<0.0004). ROC curves were used to determine sensitivity and specificity for CRP and lactoferrin for detecting a UTI. A CRP cut-off of 1.87ng/ml, gave a sensitivity of 52% and specificity of 90%. A lactoferrin cut-off of 151.3ng/ml, gave a sensitivity of 80% and specificity of 100%. Combining CRP and lactoferrin gave a sensitivity and specificity of 100% for a UTI. Correlation between CRP and lactoferrin was excellent (r=0.95).

This pilot study demonstrates novel urine biomarkers, either alone or in combination, can identify UTI in dogs. Some bacteria increase the concentration of biomarkers in the urine more than others. These results demonstrate potential value in measuring urinary biomarkers in-clinic to screen urine samples for infection, improving antibiotic stewardship.

DISCLOSURES

Disclosures to report:

Dr Dunning has a consultancy role for AVACTA animal health. Dr Slater is Chief Scientific Officer for AVACTA animal health Dr's Moody and Barrass-Hemmens are assay development scientists employed by AVACTA animal health.
Evolution of Ionised Calcium Concentration Over Time in Cats with Ureteral Obstruction: 39 Cases

M. Garcia1; M. Manassero2; M. Canonne-Guibert2; V. Fabres2; M. Menard2; G. Benchekroun2; C. Maurey2

1École Veterinaire d'Alfort, Maisons Alfort, France; 2National School of Alfort, Maisons Alfort, France

Calcium oxalate (CaOx) ureterolithiasis has emerged as a cause of feline ureteral obstruction (UO) in the last few years. Several risk factors of UO were identified including hypercalcemia. One study showed that hypocalcemia is frequent in cats with urethral obstruction and hyperphosphatemia has been hypothesized as a causal factor. The aim of this retrospective study was to assess how ionized calcium concentration (iCa) varies in cats with UO after UO management.

Cats with UO (group 1) in which iCa was measured at least three times over a minimal period of 15 days, were enrolled and compared to a control group including cats with CKD (stage IRIS 2 or over: group 2). UO was treated by medical or surgical procedure.

Group 1 included 39 cats and group 2 included 37 cats. At time of diagnosis (D0), there was no difference in median creatinine concentration, median iCa and distribution of hypercalcemic, normocalcemic or hypocalcemic cats between both groups. Median phosphorus concentration was significantly higher in group 1 (73.7 mg/l [32–200] vs 42 mg/l [25–91]) (p< 0.001) at D0.

Over time, a significant increase in proportion of hypercalcemic cats was observed in the group 1 at the end of the study vs at D0: 33.3% [95%CI, 18.5–48.1] vs 12.8% [95%CI, 2.3%–23.3%] (p<0.001). The average time of onset of hypercalcemia in these 13 cats was 50.5 days (range: 2–1170) and amongst them only 2 were hypercalcemic from D0. In group 2 proportion of cats normo- or hypercalcemic did not vary during the study period.

Our results suggest that iCa should be monitored in cats with UO as presence of ionised hypercalcemia could be misdiagnosed at time of diagnosis and becomes evident after UO treatment. These results suggest that concurrent hyperphosphatemia could explain this finding. Identification of ionised hypercalcemia as a potential risk factor for UO is important and should appropriately be managed in these cats.

DISCLOSURES

No disclosures to report.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Melanie Garcia
École Veterinaire d'Alfort
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8172719
Urinary Findings Suggesting Early Renal Involvement in Cats with Feline Morbillivirus Infection

P.E. Crisi1; F. Dondi2; E. de Luca3; E. Febo1; K. Vasylyeva2; E. Ferlizza2; G. Savini2; A. Luciani1; A. Lorusso3; A. Boari1

1University of Teramo, Teramo, Italy; 2Alma Mater Studiorum, University of Bologna, Ozzano dell’Emilia, Bologna, Italy; 3Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise (Izsam), Teramo, Italy

Feline morbillivirus (FeMV) has been associated with renal lesions in cats; however, a clear association between infection and the development of chronic kidney disease (CKD) remains to be elucidated.

With the aim of characterizing urinary findings, urinalysis, urine chemistry and qualitative proteinuria results were retrospectively evaluated in 14 cats with RT-PCR positive urine for FeMV (FeMV+). FeMV+ were compared to 21 CKD and 22 healthy blood donor cats. For all of the animals the following information was available: signalment, history, physical exam, clinicopathological evaluation including CBC, serum chemistry profile, urinalysis including urine specific gravity (USG), dipstick, sediment examination, urine protein-to-creatinine ratio (UPC), fractional excretion of electrolytes, urine SDS-PAGE stained with Coomassie blue, and urine culture. Kidney histopathology and immunohistochemistry for FeMV were evaluated at necropsy (n=3). Data were analysed with descriptive statistics and compared using non-parametric tests (Kruskal-Wallis test). P-values <0.05 were considered significant.

The FeMV+ were outdoor domestic shorthaired cats, 8 neutered males, 6 females (5/6 spayed), median age was 35 months (range 14–101). FeMV+ had significantly decreased USG (median 1054, range 1022–1065) and urine creatinine (median 227.23 mg/dl, range 83.02–489.75) when compared to healthy subjects (median 1067, range 1040–1080, p<0.00001; median 406.50 mg/dl, range 195.32–575.58; p<0.00001; respectively). No statistical differences were detected for serum creatinine (median 0.81 mg/dl, range 0.67–2.13 vs. median 1.46 mg/dl, range 0.78–2.13) and urea (median 45.35 mg/dl, range 30.20–63.30 vs. median 46.47 mg/dl, range 31.47–73.01) and for electrolyte fractional excretions. All urine cultures were negative.

A significant increase in UPC was observed in FeMV+ (median 0.19, range 0.08–1.03) when compared to healthy subjects (median 0.10, range 0.04–0.40, p<0.0003), while statistical differences were not detected between infected cats and CKD cats (median 0.23, range 0.10–0.80). In FeMV+, SDS-PAGE qualitative proteinuria showed differences if compared to the healthy cats. In particular, a tubular pattern was evidenced, with a decrease of uromodulin and an increase in the number and intensity of low molecular weight proteins, indicating a renal involvement, although less severe than in CKD cats. Renal pathology showed tubulo-interstitial nephritis and positive immunohistochemical stain for FeMV-N protein in tubular cells.

Urine findings in FeMV+ suggest the presence of early tubulo-interstitial damage characterized by tubular proteinuria and mild reduction of urine concentrating ability. No urine electrolyte handling dysfunctions were detected. Further prospective studies combining long-term patient follow-up, renal pathology and urine evaluation are warranted to obtain a better characterization of potential FeMV-associated renal damage.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

P.E. Crisi
University of Teramo
Teramo, Italy

URL: http://www.vin.com/doc/?id=8172720
Effects of a Non-absorbent Litter on Urinalysis Results in Cats

J.G. Pebre; H.P. Lefebvre; B.S. Reynolds
National Veterinary School, Toulouse, France

Commerically available non-absorbent litters are becoming increasingly popular for urine collection in cats. The objective of this study was to assess the effects of such device on routine feline urinalysis results, a potential issue that has not been addressed to date.

Thirty-one cats subjected to cystocentesis for urinalysis as part of their diagnostic work-up were included. A fraction of the urine sample collected by cystocentesis was immediately processed to obtain a reference urinalysis (USG, dipstick and UPC). The remaining urine was poured on the non-absorbent litter in a tray, urine specimens were then retrieved from the tray immediately and after 3, 6 and 12 hours at room temperature and urinalysis was repeated at each term. The effects of urine timely contact with litter on urinary analytes were assessed using a General Linear Model and Dunnett's test.

The range of results obtained from the reference specimens was wide but the vast majority of samples were negative for ketones, glucose and bilirubin. Testing urine retrieved from the tray with ketones reagent pads was found to be unreliable. Results for 5/8 analytes tested were statistically different from those of the reference specimen at 9 occasions. The observed differences were clinically relevant for USG after 3, 6 and 12 hours and for the protein reagent pad result of the dipstick after 12 hours.

In conclusion, urine collected within 12 hours of contact with the non-absorbent litter tested is suitable for UPC measurement and most dipstick reagent-pads but not for USG assessment.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B.S. Reynolds
National Veterinary School
Toulouse, France

URL: http://www.vin.com/doc/?id=8172721
Determination of the pH in Canine Urine: Comparing Visual and Automated Reading Variability of Urine Dipstick Analysis Within a Small Animal Teaching Hospital

M. Garcia; M. Ferreira; A. Gow
Royal (Dick) School of Veterinary Studies, Roslin, UK

Urine pH measurement is performed during routine urine analysis evaluation. Although using a pH meter has been shown to give more accurate results, urine dipsticks are most commonly used in veterinary medicine. Accurate pH measurement is important, as it may indicate urinary infection, risk of urolith formation and reflect the acid-base systemic status of a patient. This study evaluated the inter-operator reproducibility of canine urine pH readings when performing urine dipstick chemical analysis by direct standard visualization and automated analysis in a small animal teaching hospital.

Urine from in-patients was collected between 28 and 40 hours prior to the study and was kept refrigerated. The pooled sample was divided in three and each sample was titrated with NaOH and HCl to achieve a consistent visual urine dipstick pH reading of 6 (Sample 1), 7 (Sample 2) and 7.5 (Sample 3). Respective readings of 5.44, 6.55 and 7.66, were obtained with a calibrated reference bench top pH meter. Samples were kept chilled during the study period.

Study participants were given one aliquot each sample and six urine dipsticks. Each operator was asked to measure and record the urine pH from each aliquot using first standard visual and then automated analyser reading methods.

Nineteen final year students, 7 veterinarian surgeons and 4 veterinary nurses participated in the study. Standard visual reading pH values, with number of participants recording the results in brackets, were: Sample 1: 6 (14), 6.5 (14), 7 (2); Sample 2: 6 (2), 6.5 (2), 7 (1), 7.5 (22), 8 (3); and Sample 3: 6 (1), 7 (1), 7.5 (3), 8 (25). Using the automated analyser, the results obtained were: Sample 1: 5.5 (1), 6 (29); Sample 2: 7 (26), 7.5 (4); Sample 3 7 (1), 7.5 (25), 8 (3), 8.5 (1). Concordance of results between study participants and the authors occurred in 39/90 (43%) of visually read, and 79/90 (88%) of automated analyser results. Sample 2 was visually reported as alkaline (pH of 8) by 4 participants and acid (pH of 6) by 2 participants.

In conclusion, standard visual reading of urinary dipstick demonstrated poorer inter-operator reproducibility when measuring canine urinary pH in comparison with an automated method. This has potential clinical implications in that the same sample was classified as acidic and alkaline in some instances, potentially affecting clinical decision making.

DISCLOSURES
No disclosures to report.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Marta Garcia
Royal (Dick) School of Veterinary Studies
Roslin, UK

URL: http://www.vin.com/doc/?id=8172722
Assessment of Kidney Injury in Canine Parvoviral Infection by Comparing Novel Urinary Kidney Injury Biomarkers with Routine Renal Functional Parameters

M.F. van den Berg1; J.P. Schoeman2; P. Defauw1; Z. Whitehead2; A. Breemersch1; K. Goethals1; S. Daminet1; E. Meyer1

1Ghent University, Merelbeke, Belgium; 2University of Pretoria, Pretoria, South Africa

Dogs with naturally occurring parvovirus infection may be at risk of developing acute kidney injury due to several risk factors, including severe dehydration, systemic inflammatory response syndrome, and sepsis. Early detection of kidney injury is important, yet challenging, because conventional renal parameters, such as serum creatinine (sCr) and blood urea nitrogen (BUN), are insensitive markers for early stages of kidney injury and dysfunction. Therefore, the aim of this study was to investigate potential kidney injury in dogs with naturally occurring parvoviral infection by comparing standard to novel urinary biomarkers.

Twenty-two dogs with parvoviral infection were prospectively enrolled and compared with eight clinically healthy control dogs. Blood and urine samples were collected at presentation (T₀) in both groups and 24 hours later (T₁) in the patient group. Urinary immunoglobulin G (uIgG) and C-reactive protein (uCRP) were measured to document glomerular injury, whereas urinary retinol-binding protein (uRBP) and neutrophil gelatinase-associated lipocalin (uNGAL) served as biomarkers for tubular injury. These biomarkers were compared to routine renal functional parameters, including sCr, BUN, urinary protein:creatinine ratio (UPC), and urine specific gravity (USG). Commercial ELISAs validated for the measurement of canine uIgG, uCRP, uRBP, and uNGAL were used. Statistical analysis was performed using non-parametric Mann-Whitney and Wilcoxon signed rank tests.

At T₀, dogs with parvovirus infection had significantly higher concentrations of uIgG (p<0.01), uCRP (p<0.0001), uRBP (p<0.001), and uNGAL (p<0.05) compared to healthy dogs. At T₁, only uCRP and uRBP remained significantly higher compared to controls (p<0.0001 and p<0.01, respectively), while concentrations of uIgG decreased significantly from T₀ (p<0.001) in parvovirus infected dogs. In marked contrast, both at T₀ and T₁, sCr was significantly lower in dogs with parvoviral infection (p<0.01 and p<0.001, respectively) compared to healthy dogs, while BUN was not significantly different (p=0.21). Although both USG and UPC were significantly higher in dogs with parvovirus at T₀ (p<0.01 and p<0.001, respectively), only UPC remained significantly higher at T₁ (p<0.05) compared to healthy dogs.

In conclusion, this study shows that dogs with parvoviral infection had acute kidney injury, which manifested both at the glomerular and tubular level, and remained undetected by the routine renal functional markers sCr and BUN. Our results emphasize the added value of novel kidney injury urinary biomarkers to detect and monitor these patients at risk.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

M.F. van den Berg
Ghent University
Merelbeke, Belgium

URL: http://www.vin.com/doc/?id=8172723
Poster Presentations

Efficacy and Safety of Two New High-Protein, Low-Carbohydrate Dry Diets in Sterile, Feline Struvite Urolithiasis  C. Maurey Guenec
The Effect of Storage Temperature and Boric Acid Preservation on Quantitative Bacterial Culture for Diagnosing Canine Urinary Tract Infection  T.M. Soerensen
Microalbuminuria in Dogs Infected with Dirofilaria repens  F. Manczur
Accuracy of Refractometric Urine Specific Gravity Determination in Cats  F. Manczur
Symmetric Dimethylarginine (SDMA) and Nephropathy in Dog: Diagnostic Utility in Clinical Practice  J. Zambarbieri
Ultrasound-Guided Renal Biopsy Significantly Increases Urinary N-Acetyl-Beta-D-Glucosaminase Index Activity in Dogs with Diffuse Parenchymal Nephropathies  A.R. Codea
Efficacy and Safety of Two New High-Protein, Low-Carbohydrate Dry Diets in Sterile, Feline Struvite Urolithiasis

C. Maurey Gueneç¹, G. Chaix², I. Leriche², S. Fournel²
ENVA, Maisons Alfort, France;²Virbac, Carros, France

Urolithiasis is a common cause of feline lower urinary tract disease (FLUTD). The most common feline uroliths are calcium oxalate and struvite. Dietary dissolution is safe and effective for eradication of sterile struvite uroliths in cats. Richness in moisture and/or sodium and/or protein in order to increase water intake and thus to increase diuresis, urinary flow and the frequency of micturition may vary between commercially diets. This prospective, multicenter, randomized, double-blinded clinical trial evaluated the efficacy and safety of two new high-protein, low-carbohydrate dry diets in sterile, struvite urolithiasis in cats with signs of non-obstructive FLUTD.

Cats enrolled in the study were randomly assigned either to diet A,¹ formulated to achieve dissolution and prevention of struvite uroliths, or to diet B,² formulated to dissolve struvite uroliths. Cats were followed up to 14 days after the uroliths had been dissolved, latest to D56±2. Physical examination, urinalysis, and abdominal ultrasound were performed weekly. Analyses were performed using the software SAS® version 9.4. The significance threshold was set to α=0.05 two-sided.

Thirty-three cases were recruited and supplied with diet A (n=17) or diet B (n=16) according to the randomization procedure. The mean time of struvite dissolution was 13.1 days and 14 days respectively for diet A and diet B (n.s). The mean time to disappearance of at least one urinary sign was 7 days for diet A and 11.4 days for diet B (p=0.03). On D7, all cats from group A and 75% of cat from group B had no more urinary signs (p=0.04). Mean urinary pH was decreased in groups A and B at the end of the study (6.1±0.5 and 6±0.6, respectively) compared to D0 (7.2±0.8 and 7.2±0.7, respectively). In group B, urine specific gravity significantly decreased (p=0.01) from D0 (1.046±0.8) to the end of the study (1.036±12.5). In group A, urine specific gravity decrease was not significant. Two and 4 cats of groups A and B respectively exhibited transitory adverse events, possibly related to the diet (mild diarrhea or mild vomiting). These events resolved spontaneously and did not lead to the exclusion of any cat.

The new high-protein, low-carbohydrate tested diets were effective for dissolution of feline struvite urolithiasis.

DISCLOSURES

Disclosures to report
This study was founded by Virbac. Three co-authors are employees of Virbac.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Maurey Gueneç
ENVA
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8172733
The Effect of Storage Temperature and Boric Acid Preservation on Quantitative Bacterial Culture for Diagnosing Canine Urinary Tract Infection

T.M. Soerensen; L.R. Jessen; M. Moeller; H. Patsekhina
University of Copenhagen, Frederiksberg C, Denmark

Quantitative bacterial culture (QBC) is the gold standard for diagnosing urinary tract infection (UTI). Current guidelines recommend that QBC is performed within 24 hours of collection and that urine, if unpreserved, is stored and transported at refrigeration temperatures. However, temperature-controlled transport is expensive and may not always be feasible in veterinary practice, indicating a need for alternative storage methods.

The aim of this study was to investigate the effect of storage temperature and boric acid preservation on QBC of canine urine.

The hypothesis was that i) urine stored non-preserved by refrigeration (COOL) or preserved in commercially available urine preservation swabs containing boric acid (Copan UriSwab™) at room temperature (BA-ROOM) for 24 and 48 hours, respectively, would be non-inferior to the reference QBC and that ii) there would be no significant difference in sensitivity and specificity of the two storage methods.

Canine urine samples received at the veterinary microbiology laboratory at UCPH between February 2015 and March 2016 were prospectively included in the study. After initial reference QBC, urine samples were split into three aliquots. Two aliquots were stored at room temperature in Copan UriSwab™, and one aliquot was stored refrigerated in an unpreserved microfuge tube, for 24 h and 48 h, respectively. Significant bacteriuria was determined with regard to urine collection method according to current recommendations.

Non-inferiority was concluded if the lower limit of the one-sided 95% confidence interval was above 85% (Δ=0.15). McNemar χ² test was performed to compare sensitivity and specificity for the two storage methods.

A total of 179 samples from 141 dogs were included. Significant bacteriuria was found in 42% of the samples according to reference QBC. With an overall accuracy of 94–97%, all storage conditions were non-inferior to reference QBC, except for BA-ROOM at 48 h which had an inferior sensitivity. However, there was no significant difference between the sensitivity of the two methods at the two time points (p=0.06–1.00).

The results show that boric acid preservation at room temperature is a valid alternative to refrigeration and that reliable QBC can be obtained after storage of canine urine for 24 h by both methods.

DISCLOSURES

Disclosures to report
Copan UriSwab™ kit kindly donated by Copan Italia

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T.M. Soerensen
University of Copenhagen
Frederiksberg C, Denmark

URL: http://www.vin.com/doc/?id=8172734
Microalbuminuria (MAU) is associated with underlying renal and systemic diseases in dogs. Glomerular disease and proteinuria is common in dogs naturally or experimentally infected with *Dirofilaria immitis*. The prevalence of MAU in dogs with experimentally infected heartworm disease is higher than in healthy animals. *Dirofilaria repens* is the causative agent of subcutaneous canine dirofilariosis and is considered an emerging zoonosis in many parts of Europe. *Dirofilaria repens* infection is usually associated with no or only minor clinical signs in dogs. It is not known whether *D. repens* is capable of producing similar glomerular lesions and proteinuria to those caused by heartworm infection.

The purpose of this study was to determine the prevalence of MAU (urinary albumin to creatinine ratio, UAC >0,03) and proteinuria (urinary protein to creatinine ratio, UPC >0,5) in dogs naturally infected with *D. repens*.

Blood and urine samples were taken from 70 clinically healthy beagles kept in two closed colonies with similar housing and feeding conditions. Extensive laboratory workup was used to reveal any underlying disease and to distinguish *D. repens* infection from occult heartworm disease (including modified Knott test, two different Ag-ELISA tests and *Dirofilaria* species specific real time PCR). Urine was obtained by cystocentesis and albumin was measured with a formerly validated commercial human immunoturbidimetric method. Exclusion criteria were severe laboratory alterations, a positive *D. immitis* test or positive urine culture. Some older, otherwise eligible, *D. repens*-infected dogs also had to be excluded, as there were no older animals without infection to age match the two groups.

After all the exclusions, there remained 29 *D. repens*-infected and 27 non-infected beagles. There were no statistically significant differences between the two groups in respect of their age, weight and sex ratio. There were significantly more dogs with MAU in the *D. repens*-infected group compared to the non-infected beagles (28% vs. 4%, p=0,0150). There were also more proteinuric dogs in the infected group (24% vs. 7%), but it did not yield a significant difference (p=0,0885).

Our study showed that the prevalence of MAU in dogs infected with *D. repens* is higher than that observed in other non-infected dogs kept in the same conditions. Further studies are needed to determine whether dogs infected with *D. repens* and MAU will progress to develop overt proteinuria and renal failure.

**DISCLOSURES**

Disclosures to report
The research was partly supported by Bayer Hungary.

**SPEAKER INFORMATION**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

F. Manczur
University of Veterinary Medicine
Budapest, Hungary

URL: http://www.vin.com/doc/?id=8172735
Urine specific gravity (USG) is used as a proxy for urine concentration or osmolality and usually determined by using a refractometer. There is a long-held belief that feline urine has higher specific refractivity than human or canine urine, thus human refractometer scales may result in falsely high readings for feline samples. There are some commercially available veterinary refractometers that are calibrated with different scales for cats and a conversion formula has also been recommended if a refractometer with human scale is used in order to avoid overestimation of the USG in cats. Two recent studies questioned whether a separate scale is necessary for the correct interpretation of the refractometer readings in feline urine.

The aim of this study was to compare canine and feline USG readings obtained by a commercial human refractometer with weight/volume measurement USG data. A second aim of the study was to test whether the centrifugation of the urine samples may have an effect on the accuracy of refractometric USG determination.

The USG of thirteen canine and fifteen feline urine specimens were compared using refractometry and precise weight/volume measurement. The accuracy of the weight/volume measurements was checked on distilled water samples. The bias between the two methods was determined by Bland-Altman analysis. The measurements were performed both on uncentrifuged and centrifuged samples. The effect of centrifugation was evaluated by paired t-test.

The median (1st, 3rd quartiles) USG of the canine samples was 1015 (1008, 1024). The mean (±SD) USG of the feline samples was 1033 (±11). There were no significant differences between the refractometric USG values of canine or feline urine samples before and after centrifugation. The mean bias between the refractometric and weight/volume determined USG values of the feline samples was 1.8±2.4. Using the generally accepted feline correction formula changed the mean bias to -3.1±3.6. For comparison, the mean bias between the differently obtained USG values of the canine samples was -2.9±5.7.

Based on our results we can conclude that it is unnecessary to use different scales or correction formulas during the refractometric USG determination of canine or feline urine samples. The use of the feline correction formula may result in a clinically important underestimation of the USG. The USG measurements can be performed both on native and centrifuged urine samples. The inaccuracies of the refractometers irrespective of the species should be taken into consideration during the clinical decisionmaking.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

F. Manczur
University of Veterinary Medicine
Budapest, Hungary

URL: http://www.vin.com/doc/?id=8172736
Symmetric dimethylarginine (SDMA) has been proposed as a sensitive and specific renal biomarker whose concentration increases earlier than serum creatinine (Scr) as glomerular filtration rate decreases. SDMA is a promising parameter in the diagnosis and management of chronic kidney disease (CKD), and it is included into the International Renal Interest Society (IRIS) guidelines.

The aim of the study is to assess the usefulness of a single determination of SDMA in the evaluation of renal status in dogs at risk or affected with CKD, and to evaluate its correlation with Scr and other parameters of renal function.

Ninety-five dogs were consecutively selected within the patients referred to the University Veterinary Hospital of Milan. On the first clinical examination, all these dogs underwent physical examination, haematology and blood chemistry (including serum SDMA and Scr). Urinalysis and urinary protein:creatinine ratio (UPC) were performed in 89 cases while ultrasound examination was done in 60 dogs. All the dogs were staged according to the IRIS guidelines. Statistical analysis was performed by JMP 7 software (SAS Institute Inc., Cary, USA).

SDMA showed, as expected, a significant correlation with Scr, urine specific gravity (USG) and UPC ratio (p<0.05). IRIS staging, according to Scr, resulted as follows: 26 (27.4%) dogs were included in stage 0, 39 (41%) in stage 1, 12 (12.6%) in stage 2, 17 (17.9%) in stage 3 and 1 (1.1%) in stage 4. SDMA evaluation modified IRIS staging in 12 (12.6%) dogs. SDMA was increased in 51 (53.7%) dogs; in 8 (15.7%) of these, SDMA was equal to the cut-off value (14 µg/dL). In 29 (56.9%) of the “high SDMA” cases, Scr was >1.4 mg/dL, while in the other 22 (43.1%) there were already one or more alterations: decrease of USG in 14 (63.6%) cases, increase of UPC ratio in 15 (68.2%) cases, ultrasound features suggestive of CKD in 9 (40.1%) cases. SDMA was the only altered parameter in 4 (4.2%) dogs. SDMA was normal and creatinine slightly increased in 1 (1.1%) dog.

SDMA is a useful and reliable parameter for the diagnosis and management of CKD, but the evaluation of other markers of renal function and diagnostic imaging are essential in order to correctly approach the patient from the diagnostic and therapeutical point of view, especially at the first clinical presentation. Furthermore, patients with normal Scr and altered SDMA require further evaluations to confirm the development of CKD.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Zambabieri
University of Milan
Milan, Italy

URL: http://www.vin.com/doc/?id=8172737
Ultrasound-Guided Renal Biopsy Significantly Increases Urinary N-Acetyl-Beta-D-Glucosaminase Index Activity in Dogs with Diffuse Parenchymal Nephropathies

A.R. Codea¹; V.M. Mircean¹; O. Sarpatakı¹; B. Sevastre¹; A. Bizo²; C.P. Popovici¹; S.A. Bogdan¹; L.I. Oana¹

¹Faculty of Veterinary Medicine Cluj-Napoca, Cluj-Napoca, Romania; ²University of Medicine and Pharmacy “Luliu Halteganu”, Cluj-Napoca, Romania

Ultrasound-guided renal biopsy is an essential diagnostics method which, by facilitating histopathological examination, can increase the accuracy of the differential diagnosis between acute and chronic nephropathies and will help the clinician perform an etiologic diagnosis, issue a prognosis and orient the therapy of the majority of parenchymal nephropathies. Due to the relative invasiveness and potential adverse effects, the use of renal biopsy is limited among practitioners. In this study we evaluate the intensity of renal damage induced by renal cortex sampling and the clinical consequences of such a procedure. We examined 28 dogs, mixed breed and variable ages, 11 (39, 29%) males and 17 (60, 71%) females that were referred to our clinic and underwent ultrasound-guided renal biopsy in order to establish a definite diagnosis. Patients were presented with a variety of diffuse nephropathies: kidney lymphoma: 1 (3.57%), glomerulonephritis: 13 (46.43%), tubulointerstitial nephritis: 11 (39.29%) and nephrocalcinosis: 3 (10.71%) of which 18 (64.29%) were in acute kidney failure and 10 (35.71%) were chronic renal patients. The type and the severity of renal lesions were correlated with changes in urinary NAG index (iNAG), and specific serum renal damage markers such as urea, creatinine, phosphorus and ionized calcium. To quantify the side effects of percutaneous renal biopsy, the magnitude of post biopsy haematuria and changes in urinary iNAG activity were evaluated. The results indicate a significant post biopsy increase in urinary iNAG activity in all patients that underwent this procedure (100.08±34.45 [U/g] pre-biopsy iNAG vs. 147.65±33.26 [U/g] post-biopsy iNAG, p<0.001) suggesting an intensification in renal tubular damage consecutive to kidney puncture and sampling.

Transitory macro- or microhaematuria was a constant finding in all dogs that underwent ultrasound-guided renal biopsy, but the magnitude and extent could not be associated with PLT (10⁹/L), aPTT (s) and PT (s) levels in our patients, and resolved after 12–24 hours without therapeutical interventions.

Percutaneous ultrasound-guided renal biopsy is a relatively safe, minimally invasive diagnostic procedure which will induce a series of deleterious effects on kidney structure and function, but we consider that a correctly obtained tissue sample with a high diagnostic value is of greater importance than the complications associated with the sampling procedure.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.R. Codea
Faculty of Veterinary Medicine Cluj-Napoca
Cluj-Napoca, Romania

URL: http://www.vin.com/doc/?id=8172738
Scientific Programme

The Metabolic Signature(s) of Ageing Organs Using the Kidney as a Paradigm  Michelangelo Campanella, Pharm D, PhD, MRPharmS, PGCAP, FHEA, FRSB
Assessing Renal Aging in Cats: Telomeres and Senescence  Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Pathology of Renal Ageing  Luca Aresu, Prof, DVM, PhD
Sarcopenia and Cachexia in Chronic Kidney Disease  Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Metabolic Signature(s) of Ageing Organs Using the Kidney as a Paradigm

Michelangelo Campanella, Pharm D, PhD, MRPharmS, PGCAP, FHEA, FRSB

1Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London; 2UCL Consortium for Mitochondrial Research, London, UK

KEYNOTE MESSAGE

Understanding the basis of ageing to slow its course is one of the great biomedical challenges for our times. Age is the most important risk factor for most of the common mammalian diseases. Although our knowledge of the ageing process remains elusive, there is consensus that the process starts with molecular damage, leading to cell, tissue, and ultimately organ dysfunction.1

Mitochondria that are the principal source of intracellular reactive oxygen species (ROS), are thought to play a central role in this as encrypted by the free radical theory of ageing. However, the importance of mitochondrial ROS in driving ageing is met by other facets of mitochondrial dysfunction playing a critical role in cellular and organismal aging such as loss of their quality control.2

Age-associated loss of function is well established in kidney, mostly underlined by mitochondrial defects, thus making this the ideal model organ to inform ageing both at molecular and systemic level. Still relatively little is known about the properties of mitochondria in different parts of the kidney,3 demanding further investigations to inform the pathophysiology of the organ over time. Adopting in vivo and in vitro approaches, we discovered differences in mitochondrial function along the nephron, framed by different metabolism and how these dictate pattern of renal injuries.

This talk will initially report the alternative metabolic features, means of reactive oxygen species (ROS) regulation, scavenging mechanisms and loss of cell quality in kidney cells. The role played by the endogenous regulator of the mitochondrial F$_1$F$_0$-ATP synthase, IF$_{1}$,4 will then be described, which contributes to the homeostasis of nephron sections and therefore represents a novel therapeutic target in both chronic and acute conditions5.

The ageing kidney model as a paradigm for animal ageing will then be considered and the contribution by key determinants of mitochondrial function and structure analysed.

KEY REFERENCES


SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Michelangelo Campanella, Pharm D, PhD, MRPharmS, PGCAP, FHEA, FRSB

Department of Comparative Biomedical Sciences, The Royal Veterinary College
University of London
UCL Consortium for Mitochondrial Research
London, UK

URL: http://www.vin.com/doc/?id=8172740
Assessing Renal Aging in Cats: Telomeres and Senescence
Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Ohio State University, Columbus, OH, USA

Keynote Message
Chronic kidney disease (CKD) is a common naturally occurring medical condition in elderly cats, yet an etiology for this disease process has not been elucidated. Human CKD is associated with progressive loss of renal parenchyma and function with age. Renal aging also involves loss of an appropriate response toward injury, as seen in aging human populations where kidney injury is more common, clinically more severe, and kidney function is less likely to recover. Whether feline CKD results from similar aging processes that predispose the organ to failure, or if other factors are involved remains to be determined. Telomeres are protective structures that serve to cap chromosome ends and so are critical for maintaining genome stability. When telomeres reach a critically shortened state they are no longer able to effectively cap the end of the chromosome, and so they themselves are detected as DNA damage and trigger a response resulting in permanent cell cycle arrest known as cellular senescence. Senescence can also occur via non-telomere-dependent pathways. Associations between oxidative stress, telomere shortening, senescence, and inflammation have been suggested. Thus, the investigation of these processes is particularly pertinent for feline CKD, as it is a disease characterized by tubulointerstitial inflammation, and decreased antioxidant defense mechanisms and increased oxidative stress have been documented in these patients. This session will discuss the pathophysiology of these processes as well as recent work demonstrating associations between telomere shortening, cellular senescence and feline CKD, which serve to further our understanding of renal aging and disease, and have the potential to present novel treatment strategies.

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Ohio State University
Columbus, OH, USA
URL: http://www.vin.com/doc/?id=8172741
The Pathology of Renal Ageing
Luca Aresu, Prof, DVM, PhD
Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy

Keynote Message

By definition, ageing represents a persistent decline in the specific fitness components of an organism, mainly due to degeneration processes. In kidney, the biologic consequences of aging include progressive structural and functional changes, and these are among the most dramatic of any organ system. The histologic and ultrastructural features of renal ageing have been insufficiently investigated in veterinary medicine, but, as far as we are aware, they tend to mimic those in humans. The anatomical, structural modifications include a decreased number of functional glomeruli from an increased prevalence of nephrosclerosis (glomerulosclerosis and tubular atrophy with interstitial fibrosis). To some extent, there is a compensatory hypertrophy mechanism of the remaining nephrons that initially preserves the renal function but progressively leads to a vicious circle of self-destruction, accelerating the probability of their destruction. The aforementioned structural changes have an impact on the glomerular filtration rate, altered tubular handling of creatinine, reduction in sodium reabsorption and potassium secretion. These changes can alter the normal renal function, causing a higher susceptibility to infectious diseases, toxic and pharmaceutical treatment, impair the ability of the kidney to withstand and recover from injury, contributing to increased propensity to develop progressive CKD. It's also true that the structural changes of aging kidneys are nonspecific and can be seen in many pathological conditions (i.e., FSGS) and it should be emphasized that comorbid conditions that are frequently found in old animals can amplify these morphological alterations.

In the near future, improved understanding of the mechanisms of renal aging in veterinary medicine will definitely help to optimize management of senior dogs and cats.

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Luca Aresu, Prof, DVM, PhD
Department of Comparative Biomedicine and Food Science
University of Padova
Padova, Italy

URL: http://www.vin.com/doc/?id=8172742
**Sarcopenia and Cachexia in Chronic Kidney Disease**

Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Ohio State University, Columbus, OH, USA

**KEYNOTE MESSAGE**

The term cachexia refers to a syndrome commonly associated with cancer and chronic diseases that is characterized by weight loss, loss of muscle mass (lean body mass) with or without loss of adipose tissue mass. It is commonly associated with cancer and chronic diseases, such as kidney disease, heart disease, and respiratory disease. The term sarcopenia refers to the degeneration of skeletal muscle mass, quality, and strength as part of normal aging (i.e., not associated with a disease process). Cachexia and sarcopenia are underrecognized syndromes in veterinary patients, and many elderly pets may have both conditions concurrently. Poor body condition in CKD has been shown to be correlated to a poorer prognosis in several species, including dogs and cats. In people, CKD cachexia is often referred to as protein-energy wasting and many factors are described that may contribute to the condition including hypermetabolism, uremic toxins, metabolic acidosis, inflammation, and comorbidities. Both cachexia and sarcopenia involve muscle dysfunction, which contributes to overall frailty. Frailty can clinically manifest as weakness, hyporexia, perceived poor quality of life, and this, in addition to poor body condition, can lead to a decision for humane euthanasia. In this session, strategies for identification and monitoring of these conditions, as well as targeted nutritional management, will be discussed.

**Key References**


**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)
The Ohio State University
Columbus, OH, USA

URL: [http://www.vin.com/doc/?id=8172743](http://www.vin.com/doc/?id=8172743)
ESVONC - European Society of Veterinary Oncology

<table>
<thead>
<tr>
<th>Speaker List</th>
</tr>
</thead>
</table>

- Oral Presentations
- Poster Presentations
- Scientific Programme
Oral Presentations

Are Protein Kinase Inhibitors of Use in the Treatment of Canine Lymphoma? A Screening in Vitro Study with Multiple Protein Kinase Inhibitors in Canine Lymphoid Cell Lines  M. Zandvliet

Masitinib Treatment for Advanced Stage III and IV Canine Melanoma  A. Giuliano

Toceranib Phosphate in Fifteen Dogs with Stage 4 Anal Sac Apocrine Gland Adenocarcinoma  J. Elliott

Effect of Toceranib Phosphate (Palladia®) on Outcome in Dogs with Anal Sac Carcinoma  K. D. Lyons

The Occurrence of Feline Neoplasia: A Comparison Between Danish and North American Cats  B. Børresen

Expression of Felis catus Gammaherpesvirus-1 ORF73, F7 and ORF50 in FIV-Associated Lymphoma Biopsies  M. Aghazadeh

High Pretreatment D-dimer Concentration is Associated with Poor Prognosis in 48 Dogs with High-Grade Lymphoma  P. Boye

Efficacy of Chemotherapy and Clinical Outcome in Primary, Metastatic Feline Pulmonary Carcinomas: An Observational Study  E. Treggiari

Ovarian Tumours in the Bitch - Pathological Findings and AMH Values  H. Aupperle-Lellbach

Initial Evaluation of Gum Arabic-Coated Radioactive Gold Nanoparticles in Canine Prostatic Cancer  S. M. Bechtel
Are Protein Kinase Inhibitors of Use in the Treatment of Canine Lymphoma? A Screening in Vitro Study with Multiple Protein Kinase Inhibitors in Canine Lymphoid Cell Lines

M. Zandvliet¹; P. Dubreuil²

¹Utrecht University, Utrecht, Netherlands; ²CRCM, Signaling, Hematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée, Marseille, France

INTRODUCTION

Canine lymphoma, the most common hematopoietic neoplasia in the dog, is routinely treated with a multi-drug chemotherapy protocol. Despite a high initial response rate, tumor relapse is common and often resistant to chemotherapy, resulting in treatment failure. Alternative treatment options are mandatory and since masitinib showed a mild anti-proliferative effect on lymphoid cells, other protein kinase inhibitors (PKIs) might provide this alternative.

MATERIALS AND METHODS

GL-1 is a canine B-cell lymphoid cell line and GL-40 its doxorubicin/vincristine resistant subline demonstrating P-gp overexpression. Cell lines were cultured as previously described. Cell viability was assessed using a colorimetric assay (AlamarBlue®). Cells were seeded in 96 well plates at a density of 2 x 10⁴ cells per well in cell culture medium containing a concentration range (0, 0.1, 1 and 10 µM) of the PKI tested and incubated for 48 hours at 37°C, 5% CO₂. AlamarBlue® (resazurin) was added three hours prior to analysis and the reduced fluorescent molecule (resorufin) was measured by light absorbance in a fluorescence spectrophotometer (560EX nm/590EM nm). Experiments were performed in triplicate.

Cell survival was calculated by dividing light absorbance in treated cells by that in control cells after correction for background absorbance. Concentration-dependent effects were analyzed by non-linear regression after log transformation of PKI concentration. Median inhibitory concentration (IC50) was calculated as a measure of the PKI's antiproliferative effect. Graphs were fitted according to a sigmoid dose-response curve.

RESULTS

IC50 for the various PKIs in the GL-1 cells ranged from <0.1 µM (BI-2536, sorafenib, quizartinib, sunitinib, toceranib), 0.1–1 µM (TAE684, SGI-1776, TAE226, tozasertib), 1–10 µM (dasatinib, pazopanib, nilotinib, erlotinib, axitinib) and >10 µM (gefitinib, imatinib, masitinib, lapatinib, vandetanib). No relevant differences were found in IC50 between GL-1 and GL-40 for any of the PKIs tested.

CONCLUSION/DISCUSSION

Several PKIs inhibited lymphoid cell proliferation with good direct activity shown for inhibitors of PLK1, Raf, FLT3, ALK, PIM-kinase, FAK, and aurora kinases and these require further (clinical) evaluation. PKIs targeting c-KIT, PDGFR, VEGFR showed variable antiproliferative effects, while PKIs targeting EGFR had little to no inhibitory effect. The PKIs tested showed similar IC50 in both the GL-1 and GL-40 cells, suggesting that P-gp overexpression has no role in tumor resistance to PKIs, guaranteeing their value in case of tumor resistance to cytostatic drugs.

DISCLOSURES

Disclosures to report
P. Dubreuil has been involved in research on masitinib and AB Science.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Zandvliet
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172789
Masitinib is a tyrosine kinase inhibitor (TKI) licensed for treatment of non-resectable canine mast cell tumours; its major targets include c-kit, PDGFR and FAK kinases. Aberrant expression of c-kit and FAK have been found in human patients affected by cutaneous and mucosal melanoma. Masitinib and other TKIs with similar targets have been used in human patients with advanced stage melanoma bearing c-kit mutations with some encouraging results. The role of c-kit, FAK and PDGFR in canine melanoma has not been extensively investigated. Although c-kit mutation seems uncommon, strong c-kit expression has been found in around 50% of canine oral melanoma; however, correlation of c-kit mutation/expression with prognosis is still uncertain. PDGFR expression has been found in around 50% of oral canine melanoma and was shown to correlate with a worse prognosis in one study. The expression and importance of FAK in canine melanoma has not been reported yet.

The aim of this small study was to assess response rates and to a lesser extent survival, in advanced stage III and IV canine melanoma treated with masitinib, as a proof of concept that masitinib may potentially play a role in treatment of this disease.

Eleven dogs were prospectively enrolled, two with digital, one anal and eight oral melanoma. Only dogs with progressive gross disease despite conventional treatment were included in the study. All the dogs were staged with thoracic radiography and fine-needle aspirate of the regional lymph node when palpable. One dog had thoracic CT and abdominal ultrasound. All dogs had previously received various combinations of surgery, radiotherapy and melanoma vaccine treatment.

Two dogs achieved partial response, five dogs stable disease and four progressive disease. For all 11 dogs median TTP (time to tumour progression) and MST (median survival time) were 66 and 124 days, respectively. Masitinib was generally well tolerated with side effects only observed in three patients. One experienced grade 1 anaemia and neutropenia, one grade 2 anorexia and one grade 1 diarrhoea.

Mucosal melanoma is an aggressive disease that carries a poor prognosis, no effective systemic treatments are currently available to control the progression of metastatic disease. This small study showing some efficacy in end-stage disease, indicates that masitinib offers potential for treatment of canine melanoma. Further studies in earlier stage disease and possibly in combination with other modalities are needed to support our findings.

DISCLOSURES

Disclosures to report
Masitinib tablets were donated by AB Science.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Giuliano
University of Cambridge
Cambridge, UK

URL: http://www.vin.com/doc/?id=8172791
Toceranib Phosphate in Fifteen Dogs with Stage 4 Anal Sac Apocrine Gland Adenocarcinoma

J. Elliott
Willows Referral Service, Solihull, UK

A variety of therapies are employed in the management of anal sac apocrine gland adenocarcinoma (ASAGA), including surgery, radiotherapy and chemotherapy. Toceranib phosphate (Palladia®) has shown anti-cancer activity in dogs with advanced ASAGA, which may be related to receptor tyrosine kinase expression such as KIT, RET and PDGFR.

Whilst some patients present with advanced regional nodal metastases (typically to the iliosacral lymphatic centre; stage 3b), unfortunately some present with distant metastases which can temper owners' desire to choose aggressive loco-regional therapies including lymph node extirpation or radiotherapy. Indeed such therapies would also not treat the distant metastatic deposits and so systemic therapy would still be a requirement for successful management.

Fifteen dogs presented between 2012 and 2016 with stage 4 ASAGA (presence of distant metastases) with no prior therapy, other than in two patients where the primary tumour in the anal sac had been surgically excised as a diagnostic procedure.

Presenting clinical signs were related to abnormal defaecation in only eight patients with other dogs diagnosed due to incidental discovery for another problem (n=4), PUPD (n=1) and spinal pain (n=2).

A variety of breeds were represented, though 40% were English Cocker Spaniels. All dogs had lymph node metastasis. Other sites of metastasis included lung (n=11), liver (confirmed in n=4 and highly suspicious in n=3), lumbar spine (n=2) and kidney, skin and peritoneum (all n=1).

The median toceranib dose was 2.4 mg/kg (range 2.1–2.6) and was administered on a Monday-Wednesday-Friday basis. Concurrent medications were firocoxib (n=5), carprofen (n=1) and prednisolone (n=1); the latter being for management of concurrent hypercalcaemia of malignancy. No serious toxicities were seen during toceranib therapy. Three episodes of haematological toxicity (grade I anaemia, n=2; and transient mild thrombocytosis, n=1) were seen. One dog experienced an episode of grade 2 diarrhoea, necessitating a short treatment break and re-institution at a lower dose.

Routine repeat staging was advised, and when performed a reduction in tumour burden (but classified as stable disease) was seen in all but one patient where progressive disease was observed.

Median survival time of toceranib-treated patients was 359 days (range 66–1024 days), which is substantially higher than 71 days (median, 95% CI 6–136 days) or 82 days (95% CI 0–247 days) previously reported with a variety of non-TKI therapies.

Toceranib phosphate can be a successful and well-tolerated monotherapy for dogs with stage 4 ASAGA.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Elliott
Willows Referral Service
Solihull, UK

URL: http://www.vin.com/doc/?id=8172792
Effect of Toceranib Phosphate (Palladia®) on Outcome in Dogs with Anal Sac Carcinoma

K.D. Lyons1; C. Siedlecki2; H. Wilson-Robles1; P. Bergman3

1Texas A&M University, College Station, TX, USA; 2VCA Bay Area Veterinary Specialists, San Leandro, CA, USA; 3VCA Clinical Studies, Los Angeles, CA, USA

Canine apocrine gland anal sac adenocarcinoma (AGASACA) comprises 17% of perianal malignancies in the dog. Despite local and systemic therapy, relapse is common. Evidence suggests varying expression of tyrosine kinase inhibitor targets in canine AGASACA. Objective responses to toceranib phosphate (Palladia®) have been reported. The purpose of this study was to evaluate progression and survival outcomes in dogs with AGASACA treated with toceranib. Medical records were retrospectively reviewed for response, outcome, and toxicity. Data was available for 83 dogs with a median age of 11 years and a median weight of 23 kg. Sixty percent of patients had presumed metastasis at the time of diagnosis. Twenty-four percent were hypercalcemic at the time of diagnosis. Seventy-seven percent received previous therapy including surgery, radiation, and chemotherapy. Toceranib was a first-line systemic agent in 48% of dogs, either adjunct to previous local therapy or as the sole treatment modality. Median toceranib dosage was 2.7 mg/kg with a median treatment duration of 126 days. Most adverse events were mild, but resulted in dose alteration and/or treatment holiday in 53% and drug discontinuation in 38%. Objective response rate was 62% with an additional 23% of patients experiencing stable disease. Twenty-two percent of patients were alive at time of statistical analysis, 23% died of disease, and 23% were lost to followup. Median overall survival time (OST) was 1395 days. Median progression-free survival (PFS) was 1247 days, including patients who received additional therapy after toceranib. Median progression-free interval (PFI) was 328 days. Response to toceranib was associated with previous treatment (p 0.026) and lack of previous steroid therapy (p 0.012). On multivariate analysis, only tumor size at diagnosis was prognostic for OST (p 0.018), although presence of metastasis at diagnosis showed a trend toward significance (p 0.055). Tumor size at diagnosis, lack of previous steroid therapy, and metastasis at diagnosis were all prognostic for PFI on multivariate analysis (p 0.01, 0.035, and 0.020, respectively). Neither response to toceranib therapy nor previous treatment (other than toceranib) were significantly associated with outcome.

This is the first study evaluating outcome and survival data in dogs with AGASACA treated with toceranib. Results suggest that toceranib may extend overall survival in dogs with AGASACA. Reported response rates and toxicity are similar to previous studies.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

K.D. Lyons
Texas A&M University
College Station, TX, USA

URL: http://www.vin.com/doc/?id=817279
The Occurrence of Feline Neoplasia: A Comparison Between Danish and North American Cats

B. Børresen; M.A. Heden; M.S. Kent; A.T. Kristensen

1Copenhagen University, Frederiksberg, Denmark; 2Evidensia Djursjukhuset Göteborg, Göteborg, Sweden; 3University of California-Davis, Davis, CA, USA

Feline cancer epidemiologic studies from North America all date prior to 1980 and suggest hemolymphatic cancers are the most common types of cancer. More recent publications are mainly European and suggest the integument is the most commonly affected system. This may be due to geographical or temporal differences. This study aimed to describe and compare the occurrence of cancer using a North American and Danish population of cats from the same time period.

Cases from the Danish Veterinary Cancer Registry (DVCR) and UC-Davis (UCD) between 2005 and 2013 were included, finding 511 neoplasms from 479 cats (DVCR) and 1544 neoplasms from 1352 cats (UCD). There were significantly more neutered males and females (p=0.041 and p<0.001) and a significantly higher percentage of malignant tumors from UCD (p<0.001) compared to the DVCR. Epithelial neoplasms were the most common tissue in both data sets. Skin and adnexa were the most commonly affected sites in both groups, followed by the gastrointestinal system. Intact females had a similar relative risk of having mammary neoplasia compared to neutered females in both data sets (UCD 5.35 [1.53–18.65], DVCR 5.42 [4.02–7.31]), but there was a significant higher proportion of mammary gland tumors in the Danish data (p<0.001).

Comparison between Danish and American cats showed that epithelial tissue and the integument were most commonly affected at both sites. The higher proportion of mammary gland tumors in DVCR data is likely related to the higher percentage of intact females.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

B. Børresen
Copenhagen University
Frederiksberg, Denmark

URL: http://www.vin.com/doc/?id=8172794
Expression of Felis catus Gammaherpesvirus-1 ORF73, F7 and ORF50 in FIV-Associated Lymphoma Biopsies

M. Aghazadeh1; M. Shi1; R. Troyer2; A. Mcluckie1; S. Lindsay1; V. Barrs1; J. Beatty1

1University of Sydney, Sydney, Australia; 2College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA

Felis catus gammaherpesvirus-1 (FcaGHV-1), a candidate lymphomagenic virus discovered in 2013, infects an estimated 200 million cats worldwide. In humans, the gammaherpesviruses (GHV) Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are causal in up to 95% of HIV-associated lymphomas. In cats, feline immunodeficiency virus (FIV) infection is associated with the development of high-grade B-cell lymphomas. Whether FcaGHV1 plays a role in FIV-associated lymphomas is under investigation.

The gold standard for determining causality in EBV-associated lymphomas is the detection of viral transcripts expressed during latency that promote uncontrolled growth. The aim of this study was to investigate FcaGHV1 gene expression in FIV-associated lymphomas. We targeted 3 FcaGHV1 open reading frames (ORFs). Two were identified by comparative sequence analyses; ORF73, a homologue of EBNA1 which is expressed in all EBV-associated malignancies and F7, a homologue of KSHV vFLIP, which encodes an anti-apoptotic protein. The third, ORF50, was identified during our RNA-seq analyses of feline lymphoma transcriptome. Its homologue is a KSHV lytic cycle activator.

Frozen biopsies from cases of high-grade B cell lymphoma arising in cats seropositive for FIV and seronegative for FeLV were identified in our tissue bank. Cases were included if tumour DNA was positive for FcaGHV1 on PCR. Nine samples met the inclusion criteria.

Total RNA was purified from frozen tissue and treated with DNase. One-step RT-PCR assays amplifying FcaGHV1 ORF73, F7, and ORF50 (mRNA splice product) were designed and optimized. The identity of RT-PCR products migrating at the expected size was confirmed by sequencing. In 5 cases, expression of 1, 2 or 3 FcaGHV1 genes was detected. Four cats tested negative for all three transcripts.

This study demonstrates, for the first time, expression of FcaGHV1 in feline lymphoma tissues. Investigations to localize FcaGHV1 gene expression to cell type and to determine tissue specificity are warranted.

DISCLOSURES

Disclosures to report
This study was funded by the Morris Animal Foundation grant number D15FE-001.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Aghazadeh
University of Sydney
Sydney, Australia

URL: http://www.vin.com/doc/?id=8172795
High Pretreatment D-dimer Concentration is Associated with Poor Prognosis in 48 Dogs with High-Grade Lymphoma

P. Boye¹; F. Serres¹; F. Floch¹; L. Marescaux¹; D. Tierny²
¹Oncovet, Villeneuve-d’Ascq, France; ²OCR, SIRIC ONCOLille, Parc EuraSanté, Loos, France

In humans, pretreatment plasma D-dimer levels have been reported to predict survival in several types of malignancies. The objective of this study was to evaluate the prognostic value of pretreatment D-dimer levels in dogs with high-grade lymphoma.

Forty-eight owned dogs with multicentric high-grade lymphoma were enrolled in a prospective and observational clinical study. Signalments, clinical findings, histology and cytology reports, immunophenotype, complete clinical staging and response to treatment were recorded for all dogs according to the WHO classification. Pretreatment D-dimer levels were measured with a quantitative D-dimer turbidimetric immunoassay (NycoCard Reader II, Nycomed).

Dogs were randomly assigned into two different treatment groups in a blinded fashion, for receiving anti-neoplastic drug (etoposide phosphate or F-14512). All dogs involved in the study followed the same protocol over a period of 8 weeks. The protocol consisted of four cycles of F14512 (0.075 mg/kg) or etoposide phosphate (100 mg/m²) IV injections every 2 weeks with a 3-hour injection once daily on 3 consecutive days. Short-term response was assessed by repeating complete staging at day 62, according to the RECIST criteria published for peripheral nodal lymphoma in dogs. Dogs were then followed every month until relapse. In case of relapse, a complementary CHOP-based chemotherapy protocol was proposed to the dog’s owner.

The median value of pretreatment plasma D-dimer was 0.4 µg/mL (range: 0.1–14.3 µg/mL). The optimal cut-off value of D-dimer based on progressive free interval (PFI) was 0.5 µg/mL (HR: 2.22, p=0.014). A D-dimer level >0.5 µg/mL was significantly associated with inferior PFI (54 vs. 104 days, p=0.01). Dogs with a D-dimer level >0.5 µg/mL had a significantly worse survival than those with a D-dimer level ≤0.5 µg/mL (OS: 93 vs. 177 days, p=0.01). High D-dimer levels were not correlated with naïve vs. relapsed lymphoma, B vs. T lymphoma, clinical stage, substage and morphotype. High D-dimer levels remained an independent predictor for treatment received (etoposide phosphate vs. F14512, p=0.97). There was no difference in response rate and PFI between dogs treated with F-14512 vs. etoposide phosphate (ORR: 44% vs. 45%, p=0.92; PFI: 86 vs. 87.5 d, p=0.34, respectively).

In conclusion, pretreatment plasma D-dimer level may serve as a simple but effective predictor of prognosis in dogs with high-grade lymphoma. High pretreatment D-dimer levels were associated with short PFI and poor overall survival in 48 dogs enrolled in a prospective double-blind randomized clinical trial.

DISCLOSURES

Disclosures to report
This study was conducted by Oncovet Clinical Research (OCR) as part of a collaborative research project between OCR and Pierre Fabre Medicament.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Boye
Oncovet
Villeneuve-d’Ascq, France

URL: http://www.vin.com/doc/?id=8172756
Efficacy of Chemotherapy and Clinical Outcome in Primary, Metastatic Feline Pulmonary Carcinomas: An Observational Study

E. Treggiari¹; A. Taylor²; M.A. Pellin³; G. Romanelli⁴; P. Valenti⁵; G.A. Polton⁶; K. Curran⁷; P. Brown⁸; S.L. Mason⁹

¹Willows Veterinary Centre and Referral Service, Solihull, UK; ²Royal Veterinary College, Hatfield, UK; ³School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA; ⁴Clinica Veterinaria Nerviano, Nerviano, Milano, Italy; ⁵Clinica Veterinaria Malpensa, Samarate, Varese, Italy; ⁶North Downs Specialist Referrals, Bletchingley, UK; ⁷College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA; ⁸Small Animal Specialist Hospital, North Ryde, NSW, Australia; ⁹Queens Veterinary School Hospital, University of Cambridge, Cambridge, UK

Pulmonary carcinomas are infrequently documented in cats and intra/extrathoracic metastatic disease appears common. While surgery is the gold standard for operable tumours, there are no studies assessing the efficacy of medical treatment in cases of metastasis. The aim of this study was to determine the clinical response to chemotherapy in primary feline pulmonary carcinomas with evidence of metastatic disease.

Medical records from multiple institutions were searched for cats with cytologically or histopathologically confirmed primary pulmonary carcinomas, with concurrent computed tomography-suspected metastases, which subsequently underwent treatment with cytotoxic chemotherapeutics or tyrosine kinase inhibitor drugs. Cats that underwent surgical resection of the primary tumour and/or associated metastases were not included.

Thirteen cats were selected for inclusion. Median age was 12 years (range 6–16 years) and median body weight 3.9 kg (range 3.1–8.2 kg). Presenting clinical signs included coughing (9), tachypnoea (5), gastrointestinal signs (4), abdominal pain (1) and lethargy (1). A diffuse nodular pattern, consistent with metastasis to the lung parenchyma, was present in all cases; additional locations were identified in 6 cases (intrathoracic nodes [5], kidneys [1]). Medical treatments included vinorelbine (3), carboplatin (4), toceranib phosphate (4) and metronomic cyclophosphamide (2). All cats had variable improvement in clinical signs after initiation of treatment and experienced moderate to mild toxicity, with no cats requiring hospitalisation due to adverse events.

Overall median time to progression (TTP) with first-line medical treatment was 99 days (range 32–317 days). Four cats had evidence of disease progression while on chemotherapy and received rescue treatment, with a TTP ranging from 8 to 85 days. In 2 cases, only a clinical response could be assessed; of these, one had renal metastases at diagnosis and the other developed renal metastases while receiving treatment. These two patients initially demonstrated stable disease but later developed intraocular and retrobulbar metastases, respectively. Of patients with repeat imaging, 1 cat had a partial response, 6 had stable disease and 4 progressive disease. The overall median survival time was 139 days (range 50–497 days). Four cats were still alive at the time of data analysis with a median follow-up of 428 days (range 81–625 days).

This study suggests that chemotherapy may achieve stable disease in cats with primary, metastatic lung tumours. Extended survival times are possible, with some cats surviving over a year. Based on these results, medical treatment appears to be well tolerated and should be considered in advanced disease stage.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION
(clic the speaker’s name to view other papers and abstracts submitted by this speaker)

E. Treggiari
Willows Veterinary Centre and Referral Service
Solihull, UK

URL: http://www.vin.com/doc/?id=8172797
Ovarian Tumours in the Bitch - Pathological Findings and AMH Values

H. Aupperle-Lellbach¹; K. Klose²; A. Coelfen³; C. Beitzinger⁴; B. Walter⁴; K. Jäger³; F. Kassous⁵; C. Weber³

¹Laboklin GmbH&Co.KG, Bad Kissingen, Germany; ²Institut of Veterinary-Pathology, Leipzig, Germany; ³Laboklin, Bad Kissingen, Germany; ⁴Clinic of Small Animal Surgery and Reproduction, München, Germany; ⁵National Veterinary School, Alfort, France

Although various neoplasms may occur in the canine ovary, only few studies with mainly small case numbers are available (Review: Arlt & Haimar 2016). Elevated anti-Müllerian hormone (AMH) concentrations have been described in granulosa cell tumours (GCT) in women and mares, but not in dogs until now.

Aims of the study:
1. Pathological characterization of a higher number of canine ovarian neoplasms with a correlation to breed and age
2. Evaluation of AMH values in canine GCTs and other ovarian tumours

Ovarian neoplasms of 280 bitches (age 9±3 years) were submitted (2013–2016) for histopathological routine diagnosis, including macroscopic and immunohistochemical (cytokeratin, CD3, CD79a, CD31, actin) investigations.

In 21 cases, preoperative serum samples were available for retrospective AMH value measurements with an automated chemiluminescense-immunoassay.

Ovarian tumours (unilateral/bilateral) were diagnosed as GCT (86/11), ovarian carcinoma (41/23) and adenoma (32/8), teratoma (17/3), dysgerminoma (14/2), leiomyoma (6/0), leiomyosarcoma (5/0), hemangiosarcoma (3/0), stromal tumour (2/0), lymphoma (4/3), luteoma (5/0), multiple different neoplasms (4/11).

Certain signs of malignancy were obvious in 23 GCTs, six dysgerminomas, one teratoma and all carcinomas, lymphomas, sarcomas and cases with multiple tumours.

Bitches with teratomas were younger (median 6 years) than dogs with other ovarian neoplasms (median 9 years).

Median diameters were 1.5 cm of normal ovaries, 3.0 cm of ovarian adenomas and carcinomas, 4.5 cm of GCTs and dysgerminomas, 5.3 cm of teratomas.

Within the ovarian tumour population, the breed groups, sheepdogs and cattledogs (FCI-1) and Spitz and primitive types (FCI-5) were represented with 14.7% and 5.3%, respectively. However, looking at all samples (AS) and percentage of all tumour samples (TS) submitted to Laboklin during the years, these breed groups were less represented: sheepdogs and cattledogs: AS 7.33% and TS 6.7%; and Spitz and primitive types: AS 7.8% and TS 1.74%.

AMH values (ng/ml) were significantly higher in GCTs (median: 5.13, 1.12 to >23.00, n=9) than in dysgerminomas (median: 0.25; 0.03–0.26, n=3), ovarian carcinomas and adenomas (median: 0.61; 0.01–0.89, n=9).

In conclusion, sheepdogs and cattledogs (FCI-1) and Spitz and primitive types (FCI-5) seem to have a predisposition for ovarian tumours. Although varying in median size and age of the bitch, ovarian neoplasms are not distinguishable by clinical or macroscopical findings. Histological investigation is needed for final diagnosis and prognosis. However, measurement of AMH serum concentration may help to identify GCT pre-surgically. Further studies will be performed to investigate AMH values in cases with ovarian cysts.

DISCLOSURES

Disclosures to report
Several authors of this study belong to Laboklin GmbH & Co.KG - a diagnostic laboratory, which is offering the AMH measurement for clients.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

H. Aupperle-Lellbach
Laboklin GmbH&Co.KG
Bad Kissingen, Germany

URL: http://www.vin.com/doc/?id=8172798
Gum Arabic-coated radioactive gold nanoparticles (GA-\(^{198}\)AuNP) are effectively retained and result in 80% tumor reduction in a mouse model of human prostatic carcinoma. Our objectives were to determine the toxicity and preliminary efficacy of GA-\(^{198}\)AuNP administered intralesionally to dogs with spontaneously occurring carcinoma of the prostate. The hypothesis was that intralesional GA-\(^{198}\)AuNP would cause short-term swelling but cause no systemic toxicity and result in tumor stabilization or shrinkage. Following Institutional Animal Care and Use Committee approval, dogs with a diagnosis of prostate carcinoma without bladder involvement were eligible for enrollment with informed owner consent. Staging was performed and injection of GA-\(^{198}\)AuNP was achieved with CT guidance (100–200 µL per site in multiple sites, total amount varied based on tumor size). A complete blood count, chemistry panel, and urinalysis were performed weekly for 4 weeks following treatment; a CT scan was performed 4 weeks after treatment. Nuclear scintigraphy was performed regularly (15 minutes, 1 h, 4 h, 1, 2, 4, and 5 days post-injection) to determine the degree of retention of GA-\(^{198}\)AuNP in the prostate. Following the 4-week trial period, chemotherapy could be started at the discretion of the pet owner. Twenty-two dogs were enrolled; 3 dogs had metastasis to the lymph nodes in the sublumbar region, and 19 dogs had no evidence of metastasis. Two dogs were treated to a biologically equivalent dose of 50 Gy, and 20 dogs were treated to 105 Gy. One dog died 12 days post injection due to urethral obstruction from either tumor swelling or disease progression. Following this event, dogs with evidence of urethral obstruction had urethral stents placed (n=15) prior to treatment. Fifteen dogs received chemotherapy. The median survival time of dogs receiving chemotherapy was 132 days (range 55–420 days) compared to 56 days (range 12–255 days) in dogs that did not. The average tumor retention of GA-\(^{198}\)AuNP was 70% at 5 days post-injection; loss occurred into the urine through the bladder. No accumulation of dose was found in heart, lung, liver, spleen, and kidney as determined by whole body planar imaging up to 5 days post-treatment. The median reduction in tumor volume was 10% one month after GA-\(^{198}\)AuNP therapy in 14 dogs. In conclusion, intratumoral administration of GA-\(^{198}\)AuNP caused no acute systemic toxicities in any dog and may be effective in decreasing tumor size; however, local tumor swelling is possible, and dogs must be closely monitored for evidence of urethral obstruction.

**DISCLOSURES**

Disclosures to report
Grant and financial support: This work was supported by a grant from the University of Missouri Institute of Clinical and Translational Sciences, NIH-SBIR Phase II contract (HHSN261201000100C), and Shasun NBI, LLC. AU, KVK and RK are co-founders of Nanoparticle Biochem, Inc.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

S.M. Bechtel
University of Missouri
Columbia, MO, USA

URL: http://www.vin.com/doc/?id=8172790
Poster Presentations

Evaluation of Infective and Replicative Properties of a Replication-Selective Oncolytic Vaccinia Virus (VVTG17990) on Canine, Feline, Porcine and Human Cell Lines  J.S. Béguin

Multiple Colorectal Granular Cell Tumours in a Dog  G.C. Ruiz

Spirocerca lupi-Induced Oesophageal Neoplasia: Predictors of Surgical Outcome  P. Pazzi

Survival of Dogs Diagnosed with Inflammatory Mammary Cancer Treated with a Multimodal Therapy  I. Clares Moral

Effect of Radiation Therapy on the Treatment of Intracranial Tumours in Dogs: Meningioma and Glioma  T. Magalhães

Ultrasound-Guided Fine-Needle Aspiration of the Canine Prostate - A Useful Sampling Method for Molecular Biological Analysis?  H. Thiemeyer

Histiocytic Sarcoma is Over-Represented in Miniature Schnauzers in the United Kingdom  J. Elliott
Evaluation of Infective and Replicative Properties of a Replication-Selective Oncolytic Vaccinia Virus (VVTG17990) on Canine, Feline, Porcine and Human Cell Lines

J.S. Béguin1; C. Maurey1; V. Nourtier2; J. Foloppe2; P. Erbs2; B. Klonjkowski1

1Université Paris Est, Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France; 2Transgene, Illkirch Graffenstaden, France

Oncolytic virotherapy with tumor selective viruses offers a promising treatment modality for cancer. In human medicine, vaccinia virus (VV) has shown encouraging results on tumor explants. This biotechnology is underused in veterinary oncology.

First objective of this study was to investigate the capacity of various species cell lines to support infection by a replication-selective oncolytic VV (VVTG17990). Our second objective was to assess replication potency of VVTG17990 on those cell lines.

A thymidine kinase and ribonucleotide reductase genes-deleted VV expressing green fluorescent protein (GFP) was designed (VVTG17990).

Non-tumoral canine (DKE1), feline (CrFK), porcine (PK-15) and human (293) cell lines were used as well as tumoral canine (A72) and human (HeLa) cell lines.

Susceptibility was evaluated 16 hours after infection with VVTG17990 using fluorescence microscopy and flow cytometry. Multiplicity of infection (MOI) of 0.1, 0.01 and 0.001 were tested.

Virus titers were evaluated 4 days after infection at a MOI of 0.0001 and 0.00001, by standard plaque forming assay on culture medium and cell lysate. All experiments were performed in triplicate.

GFP expression was detected by fluorescence microscopy 16 hours after infection for all cell lines even with low infective doses. Flow cytometry allowed an assessment of a dose-dependent infection of cells. For all cell lines, more than 88% of cells were infected at a MOI of 0.1. Equivalent percentage of infection was noticed for HeLa, 293 and PK-15 at a MOI of 0.01. On the other hand, lower infection was assessed for DKE1 (55%), A72 (27%) and CrFK (21%). At a MOI of 0.001, higher percentage of infection was observed for 293 (32%) and PK-15 (25%). For the others, less than 13% of cells were infected. Tumoral status of cell lines didn't seem to influence susceptibility to VVTG17990.

Interestingly, 16 hours after infection VVTG17990 proved effective lytic potency on cell lines. Lytic potency was more important with higher viral doses.

A replication factor of $10^6$ to $10^7$ was determined 4 days after infection for all cell lines, except for feline cell lines (about $10^{3}$). Tumoral status of cell lines didn't seem to influence the replication factor.

This study proves that canine, porcine and human cell lines support infection by VVTG17990 with a high replication factor. In comparison, susceptibility and replication potency were lower for feline cell lines. An in vitro lytic potency was also noticed. These promising results support the use of replication-selective oncolytic VV on canine tumors.

**DISCLOSURES**

Disclosures to report

This study was supported by Transgene.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.S. Béguin
Université Paris Est
Ecole Nationale Vétérinaire d'Alfort
Maisons-Alfort, France

URL: [http://www.vin.com/doc/?id=8172800](http://www.vin.com/doc/?id=8172800)
Multiple Colorectal Granular Cell Tumours in a Dog

G.C. Ruiz, S. Gould, S. Warman
University of Bristol, Langford, Bristol, UK

Granular cell tumours are uncommon soft tissue neoplasms believed to arise from Schwann cells. Oral, ocular and neurological forms have been reported in dogs, and various locations including the gastrointestinal tract have been reported in humans. This latter location has not been reported in dogs.

A four-year-old female neutered Jack Russell Terrier presented with one-year history of haematochezia and intermittent diarrhoea that did not respond to dietary changes, and antibiotics. On presentation, the dog was bright and alert and in good body condition. Rectal examination revealed multiple (>20) nodular masses (approximately 3–4 mm in diameter) in the rectum. The remainder of the examination was unremarkable.

Bloodwork revealed hypocobalaminaemia (138 pmol/L, reference range 200–408) and hypofolataemia (6.7 nmol/L, reference range 12–30) consistent with diffuse small intestinal disease. Haematology and biochemistry were unremarkable. A gastrointestinal endoscopy documented multiple small masses in the rectum and the colon (>50 in total). These masses were present on the last 20 cm of the large intestine. The mucosa around the masses appeared irregular and swollen. The ileum appeared mildly irregular. Histopathology of the masses identified a population of large cells with granular cytoplasm multifocally expanding the lamina propria between the glands, consistent with granular cell tumours. There was also a mild aggregation of lymphocytes, plasma cells and sparse eosinophils in the colic mucosa between the masses. There was minimal lacteal dilation in the ileum, with no evidence of inflammation. Additional stains did not yield significant information. Bacterial and fungal cultures of colic biopsies were negative.

Diet change to a hypoallergenic diet (Purina HA) and parenteral cobalamin supplementation led to resolution of the diarrhoea. At the most recent follow-up one year after diagnosis, the dog was still clinically well on hypoallergenic diet. The owners reported intermittent haematochezia and very occasional tenesmus. Rectal examination was similar to the initial visit.

Granular cell tumours are uncommon and predominantly benign neoplasms in humans; 10% of the tumours develop in the gastrointestinal tract. Endoscopic surveillance is usually sufficient for small and asymptomatic tumours. Surgical excision is recommended for large, malignant and multifocal tumours. Endoscopic resection has also been recently reported. No surgical excision was attempted in our dog given the multiplicity of the masses and the absence of significant clinical signs. To our knowledge, this is the first description of multiple granular cell tumours affecting the gastrointestinal tract in dogs, and these appeared to have a benign clinical course.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

G.C. Ruiz
University of Bristol
Langford, Bristol, UK

URL: http://www.vin.com/doc/?id=8172801
**Spirocerca lupi-Induced Oesophageal Neoplasia: Predictors of Surgical Outcome**

P. Pazzi¹; A. Kavkovsky²; A. Shipov²; G. Segev²; E. Dvir³

¹University of Pretoria, Pretoria, South Africa; ²The Hebrew University of Jerusalem, Rehovot, Israel; ³Tel Hai Academic College, Upper Galilee, Israel

Canine spirocercosis is caused by the nematode *Spirocerca lupi*. Oesophageal fibro-inflammatory nodules may undergo neoplastic transformation. No studies assessed pre- or post-surgical prognostic indicators in dogs that undergo intervention.

This observational multi-center study aimed to assess the outcome of dogs with neoplastic spirocercosis undergoing endoscopic-guided ablation (n=12) or surgery (n=18), and identify prognostic indicators. Parameters evaluated included: age, weight, body condition score at diagnosis, gender, duration of clinical signs, hematology, biochemistry, tumor size, placement of percutaneous endoscopically placed gastrostomy tube, histopathological mitotic indices, days to discharge and chemotherapy administration.

Kaplan-Meier survival curves showed no difference in survival between ablation and surgery [median: 68 days (range: 0–1550) vs. 107 days (0–1511), respectively (p=0.662)]. When only dogs surviving the first 21 days (T²¹) after ablation or surgery were evaluated, the significance in survival was borderline [79 days (45–1550) vs. 250 days (80–1511), respectively, p=0.082]. None of the parameters measured were associated with survival advantage. Intra-treatment group survival analysis identified survival advantage for chemotherapy within the surgical group (p=0.021); this became insignificant (p=0.430) in T²¹. When the latter were evaluated, Ht >36% (p=0.016) and white cell count <15.0x10⁹/L at presentation (p=0.021) were associated with an improved outcome. Ht <36% at presentation for all dogs and T²¹ showed a significant hazard ratio (0.960, p=0.037 and 0.947, p=0.022 respectively).

No clear benefit was identified for surgery, when ablation is technically possible. Prognostic indicators were only useful if the dog survived the first 21 days post-surgery. Chemotherapy post-intervention made no difference to survival.

**DISCLOSURES**

No disclosures to report

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Pazzi

University of Pretoria
Pretoria, South Africa

URL: [http://www.vin.com/doc/?id=8172802](http://www.vin.com/doc/?id=8172802)
Survival of Dogs Diagnosed with Inflammatory Mammary Cancer Treated with a Multimodal Therapy
I. Clares Moral; L. Peña; P. García San José; S. González Sanz; D. Alonso Miguel; P.M. García Fernández; M. Suárez Redondo; M.D. Pérez Alenza
Veterinary Teaching Hospital Complutense of Madrid, Madrid, Spain

Inflammatory mammary cancer (IMC) is a specific type of locally advanced mammary cancer in dogs. It is an uncommon tumor, but the most aggressive type of mammary cancer in female dogs with an extremely poor survival rate. No effective treatment has been reported for dogs with IMC and surgery is not indicated as first option. Based on the different molecular features of this highly angiogenic cancer, new therapies focused on specific targets have been proposed.

The aim of this study was to evaluate the survival time in dogs diagnosed with IMC treated with a multimodal therapy based on an anti-COX-2 drug (firocoxib), a tyrosine kinase inhibitor (toceranib) and an androgen receptor inhibitor (flutamide).

Ten dogs diagnosed with IMC, presented to the Veterinary Teaching Hospital Complutense of Madrid, were included. Diagnosis was based on clinical features (edema, erythema, warmth and firmness in the mammary glands) and histopathological confirmation. Immunohistochemical analysis (Ki-67 index, C-kit, COX-2 and androgen receptor) were performed. Five dogs received palliative treatment (antibiotics, corticoids) (control group or CG) and the other 5 dogs were treated with a combination of firocoxib, flutamide and toceranib (treatment group or TG). One dog of the TG refused treatment with toceranib due to economy matters. Survival time was defined as the time from IMC diagnosis to euthanasia or death of the dog. Age at the time of IMC diagnosis, reproductive status, previous history of mammary tumors and evolution of IMC after treatment were also analyzed. A paired Student's t-test was performed for statistical analysis of parametric variables with an alpha error of 0.05 and chi-square test for no parametric variables.

The mean survival time of dogs of TG was significantly higher than that of CG (34.6±15.0 and 10.6±13.4 days, respectively; p=0.028). Age at the time of IMC diagnosis (10.8±2.7 years in TG and 11.0±1.9 years in CG), reproductive status and immunohistochemical profile were not significantly different between the 2 groups. In TG, a complete remission was obtained in one case, stable disease in 2/5 dogs and progressive disease in 2/5. In TG grade 2 (n=2) and grade 3 (n=1), toxicities were observed after 3–4 weeks, but an increase in quality of life was referred in all cases after the initiation of the treatment.

Despite poor prognosis, the multimodal therapy increases survival time in dogs diagnosed with IMC with an adequate quality of life.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
I. Clares Moral
Veterinary Teaching Hospital Complutense of Madrid
Madrid, Spain

URL: http://www.vin.com/doc/?id=8172803
Effect of Radiation Therapy on the Treatment of Intracranial Tumours in Dogs: Meningioma and Glioma

T. Magalhães 1; J. Benoit 2; S. Necova 2; S. North 2; F.L. Queiroga 1

1University of Trás-os-Montes and Alto Douro, Vila Real, Portugal; 2VRCC - Veterinary Referrals, Laindon, UK

Radiation therapy has been considered the treatment of choice for many brain tumors in dogs, like glioma and intracranial meningioma.

A retrospective study was carried out, with information about patients treated between 2011 and 2015, in a veterinary referral hospital. The goals were set to evaluate the efficacy of this therapeutic approach and to search associations between different epidemiological, clinical, diagnostic and therapeutic features with the tumor type and the survival times. This study included 32 dogs diagnosed with intracranial meningioma and glioma which underwent radiation therapy. The clinical reports were analyzed. Two survival times were calculated: overall (OST) and post-treatment (PTST), from the diagnosis or the end of radiation, respectively, until death or end of the study period.

Sex and contrast enhancement exhibited statistically significant associations (p<0.05) with tumor diagnosis. These results showed a sexual predisposition of males for glial type and females for meningeal type and a greater specificity of contrast enhancement, observed on MRI, for meningioma. It was found that just the breed and the sex are prognostic factors, as they were significantly associated (p<0.05) with survival times. Boxer and Labrador retriever breeds and the female sex were considered as a survival benefit in these patients. Median values were 372 days for TSPT and 446.5 days for the TST. The 1- and 2-year survival rates were, respectively, 50% and 23.3%. Thus, radiation therapy is an effective treatment option for these neoplastic cases, with better results than other therapeutic approaches.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Magalhães
University of Trás-os-Montes and Alto Douro
Vila Real, Portugal

URL: http://www.vin.com/doc/?id=8172804
Ultrasound-Guided Fine-Needle Aspiration of the Canine Prostate - A Useful Sampling Method for Molecular Biological Analysis?

H. Thiemeyer¹; J.T. Schille¹; L.K. Harder¹; S.O. Hungerbuehler¹; R. Mischke³; M. Hewicker-Trautwein²; B. Brenig³; J. Beck⁴; E. Schütz⁴; L. Taher⁵; H. Murua Escobar⁶; I. Nolte¹

¹Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany; ²Institute of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany; ³Institute of Veterinary Medicine, Georg-August-University Göttingen, Göttingen, Germany; ⁴Chronix Biomedical, Göttingen, Germany; ⁵Department of Biology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany; ⁶Department of Medicine, Clinic III-Hematology/Oncology/Palliative Care, Rostock, Germany

Male dogs with prostate carcinoma are often diagnosed at a late stage and therapeutic approaches are limited. Therefore, new diagnostic strategies for early detection are needed. Whereas prostate-specific antigen (PSA) as a biomarker is controversially discussed for early detection in human medicine, potential biomarkers have not yet been established for dogs. Gene expression data sets, generated by next-generation sequencing, offer new possibilities in cancer research for biomarker discovery, understanding of carcinogenesis and development of therapeutic strategies. Since ultrasound-guided fine-needle aspiration biopsies (US-FNA) of the prostate are routinely used for cytology in dogs, aspirated cells can represent a source for gene expression studies. The aim of the present study was to evaluate US-FNA material for routine cytologic diagnosis and leftover cells for molecular biological analysis. US-FNAs were taken prospectively from 16 male dogs after clinical examination. Collected cells were used for cytological examination as well as molecular biological analysis. Prostate tissue samples were taken from 18 euthanized dogs. All samples were immediately frozen in liquid nitrogen. RNA was extracted from US-FNA samples using the miRNeasy® Micro Kit and RNA concentration was measured with Qubit. Prostate tissue samples were classified histopathologically. RNA isolation from prostate tissue was performed with AllPrep® DNA/RNA/miRNA Universal Kit, and quantity was measured with the Synergy system. A bioanalyzer was used to determine RNA integrity number (RIN). Whole transcriptome next-generation sequencing (NGS) was performed on an Illumina NextSeq500 system. Tissue samples were examined histologically: nine were diagnosed as malignant and nine were classified as non-neoplastic. Cytological examination of US-FNA was possible in 14 cases, 11 being diagnosed as normal to hyperplastic and three specimens being classified as prostate carcinoma. RNA concentration was detectable in all samples ranging from 9 ng/µl to 99 ng/µl. RNA quantity was sufficient as starting material for NGS. Transcriptome analyses from samples with RIN value ≥5.5 were successful. Data sets of differentially expressed genes (DEGs) were summarized in principal component analysis and showed major variances in DEGs between non-neoplastic and malignant samples and minor differences between US-FNA and tissue with comparable diagnosis. Globin genes were identified and significantly upregulated in US-FNA samples. Based on isolated total RNA concentration and integrity, residual cells from diagnostic US-FNA of the canine prostate can be considered as an adequate sample source for gene expression studies, biomarker research and a potential tool for advanced diagnostics of canine prostatic diseases.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

H. Thiemeyer
Small Animal Clinic, University of Veterinary Medicine Hannover
Hannover, Germany

URL:  http://www.vin.com/doc/?id=8172805
Histiocytic sarcoma (HS) is an aggressive neoplasm of dogs. Over-representation has been documented in several breeds, including Bernese mountain dogs, flat-coated retrievers, golden retrievers, and Rottweilers. The purpose of this retrospective study was to describe a series of miniature schnauzers (MS) diagnosed with HS in the UK and assess whether they were over-represented when compared to the hospital population.

Medical records of MS with a cytological or histopathological diagnosis of HS between January 2010 and March 2017 were reviewed. Breed predisposition was assessed with odds ratios, using the total number of hospital admissions for each breed without HS admitted during the study period as controls. This was also performed where two or more cases with HS were recorded for a particular breed.

Ten MS were diagnosed with HS during the study period, making them over-represented among the hospital population (odds ratio=8.98 [95% CI 4.64–17.41]). Seven were diagnosed with primary pulmonary HS based on the presence of a large pulmonary mass with or without evidence of intrathoracic metastasis or abdominal involvement, though only five exhibited overt respiratory signs. No patients had solitary HS. Five patients were treated with chemotherapy (lomustine +/- epirubicin) but an aggressive clinical course was found in all patients. Median survival time of all patients was 54 days (range: 0–232 days). Several other previously reported breeds were also noted to be predisposed to HS.

MS, in addition to previously reported breeds, were over-represented amongst dogs with HS in this patient population. Primary pulmonary involvement was common and patients presented with advanced disease, though some patients had no overt respiratory signs. The prognosis appears to be poor despite chemotherapy.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Elliott
Willows Referral Service
Solihull, UK

URL: http://www.vin.com/doc/?id=8172806
Scientific Programme

Diagnosis and Prognosis of Mast Cell Tumors - The 2017 Oncologist Perspective  Laura D. Garrett, DVM, DACVIM (Oncology)

Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors: The 2017 Pathologists’ Perspective  Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)

Immunohistochemistry for Neoplastic Disease: Reaching a Final Diagnosis (Sometimes) and More  Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)

Prognostic Biomarkers in Veterinary Oncology - Are We There Yet?  Laura D. Garrett, DVM, DACVIM (Oncology)
Diagnosis and Prognosis of Mast Cell Tumors - The 2017 Oncologist Perspective
Laura D. Garrett, DVM, DACVIM (Oncology)
College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA

**Keynote Message**

Mast cell tumours (MCT) are the most common skin cancer in dogs, and significant variability exists in their biological behaviour. Most of the tumours are cured with appropriate local therapy, but a subset shows malignant behaviour. This behaviour is evidenced by the potential to spread to lymph nodes, liver, spleen, and other areas and to thus become a systemic cancer. The variable behaviour makes it difficult to predict how an individual tumour is going to behave, and thus difficult to know what staging tests are needed, what treatments to offer, and what the prognosis will be in many cases. In addition to the controversies about systemic disease potential and prediction, opinions also vary over what treatment is needed to best attain local control of these tumours. In this session, findings of recent studies will be used to highlight what is known and what is still controversial in the diagnosis and treatment of mast cell tumours. Case examples will be used to illustrate the key points.

**Key References**

Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors: The 2017 Pathologists' Perspective
Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)
KamPath Diagnostics & Investigation, Fort Collins, CO, USA; Colorado State University, Fort Collins, CO, USA

KEYNOTE MESSAGE

Histological grade remains the cornerstone for determining prognosis in canine cutaneous mast cell tumors (MCTs), however has not been without its challenges diagnostically and clinically, when biological behavior does not follow the anticipated clinical course. In an attempt to improve diagnostic accuracy of grade as well as predictability of prognosis, a new grading scheme was proposed in 2011. A number of studies followed implementing this scheme, which proved improvement in some areas but continued limitations in others. In April 2017, based on critical review of the literature, the VCS/ACVP Oncology-Pathology Working Group put forth a consensus ultimately suggesting the two schemes may be complementary and proposed a combined grading system. It is recognized that even this method cannot be considered foolproof but may provide improved accuracy/predictability or at least harness a better understanding of the potential biological behavior of the tumor in question. Additionally, grade should not be considered as a stand-alone prognostic factor but instead considered in conjunction with the overall clinical picture as well as with proliferation and molecular markers (e.g., mitoses, Ki67, KIT, c-kit) when possible.

Key References

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)
KamPath Diagnostics & Investigation
Fort Collins, CO, USA

URL: http://www.vin.com/doc/?id=8172809
Immunohistochemistry for Neoplastic Disease: Reaching a Final Diagnosis (Sometimes) and More
Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)
KamPath Diagnostics & Investigation, Fort Collins, CO, USA; Colorado State University, Fort Collins, CO, USA

**KEYNOTE MESSAGE**

Immunohistochemistry (IHC) is a complex technique which, put simply, employs the use of commercial antibodies to identify antigens (molecular markers) in tissue sections. The use of IHC in veterinary medicine has grown significantly over the last 20 years and, while once primarily utilized in diagnostics for further characterization of neoplastic processes, has evolved for use in prognostication as well as in research for the elucidation of pathogenesis of disease processes. Following an introduction to basic concepts of IHC, this session will focus on IHC application in cancer diagnostics. Cell-specific markers of various tumor types will be addressed, as will the pros and cons of individual versus panels of immunohistochemical stains. Fundamental aspects of IHC to include controls, appropriate interpretation, and understanding recommendations or results provided on the biopsy report, as well as limitations of IHC will also be discussed.

**Key References**

**SPEAKER INFORMATION**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)
KamPath Diagnostics & Investigation
Fort Collins, CO, USA

URL: [http://www.vin.com/doc/?id=8172810](http://www.vin.com/doc/?id=8172810)
**Prognostic Biomarkers in Veterinary Oncology - Are We There Yet?**
Laura D. Garrett, DVM, DACVIM (Oncology)
College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA

**KEYNOTE MESSAGE**

As our understanding of the molecular basis of cancer has grown, so has the availability of tests to assess disease processes in dogs and cats. A cancer biomarker can be broadly defined as a molecule that indicates the presence of cancer or provides information about the likely future behavior of the cancer. To be able to assess the potential value and application of currently available biomarkers in veterinary medicine, it is essential to understand the process and pitfalls of discovery and validation of biomarkers. Analytic validity, clinical validity, and clinical utility of a biomarker all need to be demonstrated. Despite decades of work and extensive resources, even in human medicine the number of biomarkers with clinical utility is limited. Rapid expansion in genomic profiling is increasingly informing care of human cancer patients. Biomarkers in veterinary oncology are still a developing field. This session will describe what is required for the discovery and development of a clinical useful cancer biomarker and will then present several of the diagnostics currently available for veterinary oncology patients, with their usefulness and limitations highlighted.

**Key References**


**Speaker Information**

Laura D. Garrett, DVM, DACVIM (Oncology)
College of Veterinary Medicine, University of Illinois at Urbana-Champaign
Urbana, IL, USA

URL: http://www.vin.com/doc/?id=8172811
Evidence-Based Veterinary Medicine

Scientific Programme
Scientific Programme

**Running Multicentre Studies: Lessons from Cardiology**  Adrian Boswood, DVC, MA, MRCVS, VetMB

**Designing and Running Cohort Studies: How to Make them Work**  Jane K. Murray, BScEcon, MSc, PhD

**Taking Advantage of Big Data in Veterinary Research**  Alan Radford, BSc, BVSc, PhD, MRCVS

**Surveillance in a Digital World**  John S.P. Tulloch, BVetMed, MSc, DipRN, MRCVS
A good quality evidence base for clinical practice requires the conduct of multicentre studies. The major advantages of multicentre studies include the ability to recruit large numbers of patients in a relatively short time period, to conduct studies less biased by the effect of individual centres, and to conduct studies with results generalizable to a larger population of patients. Multicentre studies inevitably involve numerous diverse investigators recruiting patients. In order for such studies to be successful, they should be conducted according to a clear and ideally simple protocol that is agreed by all investigators prior to initiation, including, if necessary, stipulation of methods of measurement of clinical variables. Ethical considerations relevant to all investigating centres should be considered and clearly addressed. Recruitment of patients should be according to criteria that are simple to measure, clear, ideally widely available and agreed by the relevant specialist community as capable of identifying the group of patients of interest. Studies should have a clearly defined primary aim and only a limited number of secondary aims. Analyses of data that will be acquired should be pre-planned. There should be a clear discrimination between information that is "must have" and information that is "nice to have." Minimise the acquisition of data that is not necessary to achieve the primary aim of the study. This will prevent participation in the study becoming onerous and will limit the cost. Large studies are likely to require significant funding which often necessitates the involvement of a commercial sponsor. Where such a sponsor is involved, the needs and aims of the sponsor should ideally be aligned with those of the investigators. Investigators need to maintain sufficient independence from the sponsor for the study to retain credibility. A right to publish, independent of study outcome, should ideally be agreed to allow negative as well as positive studies to enter the literature. When results have been obtained, investigators have a responsibility to ensure those results enter the public domain and are disseminated appropriately.

Key References

Designing and Running Cohort Studies: How to Make them Work
Jane K. Murray, BScEcon, MSc, PhD
Dogs Trust, London, UK

Key References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Jane K. Murray, BScEcon, MSc, PhD
Dogs Trust
London, UK

URL: http://www.vin.com/doc/?id=8172892
Illness in pet animals impacts both on their welfare, and that of their owners and wider public. Despite the size of these populations, they have become information-poor due to the historical lack of centralised data collection. Projects like the Small Animal Veterinary Surveillance NETwork (SAVSNET - University of Liverpool) and VetCompass (Royal Veterinary College) seek to fill this gap using Health Informatics, which allows electronic health records (EHRs) to be anonymised and used for research. Both projects are collecting EHRs at scale to better understand the real world of companion animal clinical veterinary practice.

Both projects have assembled a strong coalition of collaborators and data partners allowing the collection of real-time data from sentinel networks of veterinary clinics (both projects) and diagnostic laboratories (SAVSNET) across the UK.

The use of these unique and rich data sources has rapidly grown. Key areas of current research include antimicrobial resistance mapping, description of antibacterial prescription, as well as real-time outbreak monitoring in both animal-only and "one health" settings. Using text-mining approaches, we are unlocking the surveillance value previously hidden in the clinical narrative of each EHR, opening new opportunities for surveillance (clinical signs, ticks), and pointing to a future that is less reliant on practitioner coding. Through the owner postcode, we are linking EHRs to other data sources and understanding the impact of climate and owner-predicted deprivation on disease and treatment.

SAVSNET has also created innovative and novel feedback loops that provide bespoke results to our data partners, increasingly in real-time. This allows for the first-time practitioners partaking in this surveillance to benchmark their own data to other anonymous practices in the network, with key features including antibacterial prescription and syndrome mapping.

Health Informatics research offers veterinary practitioners and their owners the chance to allow their animal's health data to be used for research, helping to fill the gap in companion animal surveillance and providing a new source of evidence to inform best clinical practice.

Key References
Surveillance in a Digital World
John S.P. Tulloch, BVetMed, MSc, DipRN, MRCVS
Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK

**KEYNOTE MESSAGE**

The landmark publication in *Nature* of the Google Flu Trends project sparked global interest in the use of internet search engines as disease surveillance tools. New epidemiological methods have now been developed to harness the huge volume of data generated from search engines. The evolution of social media platforms has given researchers novel ways to explore disease outbreaks, and to understand the general public’s response to them. Unfortunately, to date little research has been published using these approaches for the surveillance of companion animal diseases.

In this session, human health case examples will initially be explored to discuss the strengths and pitfalls of this type of research. Exploratory research around companion animal infectious diseases will be presented to highlight the ease of compiling such data. Potential new exciting avenues for quantitative and qualitative companion animal research will be presented.

Key References

**SPEAKER INFORMATION**

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

John S.P. Tulloch, BVetMed, MSc, DipRN, MRCVS
Health Protection Research Unit in Emerging and Zoonotic Infections
University of Liverpool
Liverpool, UK

URL: [http://www.vin.com/doc/?id=8172894](http://www.vin.com/doc/?id=8172894)
ISCAID - International Society for Companion Animal Infectious Diseases

Oral Presentations
Poster Presentations
Oral Presentations

Re-emergence of Feline Panleukopenia in Australia  V. Barrs
Investigation of Faecal Parvovirus Shedding in Asymptomatic Shelter-Housed Cats in Australia  P.J. Byrne
Class A CpG Oligonucleotides in Cats with Naturally Occurring Feline Panleukopenia Infection: A Prospective Case-Control Study  F.F. Ferri
Feral Carnivores are Reservoirs of Carnivore protoparvovirus 1 in Australia  J. Brailey
Feline Morbillivirus Infection in Domestic Cats in Italy: Epidemiological and Pathological Aspects  E. de Luca
Evaluation of a Discriminative Realtime RT-PCR in Cerebrospinal Fluid for the Diagnosis of Feline Infectious Peritonitis  S. Felten
Screening for Selected Pathogens in Ticks Infecting Cats in the United Kingdom: A Large-Scale Surveillance Programme  F. Duplan
The Role of Hypovitaminosis D in Complicated Canine Babesiosis  E. Dvir
Is Urine Culture the Poor Man's Blood Culture? Concordance Between Parallel Canine Blood and Urine Cultures  N.R. Barash
Companion Animals and Humans with UTI Share Common Uropathogenic Klebsiella pneumoniae  C. Pomba
Validation of a qPCR Panel to Aid in the Diagnosis of Dermatophytosis  C. Leutenegger
Re-emergence of Feline Panleukopenia in Australia

V. Barrs1; J. Brailey1; A. Allison2; M. Kelman1; J. Meers3; J.A. Beatty1; E.C. Holmes1

1University of Sydney, Camperdown, NSW, Australia; 2Cornell University, Ithaca, NY, USA

Feline panleukopenia, a highly contagious and often fatal disease of cats, is caused by feline panleukopenia virus (FPV) or canine parvovirus (CPV), both strains of Carnivore protoparvovirus 1. Clinical disease has rarely been seen in Australia since the mid-1970s until 2014, when an outbreak was reported to a national online disease surveillance reporting tool.

The aim of this study was to determine the strains of canine protoparvovirus 1 and epidemiological factors involved in outbreaks of feline panleukopenia reported since 2014. Veterinarians and shelter owners were contacted to arrange site visits, collect samples and obtain information about animal movements, biosecurity and vaccination protocols for qualitative analysis. DNA was extracted from faeces or tissues of representative cats from each outbreak with clinical signs of panleukopenia and/or positive faecal antigen CPV tests, for PCR and sequencing of the VP2 gene. Phylogenetic analysis of outbreak and CPV-like and FPV-like VP2 sequences available on GenBank was performed using the maximum likelihood method.

Three outbreaks causing over 350 fatalities were identified in: (A) 2014, Melbourne; (B) 2015, Melbourne and Mildura, a city 540 km from Melbourne; (C) 2016, Melbourne and Sydney. Outbreaks in Mildura and Melbourne were caused by identical or closely related FPV genotype(s), while the Sydney outbreak was caused by a different FPV genotype. Most cases were from municipal, charitable or private shelters. Shelters with the highest number of fatalities did not perform routine vaccination. In shelters that did administer vaccines, disease occurred in incompletely vaccinated cats or cats not vaccinated due to respiratory disease. Movement of unvaccinated cats from municipal shelters to networks of private foster carers was identified in all outbreaks, including between Melbourne and Mildura in outbreak B. The median age of cats at diagnosis was 8 weeks. All outbreaks occurred from summer to autumn, coinciding with peak shelter intakes of kittens.

Feline panleukopenia, caused by FPV, has re-emerged as a major cause of mortality in Australian feline shelters in association with inadequate vaccination and biosecurity practices.

DISCLOSURES

Disclosures to report
This study was funded by grants from the NSW Cat Protection Society and the Australian Companion Animal Health Foundation, IRMA Project ID 1822469.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Barrs
University of Sydney
Camperdown, NSW, Australia

URL: http://www.vin.com/doc/?id=8172960
Canine parvoviruses (CPVs) and feline panleukopenia virus (FPV) are strains of *Carnivore protoparvovirus 1*. CPV2a-c can infect and replicate in both canids and felids. Using conventional PCR, a recent study reported a high prevalence of faecal shedding of CPVs among asymptomatic shelter cats in the UK, identifying cats as a potential reservoir of infection.

The aim of this study was to determine the prevalence of faecal shedding of CPVs in asymptomatic shelter-housed cats in Australia. One hundred stool samples from unvaccinated cats housed in a dual canine/feline shelter were collected and stored at -80°C until testing. Viral DNA was extracted from faeces by homogenisation of a 10% w/v solution of faeces in phosphate-buffered saline (PBS), boiling of the supernatant after centrifugation, chilling on ice and repeat centrifugation. To identify PCR inhibition in faecal DNA extracts, dilutions (1:10 and 1:20) of supernatant were spiked with feline genomic DNA (138 ng) and tested using a PCR amplifying the feline GAPDH gene. Feline GAPDH was amplified in all spiked faecal samples at a 1:20 dilution, and in 99 samples at a 1:10 dilution. PCR inhibition of GAPDH in one sample at 1:20 dilution was abolished at a 1:50 dilution.

Faecal DNA extracts (1:10 and 1:20 dilutions [n=99], 1:50 dilution [n=1]) from shelter cats were screened for the presence of CPV and FPV using a PCR assay amplifying a 529 bp region of the VP2 gene using primers 555-F and 555-R. PBS processed in parallel with samples from extraction to PCR served as a negative control and DNA from a previously sequenced canine CPV isolate as a positive control. In samples testing positive, the complete VP2 gene was sequenced to differentiate FPVs from CPVs. CPV DNA was not detected in the stool of any cat. FPV DNA was detected in the stool of 4 cats.

In contrast to results of a UK shelter, faecal shedding of CPV by asymptomatic shelter-housed cats was not detected in this study, and the prevalence of FPV shedding was low. Future studies to screen for *Carnivore protoparvovirus* using quantitative PCR assays are warranted to rule out low-level shedding undetectable by conventional PCR.

**DISCLOSURES**

Disclosures to report

Conflict of interest: The authors declare no potential conflict of interest regarding research, authorship and/or publication of this article.

Funding: The authors received research grants from Boehringer Ingelheim PTY LTD, 78 Waterloo Rd, Macquarie Park, NSW 2113 Australia, and the University of Sydney, Camperdown, NSW 2006 Australia.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**P.J. Byrne**
University of Sydney
Camperdown, NSW, Australia

URL: [http://www.vin.com/doc/?id=8172963](http://www.vin.com/doc/?id=8172963)
Class A CpG Oligonucleotides in Cats with Naturally Occurring Feline Panleukopenia Infection: A Prospective Case-Control Study

F.F. Ferri¹, F. Porporato¹, H. Lutz², M. Mei², G. Gerardi³, L.M. Coppola³, D. Bernardini³, B. Contiero³, N. Kohan Ranjbar², C. Callegari¹, R. Hofmann-Lehmann², E. Zini⁴

¹Istituto Veterinario di Novara, Granazzo con Monticello, Novara, Italy; ²Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; ³University of Padua, Padua, Italy; ⁴Clinic for Small Animal Internal Medicine, University of Zurich, Zurich, Switzerland

Feline panleukopenia virus (FPV) infection leads to severe leukopenia and gastrointestinal signs in cats, with mortality rate of up to 70%. Besides supportive therapy, information regarding specific treatments is yet very limited in affected cats. Class A CpG oligodeoxynucleotides (CpG-A) are short single-stranded DNA molecules containing unmethylated cytosine-phosphate-guanosine motifs that stimulate production of type I interferons. Studies in cats showed the ability of CpG-A to induce an antiviral state in vivo and to inhibit replication of FPV in vitro. Therefore, aims of this study were to investigate the effects of CpG-A on survival and clinical score, white blood cell (WBC), red blood cell (RBC) and platelet counts, as well as viremia and fecal viral shedding in cats naturally infected with FPV. Cats with positive fecal parvovirus antigen test were prospectively enrolled if presenting clinical or laboratory signs of FPV, had body weight >500 gr, were unvaccinated and not previously treated. Cats were randomly allocated to receive 100 µg/kg of CpG-A or placebo subcutaneously, at admission and after 48 hours; all cases were treated with supportive therapy. A clinical score derived from attitude, appetite, vomiting, diarrhea and temperature was assigned daily until death or during 7 days. Blood and fecal samples were collected at admission and at 1, 2, 7 days; complete blood counts were obtained and real-time PCR was performed to quantify FPV DNA in blood and fecal samples. Chi-square test and mixed ANOVA were used to compare treatment groups. Forty-two cats were included: 22 received CpG-A and 20 placebo. Survival rate did not differ between cats treated with CpG-A and placebo [11 of 22 (50%) vs. 8 of 20 (40%), respectively; p=0.516]. Differences between groups were not observed for clinical score, RBC, platelets, viremia and fecal viral shedding at any time point. Mean WBC count was higher in cats treated with CpG-A than with placebo at 7 days (25800±13800/µl vs. 14900±8400/µl, respectively; p=0.017) but not at the other time points. All cats showed discomfort during CpG-A injections.

In conclusion, treatment with CpG-A did not improve survival or clinical score and did not reduce viral shedding, suggesting that the drug or the treatment regimen used in this study is not beneficial in cats affected with FPV. The lack of favorable response to CpG-A might be due to the delayed improvement of WBC counts. Of note, the administration of CpG-A may be painful in cats.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
F.F. Ferri
Istituto Veterinario di Novara
Granazzo con Monticello, Novara, Italy

URL: http://www.vin.com/doc/?id=8172964
Feral Carnivores are Reservoirs of *Carnivore protoparvovirus 1* in Australia

J. Brailey1; D. Jenkins2; M. Aghazadeh1; J. Slapeta3; J. Gorrell3; J.A. Beatty1; V.R. Barrs1

1University of Sydney, Camperdown, NSW, Australia; 2Charles Sturt University, Wagga Wagga, NSW, Australia; 3University of New England, Armidale, NSW, Australia

Disease in dogs caused by canine parvovirus (CPV) is common in Australia. A related strain of canine protoparvovirus 1 (CPPV1), feline panleukopenia virus (FPV), re-emerged in 2014 in Australia as a major pathogen in shelter cats. In North America and Europe, wild carnivore hosts are implicated in the emergence of novel strains of CPPV1. Australia has large populations of introduced feral carnivores including cats (*Felis catus*) and foxes (*Vulpes vulpes*) as well as endemic carnivores such as the endangered Tasmanian devil (*Sarcophilus harrisii*).

The aim of this study was to (i) determine whether there is evidence of CPPV1 infection in feral carnivores and viral traffic between these and companion animals; (ii) model *in silico* the susceptibility of the Tasmanian devil to CPPV1. Reticuloendothelial tissue samples were sourced from deceased feral carnivores for PCR amplification and sequencing of a 529 bp region of the CPPV1 VP2 gene. Phylogenetic analysis of partial VP2 gene sequences was performed using the maximum likelihood method. Tasmanian devil susceptibility to infection was investigated by comparison of their transferrin receptor type 2 (TfR) sequence at binding sites for CPPV1 to susceptible carnivores, and phylogenetic analysis of TfR protein.

Tissue samples from 62 feral cats and 53 foxes collected between 2010 and 2016 were analysed. CPPV1 DNA was detected in 14/62 feral cats and 0/53 foxes. CPPV1-positive cat samples, all from animals culled in 2010, comprised 5 related FPV genotypes, including one genotype identical to that detected in FPV outbreaks in cat shelters in Melbourne (2014–2016), and another that was closely related to an FPV strain identified in a Burmese kitten in Melbourne in 1970. TfR amino-acid residues 224 and 389, critical to parvovirus binding, are glutamate and arginine, respectively in Tasmanian devil TfR, in contrast to leucine and lysine or asparagine in canid and felid hosts. Tasmanian devil TfR protein was only distantly related to these hosts.

This study provides evidence of feral cat reservoirs of CCPV1 infection and viral traffic between feral carnivores and companion animals in Australia. TfR gene analysis indicates that Tasmanian devils are unlikely to be susceptible to CCPV1, which has important biosecurity implications for captive breeding programs.

DISCLOSURES

Disclosures to report

This study was funded by the Australian Companion Animal Health Foundation, A University of Sydney Charles Perkins Centre Fellowship grant and Boehringer Ingelheim.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Brailey
University of Sydney
Camperdown, NSW, Australia

URL: [http://www.vin.com/doc/?id=8172965](http://www.vin.com/doc/?id=8172965)
Feline Morbillivirus Infection in Domestic Cats in Italy: Epidemiological and Pathological Aspects

E. de Luca; P.E. Crisi; E. Febo; M. di Tommaso; D. Malatesta; G. Zaccaria; M. Maracci; G. di Francesco; M. di Domenico; A. Giovannini; G. di Guardo; G. Savini; A. Boari; A. Lorusso

1Istituto Zooprofilattico Sperimentale of Abruzzo and Molise, Teramo, Italy; 2University of Teramo, Teramo, Italy

A novel paramyxovirus, feline morbillivirus (FeMV), has recently been detected in a stray cat in Italy (Piuma/2015). According to previous studies conducted in other countries, FeMV has been suspected to be associated with feline chronic kidney diseases (CKD). We aimed at: i) investigating FeMV occurrence in the province of Teramo, central Italy; ii) associating FeMV with CKD lesions; iii) analyzing the genome of circulating FeMVs.

Urine samples collected from cats presented to the Veterinary Teaching Hospital (VTH, UniTE) or to local veterinary practitioners were screened (group A, n 60). In addition, urine from cats (group C, n 72) belonging to 4 colonies were also tested, as well as internal organs of carcasses (group B, n 35). Formalin-fixed and paraffin-embedded sections of kidney of cats were either stained with H&E or incubated with Ab against FeMV-N protein. qPCR-positive RNAs were employed for SISPA/NGS. Finally, a portion of the polymerase (L) gene was amplified by RT-PCR from all positive samples. Carcasses were divided into subgroups, including B1 (+virus +lesions), B2 (+virus -lesions) and B3 (-virus +lesions).

In group A, 7/60 urine samples were positive by qPCR, whereas in group C, 20/72 samples were positive. Eight/35 carcasses resulted positive by qPCR, with kidneys and urinary bladders being constantly positive. Viral RNA was also detected in the brain and spleen of one cat. A bilateral, subacute-to-chronic, lymphoplasmacytic interstitial nephritis was observed in all the qPCR-positive cats, which also showed scattered immunolabeling for viral antigen within their renal parenchyma, mostly involving the cortical kidney tubules and the surrounding inflammatory cells. Sequences of the L gene also have been obtained from all positive samples. Genetic diversity has been observed between different groups. In C1, two putative different viral variants (97.8% of nt id) have been observed, with one of these variants being present in C2. The highest nt difference was shown by most of the obtained sequences from all groups with Piuma/2015 (88.4–88.9% of nt id).

While the occurrence of FeMV in group A mirrors that seen in cats from other countries, FeMV occurrence in group C is higher. As in previous studies, genome diversity also has been demonstrated in FeMVs circulating in our province. We believe that the scattered viral antigen immunolabeling detected in renal tubular epithelia, as well as in the surrounding inflammatory cells, gets along very well with an intermittent viral excretion through urine. Statistical analyses are currently underway.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
E. de Luca
Istituto Zooprofilattico Sperimentale of Abruzzo and Molise
Teramo, Italy

URL: http://www.vin.com/doc/?id=817966
Evaluation of a Discriminative Realtime RT-PCR in Cerebrospinal Fluid for the Diagnosis of Feline Infectious Peritonitis

S. Felten¹; C.M. Leutenegger²; H.J. Balzer²; N. Pantchev⁵; K. Matiaszek⁴; L. Sangi¹; S. Doenges¹; S. Gruendl¹; A. Fischer¹; K. Hartmann¹

¹Clinic of Small Animal Medicine, Ludwig-Maximilians-Universitaet Munich, Munich, Germany; ²IDEXX Laboratories, Inc., West Sacramento, CA, USA; ³IDEXX Vet Med Labor GmbH, Ludwigsburg, Germany; ⁴Section of Clinical and Comparative Neupathology, Ludwig-Maximilians-Universitaet Munich, Munich, Germany

Antemortem diagnosis of feline infectious peritonitis (FIP) is particularly difficult in cats without effusions, of which about 40% have neurological signs indicative of central nervous system (CNS) manifestation.

Aim of this study was to evaluate sensitivity and specificity of a realtime reverse transcription polymerase chain reaction (RT-qPCR) able to distinguish the two feline coronavirus (FCoV) pathotypes (feline infectious peritonitis virus [FIPV] and feline enteric coronavirus [FECV]) in cerebrospinal fluid (CSF) of cats suspected of having FIP.

The study population consisted of 31 cats with confirmed FIP (six with neurological signs) and a control group of 29 cats (ten with neurological signs) for which FIP was considered a differential diagnosis, but which were definitively diagnosed with other diseases. CSF of these cats was tested for presence of feline coronavirus (FCoV) RNA by RT-qPCR and in positive cases, the pathotype was determined according to the S gene sequence. Sensitivity and specificity including 95% confidence intervals (95% CI) were calculated.

FIPV was detected in the CSF of three cats with FIP. In six cats with FIP, FCoV RNA was detected, but virus load was too low to allow pathotyping. FCoV was not detected in any of the control cats.

Specificity of the RT-qPCR was 100% (95% CI 88.1–100.0); sensitivity for detection of any FCoV was 29.0%; sensitivity of detection of the FIPV pathotypes in all cats was 9.7% (95% CI 2.0–25.8), 16.7% in cats with neurological signs.

Specificity of the RT-qPCR was excellent, but a negative test result cannot rule out FIP.

DISCLOSURES

Disclosures to report
Dr. Christian Leutenegger is the Head of Molecular Diagnostics at IDEXX Laboratories, Inc. Dr. Hans-Jörg Balzer and Dr. Nikola Pantchev are employed at IDEXX Laboratories, Ludwigsburg. This laboratory offers the FCoV and FIP virus realtime RT-PCR on a commercial basis and performed the testing in this study. IDEXX played no role in the study design, in the collection and interpretation of data, or in the decision to submit the manuscript for publication. There is no commercial conflict of interest, as the information generated here is solely for scientific dissemination. The authors declare that they have no competing interests.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

S. Felten
Clinic of Small Animal Medicine
Ludwig-Maximilians-Universitaet Munich
Munich, Germany

URL: http://www.vin.com/doc/?id=8172967
Screening for Selected Pathogens in Ticks Infesting Cats in the United Kingdom: A Large-Scale Surveillance Programme

F. Duplan1; S. Davies2; S. Filler3; S. Abdullah2; S. Keyte1; H. Newbury1; C.R. Helps3; S. Tasker1; R. Wall2

1Langford Vets, University of Bristol, Langford, UK; 2Veterinary Parasitology and Ecology Group, School of Biological Sciences, Life Sciences, Bristol, UK; 3Molecular Diagnostic Unit, Diagnostic Services, Langford Vets, School of Veterinary Sciences, University of Bristol, Langford, UK; 4MSD Animal Health, Milton Keynes, UK

Ticks are important vectors; cats acquire tick-borne pathogens when bitten by ticks. Ticks derived from cats have rarely been evaluated for the presence of pathogens; small studies have been described in Spain, Italy and Poland, but no studies have yet been performed in ticks found on cats in the UK.

The aim of this study was to determine the prevalence of selected tick-borne pathogens in ticks collected from cats in the UK; pathogens evaluated were Anaplasma phagocytophilum, Bartonella spp. including Bartonella henselae, Hepatozoon spp., Babesia spp., Borrelia spp. including Borrelia burgdorferi sensu lato, and haemoplasma species including Mycoplasma haemofelis (Mhf), 'Candidatus Mycoplasma haemominutum' (CMhm) and 'Candidatus Mycoplasma turicensis' (CMT).

Ticks were collected from cats presenting to veterinarians in UK practices. Tick species were identified morphologically and underwent DNA extraction using commercially available kits followed by PCR assays (either conventional or quantitative real-time [qPCR]) for the tick-borne pathogens specified above. All assays had been previously validated for detection of the target species. Feline 28S rDNA served as an endogenous internal PCR control (assessed within the haemoplasma qPCRs). Additionally, the samples were spiked with an internal amplification control (IAC) to monitor for inhibition. Positive samples from the generic PCRs (Bartonella spp., Hepatozoon spp., Borrelia spp.) were submitted for DNA sequencing for species identification.

A total of 541 ticks were collected. Of these 309 (57.1%) were Ixodes ricinus, 224 (41.4%) were Ixodes hexagonus and 8 (1.5%) were Ixodes trianguliceps. 28S rDNA was amplified from 476 (88.0%) of the ticks (undetected results likely being due to some ticks being unfed). The IAC PCR results revealed no evidence of inhibition. Of 541 ticks, 33 (6.1%) contained pathogens, and 1 tick contained two. Agents detected were: 6 (1.1%) Babesia spp. (Babesia microti-like and Babesia venatorum), 10 (1.8%) Borrelia spp. (Borrelia afzelii and Borrelia garinii), 5 (0.9%) A. phagocytophilum, 7 (1.3%) Bartonella spp. (including B. henselae and Bartonella clarridgeiae), 6 (1.1%) haemoplasma species [4 (0.7%) CMhm, 1 (0.2%) Mhf and 1 (0.2%) CMT]. Additionally, Hepatozoon silvestris was detected.

The resulting data provide valuable information on the prevalence of tick-borne pathogens in ticks found on cats in the UK. The prevalences found were similar to those reported in ticks collected from dogs in the UK but lower than those reported in ticks from cats in other European countries. This is the first report of the detection of H. silvestris in ticks collected from domestic cats in the world.

DISCLOSURES

Disclosures to report

This study was supported financially by MSD Animal Health. FD and SD have no competing interests. SF is supported by a Langford Trust-funded PhD scholarship. SA is supported by a Zutshi Smith PhD scholarship. SK, FD and ST have received grants from Langford Vets Clinical Research Fund for another research project. HN is an employee of MSD Animal Health. CH, ST and RW have previously had research funded by a wide range of funding organisations (e.g., BSAVA Petsavers, Langford Trust, Pethelp Charitable Trust, Morris Animal Foundation, Dog Trust, South West Biosciences DTP, Elizabeth Blackwell Institute of the University of Bristol, ECVIM Clinical Studies Fund, the University of Bristol Campaigns and Alumni Fund, the RCVS Trust Fund Blue Skies, The Wellcome Trust and Langford Vets Clinical Research Fund), pharmaceutical companies (e.g., Zoetis Animal Health, Bayer Animal Health, MSD Animal Health), and animal health charities. ST and CH work for the Molecular Diagnostic Unit, Langford Vets, University of Bristol, which carried out the PCRs described in the study. RW is a director of AgriEnt Ltd. ST has been paid for providing continuing professional development for not-for-profit organisations, and occasionally for commercial companies, around the world. ST is a member of the World Forum for Companion Animal Vector Borne Diseases, supported by Bayer Animal Health. ST is a member of the European Advisory Board on Cat Diseases, which is supported by Merial.

Speaker Information

(click the speaker's name to view other papers and abstracts submitted by this speaker)

F. Duplan
Langford Vets
University of Bristol
Langford, UK

URL: http://www.vin.com/doc/?id=8172968
The Role of Hypovitaminosis D in Complicated Canine Babesiosis

E. Dvir¹; C.T. Rosa²; R.J. Melianby³; J.P. Schoeman²

¹Tel Hai Academic College, Upper Galilee, Israel; ²University of Pretoria, Pretoria, South Africa; ³University of Edinburgh, Edinburgh, Scotland

Canine babesiosis is caused by Babesia rossi and the infection is very virulent. Some cases suffer from major complications including haemolytic anaemia, hepatopathy, acute renal failure, acute respiratory distress syndrome, hypoglycaemia, cerebral haemorrhages and pancreatitis. The disease has a mortality rate between 7–10%. Consequently, there is a need to improve understanding of the risk factors associated with poor clinical outcome. The current study examines the association between B. rossi infection and serum concentrations of 25 hydroxyvitamin D (25(OH)D), the major circulating vitamin D metabolite. Hypovitaminosis D has been reported in a wide range of infectious diseases in humans and dogs and low vitamin D status has been associated with poor clinical outcomes. This is the first study to investigate vitamin D status in canine babesiosis.

The hypothesis of this study was that dogs with babesiosis would have a lower vitamin D status than healthy dogs and that hypovitaminosis D would be associated with disease severity. The serum 25(OH)D metabolites were measured by high-performance liquid chromatography. Dogs were excluded from all groups if they were less than 1 year old, had concurrent diseases or were receiving corticosteroids. Blood was collected upon admission. The babesiosis cases were scored for severity. Each of the previously described babesiosis complications, inter alia, high serum lactate, hypoglycaemia, hypercortisolaemia, hypothyroxinemia, presence of SIRS received a score of 1. Finally, the total individual severity score was calculated.

Dogs with babesiosis (n=35) had significantly lower 25(OH)D concentrations than the control group (n=24) (24.05±17.71 vs. 88.75±38.25, p<0.001). ANCOVA analysis demonstrated that the effect of babesiosis on 25(OH)D concentrations compared to control dogs was still significant after considering the effect of age and weight. In addition, hypovitaminosis D was not significantly affected by serum creatinine and ALT concentrations, thereby eliminating the effect of renal insufficiency or liver damage, respectively. Moreover, correlation analysis revealed that hypovitaminosis D was not significantly correlated with the time from last meal (anorexia). Yet, hypovitaminosis D was significantly influenced by hypoproteinemia, hypoalbuminemia and hypoglobulinemia. Finally, among the babesiosis cases, the severity score had a significant inverse correlation (r=-0.39, p=0.04) with serum 25(OH)D concentrations.

These results indicate that hypovitaminosis D is associated with canine Babesia rossi infection. The inverse correlation between 25(OH)D concentrations and the severity score and the association between hypovitaminosis D and hypoproteinemia, hypoalbuminemia and hypoglobulinemia indicate that hypovitaminosis D might be a helpful indicator of severity and prognosis.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

E. Dvir
Tel Hai Academic College
Upper Galilee, Israel

URL: http://www.vin.com/doc/?id=8172969
Bloodstream infections are a substantial cause of morbidity and mortality in critically ill veterinary patients. Blood cultures are the gold standard for diagnosis of bacteremia, but are infrequently obtained due to technical and practical difficulties in sample acquisition. In ill patients, urine cultures are sometimes recommended as surrogates for blood cultures as part of a "better than nothing" approach. This study evaluated the ability of urine culture to predict bloodstream infection. We retrospectively evaluated all blood, aerobic, and anaerobic cultures submitted at NC State Veterinary Hospital between 2011 and 2016. We calculated growth rates of 18% (blood), 24% (urine), and 61% (non-urine) from 511 blood, 6797 urine, and 6552 non-urine cultures submitted. Blood isolates were most commonly coagulase-positive \textit{Staphylococcus} spp. (27%) and \textit{Escherichia coli} (14%); \textit{Escherichia coli} was the most common urinary isolate (43%), along with \textit{Enterococcus} (14%) and coagulase-positive \textit{Staphylococcus} (11%). 324 urine and blood samples were submitted in parallel, of which 21 yielded simultaneous growth. Of these, only 14 samples were concordant, while 7 yielded discordant urinary and bloodstream infections. Overall, urinary isolates were poorly reflective of bloodstream isolates, with a sensitivity of 24% but a specificity of 87%. General concordance, including true positive (n=14) and true negatives (n=232), between urinary and bloodstream isolates was 76%. Urine culture isolates had a poor positive predictive value (29%) but a negative predictive value of 84% for bloodstream infection. An apparent exception is patients with suspected urogenital infection sources (renal, prostatic, etc.), in which 100% (n=7) had concordant urinary and bloodstream infections. Coagulase-positive \textit{Staphylococcus} infections were most likely to be concordant. 133 non-urine samples submitted in parallel with blood cultures were also evaluated; only biliary and intravenous catheter samples carried a PPV >40%. In short, we recommend that if bloodstream infection is suspected, blood cultures be acquired. Coagulase-positive \textit{Staphylococcus}, if isolated from urinary tract of ill patient, should raise clinical suspicion of a potential concordant bloodstream infection. Due to a high discordance rate, in particular, blood cultures should be performed in any potentially septic animal who is immunosuppressed. Bacteriuria is neither a substitute nor a screen for bacteremia, and in fact, based off of our calculated false-negative rate, treatment of urinary tract pathogens in likely bacteremic animals would lead to treatment for the incorrect bloodstream pathogen 76% of the time. Though urine cultures are encouraged as part of a complete diagnostic workup, they do not substitute for blood cultures.

**DISCLOSURES**

Disclosures to report
Jacob ME: Director of NCSU Clinical Microbiology Laboratories. No other disclosures to report.

**SPEAKER INFORMATION**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

**N.R. Barash**
North Carolina State University
Raleigh, NC, USA

URL: [http://www.vin.com/doc/?id=8172970](http://www.vin.com/doc/?id=8172970)
Companion Animals and Humans with UTI Share Common Uropathogenic *Klebsiella pneumoniae*

C. Marques1; G. Trigueiro2; P. Cavaco3; J. Menezes1; A. Belas1; C. Pomba1

1Faculty of Veterinary Medicine, CIISA, University of Lisbon, Lisbon, Portugal; 2Laboratório de Análises Clínicas Dr. Joaquim Chaves, Lisbon, Portugal; 3Centro de Investigação Interdisciplinar Egas Moniz (CiIEM), Instituto Superior de Engenharia de Lisboa, Lisbon, Portugal

*Klebsiella pneumoniae* are important nosocomial pathogens that are increasingly reported as multidrug resistant (MDR). Companion animals (CA) with urinary tract infections (UTI) may become infected with MDR and virulent *K. pneumoniae* and thus act as reservoir to humans. This study aimed to characterize and compare the clonal relatedness of *K. pneumoniae* isolated from companion animals and humans with UTI. *K. pneumoniae* isolated from CA (n=26) and from community and hospital-acquired human UTIs (n=76) were tested by disk diffusion for susceptibility (AST) against 28 antimicrobials according to CLSI. Resistant isolates were screened for sixteen resistance genes and seven virulence genes by PCR. All CA isolates and third-generation cephalosporin-resistant (3GCr) human isolates were typed by MLST. Population structure of CA and human isolates were further characterized by PFGE-XbaI macro-restriction using Dice/UPGMA clustering analysis with a 1.5% tolerance.

The high-risk clonal *K. pneumoniae* lineage ST15 predominated in CA isolates (61.5%, n=16/26) and clustered together with a similarity index (SI)=69%. Most CA ST15 isolates belonged to two clusters (ST15a, ST15b) with SI>80%. Interestingly, all CA ST15 showed resistance to fluoroquinolones and 75% (n=12/16) were 3GCr mainly due to CTX-M-15. Two human ST15-CTX-M-15 *K. pneumoniae* were detected, one of which belonged to ST15b cluster. CA and human ST15-CTX-M-15 *K. pneumoniae* shared *fimH-mrkD-kfu-ycfK* virulence profile with few (n=4) also harboring yersiniabactin. Additionally, 3GC-susceptible human *K. pneumoniae* (unknown ST) also clustered with ST15a (n=2) and ST15b (n=1). All CA/human ST15a and ST15b strains were fluoroquinolone-resistant. The hospital adapted ST11 *K. pneumoniae* clonal lineage was detected in CA (n=1) and humans (n=1) showing the same MDR AST profile. On PFGE analysis, both ST11 were closely related (SI=81.1%) and shared several virulence (*fimH-mrkD-kpn-ycfM-yersiniabactin*) and resistance (DHA/aphAl-IA/aac(6')-Ib/tet(A)/sul1) genes. CA ST11 strain also harbored CTX-M-15 and *qnrB*.

3GCr ST348 from CA (n=1) and humans (n=1) showed a cluster SI=86.7%. Although similar in PFGE analysis, the AST varied between the strains with CA and human ST348 harboring CMY-2 and CTX-M-15, respectively.

This study shows that CA and humans can become infected with clonal-related *K. pneumoniae* some of which belong to high-risk clonal lineages. These results reveal the potential zoonotic nature of *K. pneumoniae* UTIs in CA, and therefore infection control measures should be advised to owners to avoid the spread of resistant and virulent *K. pneumoniae*.

**DISCLOSURES**

Disclosures to report

With financial support of CIISA and FCT through Project UID/CVT/00276/2013. AB and CM hold FCT PhD grants SFRH/BD/113142/2015 and SFRH/BD/7786/2011, respectively.

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Pomba
Faculty of Veterinary Medicine
CIISA
University of Lisbon
Lisbon, Portugal

URL: [http://www.vin.com/doc/?id=8172961](http://www.vin.com/doc/?id=8172961)
Validation of a qPCR Panel to Aid in the Diagnosis of Dermatophytosis

C. Leutenegger
IDEXX Laboratories, Inc., West Sacramento, CA, USA

Dermatophytosis (ringworm) is a common cutaneous fungal infection in both cats and dogs. As many as 90% of cats with dermatophytosis are infected by Microsporum canis. This strain is highly contagious and has zoonotic potential, but it is not life-threatening and it is treatable and curable. Due to the highly contagious nature of this disease, an accurate and timely diagnosis of dermatophytosis is very important.

The laboratory diagnosis of dermatophytes routinely includes direct microscopic evaluation of clinical specimens followed by culture on special media considered to be the gold standard. It is considered sensitive, is able to speciate, but requires 21 days of plate observation to yield a negative result.

Real-time polymerase chain reaction (PCR), also called quantitative PCR (qPCR) is an advanced molecular technology ideally suited for the detection of infectious pathogens. qPCR tests were developed targeting the ITS-1 gene sequences for genus-specific Trichophyton spp. and Microsporum spp. and a beta-actin-specific Microsporum canis assay. A clinical validation included 273 samples collected from 214 cats. Two hundred and one samples were collected from 195 exposed cats without lesions; 72 samples were collected from 19 cats with confirmed dermatophytosis lesions. Culture was positive in 17 lesion samples from 7 dermatophytosis-confirmed cats. PCR was positive in 15 of those samples, as well as in an additional 7 positive lesion samples from a total of 8 cats. Culture was 87% sensitive and 88% specific when compared to PCR on lesioned samples. Cats without lesions but exposed to diseased cats were also tested to determine if PCR is too sensitive by detecting fomite carriers. PCR detected 7 positive samples from 4 exposed cats, compared to 10 culture positives from 10 exposed cats. Of the 19 cats with lesions, 6 were monitored at regular intervals during systemic and topical therapy. The average time to resolution was 47 days. The shortest duration to resolution was 23 days. It is therefore recommended that PCR monitoring should start at around 3 weeks of treatment.

In summary, qPCR compared to conventional culture showed excellent sensitivity in clinical cases with lesions, did not pick up significant false-positive signals in cats exposed to but not infected with dermatophytes and can be used to monitor therapy success. Paired with its speed to result, the qPCR panel has excellent utility in the diagnosis of dermatophytosis.

DISCLOSURES
Disclosures to report
Author and coauthors are employees of IDEXX Laboratories, Inc.

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

C. Leutenegger
IDEXX Laboratories, Inc.
West Sacramento, CA, USA

URL: http://www.vin.com/doc/?id=8172962
## Poster Presentations

**Seroprevalences to Anaplasma phagocytophilum, Borrelia burgdorferi and Babesia canis in 2948 Dogs from Germany**  
D. Breu

**A Prospective Study of Urinary Adverse Effects of Allopurinol Treatment for Canine Leishmaniosis**  
M. Planellas

**Detection of Leishmania in Archived Canine Colonic Inflammatory Biopsies in an Endemic Area for Canine Leishmaniosis**  
L. Solano-Gallego

**Comparison of the Severity of Myocardial Damage with the Quantitative Estimation of the Myocardial Parasitic Load by Real-Time PCR in Dogs with Canine Visceral Leishmaniosis**  
J. Duque

**Detection of Leishmania in Archived Canine Colonic Inflammatory Biopsies in an Endemic Area for Canine Leishmaniosis**  
L. Solano-Gallego

**Investigation of the Presence of Bacteraemia in Puppies with Canine Parvoviral Enteritis**  
L. Kalogianni

**Identification of Serum Biomarkers in Dogs Naturally Infected with Anaplasma phagocytophilum and Borrelia burgdorferi**  
Z. Yilmaz

**At Least Three Years of Proven Protection Against Distemper, Infectious Canine Hepatitis and Parvovirus in Dogs Vaccinated with the Multivalent Canigen™ DHPPi/L Vaccine**  
C. Fontaine

**SNAP 4Dx Plus Correlates Well with IFA for Detection of E. canis Antibodies**  
J. Liu

**Seroprevalence of Infectious Diseases in Feral Cats in the American Midwest**  
J.S. Palerme

**SNAP 4Dx Plus Correlates Well with IFA for Detection of E. canis Antibodies**  
J. Liu

**Seroneutralisation of Canine Parvovirus by Sera of Cats Vaccinated with Either Leucofeligen™ FeLV/RCP or Feligen™ CRP Vaccines**  
C. Fontaine

**Serologic and Molecular Diagnostic Survey of Babesia spp. Infections in Hunting Dogs from Southern Italy**  
V. Veneziano

**Antibody Production as Reaction to Feline Panleukopenia Virus Vaccination in Cats with Feline Immunodeficiency Virus and Feline Leukaemia Virus Infection**  
M. Bergmann

**Evaluation of Rapid Diagnostic Test Kits for Canine Vector-Borne Diseases**  
J. Rodon Vernet

**Antimicrobial Use in 44 Dutch Companion Animal Clinics**  
N.E.M. Hopman

**Prevalence and Risk Factor for Harbouring Campylobacter jejuni in Young Dogs in Copenhagen**  
L.R. Jessen

**Surveillance of Bacterial Contamination in Stethoscopes and Effectiveness of Different Disinfecting Protocols**  
P. Sebastian

**Identification of Attaching and Effacing Enteropathogenic Escherichia coli in Dogs with Parvoviral Enteritis**  
J. Rubin

**Combined Therapy with Clindamycin, Doxycycline and Metronidazole Induces Complete Sterilisation of Babesia gibsoni Infection in Dogs - A Case Report**  
O. Sarpataki

**First Documentation of Cytochrome B Gene Mutations Associated with Atovaquone and Azithromycin Treatment in Cytauxzoon felis**  
A.N. Hartley

**Lethal Fox Disease in a Cat: Classical Cowpox or Novel Orthopoxvirus Infection?**  
N. Decaro

**Evidence of Sharing of MDR K. pneumoniae Between Infected and Non-Infected Cats from Same Household**  
C. Pomba
Dogs with exposure to ticks may contract multiple infections simultaneously. Our study aimed (1) to find seroprevalences to *Borrelia*, *Anaplasma* and *Babesia* of the dogs with a suspected history of ‘vector-borne diseases’ and (2) to evaluate specific seroprevalences in five most common pedigree breeds. Antibodies to *Anaplasma* were assayed by an IFAT test and antibodies to *Babesia* and *Borrelia* were tested using respective ELISA.

During the study period (2015/2016) involving 2948 dogs, overall seropositivity was 44% to ≥1 pathogen(s). Single-positivity accounted for 34.4% and was composed of *Anaplasma* (73.7%), *Borrelia* (22.1%) and *Babesia* (4.1%). Double-positivity was 9.2%; *Anaplasma/Borrelia* (83.8%), *Anaplasma/Babesia* (11.8%) and *Borrelia/Babesia* (4.4%).

Triple-positivity (*Anaplasma/Borrelia/Babesia*) was seen in 11 (0.4%) dogs.

Regarding the 868 dogs belonging to 5 pedigree breeds, overall seropositivity to ≥1 pathogen(s) was 49.5%; Bernese Mountain Dogs (68.1% of 113) > Golden Retrievers (54.3% of 151) > Australian Shepherds (50.5% of 105) > German Shepherds (47.7% of 174) > Labradors (41.5% of 325). For all breeds, single-positivities ranged from 32% (Labradors) to 46% (Golden Retrievers). Except for Bernese Mountain Dogs, the seropositivity to *Anaplasma* accounted for 73–84% while the seropositivity to *Borrelia* accounted for 73–84% while the seropositivity to *Borrelia* accounted for 14–27%. For Bernese Mountain Dogs, seropositivities to *Anaplasma* and *Borrelia* were 36% and 64%, respectively.

Double-positivities were between 7% (Golden Retrievers) and 13% (German Shepherds), whereas they were 28% for Bernese Mountain Dogs. With regard to specific combinations of pathogens, *Anaplasma/Borrelia* accounted for nearly 100% in Bernese Mountain Dogs, Australian Shepherds and Golden Retrievers, whereas German Shepherds and Labradors exhibited somewhat different susceptibilities: *Anaplasma/Borrelia* (68% and 80%, respectively) and *Anaplasma/Babesia* (27% and 20%), respectively.

Within the scope of this study, our data suggested a certain dichotomy of seropositivity patterns depending on dogs of pedigree breeds. Overall, single-positivities were seen in 32–46% of the dogs and *Anaplasma* was the principal pathogen representing 73–84% cases. Bernese Mountain Dogs were exceptional: *Borrelia* represented 64% and *Anaplasma* 36%. While double-positivities were comparatively low (7–13%), Bernese Mountain Dogs were outstanding with 28%. Furthermore, *Anaplasma/Borrelia* accounted for nearly 100% seropositivities in 3 breeds, whereas *Anaplasma/Babesia* accounted for 20–27% in 2 other breeds (German Shepherds, Labradors). Under the circumstances where multiple factors - habitats, ectoparasite controls among others - influence the occurrence and prevalence of antibodies, our data showed certain breed-specific patterns of differences in susceptibility/infectivity toward the pathogens.

**DISCLOSURES**

The authors D. Breu and J. Guthardt are employed at Laboklin GmbH & Co.Kg, Germany. E. Mueller is owner/manager of the Laboklin GmbH & Co.Kg, Germany.
A Prospective Study of Urinary Adverse Effects of Allopurinol Treatment for Canine Leishmaniosis

M. Planellas¹; X. Roura²; Y. Espada¹; R. Novellas¹; C. Anselmi²; L. Solano-Gallego¹

¹Universitat Autònoma de Barcelona, Bellaterra, Spain; ²Hospital Clinic Veterinari, Universitat Autònoma de Barcelona, Barcelona, Spain

Canine leishmaniosis is a life-threatening zoonotic disease with a wide distribution and allopurinol is a parasitostatic drug used in its long-term fashion treatment. Some retrospective reports indicate that xanthinuria deposits can appear secondary to prolonged therapy with allopurinol in dogs. The purpose of this prospective study was to evaluate the incidence, characteristics and the time of appearance of urinary adverse effects in dogs with leishmaniosis treated with allopurinol. Moreover, in dogs with xanthine deposits, clinical response to low purine diet was also evaluated.

This study included 20 dogs with a new diagnosis of leishmaniosis under allopurinol treatment (10 mg/kg/12 h during 12 months). Dogs were evaluated at time of diagnosis, one, six and twelve months after diagnosis and treatment with allopurinol, additionally 11/20 dogs were also evaluated at 3 months. Each clinical evaluation included the following tests (physical exam, abdominal ultrasound, UPC ratio, urinalysis, hematology, biochemical panel and Leishmania serology). All dogs had an unremarkable urinary ultrasound without urinary sediment before treatment. At one-month control, 4/20 dogs had xanthinuria, 2/20 mineralization of pelvic recesses (MPR) and 1/20 vesical urolithiasis. At three-month control, 4/11 had xanthinuria, 4/11 bilateral MPR and 2/11 urolithiasis (located in renal pelvis and bladder in 1 dog and the other in bladder). At 6-month control, 4/20 dogs had xanthinuria, 6/20 bilateral MPR, and 4/20 urolithiasis (located in renal pelvis and bladder in 2 dogs and in renal pelvis in the other two). At 12-months control, 7/20 dogs had xanthinuria, 7/20 bilateral MPR, and 6/20 urolithiasis (located in bladder in 3 dogs and in renal pelvis in the other 3). Dogs that suffered from xanthinuria and renal mineralization or urolithiasis were treated with low purine diet. Reduction of xanthinuria and uroliths size was observed in 3 dogs with compliant owners and strict diet treatment, but MPR persisted.

In conclusion, the present study describes an elevated and prompt incidence of urinary adverse effects associated with allopurinol treatment. A closer followup including urinalysis and abdominal ultrasound is mandatory in dogs treated with allopurinol. Moreover, according to our results, low purine diet seems to be an option in reducing xanthine deposits. Further studies are required to evaluate the efficacy of dietary treatment. According to authors’ knowledge, this is the first prospective study that confirms previous suspicion of urinary adverse effects of allopurinol treatment in dogs with leishmaniosis.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker’s name to view other papers and abstracts submitted by this speaker)

M. Planellas

Universitat Autònoma de Barcelona

Bellaterra, Spain

URL: http://www.vin.com/doc/?id=8172983
Detection of *Leishmania* in Archived Canine Colonic Inflammatory Biopsies in an Endemic Area for Canine Leishmaniosis

L. Solano-Gallego\(^1\); I. Casanova\(^2\); S. Martin\(^1\); A. Marco\(^2\)

\(^1\)Universitat Autònoma de Barcelona, Bellaterra, Spain; \(^2\)Servei de Diagnostic Patologia, Universitat Autònoma de Barcelona, Bellaterra, Spain

Previous studies have demonstrated *Leishmania infantum* infection in colonic samples with histiocytic or lymphoplasmacytic inflammation from seropositive sick dogs. However, there are no studies that have investigated the presence of *L. infantum* infection in dogs diagnosed with inflammatory bowel disease (IBD) by clinical and histopathological examination. The objectives of this study were to retrospectively investigate the presence of *Leishmania* infection by immunohistochemistry (IHC) in archived canine colonic biopsies previously diagnosed with IBD in an area endemic for canine leishmaniosis as well as to describe the main histopathological findings. A total of 109 cases of canine colitis were retrospectively retrieved from the archived biopsies of Servei de Diagnòstic de Patologia of the Universitat Autònoma de Barcelona. Information regarding clinicopathological data including signalment, histological results and further diagnostic testing to detect *Leishmania* infection such as *Leishmania* IHC staining was compiled from the selected cases. Lymphoplasmacytic (n=101), histiocytic (n=5), and lymphoplasmacytic with mild eosinophilic/neutrophilic component (n=3) colitis were diagnosed between January 1997 and September 2015 performed by endoscopic colonic biopsies. Interestingly, *Leishmania* IHC was only carried out in 13 of 109 (11.9 %) colonic samples to confirm or exclude *Leishmania* infection based on the diagnostic database. From those, 5 were diagnosed as granulomatous and 8 as lymphoplasmacytic colitis. Four biopsies were classified as positive, two as unclear results due to unspecific background staining, and the rest were negative for *Leishmania* IHC. *Leishmania* IHC was performed in 56 of the remaining 96 colonic samples with a diagnosis of lymphoplasmacytic or histiocytic inflammation that were not previously tested to confirm or exclude this infection. Due to economical restrictions, only 56 colonic samples retrieved could be investigated. Only one out of 56 (1.8%) colonic biopsies examined was classified as positive by IHC. A total of 5 out of 109 (4.6%) dogs were diagnosed with *Leishmania* infection. Two dogs presented intense histiocytic inflammation while three dogs showed mild to intense lymphoplasmacytic inflammation. The number of amastigotes per 5 microscopic fields viewed at 40x assessed by IHC was variable and ranged between 2 to countless.

In conclusion, *Leishmania* infection should be included in the list of differentials of inflammatory colonic biopsies. *Leishmania* amastigotes are commonly not visualized by routine histological staining. Therefore, IHC for *Leishmania* should be routinely used as a diagnostic tool in endemic areas of leishmaniosis, to exclude or confirm an infection by this parasite in patients with a diagnosis of IBD.

**DISCLOSURES**

No disclosures to report

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

L. Solano-Gallego

Universitat Autònoma de Barcelona
Bellaterra, Spain

URL: [http://www.vin.com/doc/?id=8172987](http://www.vin.com/doc/?id=8172987)
Comparison of the Severity of Myocardial Damage with the Quantitative Estimation of the Myocardial Parasitic Load by Real-Time PCR in Dogs with Canine Visceral Leishmaniosis

J. Duque; D. Casamian-Sorrosal; S. Belinchón-Lorenzo; J. Salado-Tato; L. Gómez-Gordo; J.J. Real-Ríos; L. Martínez-Hernández; R. Barrera-Chacón

1Veterinary Teaching Hospital, Cáceres, Spain; 2Dick White Referrals, UK

It has been previously shown that canine leishmaniasis (CanL) causes severe myocardial damage which leads to elevation of troponin I (cTnI). It has also been previously shown that this myocardial damage is likely to be primarily associated with the severity of the protozoal disease and not with the degree of azotaemia, anaemia or systemic arterial hypertension. It remains to be determined, however, whether this myocardial damage is directly correlated with the cardiac parasitic load or the damage is primarily indirect through other mechanisms such as systemic inflammation.

The aim of this study was to evaluate and compare the concentration of cTnI, histopathology severity and plasma creatinine concentration (Cr) with the parasitic load within cardiac tissue samples in a cohort of dogs with CanL.

Ethical approval was granted by the University of Extremadura committee. Five dogs without previous history of cardiac disease and severe CanL and renal azotaemia (Stage IV, LeishVet scheme) were included in the study. All dogs underwent full physical examination, haematology, biochemistry, and urinalysis including protein-creatinine ratio, ELISA serology for L. infantum, cTnI measurement, blood pressure, abdominal ultrasound, electrocardiography, thoracic radiographs and echocardiographic examination. All dogs were euthanased due to the severity of the disease and underwent postmortem examination. Myocardial samples were taken for histopathology and were tested for L. infantum by real-time PCR (RT-PCR) by detection and quantification of Kinetoplast minicircle DNA.

Elevation of cTnI (dog 1: 0.36 ng/ml; dog 2: 0.59 ng/ml; dog 3: 4.56 ng/ml; dog 4: 7.69 ng/ml; dog 5: 9.23 ng/ml; median 4.56 ng/ml; IQR 0.59–7.56 ng/ml; normal <0.06 ng/ml) and Cr (dog 1: 2.7 mg/dL; dog 2: 4.3 mg/dL; dog 3: 15.5 mg/dL; dog 4: 3.8 mg/dL; dog 5: 7 mg/dL; median 4.3 mg/dL; IQR 3.8–7 mg/dL; normal 0.7–1.2 mg/dL) was detected in all dogs. Severe lymphoplasmacytic myocarditis was observed in all myocardial samples. L. infantum DNA was detected in the myocardial tissue of all five dogs and RT-PCR assay was performed in the samples to estimate the parasite load (dog 1: 20,72 parasites/mg; dog 2: 25.57 parasites/mg; dog 3: 146.19 parasites/mg; dog 4: 284.88 parasites/mg; dog 5: 290 parasites/mg; median 146.19 parasites/mg; IQR 25.57–258.88 parasites/mg). A positive strong correlation was observed between cTnI and the parasitic load (p<0.001), but no correlation (p>0.05) was observed between cTnI and Cr concentrations.

The results of this study show for first time an association between the severity of myocardial damage in canine leishmaniasis and the severity of myocardial parasitic load.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Duque
Veterinary Teaching Hospital
Cáceres, Spain

URL: http://www.vin.com/doc/?id=8172988
Investigation of the Presence of Bacteraemia in Puppies with Canine Parvoviral Enteritis

L. Kalogianni¹; G. Kazakos¹; Z.S. Polizopoulou²; K. Kontopoulou²; V. Siarkou¹; E. Triantafyllou³; S.C. Chaintoutis¹; C.I. Dovas¹; N. Soubasis¹; T.S. Rallis¹

¹Faculty of Health Sciences, School of Veterinary Medicine, Aristotle University, Thessaloniki, Greece; ²General Hospital of Thessaloniki, G. Gennimatas, Thessaloniki, Greece; ³Vet Analyseis, Veterinary Diagnostic Laboratory, Larissa, Greece

The aim of this prospective study was to investigate bacteraemia in puppies with enteritis attributed to canine parvovirus 2 (CPV-2) infection.

Blood samples were obtained for culture from 17 puppies with parvoviral enteritis (group 1), aged 2–10 months, prior to treatment on admission (time 1), 48 hours later (time 2), and on the day of sudden deterioration or discharge (time 3). Thirteen healthy puppies (group 2), aged 2–6 months, were selected as controls and sampled for blood culture once. Dogs were eligible for inclusion in group 1 according to clinical and clinicopathological abnormalities, incomplete vaccination against canine parvoviral enteritis, and presence of CPV antigens (rapid immunoassay) and of CPV-2 DNA (real-time PCR) in feces. Group 2 dogs were healthy on physical examination, complete blood count, serum biochemistry, urinalysis, abdominal ultrasonography, buffy coat cytology, and tested negative for CPV antigens and CPV-2 DNA in feces. All animals had not received antimicrobials for 4 weeks prior to inclusion in the study. Blood samples from all dogs were aseptically obtained from both jugular veins at each time point, placed in pediatric culture bottles and shipped to the laboratory immediately. Blood cultures were performed by BACTEC 9120 blood culture instrument (Becton Dickinson) using pediatrics (PEDS) bottles. Isolates from positive blood cultures were identified to the species level by the VITEK 2 automated system (Bio Merieux, France). Standardized treatment included intravenous administration of fluids, maropitant, metoclopramide, ampicillin and enrofloxacin.

In group 1, 11/17 dogs survived to discharge. *Escherichia coli* was isolated in 4/6 dead dogs, *Klebsiella pneumoniae* in 1/6, and blood cultures were negative in 1/6. Nine out of 11 survivors were blood culture-negative and 2/11 presented with asymptomatic bacteremia on the day of discharge (*K. pneumoniae* and *Enterobacter cloacae*, respectively). Repeat blood cultures in the latter 9 days post-discharge, during which no antimicrobials had been administered, were negative. Median duration of hospitalization for group 1 was 7 days (range 1–9 days). All blood cultures from group 2 were negative.

Limited data exist regarding blood culture results in puppies naturally infected with CPV-2. *E. coli*, *Enterobacter* spp. and *K. pneumoniae* have been previously reported in cultures from intravenous catheters in dogs with paroviral enteritis, and *E. coli* has also been recovered from blood in 3 cases. To the best of our knowledge, this is the first prospective study to monitor bacterial blood cultures longitudinally in such dogs.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

L. Kalogianni
Faculty of Health Sciences
School of Veterinary Medicine
Aristotle University
Thessaloniki, Greece

URL: http://www.vin.com/doc/?id=8172989
Identification of Serum Biomarkers in Dogs Naturally Infected with *Anaplasma phagocytophilum* and *Borrelia burgdorferi*

Z. Yilmaz¹; L. Franco²; D. Escribano³; P. Schanilec³; P. Levent¹; S. Martinez-Subiela³; A. Tvarijonaviciute²; A. Sarı¹; N. Aytuğ⁴; J. Ceron²

¹Department of Internal Medicine, Faculty of Veterinary Medicine, Uludag University, Bursa, Turkey; ²Interdisciplinary Laboratory of Clinical Pathology, Interlab-UMU, University of Murcia, Murcia, Spain; ³Faculty of Veterinary Medicine, University of Veterinary & Pharmaceutical Sciences, BRNO, Czech Republic; ⁴Department of Internal Medicine, Veterinary Medicine, Near East University, Lefkosa, Cyprus

Anaplasmosis caused by *Anaplasma phagocytophilum* and Lyme disease caused by *Borrelia burgdorferi sensu lato* (borreliosis) are the most frequently diagnosed vector (tick)-borne disease (VBD) in humans and dogs. To the authors' knowledge, there are limited data of serum proteomics on these clinical animals and the modifications in their proteome. Thus, the aim of the present study was to identify the potential serum biomarkers of diagnosis of anaplasmosis and Lyme disease using a proteomic approach.

Pools of serum samples from dogs naturally infected with *A. phagocytophilum*, *B. burgdorferi*, and infected with both agents were collected before treatment, and compared with a control group. Anaplasmosis and Lyme disease were diagnosed based on specific IgG and IgM antibody titers. Serum C-reactive protein and ferritin levels in infected dogs were higher (p<0.05) than those of controls. Two-dimensional electrophoresis (2DE) of pooled samples was run in triplicate. 2DE image analysis showed 57 differentially expressed spots between infected animals and controls. Compared to healthy controls, vitamin D-binding protein decreased, while haptoglobin and Ig chains with different spots increased in both diseases. Serum apolipoprotein-A1 (Apo-A1) level decreased in dogs with lyme, but this did not express differentially in dogs with anaplasmosis. In dual infections, concentrations of vitamin D-binding protein and albumin decreased, whereas alpha glycoprotein, haptoglobin and Ig chain increased compared to controls.

These study results showed that many proteins might be changed in the VBDs, and they could be useful biomarkers for diagnosis, pathophysiology and treatment strategies. Understanding the role of these proteins in many biological processes such as acute phase response, immunological reactions, transport, oxidative stress, apoptosis, calcium, iron and lipid metabolism and blood coagulation cascade provide advantages during diagnostic and therapeutic approaches in clinical settings.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Z. Yilmaz
Department of Internal Medicine
Faculty of Veterinary Medicine
Uludag University
Bursa, Turkey

URL: [http://www.vin.com/doc/?id=8172990](http://www.vin.com/doc/?id=8172990)
At Least Three Years of Proven Protection Against Distemper, Infectious Canine Hepatitis and Parvovirus in Dogs

Vaccinated with the Multivalent Canigen™ DHPPi/L Vaccine

F. Senseby; T. Butaud; P. Schreiber; L. Guegand; C. Fontaine; S. Gueguen
Virbac, Carros, France

Distemper, infectious canine hepatitis and parvovirus are life-threatening diseases due respectively to canine distemper virus (CDV), canine adenovirus virus (CAV)-1 and canine parvovirus (CPV). The maintenance of the serological response post-vaccination is often used to evaluate the protective status of a dog. However, as live vaccines stimulate mainly the cell-mediated pathway of the immune system, this method may underestimate the real duration of efficacy of these vaccines. The study aim was to evaluate the efficacy of the attenuated CDV, CAV and CPV strains of the multivalent Canigen™ DHPPi/L vaccine (Virbac, France) after experimental infections performed at three years after the first annual booster.

Forty-seven SPF Beagle puppies, males and females, participated in the study. Puppies were allocated to either the vaccinated group (group 1, n=23) or the unvaccinated group (group 2, n=24). Puppies of group 1 received Canigen™ DHPPi/L vaccine, formulated at minimum titre for the live components, for primary vaccination with two injections at a three-week interval (respectively at 9 and 12 weeks of age) and for the first annual booster. Blood samples were taken on several occasions for serological followup. CDV, CAV-1, CPV-2 and CPV-2c antibody titres were measured by seroneutralisation tests (SN). After vaccination, SN antibody titre ≥10^{0.7} for both CDV and CAV-1 and ≥10^{1.17} for CPV-2 variants are considered as positive. At three years after the first annual booster, dogs of both groups were administered either a pathogenic CDV (n=10) or CAV-1 (n=12) or CPV-2c (n=12) strain and followed for the appearance of any typical sign of the related disease for 21 days. Vaccinated dogs with the lowest SN titres were selected to receive the pathogenic agents.

In group 1, 23/23 puppies seroconverted after the primary vaccination course. At 3 years after the first annual booster, SN antibodies against CAV-1, CPV-2 and CPV-2c were still present in 23/23 dogs and in 21/23 dogs for CDV. After the experimental infections, typical signs of distemper and infectious hepatitis leading to death were observed respectively in 5/5 and 6/6 non-vaccinated dogs and in none of the vaccinated dogs (respectively n=0/5, n=0/6). Typical signs of parvovirus including CPV viral shedding were observed only in the non-vaccinated dogs.

In conclusion, this experimental study demonstrated that the protection against distemper, infectious canine hepatitis and parvovirus lasts at least three years after any annual vaccination booster with Canigen™ DHPPi/L vaccine.

DISCLOSURES
Disclosures to report
All authors are employees of Virbac.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
C. Fontaine
Virbac
Carros, France

URL: http://www.vin.com/doc/?id=8172991
Comparative Killing of Canine Urinary Pathogens by Cephalexin (CP), Marbofloxacin (MR), Pradofloxacin (PR) and Trimethoprim/Sulfamethoxazole (TMP/SMX)

M. Blondeau; D. Shebelski
Royal University Hospital, Saskatoon, SK, Canada

Urinary tract infections are common in dogs, necessitating antimicrobial therapy. In humans, short-course therapy is used for uncomplicated cases, thereby questioning if shorter courses are possible in dogs. Rapid and complete killing of bacteria by antibiotics affects clinical cure and may influence shorter durations of therapy.

The aim of this study was comparing killing of canine urinary pathogens by 4 antimicrobial agents at clinically relevant drug concentrations. Approximately 100,000 colony-forming units/milliliter of canine isolates (3 strains each) of *Escherichia coli* (EC), *Enterobacter faecalis* (EF), *Proteus mirabilis* (PM) and *Staphylococcus pseudintermedius* (SP) were exposed to the maximum serum (C<sub>max</sub>) and maximum urine (U<sub>max</sub>) concentrations of each drug and the log10 (LT) and percent (%) kill measured at 5, 10, 15, 20, 25, 30, 60, 120 and 180 minutes after drug exposure. All measurements were in triplicate and averaged such that each data point was based on 9 averaged values, i.e., triplicate and 3 strains. Exposure of EC to the C<sub>max</sub> of CP, TMX/SMX, MR and PR resulted in 22 (0.22 LT), 3 (0.01 LT), 94 (2.1 LY) and 99 (2.41 LT) % kill following 30 minutes of drug exposure; at the U<sub>max</sub> 23 (0.11 LT), growth (+0.02 LT), 95 (1.6 LT) and >99 (2.5 LT) % kill following 5 minutes of drug exposure. Following 180 minutes of drug exposure at the U<sub>max</sub>, 82% kill was seen for CP and growth for TMP/SMX. Exposure of PM to the C<sub>max</sub> of CP, TMP/SMX, MR, PR resulted in 64%, >99%, 96% kill and growth respectively following 60 minutes of drug exposure; at the U<sub>max</sub> 42%, 4%, 96% and >99% kill was observed following 15 minutes of drug exposure. Exposure of SP to the C<sub>max</sub> of CP, TMP/SMX, MR, PR resulted in 3, 9, 53 and 93% kill following 30 minutes of drug exposure; at the U<sub>max</sub> 2, 3, 64 and 94% kill was seen respectively following 15 minutes of drug exposure. Exposure of EF to U<sub>max</sub> for TMP/SMX, MR, PR resulted in growth, 86 and 96% kill respectively following 120 minutes of drug exposure.

Killing of bacterial pathogens is necessary for clinical cure and rapid and complete killing influence duration of therapy. MR and PR more rapidly and completely killed urinary pathogens than did CP and TMP/SMX. Such observations may be important clinically for empiric antimicrobial treatment of canine urinary tract infections and is consistent with antimicrobial stewardship goals.

DISCLOSURES
Disclosures to report
Unrestricted research grant from Bayer Animal Health

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Blondeau
Royal University Hospital
Saskatoon, SK, Canada

URL: http://www.vin.com/doc/?id=8172992
Canine monocytic ehrlichiosis (CME) is a major tick-borne disease worldwide. Diagnosis of CME can be challenging, as the patients may present with variable, often non-specific, clinical signs associated with different stages of the infection, or co-infections. *Ehrlichia canis* is the etiological agent. Diagnosis of CME is generally supported by detection of *E. canis* antibodies either by indirect immunofluorescence assay (IFA) and/or ELISA. Several rapid point-of-care test kits are also available, but their relative accuracies have not been reported. The aim of this study was to evaluate the performance of three point-of-care test kits for detection of *E. canis* antibodies.

Three test kits evaluated included SNAP® 4Dx® Plus (IDEXX), Speed Duo Leish K/Ehrli™ (BVT/Virbac), and FASTest® EHRLICHIA canis (MegaCor). Surplus samples were collected from IDEXX Reference Laboratories (IRL) at Ludwigsburg, Germany, and Phoenix, AZ, USA after requested diagnostic testing was completed. These were serum samples from suspected CME cases submitted by veterinarians for *E. canis* IFA and other testing. A total of 104 positive (IFA titre ≥1:400) and 163 IFA-negative samples were included in this study. Samples were blinded and randomized for testing with rapid tests. Each result was interpreted by 3 technicians. A test was considered positive when 2 or 3 technicians called it positive; negative when 2 or 3 technicians called it negative.

Compared to *E. canis* IFA, sensitivity/specificity was 95.2%/100% for SNAP, 84.6%/82.0% for Speed Duo and 82.2%/84.0% for FASTest, respectively.

The number of false-positive results was surprisingly high on Speed Duo and FASTest tests. To further confirm these results, all 163 IFA-negative samples were evaluated using a species-specific ELISA (McBride et al. 2007) and they all tested negative. Of these, 118 were sourced from dogs living in Germany, non-endemic for *E. canis*, yet 21 (17.8%) were tested positive by the Speed Duo test, and 16 (13.6%) positive by the FASTest test.

For *E. canis*, which has a reported prevalence rate of 1–5% in the U.S. and many European countries, tests with low specificity could have a very low positive predictive value. Consistent with previously published studies (Miró et al. 2013; Rene-Martellet et al. 2015), results from this study suggest that SNAP 4Dx Plus is an accurate point-of-care test useful for differential diagnosis or screening.

DISCLOSURES

Disclosures to report
All authors are employees of IDEXX Laboratories, Inc.

SPONSOR INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Liu
IDEXX Laboratories, Inc.
Westbrook, ME, USA

URL: http://www.vin.com/doc/?id=8172993
Seroprevalence of Infectious Diseases in Feral Cats in the American Midwest

J.S. Palerme; J.E. Olds; E. Lampereili; J. Gagne; C. Cadlan
College of Veterinary Medicine, Iowa State University, Ames, IA, USA

By the nature of their environment and behavior, feral cats have an increased risk of exposure to a wide range of pathogens compared to domestic cats. Consequently, feral cats can act as both a reservoir for possible zoonotic diseases as well as a sentinel species for seroprevalence in other animal populations. We assessed the seroprevalence and risk factors associated with exposure to *Leptospira*, *Toxoplasma* and *Dirofilaria* in a population of feral cats from the American Midwest. Serum samples from a total of 140 cats were available for testing. Twelve cats (8.6%) were seropositive for leptospirosis based on a microscopic agglutination test titer of 1:100 or greater. Bratislava was the most commonly reported serovar, accounting for 6/12 positive titers. Forty-two cats (30%) were seropositive for *Toxoplasma* based on competitive ELISA testing, and nine cats (5.3%) were seropositive for *Dirofilaria* antibodies based on a lateral flow immunoassay. All of the cats for which a *Dirofilaria* antigen test was performed were negative. Body weight and sexual status were not significantly correlated with seropositivity to any of the studied pathogens. Seropositivity to one pathogen was not found to be a risk factor for seropositivity to other pathogens. Seroprevalence for leptospirosis was significantly greater in spring than in fall (p=0.023) and varied significantly between age groups (p=0.014). Similarly, seroprevalence for *Toxoplasma* varied according to age, with cats between 73 and 120 months of age being significantly overrepresented (p=0.013). Compared to previous seroprevalence reports of feline feral populations from the United States and abroad, this population of cats from the American Midwest had a slightly lower seroprevalence of *Toxoplasma* but higher seroprevalence of leptospirosis.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.S. Palerme
College of Veterinary Medicine
Iowa State University
Ames, IA, USA

URL: http://www.vin.com/doc/?id=8172973
Seroneutralisation of Canine Parvovirus by Sera of Cats Vaccinated with Either Leucofeligen™ FeLV/RCP or Feligen™ CRP Vaccines

M. Gillet; S. Arcidiaco; T. Almeras; C. Lesbros; S. Fournel; C. Fontaine; S. Gueguen
Virbac, Carros, France

Canine parvovirus (CPV)-2 has been isolated from cats presenting with signs of panleukopenia. CPV-2c is reported as the most pathogenic genetic variant in this species. Few efficacy data support the ability of current feline parvovirus containing vaccines to protect cats against parvovirus from canine origin. As canine and feline parvovirus seroneutralising antibodies correlate with clinical protection in each respective species, the study objective was to demonstrate the ability of both Leucofeligen™ FeLV/RCP and Feligen™ CRP vaccines (Virbac, Carros, France) to protect cats against parvovirus due to CPV variants by serology.

In this retrospective study, kitten sera samples obtained within the frame of two studies were used. In study A, sera were obtained from 18 kittens, 9/18 vaccinated with Leucofeligen™ FeLV/RCP and 9/18 unvaccinated kittens. From study B, sera were from 26 kittens, vaccinated with either Feligen™ CRP (11/26) or Leucofeligen™ FeLV/RCP (15/26). All vaccinated kittens had received two subcutaneous vaccine injections 3 weeks apart for primary vaccination, starting at 9–10 weeks of age. Sera were taken prior to vaccination and 4 weeks after the last vaccine injection, and used to assess the ability of the vaccine-induced antibodies to neutralise CPV-2 and CPV-2c antigens by seroneutralisation (SN) assays. SN titre below 10^{1.17} was considered as negative. All results are expressed in mean±standard deviation, in log_{10} units.

In both studies, none of the cat sera was able to neutralise CPV-2 or CPV-2c antigen prior to vaccination. At 4 weeks after the last vaccine injection for primary vaccination, whatever the study, kittens vaccinated with either Leucofeligen™ FeLV/RCP (9/9 from study A and 15/15 from study B) or Feligen™ CRP (11/11 from study B) were able to neutralise both CPV-2 and CPV-2c antigens. After vaccination, SN titres against CPV-2 were respectively 3.35±0.69, 4.02±0.54 and 4.03±0.86 for sera of kittens vaccinated with Leucofeligen™ FeLV/RCP in study A, study B and kittens vaccinated with Feligen™ CRP from study B. CPV-2c SN titres obtained post-vaccination were, for the same groups, 3.35±0.65, 4.03±0.51 and 3.97±0.82. No significant difference could be demonstrated for any CPV-2 variant and for any vaccine (p>0.05).

Cats vaccinated with either Leucofeligen™ FeLV/RCP and Feligen™ CRP vaccines developed an acquired immunity against CPV variants. Based on the correlation between seroneutralising antibodies and protection for parvovirus, both Leucofeligen™ FeLV/RCP and Feligen™ CRP vaccines protect cats against parvovirosis due to CPV variants.

DISCLOSURES
Disclosures to report
All authors are employees of Virbac.

SPAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)
C. Fontaine
Virbac
Carros, France

URL: http://www.vin.com/doc/?id=8172974
Serologic and Molecular Diagnostic Survey of *Babesia* spp. Infections in Hunting Dogs from Southern Italy

V. Veneziano; D. Piantedosi; B. Neola; N. d’Alessio; M. Santoro; L. Pacifico; G. Sgroi; L. Auletta; C. Leutenegger; P. Tymef; C. Genevieve; J. Sauzier; J. Buch; R. Chandrashekar

1University of Naples Federico II, Napoli, Italy; 2Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy; 3IRCCS SDN, Naples, Italy; 4IDEXX Laboratories, Inc., Westbrook, ME, USA

Canine babesiosis is a potentially serious canine vector-borne disease (CVBD) caused by intraerythrocytic protozoan parasites of the genus *Babesia*. Clinical signs of babesiosis include moderate to severe hemolytic anemia, fever, anorexia, depression, pallor, and splenomegaly. Infections are tick-transmitted, and geographic distribution throughout Europe is expanding along with the spread of the tick species *Dermacentor reticulatus* and *Rhipicephalus sanguineus*. The present study aimed to perform a serological and molecular diagnostic survey of *Babesia* spp. infections in hunting dogs from southern Italy.

Blood samples were collected from hunting dogs (n=1,311) without any specific signs associated with babesiosis in the Avellino, Napoli, and Salerno provinces of Campania region of southern Italy. Signalment and history of tick infestation were recorded for each dog at the time of blood collection. Serology testing was performed by two enzyme-linked immunosorbant assays (ELISAs), with one designed to detect canine antibodies to *B. canis* and *B. vogeli* and the other designed to detect canine antibodies to *B. gibsoni*. All samples were tested by real-time polymerase chain reaction (RT-PCR) assays for the presence of two large-form *Babesia*, *Babesia canis* and *Babesia vogeli*, and one small-form *Babesia, Babesia gibsoni*.

Nearly half (634/1311, 48.4%) of all hunting dogs had a history of tick infestation. Seropositive rates were 14.0% (184/1311) for *B. canis/B. vogeli* and 0.2% (3/1311) for *B. gibsoni*. PCR-positive rates for *B. canis* and *B. vogeli* were 0.2% (2/1311) and 1.1% (15/1311), respectively. No dog tested positive by RT-PCR for *B. gibsoni*. Salerno had the highest prevalence of *Babesia* spp. infections with 22.5% of dogs testing positive by either PCR or ELISA followed by Avellino (15.7%) and Napoli (8.6%).

The present study represents the first large-scale survey of *Babesia* spp. infections in hunting dogs from southern Europe and demonstrates that hunting dog populations in southern Italy are at risk for babesiosis. Further studies are needed to determine the prevalence of clinical babesiosis in this at-risk population and to evaluate the relationship between hunting dogs and sympatric populations of wild animals in the epidemiology of *Babesia* spp.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

V. Veneziano
University of Naples Federico II
Napoli, Italy

URL: [http://www.vin.com/doc/?id=8172975](http://www.vin.com/doc/?id=8172975)
So far, there are a few data regarding how immunocompromised cats, such as cats infected with feline leukemia (FeLV) and immunodeficiency virus (FIV), react to vaccination. Therefore, this study's aims were to measure feline panleukopenia virus (FPV) antibodies in FIV- and FeLV-infected cats within a period of 28 days after FPV vaccination, and to compare the titre increase to that of healthy cats.

FIV- (n=5), FeLV-infected (n=5), and healthy cats (n=112) were vaccinated with a commercial FPV modified-live vaccine. Pre- and post-vaccination antibody titres were measured by haemagglutination inhibition (HI) on day 0, 7, and 28. An HI titre ≥1:40 was defined as protective. An adequate immune response to vaccination was defined as a 4-fold titre increase. Differences regarding titre increase between FIV-, FeLV-infected, and healthy cats were analysed using chi-squared test.

Protective pre-vaccination FPV antibody titres were present in 80% (8/10; 95% CI: 47.9–95.4) of retrovirus-infected cats and in 64% (72/112; 95% CI: 55.1–72.6) of healthy cats. An adequate titre increase was observed in 30% (3/10; 95% CI: 10.3–60.8) of retrovirus-infected cats and in 48% (54/112; 95% CI: 10.3–60.8) of healthy cats. There was neither a significant difference in presence of protective pre-vaccination titres (p=0.491), nor in titre increase (p=0.335), or vaccination adverse effects (p=0.597).

FIV and FeLV infections did not negatively influence efficacy and safety of MLV FPV vaccination; thus, FPV vaccination can be given to retrovirus-infected cats according to current guidelines. Further studies should be performed involving larger numbers of retrovirus-infected cats.

DISCLOSURES
Disclosures to report
The study was funded by Merial, Lyon, France. Merial played no role in the interpretation of data, nor in the decision to submit the abstract for publication. There is no commercial conflict of interest, as the information generated here is solely for scientific dissemination. The authors declare that they have no competing interests.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Bergmann
Clinic of Small Animal Medicine
München, Germany

URL: http://www.vin.com/doc/?id=8172976
Evaluation of Rapid Diagnostic Test Kits for Canine Vector-Borne Diseases

H. Bewsey1; J. Liu1; J. Rodon Vernet2; R. Chandrashekar1

1IDEXX Laboratories, Inc., Westbrook, ME, USA; 2IDEXX Laboratories, Inc., Barcelona, Spain

Canine vector-borne diseases (CVBD), including leishmaniasis (CanL), canine monocytic ehrlichiosis (CME) and anaplasmosis, are prevalent in Mediterranean countries, South America, parts of Asia and Africa. Diagnosis of CVBD is generally supported by hematologic and serologic findings. Commonly used serological tests include immunofluorescence assay (IFA) and/or ELISA. Rapid in-clinic tests are also available. The aim of this study was to compare the performance of rapid tests with gold standard IFA and/or ELISA for detection of canine antibodies to Leishmania infantum, Ehrlichia canis and Anaplasma platys.

The rapid tests evaluated included SNAP® Leishmania and SNAP® 4Dx® Plus (IDEXX), Uranotest Leishmania and Uranotest Ehrlichia-Anaplasma (Uranovet). Study samples were collected from IDEXX Reference Laboratories from samples remaining after requested diagnostic testing was completed. These samples were originally submitted by attending veterinarians for detection of Leishmania antibodies using LEISCAN® Leishmania ELISA test, or for detection of E. canis antibodies using E. canis IFA. Positive samples for Leishmania were defined for this study as those with ≥1/160 equivalent titer (converted from OD ratio per manufacturer’s instructions), negatives with ≤1/20 equivalent titer. To control for potential cross-reactivity of E. canis IFA, a species-specific ELISA (McBride et al. 2007) was used to confirm E. canis samples. Another species-specific ELISA (Qurollo et al. 2014) was used to identify A. platys samples.

Compared to the respective diagnostic standards, the sensitivities of SNAP and Uranotest were 90.3% and 67.7%, respectively, for Leishmania; 96.2% and 65.4% for E. canis; 83.0% and 48.9% for A. platys. Specificities were high for all test kits.

This study revealed that the accuracy of in-clinic rapid tests for CVBD varies significantly. Consistent with previously published studies (Ferroglio et al. 2007; Marcondes et al. 2011; Miró et al. 2013; Stillman et al. 2014; Rene-Martellet et al. 2015), this study using clinical samples continued to demonstrate the high sensitivity and specificity of SNAP tests for detection of Leishmania, E. canis, and A. platys antibodies.

DISCLOSURES

Disclosures to report
All authors are employees of IDEXX Laboratories, Inc.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J. Rodon Vernet
IDEXX Laboratories, Inc.
Barcelona, Spain

URL: http://www.vin.com/doc/?id=8172977
Antimicrobial use (AMU) in veterinary medicine is considered a potential threat for public health and animal health, as it selects for antimicrobial resistance. Therefore, a combination of compulsory and voluntary actions was implemented in the last 5 years to reduce AMU in animals in the Netherlands. In food-producing animals, a considerable reduction in AMU has been accomplished over the last years. Previous research in companion animals showed that total AMU in companion animals is relatively low, but large differences between clinics exist, and especially in the choice of antimicrobial agents there is room for improvement. Therefore, from the end of 2014 onward, an antimicrobial stewardship program (ASP) was developed and implemented stepwise in 44 Dutch companion animal clinics.

Aims of the present study are to calculate defined daily dosages (DDDs) from these 44 clinics before start of the ASP implementation and to identify clinic-related factors influencing AMU in these Dutch companion animal clinics.

At the beginning of the ASP implementation, clinics filled in a questionnaire and provided data on AMU from July 2012 until July 2015. Questionnaires were used to study clinic-related factors which might influence AMU by companion animal veterinarians. Antimicrobial usage data were converted to the number of DDDs with a standardized Dutch database built for this purpose. A number of DDDs during a specified period (mostly a year) represents the number of days during that period that an average dog, cat or rabbit in a clinic is treated with AMs. DDDs were differentiated in first- (not selecting for ESBLs), second- (might select for ESBLs) and third-choice AMs (critically important to public health; i.e., third- and fourth-generation cephalosporins and fluoroquinolones).

Results show that AMU decreased over the last years. There is a significant decrease in the use of third-choice antimicrobials. Further statistical analyses will be performed to explore associations between DDDs and clinic characteristics (e.g., number of veterinarians working in a clinic; rural versus urban clinics; and number of dogs, cats and rabbits being treated in a clinic).

DISCLOSURES

Disclosures to report
This study was funded by ZonMW (Netherlands Organization for Health Research and Development), project number: 205300003.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

N.E.M. Hopman
Faculty of Veterinary Medicine
Utrecht University
Utrecht, Netherlands

URL: http://www.vin.com/doc/?id=8172978
Prevalence and Risk Factor for Harbouring Campylobacter jejuni in Young Dogs in Copenhagen
L.R. Jessen; S. Lund; C.K. Vøls; R. Langebæk; C.R. Bjørnvad
University of Copenhagen, Frederiksberg, Denmark

Campylobacter jejuni (C. jejuni) is the most common cause of clinical campylobacteriosis in people. In Denmark, the incidence of human campylobacteriosis is constant, despite a significant reduction in food-borne cases over the last couple of years, indicating a role for other sources of infection.

The aims of the study were as follows: 1) to examine the prevalence of C. jejuni in family dogs younger than 2 years of age in Copenhagen, Denmark; 2) to identify risk factors associated with carriage of C. jejuni; and 3) to examine the association between carriage of C. jejuni and clinical signs of diarrhea. A cross-sectional study in dogs younger than 2 years presenting to the University Hospital for Companion Animals, University of Copenhagen, Denmark, was carried out from May to November 2016. Samples were collected by rectal swabs and stored in a charcoal medium at 4°C for a maximum of 32 hours before culturing. Positive samples were verified using phase-contrast microscopy and whole genome sequencing. All dog owners completed a questionnaire regarding the management of their dogs. Data was analyzed using chi-squared tests and multivariate analyses in SPSS Statistics 24; p<0.05 was considered significant.

Two hundred twenty-four dogs were included. The prevalence of C. jejuni was 9.4% (21/224). Primary feeding with "bones and raw food" (BARF, p=0.008) and regular feeding with dried meat (p=0.01) were significant risk factors for Campylobacter carriage. Dogs younger than 1 year of age fed with BARF and/or dried meat were at greater risk of carrying Campylobacter than dogs older than 1 year of age with the same feeding routines. There was no association between a positive C. jejuni status and concurrent diarrhea, swimming in sea or lake water, having been abroad or living with other pets or children in the family.

Dogs can act as reservoirs for C. jejuni, and raw feeding increases the risk. The carriage of C. jejuni in dogs may pose a zoonotic risk to humans.

DISCLOSURES

Disclosures to report
The Department of Veterinary Clinical Sciences, University of Copenhagen, was granted 25000 DKr (3300 Euro) by the Danish Food Administration for performing the study.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

L.R. Jessen
University of Copenhagen
Frederiksberg, Denmark

URL: http://www.vin.com/doc/?id=8172979
Surveillance of Bacterial Contamination in Stethoscopes and Effectiveness of Different Disinfecting Protocols

P. Sebastian¹; D. Hermes²; M. Sharman²

¹Hospital Veterinario Universidad de Murcia, Murcia, Spain; ²Animal Health Trust, Newmarket, UK

Hospital-acquired infections (HAIs) can be an important cause for morbidity and potentially mortality. There is increasing concern for the role of multi-drug resistant (MDR) organisms in HAIs. Surfaces, including stethoscopes, could act as fomites; however, there is no current consensus on decontamination protocols. Furthermore, there is increasing concern regarding the development of bacterial resistance to topically applied antiseptic agents, leading to evaluation of innovative decontamination methods.

The purposes of this project were to evaluate the type of bacterial contamination of stethoscopes in a referral hospital setting and to compare the effectiveness of three decontamination protocols.

This study was prospective and interventional. Based upon available information, a sample size of thirty stethoscopes per group was calculated to be adequate to determine differences between protocols. Three decontamination protocols were used in a crossover design across a six-week period. Decontamination protocols included 70% isopropyl alcohol, a quaternary ammonium/biguanide disinfectant (Anistel) and exposure to UV light (253.7 nm). For each, the diaphragm membrane of each stethoscope was sampled using a sterile cotton-tipped swab moistened in PBS before and after. Colony numbers were determined, and bacterial identification was performed. Between collection time points, stethoscopes were in regular clinical circulation.

For group comparisons, delta-change values in colony counts were determined for each stethoscope. Differences between groups were analysed using a non-parametric analysis of variance (Kruskal-Wallis test). Where differences were returned between groups, post-hoc analysis with Dunn's multiple comparisons method was performed to identify where differences occurred.

A variety of bacterial types were cultured across the course of the study. No MDR bacteria were isolated. There was no difference between delta change values when comparisons were made between decontamination protocols (p=0.07).

In this referral setting, stethoscope contamination with MDR bacteria was not present. There was no difference between groups regarding expected reductions in bacterial colony counts. UV light appeared equivalent to other topical solutions in reducing contamination rates of stethoscopes.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Sebastian
Hospital Veterinario Universidad de Murcia
Murcia, Spain

URL: http://www.vin.com/doc/?id=8172980
Identification of Attaching and Effacing Enteropathogenic Escherichia coli in Dogs with Parvoviral Enteritis

J. Rubin; A. Carr; M. Gaunt
University of Saskatchewan, Saskatoon, SK, Canada

Canine parvovirus is a common cause of severe gastroenteritis in young, incompletely vaccinated dogs. Concurrent infections with gastrointestinal parasites and canine coronavirus exacerbate clinical disease, increasing mortality. The ability of bacterial pathogens to potentiate clinical signs has not been thoroughly investigated. Enteropathogenic E. coli, defined by the presence of the eae gene, produce characteristic attaching and effacing lesions on the enterocyte brush border. These E. coli have been identified in up to 36% of dogs with both acute and chronic diarrhea, suggesting a pathogenic role. Dogs with severe diarrhea infected with enteropathogenic E. coli have clinical signs and gross pathological lesions that are indistinguishable from parvovirus infection. The aim of this study was to identify the prevalence of eae-positive E. coli in dogs with parvoviral enteritis. Twenty-five dogs admitted to the Veterinary Medical Centre in Saskatoon, Canada were included in this study if they met the following criteria: 1. Less than two years of age; 2. Acute-onset vomiting and/or diarrhea; and 3. Incomplete vaccination history. Feces were cultured and E. coli identified using standard biochemical methods. Isolates were screened for the eae gene by PCR, and amplicon identity was confirmed by DNA sequencing. Feces were evaluated for gastrointestinal parasites by flotation and for Giardia and Cryptosporidium by immunofluorescent antibody. Complete blood count, serum biochemical profile or venous blood gas, urinalysis and parvovirus fecal ELISA were performed for each dog to identify other potential causes of gastroenteritis. E. coli were cultured from feces of 92% (23/25) of dogs; 8.7% (2/23) were eae positive. All dogs were identified as parvovirus positive, including 22/25 dogs by fecal ELISA, 1/25 by immunohistochemistry and 2/25 by histopathological examination. Fecal culture identified Clostridium perfringens in 17/24 and Campylobacter in 3/24 dogs. Salmonella were not identified. Concurrent gastrointestinal parasitism was identified in 5/20 dogs tested, identifying Isospora (2/20), Sarcocystis (1/20), and Toxascaris (1/20). Giardia sp. were identified in 2/20 by flotation or IFA. The role of these organisms as canine intestinal pathogens is poorly defined. The low prevalence of eae-positive E. coli identified among young dogs with parvovirus suggests that these organisms are unlikely to be significant gut pathogens in patients with parvoviral enteritis. Further study is required to define the role of these potential pathogens in canine enteric disease.

Disclosure
No disclosures to report

Speaker Information
J. Rubin
University of Saskatchewan
Saskatoon, SK, Canada

URL: http://www.vin.com/doc/?id=8172981
Combined Therapy with Clindamycin, Doxycycline and Metronidazole Induces Complete Sterilisation of Babesia gibsoni Infection in Dogs - A Case Report

O. Sarpataki; A.R. Codea; M. Mircean; I. Marcus; S. Bogdan; A.A. Daskalaki; B. Sevastre
Faculty of Veterinary Medicine, Cluj-Napoca, Romania

Canine babesiosis is a tick-borne protozoal disease, affecting dogs worldwide. According to previous studies, B. canis is considered as the main species involved in canine babesiosis, but in recent years more studies show the existence of Babesia gibsoni infected dogs both in Europe and Romania. B. gibsoni infection in dogs is mainly described in American Pit Bull Terriers, although the significance of this breed predisposition is not yet fully understood; however, the possibility of both blood-to-blood transfer and transplacental infection has been considered as a possible modality of host contamination. A 3-year-old female, American Staffordshire Terrier was referred to our clinic, previously diagnosed with Babesia canis infection and treated with one dose of imidocarb dipropionate three days prior. The dog presented with fever, pale mucous membranes and hemoglobinuria. Complete blood count revealed severe anemia (HCT 13%, Hg 4 g/dl, RBC 1,56x10^{12}/l), thrombocytopenia (PLT 32x10^{9}/l) and mild leukocytosis with neutrophilia. Coombs test (Alvedia) and rapid test for Dirofilaria immitis antigen, Ehrlichia canis antigen, Borrelia burgdorferi antigen, Anaplasma phagocytophilum/Anaplasma platys antibody (Rapid CaniV-4 Test Kit, BioNote) showed negative results. Giemsa-stained blood films were positive for small (1–2.7 μm) pleomorphic inclusions. Babesia spp. DNA was detected by polymerase chain reaction (PCR) assay; further molecular characterization of the sample showed the involvement of Babesia gibsoni (Macrogen Europe, Amsterdam). Following molecular identification of Babesia gibsoni, combination therapy was initiated with clindamycin (25 mg/kg PO BID), doxycycline (15 mg/kg PO BID), and metronidazole (5 mg/kg PO BID). Fourteen days after therapy, Hb, HCT, RBC and PLT values increased, but the blood sample tested positive for B. gibsoni by PCR. Therapy was ceased after 6 weeks, when HCT reached 40% and PCR showed complete B. gibsoni infection sterilization of the patient. Blood samples tested 3 and 6 months after the initiation of the treatment remained negative for B. gibsoni. Since the female was 5 weeks postpartum at the time babesiosis diagnosis was established, four samples from two different litter pups were tested and found negative for B. gibsoni, although transplacental transmission is possible in B. gibsoni infection. Accurate diagnosis is important in dogs presenting with hemolytic anemia, because B. gibsoni is resistant to traditional anti-Babesia therapy, but combination therapies may be efficient in order to reduce and eliminate parasitemia.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

O. Sarpataki
Faculty of Veterinary Medicine
Cluj-Napoca, Romania

URL: http://www.vin.com/doc/?id=8172942
First Documentation of Cytochrome B Gene Mutations Associated with Atovaquone and Azithromycin Treatment in *Cytauxzoon felis*

A.N. Hartley; H.S. Marr; A.J. Birkenheuer
College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA

*Cytauxzoon felis* is an emerging tick-transmitted protozoan parasite of domestic and wild felids. Cytauxzoonosis is typically fatal in clinical cases without aggressive treatment. Combination treatment with atovaquone and azithromycin (A&A) along with supportive care has improved survival rates to over 60%; in contrast, survival rates with imidocarb dipropionate are 26%. Parasite resistance to atovaquone via a cytochrome b parasite gene (*cytb*) mutation has been identified in other protozoans and is a concern for *C. felis*. Specifically, mutations at the M128 amino acid position of the putative atovaquone binding site on *cytb* have been associated with resistance.

We aimed to characterize the atovaquone binding region of *cytb* in samples from a *C. felis*-infected domestic cat that remained parasitemic despite treatment with atovaquone and azithromycin. An approximately nine-year-old, female spayed domestic shorthair was presented for adoption assessment; the cat was anemic, which persisted despite fenbendazole and doxycycline treatment. Comprehensive infectious disease testing detected *C. felis* via microscopy and polymerase chain reaction (PCR). Atovaquone (15 mg/kg PO q 8 h x 10 days) and azithromycin (10 mg/kg PO q 24 h x 10 days) treatment were administered, and the PCV improved, but the cat remained persistently infected with *C. felis*. Sequencing of the atovaquone binding region of *cytb* over the course of infection (pre- and post-treatment samples) would reveal a transition from wild-type (M128) to isoleucine and valine (M128I and M128V) at 2 and 4 months post-treatment. A repeat treatment course with A&A using an increased atovaquone dose (25 mg/kg PO q 8 h x 10 days) would fail to clear the *C. felis* infection and M128I and M128V mutations persisted. The wild-type M128 *cytb* was not detected in post-treatment samples up to 210 days.

This is the first documentation of resistance of *C. felis* to atovaquone associated with M128 *cytb* mutations. Additionally, this carrier cat appears to be the first chronically *C. felis*-infected felid with persistent anemia. This case suggests that parasites with mutations of *cytb* M128 can be selected and impart resistance to A&A treatment even in the face of increased atovaquone dosing.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

A.N. Hartley
College of Veterinary Medicine
North Carolina State University
Raleigh, NC, USA

URL: http://www.vin.com/doc/?id=8172984
Lethal Pox Disease in a Cat: Classical Cowpox or Novel Orthopoxvirus Infection?

N. Decaro; G. Dowgier; F. Albanese; G. Lanave; E. Brogi; A. Parisi; M. Losurdo; M.L. Colaianni; A. Lavazza; V. Martella; A. Lavazza

1University of Bari, Valenzano, Italy; 2Laboratorio Analisi La Vallonea, Aradeo (LE), Italy; 3Centro Veterinario Montarioso, Siena, Italy; 4Istituto Zooprofilattico Serimentale di Puglia e Basilicata, Putignano, Italy; 5Istituto Zooprofilattico Serimentale di Lombardia ed Emilia Romagna, Brescia, Italy

Orthopoxvirus (OPXV) is a genus of the family Poxviridae, subfamily Chordopoxvirinae, which includes several viruses infecting humans and animals. Among these are Ectromelia virus (ECTV), which infects only mice, and Cowpox virus (CPXV), which recognises wild rodents as reservoirs, while several species, including humans and cats, are considered incidental hosts. Here, we report a case of lethal infection in a cat that was caused by a putative novel OPXV displaying an intermediate position between CPXV and ECTV at the genomic level.

The cat, a European 6-month-old male, was presented with wide alopecic and erythematous areas on the face and paws. After a few days, the skin lesions spread to other areas of the body and ulcers appeared on the tongue and palate. After the diagnosis of OPXV infection, the cat was treated with antivirals (famciclovir and subsequently acyclovir), but after an initial improvement the animal rapidly worsened and was euthanized.

Bioptic samples, collected intra-vitam from the skin lesions, were processed for histologic and virological investigations. By histopathology, leukocyte infiltration and eosinophilic cytoplasmic inclusion bodies were evident in the skin punches. Different PCR approaches for detection and characterisation of poxviruses showed that the collected samples contained a poxvirus, but they were unable to assign definitively the virus to a species within the genus Orthopoxvirus. The OPXV strain, Italy-09/17, was isolated on African green monkey kidney CV-1 cells and also on embryonated eggs, as demonstrated by the development of the typical pocks in the chorioallantoic membrane. A large amount of typical brick-shaped virions, approximately 320x240 nm in size, morphologically related to the genus Orthopoxvirus, were observed by negative-staining electron microscopy. The nearly full-length genome of the virus was obtained through a next-generation sequencing approach carried out on the isolated virus. By sequence and phylogenetic analysis of selected genomic regions, which are commonly used to classify OPXVs, isolate Italy-09/17 was proven to form a separate cluster from both CPXV and ECTV. Extensive epidemiological surveillance in cats and wild animals, including rodents, will assess whether this feline OPXV circulates in domestic cat populations and whether cats are incidental hosts or represent the main reservoir of the virus.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

N. Decaro
University of Bari
Valenzano, Italy

URL: http://www.vin.com/doc/?id=8172985
Evidence of Sharing of MDR K. pneumoniae Between Infected and Non-Infected Cats from Same Household

C. Marques1; A. Belas1; T. Vet.Point2; C. Pomba1

1Faculty of Veterinary Medicine, CIISA, University of Lisbon, Lisbon, Portugal; 2Vet.Point, Instituto Veterinário da Linha, Oeiras, Portugal

The dissemination of ESBL and carbapenemase-producing Klebsiella pneumoniae is a worldwide concern. Multidrug-resistant (MDR) K. pneumoniae UTIs in companion animals raise great concerns regarding their role as reservoirs and in the spread of such bacteria. The aim of this study was to evaluate the within-household sharing of ESBL-producing MDR K. pneumoniae from a UTI infected cat.

Antimicrobial susceptibility testing of the uropathogenic bacteria was conducted by microdilution methods according to CLSI and screening for the presence of CTX-M ESBL was performed by PCR and sequencing. Fecal samples from the infected cat (ICat) and co-habiting pets (cat-1, dog-1, dog-2) were collected for detection and quantification of colonization by the infection K. pneumoniae strain. Environment swabs from the animals’ food/water bowls and bedding were also collected. Samples were serially diluted and cultured in MacConkey agar plates containing 1.5 µg/mL ceftaxime (CTX). Negative samples were grown in enrichment media prior to plating to detect low levels of colonization. When positive, up to five K. pneumoniae colonies were obtained for further analysis.

Unique clones were resolved by PFGE-XbaI macro-restriction using Dice/UPGMA clustering analysis.

A cat with history of urolithiases underwent a subcutaneous ureteral bypass system (SUB) implantation. During SUB maintenance, a UTI by K. pneumoniae was diagnosed. The K. pneumoniae was a CTX-M-15 producer with MDR phenotype. Fecal samples from the infected cat (ICat) were positive for CTX-resistant K. pneumoniae. Samples from dog-1 and dog-2 prior and after ICat treatment were all negative, thus no colonization was detected. Regarding cat-1, only one sample collection was possible (during ICat treatment), yet it revealed a high fecal burden of CTX-resistant E. coli and K. pneumoniae. PFGE-XbaI analysis showed a similarity index of 100% between CTX-resistant K. pneumoniae from cat-1 feces and K. pneumoniae from ICat urine, thus proving the colonization/transfer. Furthermore, 100% similar CTX-resistant K. pneumoniae was also detected from the cat's bedding.

To our best knowledge, this is the first study reporting the sharing of MDR K. pneumoniae between infected and healthy pets from the same household. Same-species transfer of MDR K. pneumoniae was likely due to sharing of litterbox and bedding, thus special control measures should be implemented in these environments. The high colonization with 3GCr Enterobacteriaceae of the co-habiting healthy cat further increases the spread of MDR K. pneumoniae.

DISCLOSURES

Disclosures to report

Acknowledgements: With financial support of CIISA and FCT through Project UID/CVT/00276/2013 and JPIAMR/0002/2016. AB and CM hold FCT PhD grants SFRH/BD/113142/2015 and SFRH/BD/77886/2011, respectively.

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Pomba
Faculty of Veterinary Medicine
CIISA
University of Lisbon
Lisbon, Portugal

URL: http://www.vin.com/doc/?id=8172986
SCH - Society of Comparative Hepatology

Oral Presentations

Poster Presentations
**Oral Presentations**

**Prednisolone Therapy for Chronic Hepatitis in the English Springer Spaniel: A Prospective Study of 14 Cases**  W.A. Bayton

**Ciclosporin in the Treatment of Canine Chronic Hepatitis**  T. Ullal

**Investigation into Hepatocyte Expression and Prognostic Significance of Senescence Marker p21 in Canine Chronic Hepatitis**  A.J. Kortum

**Chronic Portal Vein Thrombosis in Eleven Dogs**  K. Sato

**Breed Predisposition to Gall Bladder Mucocoeles in Border Terriers**  F. Allerton

**Outcome of Cats Undergoing Surgical Attenuation of Congenital Extrahepatic Portosystemic Shunts Through Cellophane Banding: 23 Cases**  P. Valiente

**Transcutaneous Fluorometric Measurement of Indocyanine Green Clearance as Dynamic Liver Function Test in Dogs with Congenital Portosystemic Shunt**  R. Neiger
Prednisolone Therapy for Chronic Hepatitis in the English Springer Spaniel: A Prospective Study of 14 Cases

W.A. Bayton1; A. Wilson2; H. Fieten3; N.H. Bexfield4; P.J. Watson1

1University of Cambridge, Cambridge, UK; 2Craig Robinson Vets, Carlisle, UK; 3University of Utrecht, Utrecht, Netherlands; 4University of Nottingham, Loughborough, UK

English Springer Spaniels (ESS) in the UK show an increased prevalence of chronic hepatitis (CH). As a viral aetiology was initially suspected, historically these dogs were rarely treated with corticosteroids. In a previous study of 68 ESS with CH, in which only 3 dogs were treated with corticosteroids, a median survival time of 189 days was noted [range: 1–1211 days]. CH in the ESS shares similarities with human autoimmune hepatitis; it occurs more commonly in young females and has a similar histological appearance. Anecdotally some ESS with CH responded well to prednisolone. This study aimed to investigate the clinical and biochemical response following corticosteroid treatment.

ESS being treated in first-opinion and referral practice with a histological diagnosis of idiopathic chronic hepatitis were enrolled prospectively between 2009 and 2017. Attending veterinary surgeons were asked to give prednisolone 1–2 mg/kg/day and submit regular blood results and progress reports to the authors. Ten female and four male ESS were enrolled with a median age at diagnosis of 5 years 7 months [range: 11 months–10 years]. No cases had been treated with corticosteroids within 6 months of the study. The mean prednisolone starting dose was 1.1 mg/kg/day [range: 1–2 mg/kg/day]. All cases received additional therapies including combinations of S-adenosylmethionine, silybin, ursodeoxycholic acid, and hepatic diet. The prednisolone dose was tapered appropriately over several months according to the patient's clinical and biochemical response, focusing on alkaline phosphatase (ALKP), alanine aminotransferase (ALT) and bilirubin.

All cases showed an improvement clinically, including resolution of jaundice (4/4), vomiting (5/5) and polyuria/polydipsia (4/4). Two out of the 14 cases were euthanased due to CH while receiving prednisolone, with survival times of 122 and 741 days from diagnosis. The remaining 12 patients are alive and clinically well, with 9 patients still receiving a mean dose of 0.4 mg/kg prednisolone every other day (EOD) [range: 0.25 mg/kg/EOD - 1 mg/kg/day]. The median time since diagnosis is 630 days [range: 60–1,350 days]. Two-sided Wilcoxon test demonstrated significant (p<0.05) reductions in serum ALKP, ALT and bilirubin following prednisolone therapy. Median values before and immediately after starting immunosuppressive doses of prednisolone were 810 to 403 IU/L, 1000 to 299 IU/L and 24.0 to 4.0 µmol/L for ALKP, ALT and bilirubin, respectively.

The results of this study demonstrate a markedly improved survival over a historical cohort when ESS with CH are managed with immunosuppressive doses of prednisolone. Serial measurements of ALKP, ALT and bilirubin are useful for monitoring the patient's progress.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

W.A. Bayton
University of Cambridge
Cambridge, UK

URL: http://www.vin.com/doc/?id=8172996
Ciclosporin in the Treatment of Canine Chronic Hepatitis

T. Ullal\(^1\); Y. Ambrosini\(^2\); C.R.L. Leveille-Webster\(^2\); D.C. Twedt\(^1\)

\(^1\)Colorado State University, Fort Collins, CO, USA; \(^2\)Tufts University, North Grafton, MA, USA

Chronic hepatitis (CH) is a common hepatic disorder in dogs. Diagnostic criteria of canine CH include persistent ALT elevations >2 times normal and histopathologic features based on WSAVA guidelines, characterized by moderate to severe chronic inflammation, hepatocellular apoptosis or necrosis, and fibrosis. Most cases are classified as idiopathic and, therefore, optimal management for CH has not been established. Corticosteroids are reported to prolong survival in some dogs, suggesting an immune-mediated mechanism to the disease. However, corticosteroids cause significant side effects and induce a steroid hepatopathy that confounds interpretation of liver enzymes during therapy. To date, there are no studies investigating the use of alternative immunosuppressive therapy, such as cyclosporine (Cys), in the management of canine idiopathic CH.

The primary aim of this retrospective study was to evaluate the safety and efficacy of Cys in the treatment of idiopathic CH. A secondary aim was to identify any factors influencing Cys treatment response or time to remission. Remission was defined as normalization of serum ALT. Our hypotheses were that: 1) Cys therapy would achieve remission and 2) lower pretreatment clinical scores and higher serum ALT would predict prolonged times to remission.

Forty-six dogs diagnosed with idiopathic CH and treated with Cys met the inclusion criteria. Cases were excluded if there was a lack of biochemical data, concurrent immunosuppressive therapy, failure to complete at least 2 weeks of Cys therapy, or evidence of biochemical improvement with penicillamine or antibiotic administration. Twenty-five different breeds were represented. Ages ranged from 0.7–14 years with a median of 8 years. Fifty-two percent were female spayed and 43% were male castrated. Treatment side effects included gastrointestinal signs ranging from mild inappetence to vomiting and diarrhea in 39% and gingival hyperplasia in 26%. Thirty-five dogs (76%) achieved remission based on ALT normalization. The median time to remission was 3 months. Three dogs (6.5%) reached partial remission (ALT values declined but remained between 1.1 and 2x the upper limit of normal). Eight cases (17%) did not achieve remission. Initial serum ALT activity, hepatic copper concentration (>1000 μg/g dry weight), and clinical score did not influence remission.

Cys proved to be effective in achieving remission based on normalization of serum ALT in canine idiopathic CH. Limitations include the retrospective nature of the study, concurrent therapies given, variability of long-term followup, and the lack of post-treatment biopsies.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

T. Ullal
Colorado State University
Fort Collins, CO, USA

URL: http://www.vin.com/doc/?id=8172997
Canine chronic hepatitis (CCH) is characterised histologically by hepatocellular apoptosis or necrosis, a variable mononuclear or mixed inflammatory infiltrate, regeneration and fibrosis. Life expectancy following diagnosis is unpredictable, ranging from days to years. Reported prognostic indicators (hyperbilirubinemia, hypoalbuminemia and presence of ascites or cirrhosis) are unreliable, particularly in end-stage disease. Hepatocyte expression of p21, a universal cell-cycle inhibitor and marker of cellular senescence, is strongly negatively correlated with outcome in humans with alcoholic- and non-alcoholic-related liver disease and is a better prognostic marker than histological or clinical scoring systems. P21 expression has not been investigated in CCH.

This study investigated whether hepatocyte p21 expression is increased in CCH and if expression is associated with survival. Cases of CCH were retrieved from the pathology database (2004–2016) and liver biopsy samples were reviewed using routine stains (haematoxylin and eosin, rhodamine, and Sirius Red). Immunohistochemistry was performed using monoclonal mouse anti-human p21 on all selected cases and four control liver samples with normal histology and no history of liver disease. P21 expression was manually quantified by scoring p21-positive and p21-negative hepatocytes in eight high-power fields for each case by two blinded observers and expressed as a percentage of total hepatocyte number. Kendall's tau correlation coefficients were used to assess relationships between p21 expression and survival time or age; significance was set at p<0.05 (2-tailed).

Twenty-two dogs with CCH were selected. There was a significant negative correlation between hepatocellular p21 expression (median 83.17%; range 15.30–99.40) and survival (460 days; range 12–1559), but no correlation between p21 expression and age (median 7.3 years; range 2.0–12.0). Inclusion or exclusion of cases with copper-associated disease gave similar results. Three of four control samples from young dogs (<6.5 y) displayed negligible p21 expression as expected (<10%). The fourth control sample from a 16.5-year-old dog had a high percentage of p21-positive hepatocytes (85%).

This study demonstrates that p21 expression in normal dogs increases with age as expected but is upregulated in CCH, indicating a state of cellular senescence irrespective of age. The median percentage of senescent hepatocytes in CCH was higher than in human hepatitis. These cells are indistinguishable from normal hepatocytes using routine stains but are unable to perform normal hepatic functions. P21 quantification in CCH may therefore provide additional information regarding hepatic function. Furthermore, a negative correlation between p21 expression and survival was identified, suggesting a role for p21 quantification in determining prognosis in CCH.

**DISCLOSURES**

No disclosures to report

**SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

**A.J. Kortum**  
University of Cambridge  
Cambridge, UK

URL: [http://www.vin.com/doc/?id=8172998](http://www.vin.com/doc/?id=8172998)
Chronic Portal Vein Thrombosis in Eleven Dogs

K. Sato; M. Sakai; Y. Sakamoto; C. Ishikawa; T. Watari
Nihon University, Fujisawa, Kanagawa, Japan

Portal vein thrombosis (PVT) causes partial or total obstruction of portal blood flow, leading to pre-hepatic portal hypertension. Canine PVT is considered a rare entity and is classified into two categories, acute and chronic, based on the presenting clinical conditions. Diagnosis of canine PVT is generally performed using abdominal ultrasound. However, ultrasound is operator dependent. In humans, computed tomography (CT) angiography is preferred for the diagnosis and extensive evaluation of PVT.

We retrospectively reviewed veterinary clinical data from 2008 through 2017, and included cases that were diagnosed as PVT using CT angiography. Chronic PVT was classified as PVT with the absence of abdominal pain or shock. Variables including signalment, clinical signs, clinicopathological data, diagnostic imaging findings, treatment, and outcome were collected.

Eleven dogs were included in this study (seven male, four female). The median age and body weight were 11 years and 9.7 kg, respectively. Ten dogs had concurrent conditions, with pancreatitis (n=6) as the most frequent one. Glucocorticoids were administered prior to the diagnosis of PVT in six dogs, and ascites was confirmed in four dogs. Clinicopathological analysis revealed elevation of liver enzyme levels in eight dogs, hypoalbuminemia in nine, and thrombocytopenia in four. Serum D-dimer concentration was measured in ten dogs, with elevated values observed in all ten. Abdominal ultrasonography revealed PVT in eight dogs, but the diagnosis was missed in three. CT scan revealed PVT of the main portal vein in ten dogs. For those dogs for which we obtained follow-up data, two were re-examined using CT angiography. A reduction in size or organizing thrombi were confirmed in both.

In our study population, pancreatitis and the administration of glucocorticoids were found to be closely associated with chronic PVT. Although we succeeded in diagnosing PVT by ultrasonography in the majority of the dogs, this technique failed to provide a correct diagnosis in three. Thus, in cases where PVT is suspected based on laboratory test results and is undetected on an abdominal ultrasound scan, CT angiography would provide an alternative option for detailed diagnosis and followup.

DISCLOSURES
No disclosures to report

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

K. Sato
Nihon University
Fujisawa, Kanagawa, Japan

URL: http://www.vin.com/doc/?id=8172999
Breed Predisposition to Gall Bladder Mucocoeles in Border Terriers

F. Allerton¹; F. Swinbourne¹; M. Dunning²; A. Kent¹

¹Willows Veterinary Referrals, Shirley, UK; ²School of Veterinary Medicine and Science, University of Nottingham, Leicestershire, UK

Gall bladder mucocoeles (GBM) are a leading cause of biliary disease in the dog. Predisposed breeds include Shetland Sheepdogs, Cocker Spaniels, Chihuahuas and Miniature Schnauzers. Border Terriers (BT) have not previously been described as being predisposed, which may reflect geographic differences in popularity.

A high incidence of GBM was noted in BTs in our hospital, suggesting a breed predisposition. Retrospective evaluation of the medical records between January 2010 and April 2017 was performed to identify all dogs with an ultrasonographic diagnosis of GBM; 27965 dogs >2 years of age were seen over the study period. Of these, 382 (1.4%) were BTs. Thirty-seven dogs (18 BTs and 19 non-BTs including 2 Labrador retrievers, 2 Affenpinschers, 2 Shetland sheepdogs, 2 Miniature Schnauzers and 11 other individual breeds) were diagnosed with a GBM based on ultrasound alone (9) or ultrasound with histopathologic confirmation (28).

Odds ratio (OR) calculation was performed to evaluate predisposition. BTs with GBM were compared to non-BTs with GBM with respect to signalment (age, sex, neuter status), haematologic and biochemical measures and outcome data.

The OR for BTs to present with a GBM was 72 (95% confidence interval 37–138). There was no significant difference in gender or neuter status between BTs with GBM and the wider hospital population. Of the dogs with GBM, BTs were significantly older than non-BTs (median 10 y 10 m [range 5 y 11 m to 13 y 11 m] vs. 8 y 9 m [range 4 y 3 m to 13 y] [p=0.032]). There was no significant difference in haematologic or biochemical parameters between BTs and non-BTs.

Six out of 19 of the non-BTs and 3/18 of the BTs were managed without surgery. Two BTs and 5 non-BTs had 1 or 2 (2 non-BTs) concomitant endocrinopathies (diabetes mellitus, hypothyroidism, hyperadrenocorticism) at presentation; post-cholecystectomy 2 BTs were diagnosed with one endocrinopathy and 1 BT with diabetes mellitus and hyperadrenocorticism. Median survival times could not be calculated for either of the groups (<50% mortality). There was no significant difference in survival rate between groups with 11/19 non-BTs and 11/18 BTs still alive at time of writing.

On the basis of this single-centre study, BTs may have a breed predisposition to GBM. It would be interesting to see if this data is replicated in other European hospitals. Further study of BTs is warranted to identify factors influencing this predisposition and possible preventative measures.

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION
(click the speaker’s name to view other papers and abstracts submitted by this speaker)

F. Allerton
Willows Veterinary Referrals
Shirley, UK

URL: http://www.vin.com/doc/?id=8173000
**Outcome of Cats Undergoing Surgical Attenuation of Congenital Extrahepatic Portosystemic Shunts Through Cellophane Banding: 23 Cases**

P. Valiente; B. de la Puerta; M. Trehy
North Downs Specialist Referrals, Redhill, UK

**Aim**
To retrospectively evaluate attenuation of congenital extrahepatic portosystemic shunts (CEHPSs) in cats by means of cellophane banding (CB). To report postoperative complications and long-term outcome (clinical response and results of serial bile acid stimulation tests [BAST]).

**Methods**
Retrospective study. Medical records (from July 2008 through February 2017) of cats with CEHPSs were reviewed. Diagnosis of CEHPSs was made by diagnostic imaging and confirmed during coeliotomy. Cats treated with CB that had BAST performed pre- and postoperatively were included.

**Results**
Twenty-three cats were included. The study population comprised 8 different breeds with a median age of 8 months (4 to 33) and median body weight of 2.5 kg (1.45 to 4.7). Eleven cats were female (5 entire, 6 spayed), and 12 cats were male (6 entire, 6 neutered).

Common clinical findings included: abnormal behaviour (20/23), ptyalism (16/23), ataxia (12/23), stunted growth (12/23), copper-coloured irides (10/23), inappetence (10/23), depression (9/23) and seizures (4/23). Post-meal BAST before surgery was abnormal in all cats. Only two cats had normal fasting bile acids.

All cats received medical treatment before and after surgery. Treatment included: lactulose (23/23); clavulanate/amoxicillin (19/23), ampicillin (4/23) or metronidazole (2/23); levetiracetam (6/23); phenobarbitone (2/23). Protein-restricted diet was prescribed in 18/23 cats. Median duration of medical treatment was 21 days (8 to 209) prior to surgery and 62 days (range from 14 to 2046) after surgery.

In most cases, CEHPSs were detected by ultrasound. One cat had computed-tomography angiography. Portovenography was performed in 9/23 cats.

BAST was performed following CB after a median of 84 days (14 to 280 days). BAST normalised in 20/23 cats and 3/23 cats had persistently increased results. Two of them developed multiple acquired portosystemic shunts (one remained free of clinical signs until 6 years later, and the other was euthanised due to seizures). Complete closure of a patent shunt was achieved with a second surgery in the remaining cat with abnormal BAST.

Nineteen cats were alive and free of signs at last followup at least 8 months after surgery (3 to 66 months). Three cats developed postoperative seizures. Treatment with anticonvulsants resulted in complete or partial resolution of seizures in two cats. One cat was euthanised due to uncontrollable seizures.

**Conclusion**
CEHPSs occlusion by CB in cats carries a very good short- and long-term prognosis.

**Disclosures**
No disclosures to report

**Speaker Information**
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Valiente
North Downs Specialist Referrals
Redhill, UK

URL: [http://www.vin.com/doc/?id=8173001](http://www.vin.com/doc/?id=8173001)
Transcutaneous Fluorometric Measurement of Indocyanine Green Clearance as Dynamic Liver Function Test in Dogs with Congenital Portosystemic Shunt

L. Hausmann¹, N. Gretz², M. Schneider¹, R. Neiger³

¹Small Animal Clinic, University of Giessen, Giessen, Germany; ²Medical Research Center, University of Heidelberg, Mannheim, Germany; ³Tierklinik Hofheim, Hofheim, Germany

Indocyanine green (ICG), a fluorescent dye, is solely excreted by the liver without enterohepatic recirculation. We have recently shown the feasibility of a noninvasive transcutaneous ICG clearance to assess hepatic function instantaneously.

In this follow-up study, 10 dogs with congenital extrahepatic single portosystemic shunt (PSS) were included. Before and 3 months after surgical closure with cellophane banding or silk ligature, a ICG clearance study was both done transcutaneously and fluorometrically by taking serial blood samples 0, 1, 3, 6, 9, 18, 42 and 64 min after IV injection of 0.2 mg/kg ICG. Transcutaneous ICG clearance was measured using 2 miniaturized devices to detect ICG fluorescence with an excitation wavelength of 760 nm and an emission wavelength of 820 nm. For both methods, half-life time (HLTₜc, HLTₜₑ), plasma disappearance rate (PDRₜc, PDRₜₑ) and 15 minutes retention rate (R₁₅ₜc, R₁₅ₜₑ) were calculated based on the curve within minutes 1 to 15 after ICG injection. PSS closure was defined based on Doppler sonography and angiography.

In 6/10 dogs, the shunt vessel was closed after 3 months. In 3/10 dogs, the PSS was still partially open. One dog died after the operation. Transcutaneous ICG clearance was easily performed without complications and was well tolerated by all dogs. There was a significant difference between open and closed PSS for PDR (PDRₜc: p=0.0095; PDRₜₑ: p<0.0001) and R₁₅ (R₁₅ₜc: p=0.0323; R₁₅ₜₑ: p<0.0001) but not for HLT. Linear correlation coefficient between PDRₜc/PDRₜₑ, R₁₅ₜc/R₁₅ₜₑ and HWZₜc/HWZₜₑ were R²=0.6169, R²=0.4629 and R²=0.08629, respectively. In contrast to the invasive method, there was no overlap except one dog of PDRₜc and R₁₅ₜₑ of open and closed PSS.

In this first transcutaneous ICG clearance study of dogs with liver disease, transcutaneous assessment was superior to the invasive method and results are available immediately. The very limited invasiveness of this method and its dynamic character make the transcutaneous liver function test with ICG clearance a worthy test for veterinary medicine.

DISCLOSURES

One author (N. Gretz) is owner of a patent using transcutaneous measuring devices.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R. Neiger
Tierklinik Hofheim
Hofheim, Germany

URL:  http://www.vin.com/doc/?id=8173002
**Poster Presentations**

Validation of a Blood Score for Non-Invasive Diagnosis of Liver Fibrosis in Dogs  
M. Menard

Diagnostic Value of Paired Serum Bile Acids in Clinical Practice in 484 Samples  
M.D. Tabar
Validation of a Blood Score for Non-Invasive Diagnosis of Liver Fibrosis in Dogs

M. Menard1; A. Lecoindre2; M. Destro3; V. Miette3; B. Rannou4; J.L. Cadore4; A. Pagnon5; M. Chevallier6; G. Benchekroun1; P. Lecoindre2

1Ecole Nationale Vétérinaire d’Alfort, Maisons Alfort, France; 2CVC Clinique des Cerisioz, Saint-Priest, France; 3Echosens, Paris, France; 4Vetagro Sup Campus Vétérinaire de Lyon, Marcy L'Etoile, France; 5Novotec, Bron, France; 6Laboratoire Biomnis, Lyon, France

The assessment of liver fibrosis is of major importance for treatment and prognosis of canine chronic liver diseases. A panel of blood scores are currently used in human medicine and combine several biochemical parameters in proprietary algorithms. These tests help the clinician to stage and monitor liver diseases, thereby decreasing the need for liver biopsy.

We already built a blood score using a training set of 58 dogs. This score uses alanine aminotransferase, alkaline phosphatase, total bilirubin, potassium, and gamma glutamyl transferase. This blood score had a sensitivity and specificity of 81% and 68%, respectively (AUROC [95% CI] = 0,80 [0,67–0,92]).

The aim of the present study was to validate the blood score performance in a new population.

Following ethical committee approval and informed owner consent, client-owned dogs ≥2 years old that underwent liver biopsy to investigate abnormal liver enzyme activity were included. Exclusion criteria were: focal liver lesion and/or extrahepatic cholestasis on abdominal ultrasound, previous medications or extrahepatic comorbid diseases that could have influenced liver enzymes activity, or diagnosis of neoplasia on histologic examination.

Fasting blood samples were collected on the day of liver biopsy. Liver fibrosis was evaluated according to the criteria of the World Small Animal Veterinary Association guidelines on canine liver pathology. Dogs were classified as follows: no or only portal fibrosis (group 1) and bridging fibrosis or cirrhosis (group 2).

Thirty-eight dogs were recruited (53% female, 47% male): 20 in group 1 and 18 in group 2.

In this validation population, the blood score discriminates dogs with significant fibrosis, with an AUROC curve of 0,83 [0,69–0,96] (sensitivity 83%, specificity 70%) versus 0,68 [0,50–0,86] for ALT and 0,59 [0,41–0,78] for ALKP.

The validation protocol demonstrated similar performances between the training and the validation population. The blood score developed in this study was designed to help clinicians to screen for dogs with liver fibrosis in order to guide further investigations. This test provides accurate and reliable results in a fast, simple and cost-effective manner. An external validation protocol is needed for further assessment of the robustness of the test.

DISCLOSURES

Disclosures to report

The authors declare a potential conflict of interest with the company Echosens that developed the blood score described in this study. Echosens supports part of the residency funding of the presenting author.

SPAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Menard
Ecole Nationale Vétérinaire d’Alfort
Maisons Alfort, France

URL: http://www.vin.com/doc/?id=8173004
Diagnostic Value of Paired Serum Bile Acids in Clinical Practice in 484 Samples

M.D. Tabar\textsuperscript{1}; C. Bertolani\textsuperscript{2}; A. Esparza\textsuperscript{1}; N. Giulia\textsuperscript{2}; M.D. Queijo\textsuperscript{2}

\textsuperscript{1}Hospital Veterinario San Vicente, San Vicente del Raspeig, Alicante, Spain; \textsuperscript{2}Hospital Veterinario Canis, Mallorca, Spain

Increased serum bile acids (SBA) can be expected with hepatic, biliary or portal disorders that limit hepatic portal blood flow or hepatocellular uptake. Best clinicopathologic tests detecting those disorders remain controversial.

Results of paired SBA (pre- and 2 hours post-feeding) were retrospectively reviewed from samples obtained from animals undergoing bile acid (BA) testing because of suspected liver disease from two veterinary hospitals. The aim was to determine the frequency of altered values of fasting, postprandial and paired SBA, to evaluate if the clinical approach would be different depending on the selected test. SBA were sent off to an outside laboratory (IDEXX Barcelona) and measured by spectrophotometry with normal fasting value <10 µmol/L (a different cut-off of 25 µmol/L was also evaluated) and postprandial value <25 µmol/L.

The study included 484 samples from 392 dogs and 12 cats (178 females and 226 males). Median age was 5.4 years (0.17–13). Three feline breeds and 60 canine breeds were included.

Two hundred fifty-two paired SBA tests were considered as abnormal; among them, 175 (69.4%) fasting samples showed values >10 µmol/L (70 samples were 10–25 µmol and 105 samples were >25 µmol/L) and 201 (79.8%) postprandial samples were >25 µmol/L. In 131 tests (52.4%), only one BA value was altered; abnormal value was detected only with fasting value in 51 tests (20.4%) and only with postprandial value in 80 tests (32%). In 121 patients (48.4%), both fasting and postprandial values were increased. Among 70 animals with fasting value in 10–25 range, 37 had increased postprandial value. In 380 tests, fasting value was lower than postprandial value, but 101 tests showed higher fasting BA value.

Some authors have recently suggested that fasting BA can be a useful screening test (Straten 2015), but this study corroborates the higher value of paired SBA for this purpose, previously confirmed by others (Center 2011). If only fasting BA had been performed, and a higher cut-off had been selected (<20–25 µmol/L) as suggested by some authors, 52.8% of cases with fasting values in 10–25 range and abnormal postprandial values would have been missed; therefore, normal fasting value <10 µmol/L seems appropriate. Moreover, postprandial values were increased more often than fasting values; therefore, if just one BA can be performed, post-feeding could be the preferred test.

Fasting value exceeding the postprandial sample can occur, as shown in 1 out of 5 tests of this study. Although spontaneous gall bladder contraction may be responsible for it, if any value is abnormal, an hepatic abnormality is suggested (Lawrence 2017).

DISCLOSURES

No disclosures to report

SPEAKER INFORMATION

(click the speaker's name to view other papers and abstracts submitted by this speaker)

M.D. Tabar
Hospital Veterinario San Vicente
San Vicente del Raspeig, Alicante, Spain

URL: http://www.vin.com/doc/?id=8173005
<table>
<thead>
<tr>
<th>Speaker List</th>
</tr>
</thead>
<tbody>
<tr>
<td>VBPS - Veterinary Blood Pressure Society</td>
</tr>
</tbody>
</table>

**Oral Presentations**

**Scientific Programme**
Oral Presentations

Efficacy of Telmisartan in Hypertensive Cats: Results of a Large European Clinical Trial  A.M. Glaus
Efficacy of Telmisartan in Hypertensive Cats: Results of a Large European Clinical Trial

A.M. Glaus¹; J. Elliott²; B. Albrecht³

¹University of Zurich, Zurich, Switzerland; ²Department of Comparative Biomedical Sciences, Royal Veterinary College, Univers, London, UK; ³Boehringer Ingelheim Vetmedica GmbH, Ingelheim, Germany

Hypertension (HT) and the associated risk of target organ damage (TOD) is a well-recognized cardiovascular problem of elderly cats. Consequently, early recognition and treatment of HT are crucial. This prospective, multicentre, placebo-controlled, blinded study evaluated telmisartan in hypertensive cats diagnosed with systolic blood pressure (SBP) ≥160 mm Hg on two days. HT causes were classified as chronic kidney disease (CKD), controlled hyperthyroidism, both combined and idiopathic. Cats with SBP >200 mm Hg, evidence of TOD or pre-treated with vasoactive substances were excluded. Cats were randomized (2:1 ratio) to either receive 2 mg/kg telmisartan oral solution, or placebo q 24 h. The study consisted of a 28-day efficacy phase and a 120-day extended-use phase. Efficacy of telmisartan was defined a priori as significant mean SBP-reduction on day 14 compared to placebo and >20 mm Hg SBP population mean reduction on day 28 compared to baseline. Pre-defined post-inclusion removal criteria were adverse events, withdrawal of owner consent, owner non-compliance, TOD and SBP >200 mm Hg. Missing SBP data were imputed in the database using the last observation carried forward method, if removal reasons had been TOD or SBP >200 mm Hg. Data are presented as mean±1SD.

The efficacy population included 174 telmisartan and 88 placebo cats. Age, body weight, breed distribution, HT causes, and baseline SBP were similar in both groups (baseline SBP: telmisartan-group: 179 (±9.9) mm Hg; placebo-group: 177 (±10.1) mm Hg). Telmisartan treatment gave rise to a significantly larger reduction in mean SBP (relative to baseline) when compared to placebo on day 14 (-19±22.0 mm Hg, n=174 vs -9±17.7 mm Hg, n=88; p<0.0001). At day 28, the data from 9 and 1 cats were excluded and that of 2 and 2 cats were imputed giving reduction in SBP relative to baseline of -25±22.8 mm Hg, (n=165) and -11±16.4 mm Hg (n=87) for the telmisartan and placebo groups, respectively. The proportion of cats with SBP reduction >20 mm Hg between baseline and day 28 was 27.6% in the placebo group and 54.6% in the telmisartan group. The mean SBP decrease in the telmisartan group on day 120 was 28±26.9 mm Hg relative to baseline (n=144). Adverse events were evenly distributed in both groups during the efficacy phase and were as would be expected for elderly cats suffering from CKD and other diseases of ageing in the extended-use phase.

In conclusion, telmisartan oral solution was safe and significantly reduced SBP by a clinically relevant magnitude in hypertensive cats for the 4-month study period.

DISCLOSURES

Disclosures to report
Study was planned, organized and financed by Boehringer Ingelheim.

SPEAKER INFORMATION
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A.M. Glaus
University of Zurich
Zurich, Switzerland

URL: http://www.vin.com/doc/?id=812783
Scientific Programme

Endocrine versus Renal Hypertension in the Cat  Rosanne E. Jepson, BVSc, MVetMed, PhD, DACVIM, DECVIM

Speckle Tracking and HDO Measurements in Cats with Myocardial Hypertrophy  Ralf Tobias, Dr.med.vet., Fachtierarzt für Kleintiere und Teilgebiet Kardiologie
Endocrine versus Renal Hypertension in the Cat
Rosanne E. Jepson, BVSc, M VetMed, PhD, DACVIM, DECVIM
Clinical Science and Services, Royal Veterinary College, London, UK

Keynote Message

Systemic hypertension is a well-recognised condition in the cat with potentially high morbidity relating to target organ damage (TOD). The classification systems used for hypertension in veterinary medicine suggest the presence of both idiopathic and secondary disease-associated hypertension, with common conditions associated with hypertension including kidney disease or endocrine disorders such as hyperthyroidism, hyperaldosteronism and less commonly, hyperadrenocorticism, and pheochromocytoma. This lecture will focus on the pathophysiology of hypertension as currently understood in feline medicine in these disease conditions. Using the currently available evidence base, this lecture will draw comparisons between the implicated mechanism for cats with underlying renal versus endocrine disease and where knowledge gaps exist, will explore some of the information that may be applicable from either human medicine or experimental studies.

Key References
Myocardial hypertrophy in cats is the most frequently seen pattern in feline cardiac disease. Primary reasons are genetic defects associated with certain breeds and European short-haired cats. Secondary reasons for myocardial thickening differ from influences over the kidney-heart-axis, feline hypertension or feline hyperthyroidism. Diagnostic approaches have developed in the last years in diagnostic imaging and laboratory tests with biomarkers. Echocardiography is still yet the golden standard in characterizing the myocardial status. The standard 2 DE and TM mode measurements are accompanied by 3 D echo and 2 DE speckle tracking as newer techniques in evaluating the myocardial status. The last one offers new parameters to assess cardiac myocardial function including regional myocardial velocities and deformation. Studies have shown that the term "strain" is related to the decrease or increase of the length/shortening of a segment of ventricular muscle and its clinical value in staging HCM. Blood pressure measurements are necessary in recognizing feline hypertension and the development of the status under therapeutic conditions. The Doppler method is a well accepted standard, but gives only systolic blood pressure values. In this study HDO blood pressure measurements were performed including systolic and diastolic blood pressures and a pulse wave analysis, which could show changes depending on stroke volume and systemic vascular resistance and arrhythmia. Those pulse wave data are to be proofed if there are any links to functional parameters from echocardiography.

The presentation looks at cats diagnosed with a normal heart status compared to mostly asymptomatic cats with myocardial hypertrophy with and without influence of drugs like atenolol, ACE-inhibitors, amlodipine, ASS, clopidogrel, diuretics. Each cat got a clinical exam, standard 2DE, TM mode echo and 2 DE speckle tracking and EF (%) Simpson technique, 3DE if possible, ECG and a HDO measurement.

Keynote References

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)
Ralf Tobias, Dr.med.vet., Fachtierarzt für Kleintiere und Teilgebiet Kardiologie
Referral Practice for Small Animal Cardiology
Hannover, Lower Saxony, Germany
URL: http://www.vin.com/doc/?id=8172786
### Speaker List

#### A

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katja-Nicole Adamik, Dr. med. vet., DACVECC, DECVECC</td>
<td>Colloids in Small Animals - What's the Evidence?</td>
</tr>
<tr>
<td>M. Aghazadeh</td>
<td>Expression of Felis catus Gammaherpesvirus-1 ORF73, F7 and ORF50 in FIV-Associated Lymphoma Biopsies</td>
</tr>
<tr>
<td>C. Albuquerque</td>
<td>Risk Factors for C. difficile Carriage in Dogs and Associations with Clinical Disease</td>
</tr>
<tr>
<td>F.A. Allaert</td>
<td>A Randomised Double-Blind, Placebo Controlled Study Evaluating the Effects of Short-Chain Fructo-Oligosaccharides (scFOS) on Cat Stools Odors</td>
</tr>
<tr>
<td>K. Allenspach</td>
<td>Correlating Gastrointestinal Histopathologic Findings to Clinical Disease Activity in Dogs with Inflammatory Bowel Disease</td>
</tr>
<tr>
<td>F. Allerton</td>
<td>Breed Predisposition to Gall Bladder Mucocoeles in Border Terriers</td>
</tr>
<tr>
<td>C.T. Amaral</td>
<td>Frequency of Heart Murmur in 69 Healthy Adult Dachshunds</td>
</tr>
<tr>
<td>Julian Archer, MRCPCH, MEd, PhD, FAcadMEd</td>
<td>Evidence Based Medical Assessment</td>
</tr>
<tr>
<td>Luca Aresu, Prof, DVM, PhD</td>
<td>The Pathology of Renal Ageing</td>
</tr>
<tr>
<td>I. Aroch</td>
<td>Pre- and Postoperative D-Dimer Concentration in Dogs: Changes in D-Dimer Concentration in Dogs Following Soft Tissue and Orthopaedic Surgery Serum Histones as Biomarkers of the Severity of Heatstroke in Dogs</td>
</tr>
<tr>
<td>M. Aromaa</td>
<td>Comparing the Submaximal Exercise Test Results and Severity of Brachycephalic Obstructive Airway Syndrome in Pugs and French Bulldogs</td>
</tr>
<tr>
<td>H. Aupperle-Lellbach</td>
<td>Ovarian Tumours in the Bitch - Pathological Findings and AMH Values</td>
</tr>
</tbody>
</table>

#### B

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>N.R. Barash</td>
<td>Is Urine Culture the Poor Man's Blood Culture? Concordance Between Parallel Canine Blood and Urine Cultures</td>
</tr>
<tr>
<td>V. Barrs</td>
<td>Re-emergence of Feline Panleukopenia in Australia</td>
</tr>
<tr>
<td>H. Bauer</td>
<td>Age Dependent Correlation of Mutation C.118G&gt;A in the SOD1 Gene to Clinical Signs of Degenerative Myelopathy in Hovawart Dogs</td>
</tr>
<tr>
<td>W.A. Bayton</td>
<td>Prednisolone Therapy for Chronic Hepatitis in the English Springer Spaniel: A Prospective Study of 14 Cases</td>
</tr>
<tr>
<td>S.M. Bechtel</td>
<td>Initial Evaluation of Gum Arabic-Coated Radioactive Gold Nanoparticles in Canine Prostatic Cancer</td>
</tr>
<tr>
<td>J.S. Béguin</td>
<td>Evaluation of Infective and Replicative Properties of a Replication-Selective Oncolytic Vaccinia Virus (VVTG17990) on Canine, Feline, Porcine and Human Cell Lines</td>
</tr>
</tbody>
</table>
E. Benvenuti
Serum Protein Profiling of 100 cats with Inflammatory Bowel Disease and Lymphoma
Diagnostic Accuracy of the Macro-endoscopic Bronchial Aspect for the Diagnosis of Eosinophilic Bronchitis

M. Bergmann
Antibody Production as Reaction to Feline Panleukopenia Virus Vaccination in Cats with Feline Immunodeficiency Virus and Feline Leukaemia Virus Infection

M. Berlanda
Symmetric Dimethyl-Arginine in Dogs with Myxomatous Mitral Valve Disease With and Without Pulmonary Hypertension

R.R. Blake
Heart Rate Variability in Dogs with Intracranial Disease

M. Blondeau
Comparative Killing of Canine Urinary Pathogens by Cephalexin (CP), Marbofloxacin (MR), Pradofloxacin (PR) and Trimethoprim/Sulfamethoxazole (TMP/SMX)

Michele Borgarelli, DVM, PhD, DECVM-CA (Cardiology)
Minimally Invasive Repair of the Mitral Valve in Dogs: Is It a Feasible Option?
The LOOK Mitral Study: Is There Any Standard Treatment for Dogs with Mitral Valve Disease?

B. Børresen
The Occurrence of Feline Neoplasia: A Comparison Between Danish and North American Cats

Adrian Boswood, DVC, MA, MRCVS, VetMB
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
How Should We Train Residents?
Running Multicentre Studies: Lessons from Cardiology

W.J. Botha
Prevalence of Clostridium difficile and Salmonella spp. in Juvenile Dogs Affected with Parvoviral Enteritis

P. Boye
High Pretreatment D-dimer Concentration is Associated with Poor Prognosis in 48 Dogs with High-Grade Lymphoma

J. Brailey
Feral Carnivores are Reservoirs of Carnivore protoparvovirus 1 in Australia

L. Bree
Major Histocompatibility Complex Class II Haplotypes Associated with Remodelling in Cavalier King Charles Spaniels with Chronic Valvular Heart Disease

H.D. Bremer
Identification of ILF2 Autoantibodies as a Promising Biomarker for Autoimmune Disease in Dogs

D. Breu
Seroprevalences to Anaplasma phagocytophilum, Borrelia burgdorferi and Babesia canis in 2948 Dogs from Germany

L. Brown
Short- and Long-Term Morbidity and Mortality in Dogs and Cats Following Cardiopulmonary Arrest

R.K. Burchell
Safety and Efficacy of Dapagliflozin, a Novel Antidiabetic Drug, in Healthy Cats
The Site of Bone Marrow Acquisition Affects the Myeloid to Erythroid Ratio in Apparently Healthy Dogs

E. Buresova
SDMA in Hyperthyroid Cats Before and After Treatment with Radioiodine

P.J. Byrne
Investigation of Faecal Parvovirus Shedding in Asymptomatic Shelter-Housed Cats in Australia

Go to Table of Contents: Main Speaker List

C

D. Caivano
Contrast-Enhanced Ultrasonography of the Duodenum in Dogs with Inflammatory Bowel Disease: Preliminary Findings

Michelangelo Campanella, Pharm D, PhD, MRPharmS, PGCAP, FHEA, FRSB
The Metabolic Signature(s) of Ageing Organs Using the Kidney as a Paradigm

A.M. Canonone
Diagnosis of Pulmonary Angiostrongylusasis in Dogs with Negative Non-invasive Tests (Baermann Analysis and AngioDetectTM®)

G. Carotenuto
Serum Symmetric Dimethylarginine (SDMA) in Dogs with Hypothyroidism

A. Caro-Vadillo
Reliability of Vena Contracta for Staging Degenerative Chronic Mitral Valve Disease in Dogs
J.A. Cartwright
Vitamin D Receptor Expression in the Dog and the Effect of Intestinal Inflammation

J.I. Casado Diaz
Evaluation of Symmetric Dimethylarginine (SDMA) in Dogs with Primary Hypoadrenocorticism Under Long-Term Mineralocorticoid Replacement Therapy

D. Casamián-Sorrosal
Therapy and Long-term Follow-up of 70 Cases of Canine Idiopathic Eosinophilic Lung Disease

Brian Catchpole, BVetMed, MSc(VetEd), PhD, FRCVS
Canine Immune-Mediated Endocrinopathies: An Immunologist's View

H. Chen
Interleukin 6 and Interleukin 18 as Markers of Kidney Injury in Dogs

I. Clares Moral
Survival of Dogs Diagnosed with Inflammatory Mammary Cancer Treated with a Multimodal Therapy

K.E. Clarke
Retrospective Study of Clinical Findings, Treatment and Outcome in Dogs and Cats Diagnosed with Dysautonomia

M.F. Coddou
Identification of IgG4-Related Disease in the English Cocker Spaniel and Dogs of Other Breeds

A.R. Codea
Ultrasound-Guided Renal Biopsy Significantly Increases Urinary N-Acetyl-Beta-D-Glucosaminase Index Activity in Dogs with Diffuse Parenchymal Nephropathies

D.J. Connolly
Towards Cardiac Stem Cell Therapy: Characterisation and Cryopreservation of Canine Cardiosphere-Derived Cells

A. Corda
Use of Two-Dimensional Speckle Tracking Echocardiography to Assess Left Ventricular Systolic Function in Dogs with Systemic Inflammatory Response Syndrome

A. Corsini
Symmetric Dimethylarginine (SDMA) in Hyperthyroid Cats

P.E. Crisi
Urinary Findings Suggesting Early Renal Involvement in Cats with Feline Morbillivirus Infection

B.Y. Cuq
Acute Myeloid Leukemia in Retrovirus-Negative Cats: A Case Series of 16 Patients
Calibrated Automated Thrombography to Evaluate Thrombin Generation in Dogs with Immune-Mediated Hemolytic Anaemia

F. Da Riz

C. Damoiseaux
Feasibility of Intracardiac Echocardiography in Dogs: A Pilot Study
Utility of the SNAP Feline N-Terminal Pro-B-Type Natriuretic Peptide Test in Detecting Asymptomatic Hypertrophic Cardiomyopathy: A Prospective Study in 61 Cats

J.R.S. Dandrieux
Effect of Immune-Suppressive Treatment on Cytokine Production in Healthy Dogs

H. Darcy
Feline Primary Erythrocytosis: A Multicentre Retrospective Case Series (18 Cases)

E. Darnis
Prevalence of Pulmonary Hypertension in Dogs Naturally Infected with Angiostrongylus Vasorum

E. de Luca
Feline Morbillivirus Infection in Domestic Cats in Italy: Epidemiological and Pathological Aspects

W.L. de Wit
CYPT17 Inhibitor Abiraterone Acetate as a Promising Future Treatment for Canine Hyperadrenocorticism: In Vitro Investigations

N. Decaro
Lethal Pox Disease in a Cat: Classical Cowpox or Novel Orthopoxvirus Infection?

F. del Baldo
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Dogs
B. Dobenecker
Knowing the Total Amount of Phosphorus in a Diet Is Not Enough - Different Sources Have Different Effects

M. Dominguez Ruiz
Prevalence of Gastric Lymphoid Follicular Hyperplasia in French Bulldogs

F. Duplan
Screening for Selected Pathogens in Ticks Infecting Cats in the United Kingdom: A Large-Scale Surveillance Programme

J. Duque
Comparison of the Severity of Myocardial Damage with the Quantitative Estimation of the Myocardial Parasitic Load by Real-Time PCR in Dogs with Canine Visceral Leishmaniosis

L.C. Dutton
Assessing the Feasibility of Allogeneic Stem Cell Therapy for Canine Dilated Cardiomyopathy

E. Dvir
The Role of Hypovitaminosis D in Complicated Canine Babesiosis

J. Elliott
Toceranib Phosphate in Fifteen Dogs with Stage 4 Anal Sac Apocrine Gland Adenocarcinoma
Histiocytic Sarcoma is Over-Represented in Miniature Schnauzers in the United Kingdom

V. Fabres

S. Felten
Evaluation of a Discriminative Realtime RT-PCR in Cerebrospinal Fluid for the Diagnosis of Feline Infectious Peritonitis

F. Ferri
Class A CpG Oligonucleotides in Cats with Naturally Occurring Feline Panleukopenia Infection: A Prospective Case-Control Study

N.C. Finch
Thyroid and Renal Function in Cats Post Low-Dose Radioiodine Therapy

C. Fontaine
At Least Three Years of Proven Protection Against Distemper, Infectious Canine Hepatitis and Parvovirus in Dogs Vaccinated with the Multivalent CanigenTM DHPPi/L Vaccine
Seroneutralisation of Canine Parvovirus by Sera of Cats Vaccinated with Either LeucofeligenTM FeLV/RCP or FeligenTM CRP Vaccines

S.J. Fowlie
Canine Electrolyte Analysis in Dogs with Hypoadrenocorticism - A Comparison of Two In-house Analysers with a Reference Laboratory

V. Freiche

Marta Garcia
Determining the pH in Canine Urine: Comparing Visual and Automated Reading Variability of Urine Dipstick Analysis Within a Small Animal Teaching Hospital

Melanie Garcia
Evolution of Ionised Calcium Concentration Over Time in Cats with Ureteral Obstruction: 39 Cases

P. Garcia San José
Systemic Hypertension in Diabetic Cats: Does It Really Matter?

Laura D. Garrett, DVM, DACVIM (Oncology)
Diagnosis and Prognosis of Mast Cell Tumors - The 2017 Oncologist Perspective
Prognostic Biomarkers in Veterinary Oncology - Are We There Yet?

Claudio Genchi, DVM, PhD, DEVPC
Are Dirofilaria Infections Really Spreading Throughout Europe? Epidemiology, Clinical Concerns and Prevention
What Have Dirofilaria and Wolbachia Taught Us About Endosymbiotic Relationship?

A.J. German
Validation of a Modified 9-Integer-Unit Body Condition Score System and a Computer-Based Modelling Tool to Estimate Body Condition in Pet Dogs

Urs Giger, DECVIM-CA, DECVCVP, DACVIM-SAIM
Feline Transfusion Therapy - Blood Compatibility and Xenotransfusion
Canine Transfusion Therapy - Blood Compatibility Testing Considering New Kits and Blood Types

M. Giraldi
Reproducibility of Urinary Sediment Examination: Stain versus Bright Field and Phase Contrast

A. Giuliano
Masitinib Treatment for Advanced Stage III and IV Canine Melanoma

A.M. Glaus
Efficacy of Telmisartan in Hypertensive Cats: Results of a Large European Clinical Trial

F. Glen
Clinical Use of a Patient-Side Feline NT-ProBNP ELISA Test in 281 Cats in General Practice

S. Gomart
Biological Variability of N-Terminal Pro-B-Type Natriuretic Peptide in Fifty-Three Healthy Labrador Retrievers Over an 8 Month Period

Kris Gommeren, PhD, DECVIM-CA
Fluid Status and Responsiveness: What's New?

S. González Sanz
Prevalence of Neurological Signs in Hypothyroid Dogs at Diagnosis

Jody L. Gookin, DVM, PhD, DACVIM-SAIM
Gallbladder Mucoceles
Host Defense Strategies for Minimally Invasive Epithelial Pathogens

Sonya Gordon, DVM, DVSc, DACVIM (Cardiology)
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Peter A. Graham, BVMS, PhD, CertVR, DECVCVP, MRCVS
Can We Trust Numbers? Daunting Lessons from the ESVE Laboratory Quality Assurance Scheme

V.G. Greci
Clinical and Laboratory Alterations in 37 Dogs Diagnosed with Lungworm Infection: A Retrospective Study (July 2010–April 2017)

M.E. Grobman
Documenting Silent Reflux and Microaspiration Events Using Nuclear Scintigraphy in Healthy Dogs
Discrimination Between Cough and Non-cough Behaviours Using Acoustic Wave Recordings

Blake C. Guard, MS, PhD
Intestinal Microbiota and Bile Acid Metabolism

A.C. Hagblom
Prevalence of Hyperaldosteronism and Hypertension in Cats with Chronic Azotaemia

Jens Häggström, DVM, DECVM (Cardiology)
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

M. Hanifeh
S100A12 and Myeloperoxidase as Possible Biomarkers for Intestinal Inflammation in Dogs

J.M. Hanson
The Use of Chromogranin A Epitopes Vasostatin and Catestatin as Biomarkers for Catecholamine-Producing Tumours in Dogs

H. Hansson-Hamlin
Identification of Antinuclear Antibodies in Dogs Using Immunodiffusion

A.N. Hartley
First Documentation of Cytochrome B Gene Mutations Associated with Atovaquone and Azithromycin Treatment in Cytaxozoon felis

R.M. Heilmann
Serum S100/Calgranulin Concentrations in Miniature Schnauzers with Idiopathic Hyperlipidemia
Feasibility of Measuring Fecal Calprotectin Concentrations in Dogs and Cats by the ICAL® Turbo Immunoassay

T.L. Hill
Factors Affecting Gastric Mucosal Barrier Function in Dogs
Utility of Capsule Endoscopy as a Complement to Traditional Endoscopy
N.E.M. Hopman  
_Antimicrobial Use in 44 Dutch Companion Animal Clinics_

H.P. Huang  
_Prevailing of Degenerative Joint Disease in Mature Indoor Cats_

M. Hugonnard  
_Metabolic and Clinical Follow-Up of Seven Inappetent Cats During Enteral Refeeding_

Christine Iben, DECVCN  
_Nutritional Management of Dermatological Diseases in Dogs and Cats - The Latest Research Insights_

O.M. Ioannidi  
_Total Serum Magnesium and Cobalamin Concentration in 20 Cats with Inflammatory Small Bowel Disease or Small Intestinal Neoplasia_

J. Jaffey  
_Methaemoglobinemia Caused by Cytochrome b5 Reductase Deficiency: Genetic Studies and Long-term Treatment with Oral Methylene Blue_

Rosanne E. Jepson, BVSc, MVetMed, PhD, DACVIM, DECVIM  
_Endocrine versus Renal Hypertension in the Cat_

L.R. Jessen  
_Prevailing and Risk Factor for Harbouring Campylobacter jejuni in Young Dogs in Copenhagen_

D.E. Jewell  
_Increased Dietary Long-Chain Polyunsaturated Fatty Acids Alter Plasma Fatty Acid Concentrations and Lower Risk of Urine Stone Formation in Cats Foods Enriched with Bioactive Ingredients Including Fish Oil Increase Circulating (N-3) Fatty Acid Concentrations, Decrease PGE₂, and Increase Lean Body Mass in Cats_

T. Johnstone  
_Whole Genome Sequencing of Escherichia coli isolated from the Urinary Tract of Individual Dogs Over Time_

F. Jolivet  
_Fasting and Postprandial Variations of Plasma TLI, Cobalamin and Folate Concentration in Healthy Beagle Dogs_

L. Kalogianni  
_Investigation of the Presence of Bacteraemia in Puppies with Canine Parvoviral Enteritis_

Debra A. Kamstock, DVM, PhD, DACVP (Anatomic Pathology)  
_Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors: The 2017 Pathologists' Perspective Immunohistochemistry for Neoplastic Disease: Reaching a Final Diagnosis (Sometimes) and More_

Aarti Kathrani, BVetMed (Hons), PhD, DACVIM, DACVN, MRCVS  
_Advancing the Nutritional Management of Chronic Enteropathies - What's at the Cutting Edge?_

S. Keegan  
_Clinical Features of 70 Cases of Canine Idiopathic Eosinophilic Lung Disease_

B. Kiefer-Hecker  
_Silica Urolithiasis in a Dog - A Case Report_

G. Kiss  
_Genetic Background of Focal Junctional Tachycardia with Isohythmic Atrioventricular Dissociation in Labrador Retrievers_

A.K. Koizumi  
_Studies in a New Body Condition Scoring by Morphometric Method in Dogs_

M.L. König  
_Analytical and Clinical Validation of a Human Enzyme-Linked Immunosorbent Assay (ELISA) for Measurement of Canine Angiopoietin-2 Plasma Angiopoietin-2 (Ang-2) Is Elevated in Dogs with Sepsis and/or Systemic Inflammatory Disease Syndrome (SIRS) and Is Associated with Severity of Disease and Outcome_

A.O. Konstantinidis  
_Serum Circulating MicroRNAs as a Marker for Canine Lymphocytic-Plasmacytic Inflammatory Bowel Disease_
A.J. Kortum
Investigation into Hepatocyte Expression and Prognostic Significance of Senescence Marker p21 in Canine Chronic Hepatitis

Hedwig S. Kruitwagen, DVM, PhD candidate
Hepatic and Intestinal Organoids

A. Lamoureux
Prevalence of Urinary Tract Infection in Dogs with Chronic Kidney Disease: A Retrospective Study of 201 Cases

K.F.A. Langner
Evidence for Regional Variation of Patient Characteristics in Dogs with Hyperadrenocorticism

M.H.M.A. Larsson
Frequency of Mitral Valve Prolapse in Adult Healthy Dachshund Dogs

N.L. Leblanc
Right Ventricular Volume Quantification Measured by Real-Time 3D Echocardiography and ECG-Gated 64 Slice MDCT in Healthy Dogs

J. Lee
Effects of Treatment with Thromboxane A2 Synthase Inhibitor on Pulmonary Hypertension: A Pilot Study

C. Leutenegger
Validation of a qPCR Panel to Aid in the Diagnosis of Dermatophytosis

P.L. Levent
Choline Concentration as a New Potential Biomarker to Distinguish Pleural Effusions from Heart Base Tumours and Cardiomyopathy in Dogs

V. Leynaud
Comparison of Serum Amyloid A and Fibrinogen to Other Inflammatory Biomarkers in Cats

Annette Liesegang
Critical Review About the Role of Vitamin D in Health and Disease

J. Liu
SNAP 4Dx Plus Correlates Well with IFA for Detection of E. canis Antibodies

C. Locatelli
Left Ventricular Hypertrophy in Dog: An Echocardiographic Study

J.G. Lyngby
C-reactive Protein in Dogs Diagnosed with Hypoadrenocorticism

K.D. Lyons
Effect of Toceranib Phosphate (Palladia®) on Outcome in Dogs with Anal Sac Carcinoma

M. Määttä
Reflux Aspiration Can Be Detected in Lungs of Dogs with Respiratory Disease

T. Magalhães
Effect of Radiation Therapy on the Treatment of Intracranial Tumours in Dogs: Meningioma and Glioma

E. Malerba
Evaluation of One Portable Blood Glucose Meter and One Portable Glucose-Ketones Meter in Cats

A.C. Manchester
Long-Term Impact of Tylosin on the Faecal Microbiota of Healthy Dogs

F. Manczur
Microalbuminuria in Dogs Infected with Dirofilaria repens
Accuracy of Refractometric Urine Specific Gravity Determination in Cats

V. Marchetti
Retrospective Study on 33 Cases of Canine Primary IMHA: Clinico-Pathological Features, Follow-up and Prognostic Factors

C. Maurey Guenec
Efficacy and Safety of Two New High-Protein, Low-Carbohydrate Dry Diets in Sterile, Feline Struvite Urolithiasis

B.A.M. Mckeever
Prevalence and Murmur Characteristics of Incidentally Detected Heart Murmurs and Heart Disease in 12,958 Young Healthy Shelter Cats
M. Menard
Validation of a Blood Score for Non-Invasive Diagnosis of Liver Fibrosis in Dogs

A.C. Merveille
Caudal Vena Cava Assessment in Dogs with Right-Sided Congestive Heart Failure: A Pilot Study

A. Miglio
Comparison of Three Different Guidelines for Blood Transfusion Applied in a Population of Italian Feline Donors to Reduce the Risk of Transfusion Transmissible Infections

N. Sydney Moise, DVM, MS, DACVIM
Advanced ECG Interpretation

Eric R. Morgan, MA, VetMB, PhD, DEVPC, MRCVS
Use of Meteorologic Data to Predict Parasite Spreads, Should We Expect More in the Future?
Factors Influencing Geographical Spread of Angiostrongylus vasorum Through Europe?

Jane K. Murray, BScEcon, MSc, PhD
Designing and Running Cohort Studies: How to Make them Work

Mathios E. Mylonakis, DVM, PhD
Infectious Diseases Affecting the Bone Marrow in Dogs and Cats
A Case-Based Approach to Bone Marrow Cytology

P.F. Navarro Martínez
Urine Protein Analysis by Capillary Electrophoresis in Healthy Dogs

Mariam Naveed, MD
Post-Graduate Assessment: How Do You Judge Competence?

R. Neiger
Transcutaneous Fluorometric Measurement of Indocyanine Green Clearance as Dynamic Liver Function Test in Dogs with Congenital Portosystemic Shunt

S. Neumann
Investigation of Interleukin-6 (IL-6) as Prognostic Marker

J. Neves
Usefulness of Colour TDI at the Level of Lateral Atrial Tissue as a Predictor of Future Development of Atrial Fibrillation in Dogs

L.N. Nielsen
Detection and Stability of MicroRNAs in Urine from Healthy Cats

S.J.M. Niessen
The Diabetic Clinical Score (DCS): Evaluation of a Simple Standardised Quantification Tool to Allow Rapid Description of Clinical Signs in Diabetic Dogs

D.G. Ohad
The Association of Clinical, Laboratory, and Echocardiographic Findings with Survival in 108 Dogs Undergoing Pericardiocentesis: A Retrospective Study

Emma J. O'Neill, BSc, BVSc, PhD, DSAM, DECVM-CA, PGDipUTL, MRCVS
Canine Cholangitis and Cholecystitis

Donal O’Shea, MD, FRCPI, FRCP(UK)
Weight Regulation by the Immune System and the Influence of Thyroid Hormones

E.M. Oxford
Immunofluorescent Localization of Plakoglobin in Endomyocardial Biopsy Samples to Diagnose Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in the Dog

J.S. Palermo
Seroprevalence of Infectious Diseases in Feral Cats in the American Midwest

Nadine Paßlack, Dr. med. vet.
Dietary Management of Urolithiasis in Dogs and Cats - The Latest Research Insights

V. Patata
Pulmonary Vein to Pulmonary Artery Ratio in Healthy and Cardiomyopathic Cats

A.E.H. Paul

Bronchoalveolar Lavage Analysis Using Urea Dilution Standardisation in Diagnosis of Respiratory Diseases in Dogs

P. Pazzi

Spirocerca lupi-Induced Oesophageal Neoplasia: Predictors of Surgical Outcome

L. Pelander

Symmetric Dimethylarginine (SDMA) Compared to Creatinine for Detection of Decreased GFR in 97 Dogs with Stable Kidney Function

M.D. Pérez Alenza

Systemic Hypertension in Dogs with Diabetes Mellitus

T. Pijnacker

The Use of a TRH Stimulation Test, with Measurement of Plasma Concentrations of Growth Hormone and Thyroid Stimulating Hormone, to Differentiate Between Primary Hypothyroidism and Non-Thyroidal illness in Dogs

Martina Piviani, DVM, MSc, DACVP (Clinical Pathology), MRCVS

Resident Masterclass: Cytology

M. Planellas

A Prospective Study of Urinary Adverse Effects of Allopurinol Treatment for Canine Leishmaniosis

C. Poissonnier


C. Pomba

Virulence and Antimicrobial Resistance of Escherichia coli Sequence Type 131 H30 and Other Human Pandemic Clones Spreading in Companion Animals Companion Animals and Humans with UTI Share Common Uropathogenic Klebsiella pneumoniae Evidence of Sharing of MDR K. pneumoniae Between Infected and Non-Infected Cats from Same Household

Roger K. Prichard, BSc, PhD, DHC, HDipEVPC

The Emergence of Macrocyclic Lactone Resistance in Dirofilaria immitis: Identification and Risk Assessment

Jessica M. Quimby, DVM, PhD, DACVIM (SAIM)

Assessing Renal Aging in Cats: Telomeres and Senescence Sarcopenia and Cachexia in Chronic Kidney Disease

Alan Radford, BSc, BVSc, PhD, MRCVS

Taking Advantage of Big Data in Veterinary Research

B. Rengaswamy

Oral Carica Papaya in the Supportive Care of Infectious Thrombocytopenia in Bleeding Dogs

B.S. Reynolds

Effects of a Non-absorbent Litter on Urinalysis Results in Cats

M. Rishniw

Development of a Simple Algorithm for Diagnosis of Left-Sided Congestive Heart Failure in Dogs with Mitral Valve Disease

E. Robin

Tracheal Stent in Dogs: Outcome Prediction and Owner Satisfaction Assessment

P.M. Rocchi

Evaluation of Continuous Positive Airway Pressure in Dogs with Cardiogenic Pulmonary Oedema Secondary to Severe Mitral Valve Disease

J. Rodon Vernet

Evaluation of Rapid Diagnostic Test Kits for Canine Vector-Borne Diseases

E. Roels

Investigation of a Fungal Aetiology in Canine Idiopathic Pulmonary Fibrosis

C. Rohdin

Prevalence of Gait Abnormalities in Pugs: A Questionnaire-Based Survey

G. Romito

Diagnostic and Prognostic Utility of Surface ECG in Cats with Left Ventricular Hypertrophy

J. Rubin
Identification of Attaching and Effacing Enteropathogenic Escherichia coli in Dogs with Parvoviral Enteritis

B. Ruggerone

Preliminary Evaluation of Protein Carbonyl Group in Canine Serum Using a Western Blotting Technique

G.C. Ruiz

Multiple Colorectal Granular Cell Tumours in a Dog

O.M. Russak

Urinary Biomarker Concentrations in Canine Urinary Tract Infections

K. Sanders

Molecular Prognostic Markers in Canine Cortisol-Secreting Adrenocortical Tumours

H.J. Sargent

Fibroblast Growth Factor 23 and Symmetric Dimethylarginine in Feline Chronic Kidney Disease

O. Sarpataki

Combined Therapy with Clindamycin, Doxycycline and Metronidazole Induces Complete Sterilisation of Babesia gibsoni Infection in Dogs - A Case Report

K. Sato

Chronic Portal Vein Thrombosis in Eleven Dogs

A.S. Savarese

Comparative Analysis of a Portable Smartphone-Based Electrocardiograph (D-Heart®) Versus Standard 6-Leads Electrocardiograph in the Canine Patient

Mike Scanlan, BA Hons, Doctorate

Living and Working Mindfully - More Than Just an Antidote to Stress

P. Scarpa

Interrelation Between Thyroid Function and Sex Hormones in Female German Shepherd Dogs

N. Schliefenbaum

Effect of Mirtazapine on Canine Gastric Emptying Assessed by 13C-Sodium Acetate Breath Test (13C-SABT)

M. Schmicke

Low Thyroxine Concentrations After Controlled Feeding of Bovine Thyroid Gland to Dogs

C.J. Scudder

Pilot Study Assessing the Use of Cabergoline in the Management of Diabetic Acromegalic Cats

P. Sebastian

Surveillance of Bacterial Contamination in Stethoscopes and Effectiveness of Different Disinfecting Protocols

G. Segev

Application of Novel Kidney-specific Biomarkers for Canine Kidney Diseases

Claire R. Sharp, BSc, BVMS(Hons), MS, MANZCVS, DACVECC

Microcirculation and the Glycocalyx: Does It Matter?

Initial Stabilisation via Early Goal-Directed Fluid Therapy

N. Sieber-Ruckstuhl

Agreement of Two Pre-Pill Cortisol Measurements in Dogs with Hypercortisolism Treated with Trilostane

Kenneth W. Simpson

Feline Triaditis

Host Genetics in Granulomatous Colitis

The Role of the Intestinal Luminal Environment in Colitis

J.E. Slovak

Evaluation of the Hemoccult® Faecal Occult Blood Test Kit in Cats

Fecal Occult Blood Testing in a Presumed Healthy Population of Cats

J.J. Söder

Plasma Metabolomics Reveals Lowered Carnitine Concentrations in Overweight Labrador Retriever Dogs

T.M. Soerensen

The Effect of Storage Temperature and Boric Acid Preservation on Quantitative Bacterial Culture for Diagnosing Canine Urinary Tract Infection

L. Solano-Gallego

Detection of Leishmania in Archived Canine Colonic Inflammatory Biopsies in an Endemic Area for Canine Leishmaniosis

S. Spence

A Comparison of the ACTH Concentrations in Dogs with Stable Hypoadrenocorticism Being Treated with Either Fludrocortisone or Desoxycorticosterone Pivalate and
**Prednisolone**

C. Stengel

Meticulous Debridement as Sole Management for Successful Outcome in 6 Dogs with Sinonasal Aspergillosis (SNA)

A. Stewart

Clinical Thiamine Deficiency in Cats in the UK Associated with the Feeding of a Defective Commercial Dry Food Diet

Jan S. Suchodolski, DrMedVet, PhD, DACVM, AGAF

Intestinal Microbiome and Metabolome Profiles Across Various Gastrointestinal Diseases

How to Alter the Gut Microbiota - Effects of Antibiotics and Fecal Microbiota Transplantation

Simon Swift, MA, VetMB, CertSAC, DECVM-CA (Cardiology), MRCVS

Evolution of a New Hybrid Technique for Treating Pulmonic Stenosis in Dogs

Harriet M. Syme, BSc, BVetMed, PhD, FHEA, DACVIM, DECVM-CA, MRCVS

Iatrogenic Hypothyroidism - Should It Affect How We Treat Hyperthyroidism?

V. Szatmári

When Should We Talk about Tachypnoea in Cats at the Veterinarian's Consultation Room?

How Often Do Primary Care Practitioners Recognise Innocent Cardiac Murmurs in Puppies during the First Veterinary Health Check?

Is Prophylactic Antibiotic Therapy Necessary to Prevent Infectious Endocarditis in Dogs That Undergo Transcatheter Embolisation of a Patent Ductus Arteriosus?

M.D. Tabar

Diagnostic Value of Paired Serum Bile Acids in Clinical Practice in 484 Samples

H. Thiemeyer

Ultrasound-Guided Fine-Needle Aspiration of the Canine Prostate - A Useful Sampling Method for Molecular Biological Analysis?

R.S. Tims

White Coat Effect in Client-Owned Dogs, as Assessed by High Definition Oscillometry (HDO)

Ralf Tobias, Dr.med.vet., Fachtierarzt für Kleintiere und Teilgebiet Kardiologie

Speckle Tracking and HDO Measurements in Cats with Myocardial Hypertrophy

F. Traub

MiRNAS in Progressing Canine Myxomatous Mitral Valve Disease

Donato Traversa, DVM, PhD, DEVPC

Feline Lungworms: What Are We Missing?

E. Treggiari

Efficacy of Chemotherapy and Clinical Outcome in Primary, Metastatic Feline Pulmonary Carcinomas: An Observational Study

John S.P. Tulloch, BVetMed, MSc, DipRN, MRCVS

Surveillance in a Digital World

T. Ullal

Ciclosporin in the Treatment of Canine Chronic Hepatitis

P. Valiente

Outcome of Cats Undergoing Surgical Attenuation of Congenital Extrahepatic Portosystemic Shunts Through Cellophane Banding: 23 Cases

K.L. van Bokhorst

Concurrent Pituitary and Adrenocortical Tumors in Dogs with Spontaneous Hypercortisolism

M.F. van den Berg

Assessment of Kidney Injury in Canine Parvoviral Infection by Comparing Novel Urinary Kidney Injury Biomarkers with Routine Renal Functional Parameters

D.H.N. van den Broek

Immunohistochemical Staining of A-Klotho Protein in Feline Kidney Tissue

G.J. van Staalden

Sterol-O-Acyl Transferase 1 (SOAT1) Expression in Canine Cortisol-Secreting Adrenocortical Tumours: Providing the Basis for a Future Treatment Option
E. Vangrinsven
Investigation of the Nasal Microbiota in Healthy Dolichocephalic Dogs and Dogs with Sinonasal Aspergillosis (SNA)

V. Veneziano
Serologic and Molecular Diagnostic Survey of Babesia spp. Infections in Hunting Dogs from Southern Italy

F. Vessieres
Specific Virulence Factors in Mucosa-Associated E. coli of Dogs with Inflammatory Bowel Disease (IBD) are Associated with Survival

T. Vezzosi
Echocardiographic Evaluation of Right Ventricular Dimension and Systolic Function in Dogs with Pulmonary Hypertension
Retrospective Analysis of Pulmonary Hypertension in Cats with Left-Sided Congestive Heart Failure

A.I. Vientos-Plotts
Development of Respiratory Dysbiosis as Cats Transition from Healthy to Asthmatic Airways

S.J. Viitanen
Bronchiectasis in Irish Wolfhounds with Recurrent Bacterial Pneumonia

Elizabeth Villiers, BVSc, DECVCP, FRCPath, CertSAM, CertVR, MRCVS
Haemopoietic Neoplasms in Dogs and Cats
A Case-Based Approach to Bone Marrow Cytology

J.P. Vitt
Utility of VHS to Predict Echocardiographic EPIC Trial Inclusion Criteria in Dogs with Myxomatous Mitral Valve Disease: A Retrospective Multicentre Study

J.L. Ward
Use of Graphic Organisers in an Elective Veterinary Cardiology Course

P.J. Watson
Clinical Features of English Cocker Spaniels with Chronic Pancreatitis Mimic Human IgG4RD

M. Weiss
Blood Reference Ranges for Rabbits from Routine Diagnostic Samples

Z. Whitehead
Evaluation of Haemostatic Changes in Dogs With Parvoviral Enteritis Before and After Fluid Resuscitation Using Thromboelastography

D.A. Williams
Serum Tocopherol and Retinol Concentrations in Dogs with Exocrine Pancreatic Insufficiency

R.L. Winter
Notched QRS Complexes in Dogs With and Without Structural Cardiac Disease: 85 Cases

V.L. Woolhead
Serial Changes in Insulin-Like Growth Factor 1 and Impact on Hypersomatropism-Screening in Feline Diabetes Mellitus
A Retrospective Evaluation of Ileocecal Perforations Associated with Routine Diagnostic Lower Gastrointestinal Endoscopy in Dogs and Cats

P.G. Xenoulis
Specificity of SNAP fPLTM for the Diagnosis of Pancreatitis in Healthy Cats and Sick Cats Without Clinical Suspicion of Pancreatitis

Z. Yilmaz
Identification of Serum Biomarkers in Dogs Naturally Infected with Anaplasma phagocytophilum and Borrelia burgdorferi

J. Zambarbieri
Symmetric Dimethylarginine (SDMA) and Nephropathy in Dog: Diagnostic Utility in Clinical Practice

M. Zandvliet
Are Protein Kinase Inhibitors of Use in the Treatment of Canine Lymphoma? A Screening in Vitro Study with Multiple Protein Kinase Inhibitors in Canine
Lymphoid Cell Lines

Faiez Zannad, MD, PhD, INSERM
Pharmacotherapy of Human Heart Failure
Device Therapy for Human Heart Failure

E. Zini
Ultrastructural Characterisation of Pancreatic Beta-Cells in Cats with Diabetes Mellitus

A. Zoia
Pleural Effusion Lactate Dehydrogenase (LDHp) Concentration and Serum Total Protein (TPs) Concentration Versus Traditional Veterinary Classification Method in the Discrimination Between Transudates and Exudates: A Cross-Sectional Study in 100 Dogs with Pleural Effusion